,id,created,pids.doi.identifier,metadata.title,metadata.description,metadata.resource_type.title.en,metadata.publication_date,metadata.creators.person_or_org.type,metadata.creators.person_or_org.name,metadata.rights.id,OpenAlex_ID,ListofAlexIds,ListofNames,ListofOrcids
0,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5091866133,Hankum Park,0000-0001-5795-3249
1,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5040242042,Qing Yu,0000-0003-0468-5353
2,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5079127441,Frances V Hundley,0000-0001-9469-301X
3,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5010446056,Katherine A. Overmyer,0000-0002-1929-1229
4,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5037217891,Lia R. Serrano,0000-0001-5662-5884
5,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5026734370,João A. Paulo,0000-0002-4291-413X
6,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5023479457,Julia C. Paoli,0000-0001-8266-1766
7,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5035448367,Sharan Swarup,0000-0003-0226-5582
8,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5086840789,Joshua J. Coon,0000-0002-0004-8253
9,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5079793809,Steven P. Gygi,0000-0001-7626-0034
10,6597542,2022-05-31T15:21:19.730448+00:00,10.5281/zenodo.6597542,"Tabular datasets for Park et al, 2022","<p>tabular datasets used for immunofluorescence (Figure 1b, Extended Data Figure 3c) and transmission electron microscopy (Extended Data Figure 1h)</p>",Dataset,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,W4393681028,A5047746208,J. Wade Harper,0000-0002-6944-7236
11,12690495,2024-08-30T13:51:25.944250+00:00,10.5281/zenodo.12690495,ASAP Team Chen PPMI Progression Project Key Resource Table,"<p>Included in this key resource table are all data, codes, and softwares used in this project.</p>",Other,2024-07-08 00:00:00,personal,"Schumacher, Jackson",cc-by-4.0,,,,
12,7153540,2022-10-06T16:58:07.398785+00:00,10.5281/zenodo.7153540,PPR_analysis_LRRK2,"<p>Script for PPR data from the manuscript:&nbsp;<strong>R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations by Xeanis</strong>&nbsp;et al.&nbsp; PR_analyzer determines the amplitudes and decay times of stimulus-evoked PSPs over a&nbsp;&nbsp;user-specified range of either 5% - 95% or 10% - 90% of baseline from&nbsp;PClamp .abf files.</p>",Software,2022-10-06 00:00:00,personal,"Harry Xenias, Savio Chan, Loukia Parisiadou",cc-by-4.0,,,,
13,10430962,2024-01-03T15:37:23.090537+00:00,10.5281/zenodo.10430962,Roatarod test and beam-walk assay of Gba L444P mice,<p>This data is motobehavior test results of Gba L444P/L444P mice comparing age matched wildtype controls.</p>,Dataset,2023-12-25 00:00:00,personal,"Han, Tae-Un",cc-by-4.0,W4393570042,A5101764645,Tae‐Un Han,0000-0002-0287-0160
14,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5100762075,Xinbo Wang,0000-0001-8524-9662
15,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5090536824,Javier Espadas,0000-0002-4559-5410
16,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5004727785,Yumei Wu,0000-0003-0878-7605
17,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5040142346,Shujun Cai,0000-0002-8558-6279
18,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5060299931,Jinghua Ge,0000-0002-5820-1521
19,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5026423769,Lin Shao,0000-0002-1905-4442
20,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5017325892,Aurélien Roux,0000-0002-6088-0711
21,8335319,2023-09-11T15:15:09.846571+00:00,10.5281/zenodo.8335319,Membrane remodeling properties of the Parkinson's disease protein LRRK2,<p>This data set contains the primary data associated with the publication in PNAS</p>,Dataset,2023-09-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Wang, Xinbo
Espadas, Javier
Wu, Yumei
Cai, Shujun
Ge, Jinghua
Shao, Lin
Roux, Aurélien
De Camilli, Pietro",cc-by-4.0,W4393826560,A5037459294,Pietro De Camilli,0000-0001-9045-0723
22,8204348,2023-08-02T16:30:00.663672+00:00,10.5281/zenodo.8204348,R code for paper Phenotype of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study,<p>This is the R code used to produce the results described in the paper.&nbsp;</p>,Other,2023-07-27 00:00:00,personal,"Toffoli, Marco",cc-by-4.0,,,,
23,8352764,2023-09-17T09:47:52.760669+00:00,10.5281/zenodo.8352764,"R scripts for analysis of publication ""Sex distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson Disease""",<p>The R code used to produce the results reported in the paper.&nbsp;</p>,Software,2023-09-17 00:00:00,personal,Marco Toffoli,cc-by-4.0,,,,
24,11244913,2024-07-09T16:22:21.193367+00:00,10.5281/zenodo.11244913,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,<p>Raw data for main figures excuding Figure2 and 5. Each Figure has: PNG file of image; Readme text file and zip file with all the raw data.&nbsp;</p>,Dataset,2024-05-22 00:00:00,personal,"Bagnoli, Enrico",cc-by-4.0,,,,
25,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5077060611,Rekha Dhanwani,0000-0002-6592-8657
26,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5057542377,João Rodrigues Lima-Júnior,
27,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5109476794,Ashu Sethi,
28,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5114235233,John Pham,
29,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5046678361,Gregory P. Williams,0000-0001-9523-1781
30,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5044515449,April Frazier,0000-0002-4722-7304
31,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5075915109,Yaqian Xu,0000-0001-5890-3446
32,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5067845430,Amy W. Amara,0000-0003-0762-9656
33,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5000374325,David G. Standaert,0000-0003-2921-8348
34,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535
35,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5006709022,Irene Litvan,0000-0002-3485-3445
36,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5037098776,Roy N. Alcalay,0000-0002-5717-4875
37,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5023547268,Bjoern Peters,0000-0002-8457-6693
38,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5026787858,David Sulzer,0000-0001-7632-0439
39,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002
40,5703708,2021-11-16T00:10:28.318356+00:00,10.5281/zenodo.5703708,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Fluorospot SFC,"<p>Fluorospot SFC (combined IFNg, IL-5, and IL-10) data and corresponding HC-PD group IDs described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>",Dataset,2021-11-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4394021969,A5010966529,Alessandro Sette,0000-0001-7013-2250
41,8280101,2023-08-24T16:51:00.629401+00:00,10.5281/zenodo.8280101,Data for Adaptor Protein-3 Produces Synaptic Vesicles that Release Phasic Dopamine,<p>Raw data for publication titled&nbsp;Adaptor Protein-3 Produces Synaptic Vesicles that Release Phasic Dopamine.</p>,Dataset,2023-08-24 00:00:00,"personal
personal","Jain, Shweta
Edwards, Robert",cc-by-4.0,W4393446757,A5101764122,Shweta Jain,0000-0001-9716-7453
42,8280101,2023-08-24T16:51:00.629401+00:00,10.5281/zenodo.8280101,Data for Adaptor Protein-3 Produces Synaptic Vesicles that Release Phasic Dopamine,<p>Raw data for publication titled&nbsp;Adaptor Protein-3 Produces Synaptic Vesicles that Release Phasic Dopamine.</p>,Dataset,2023-08-24 00:00:00,"personal
personal","Jain, Shweta
Edwards, Robert",cc-by-4.0,W4393446757,A5027616900,Robert H. Edwards,0000-0002-8650-3260
43,7057419,2022-09-07T12:48:17.071937+00:00,10.5281/zenodo.7057419,Figure 3–Figure Supplement 4 of the paper 'A Feed-forward Pathway Drives LRRK2 kinase Membrane Recruitment and Activation',"<p>Raw immunoblotting and quantitation data for Figure 3&ndash;Figure Supplement 4 of the paper &quot;A Feed-forward Pathway Drives LRRK2 kinase Membrane Recruitment and Activation&quot; (Edmundo G. Vides, Ayan Adhikar, Claire Y. Chiang, Pawel Lis, Elena Purlyte, Charles Limouse, Justin L. Shumate, Elena Sp&iacute;nola-Lasso, Herschel S. Dhekne,&nbsp; Dario R. Alessi, and Suzanne R. Pfeffer)</p>

<p><strong>File descriptions:</strong></p>

<p><strong>Figure 3&ndash;Figure Supplement 4A</strong><br>
<strong>Fig.3.S4A_700(tRab10;tLRRK2)_High.tif </strong>- Licor scan (channel 700) showing total Rab10 and total LRRK2 blots; high contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4A_700(tRab10;tLRRK2)_Low.tif</strong> - Licor scan (channel 700) showing total Rab10 and total LRRK2 blots; low contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4A_800(pRab10;pLRRK2)_High.tif</strong> - Licor scan (channel 800) showing Rab10 pT73 and LRRK2 pS935 blots; high contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4A_800(pRab10;pLRRK2)_Low.tif</strong> - Licor scan (channel 800) showing Rab10 pT73 and LRRK2 pS935 blots; high contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4A_HA.tif </strong>- ChemiDoc Scan (ECL) showing HA blot</p>

<p><strong>Figure 3&ndash;Figure Supplement 4B</strong></p>

<p><strong>Fig.3.S4B_700(tRab10;tLRRK2)_High.tif </strong>- Licor scan (channel 700) showing total Rab10 and total LRRK2 blots; high contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4B_700(tRab10;tLRRK2)_Low.tif</strong> - Licor scan (channel 700) showing total Rab10 and total LRRK2 blots; low contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4B_800(pRab10;pLRRK2)_High.tif</strong> - Licor scan (channel 800) showing Rab10 pT73 and LRRK2 pS935 blots; high contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4B_800(pRab10;pLRRK2)_Low.tif </strong>- Licor scan (channel 800) showing Rab10 pT73 and LRRK2 pS935 blots; high contrast<br>
Panel 1 - top left membrane<br>
Panel 2 - top right membrane<br>
Panel 3 - bottom left membrane<br>
Panel 4 - bottom right membrane</p>

<p><strong>Fig.3.S4B_HA.tif </strong>- ChemiDoc Scan (ECL) showing HA blot</p>

<p><strong>Fig.3.S4_immunoblotting_numerical_data.xlsx</strong> - Excel sheet containing raw quatitation values from Licor scans as well as calculated pRab10/Rab10 ratios (values used in Figure 3C and 3D)</p>",Dataset,2022-09-07 00:00:00,personal,Lis Pawel,cc-by-4.0,W4394055139,A5094306339,Lis Pawel,
44,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5046678361,Gregory P. Williams,0000-0001-9523-1781
45,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5052801583,Kaylin Muskat,
46,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5044515449,April Frazier,0000-0002-4722-7304
47,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5075915109,Yaqian Xu,0000-0001-5890-3446
48,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5063444034,José Mateus,0000-0002-1402-3452
49,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5083647614,Alba Grifoni,0000-0002-0369-1746
50,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5075614639,Ricardo da Silva Antunes,0000-0001-9785-5272
51,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5071431150,Daniela Weiskopf,0000-0003-2968-7371
52,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5067845430,Amy W. Amara,0000-0003-0762-9656
53,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5000374325,David G. Standaert,0000-0003-2921-8348
54,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535
55,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5006709022,Irene Litvan,0000-0002-3485-3445
56,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5037098776,Roy N. Alcalay,0000-0002-5717-4875
57,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5026787858,David Sulzer,0000-0001-7632-0439
58,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002
59,6426141,2022-04-08T20:35:15.823437+00:00,10.5281/zenodo.6426141,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (1.2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1.2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393893587,A5010966529,Alessandro Sette,0000-0001-7013-2250
60,10896376,2024-03-30T03:41:24.990560+00:00,10.5281/zenodo.10896376,"Figure S2. pS72 Rab7 formation following depolarization, starvation, and iron chelation [FINAL]",,Dataset,2023-03-29 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
61,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5046225091,Louise Uoselis,0000-0001-8538-9817
62,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5082909714,Runa Lindblom,0000-0001-6755-8744
63,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5080220622,Wai Kit Lam,0000-0002-7433-9205
64,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5019073167,Catharina J. Küng,0009-0008-0175-7810
65,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5033276727,Marvin Skulsuppaisarn,0000-0003-4041-7014
66,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5084050236,Grace Khuu,0000-0002-2550-0605
67,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020
68,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5009876179,Danielle L. Rudler,0000-0002-5540-6548
69,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5050949179,Aleksandra Filipovska,0000-0002-6998-8403
70,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5087390081,Ralf B. Schittenhelm,0000-0001-8738-1878
71,8253926,2023-09-24T22:39:16.015574+00:00,10.5281/zenodo.8253926,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,"<p>Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR<sup>mt</sup>) and PINK1/Parkin mitophagy. However, beyond the upregulation of chaperones and proteases, we have a limited understanding of how the UPR<sup>mt</sup> remodels and restores damaged mito-proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (<strong>Mito</strong>chondrial <strong>P</strong>roteostasis <strong>Q</strong>uantification), to dissect the UPR<sup>mt</sup>&rsquo;s role in maintaining proteostasis during stress. We discover essential roles for the UPR<sup>mt</sup> in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR<sup>mt</sup>. Transcriptome analyses together with MitoPQ reveal that UPR<sup>mt</sup> transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR<sup>mt</sup> and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR<sup>mt</sup> failed. Collectively, this study defines the network of proteostasis mediated by the UPR<sup>mt</sup> and highlights the value of functional proteomics in decoding stressed proteomes.</p>",Journal article,2023-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Uoselis, Louise
Lindblom, Runa
Lam, Wai Kit
Küng, Catharina
Skulsuppaisarn, Marvin
Khuu, Grace
Nguyen, Thanh
Rudler, Danielle
Filipovska, Aleksandra
Schittenhelm, Ralf
Lazarou, Michael",cc-by-4.0,W4387001205,A5061877082,Michael Lazarou,0000-0003-2150-5545
72,7714308,2023-03-10T01:44:28.612424+00:00,10.5281/zenodo.7714308,Liposome_BAM_depletion_T_cell,<p>This dataset contains .fcs files from AAV2-SYN transduced animals given clodronate or saline liposomes i.c.v. This experiment specifically investigated T helper subsets.</p>,Dataset,2023-03-10 00:00:00,personal,Aubrey M. Schonhoff,cc-by-4.0,W4394057285,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
73,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020
74,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5065987196,Justyna Sawa‐Makarska,0000-0002-9321-976X
75,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5084050236,Grace Khuu,0000-0002-2550-0605
76,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5080220622,Wai Kit Lam,0000-0002-7433-9205
77,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5067997102,Elias Adriaenssens,0000-0001-9430-917X
78,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5038589622,Dorotea Fracchiolla,0000-0002-1612-5225
79,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5045624897,Stephen Shoebridge,0000-0002-3555-2855
80,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5075781636,Daniel Bernklau,
81,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5078421822,Benjamin Scott Padman,0000-0002-5710-6100
82,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5033276727,Marvin Skulsuppaisarn,0000-0003-4041-7014
83,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5082909714,Runa Lindblom,0000-0001-6755-8744
84,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5029002091,Sascha Martens,0000-0003-3786-8199
85,7902562,2023-05-08T11:32:39.394927+00:00,10.5281/zenodo.7902562,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,"<p>Cargo sequestration is a fundamental step of selective autophagy in which cells generate a double membrane structure termed an autophagosome on the surface of cargoes. NDP52, TAX1BP1 and p62 bind FIP200 which recruits the ULK1/2 complex to initiate autophagosome formation on cargoes. How OPTN initiates autophagosome formation during selective autophagy remains unknown despite its importance in neurodegeneration. Here, we uncover an unconventional path of PINK1/Parkin mitophagy initiation by OPTN that does not begin with FIP200 binding nor require the ULK1/2 kinases. Using gene-edited cell lines and&nbsp;in vitro&nbsp;reconstitutions, we show that OPTN utilizes the kinase TBK1 which binds directly to the class III phosphatidylinositol 3-kinase complex I to initiate mitophagy. During NDP52 mitophagy initiation, TBK1 is functionally redundant with ULK1/2, classifying TBK1&rsquo;s role as a selective autophagy initiating kinase. Overall, this work reveals that OPTN mitophagy initiation is mechanistically distinct and highlights the mechanistic plasticity of selective autophagy pathways.</p>",Journal article,2023-05-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Nguyen, Thanh Ngoc
Sawa-Makarska, Justyna
Khuu, Grace
Lam, Wai Kit
Adriaenssens, Elias
Fracchiolla, Dorotea
Shoebridge, Stephen
Bernklau, Daniel
Padman, Benjamin Scott
Skulsuppaisarn, Marvin
Lindblom, Runa S.J.
Martens, Sascha
Lazarou, Michael",cc-by-4.0,W4375848751,A5061877082,Michael Lazarou,0000-0003-2150-5545
86,11065259,2024-04-25T09:45:59.964913+00:00,10.5281/zenodo.11065259,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system - Supplementary Figure files,"<p><strong>Loss of function mutations in PTEN-induced kinase 1 (PINK1) are a frequent cause of earlyonset Parkinson&rsquo;s disease (PD). Stabilisation of PINK1 at the Translocase of Outer Membrane&nbsp; (TOM) complex of damaged mitochondria is a critical step for its activation. To date the&nbsp; mechanism of how PINK1 is activated in the TOM complex is unclear. Herein we report co-expression of human PINK1 and all seven TOM subunits in Saccharomyces cerevisiae is&nbsp; sufficient for PINK1 activation. We use this reconstitution system to systematically assess the&nbsp; role of each TOM subunit towards PINK1 activation. We unambiguously demonstrate that the TOM20 and TOM70 receptor subunits are required for optimal PINK1 activation and map their sites of interaction with PINK1 using AlphaFold structural modelling and mutagenesis. We also demonstrate an essential role of the pore-containing subunit TOM40 and its structurally associated subunits TOM7 and TOM22 for PINK1 activation. These molecular findings will aid in the development of small molecule activators of PINK1 as a therapeutic strategy for PD.&nbsp;</strong></p>
<p>&nbsp;</p>
<p><strong><span>Supplementary figure 3</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>pUB</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1(pS228)</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM22</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>CDC28</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-6: WTPINK1+TOM complex; Lane 7-10: PINK1(KI) + TOM complex; Lane 11-14: PINK1 alone.</span></p>
<p><strong><span>Supplementary figure 4A</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>pUb</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1(pS228)</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM22</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>CDC28</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI)+TOM complex; Lane 7-8: hPINK1 Q126P; Lane 9-10: hPINK1 E240K; Lane 11-12: hPINK1 G309D; Lane 13-14: hPINK1 ins539Q.</span></p>
<p><span>&nbsp;</span></p>
<p><strong><span>Supplementary Figure 4B</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1 </span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM22</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM7</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM6</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>Ponceau S</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: WT PINK1 only without TOM-complex, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><strong><span>Supplementary 5</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>pUb</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1(pS228)</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM22</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>CDC28</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM5; Lane8-11: -TOM6; Lane12-15: -TOM7; Lane 16-19: -TOM20; Lane 20-23: -TOM22.</span></p>
<p><strong><span>Supplementary 6</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>pUb</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1(pS228)</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM22</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>CDC28</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Uninduced cells; Lane 2: WT-PINK1 + TOM complex; Lane 3: PINK1(KI) + TOM complex; Lane 4-7: -TOM40; Lane 8-11: -TOM70; Lane12-15: -TOM20/70.</span></p>
<p><strong><span>Supplementary figure 9</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>pUB</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1(pS228)</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM22</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>CDC28</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: Uninduced cells; Lane 3-4: WT-PINK1 + TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-14: hPINK1 K135E; Lane 15-22: hPINK1 K135M.</span></p>
<p><span>&nbsp;</span></p>
<p><strong><span>Supplementary Figure 13</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1 native blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: <span>&nbsp;</span>3-FLAG Empty, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40 native blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: Veh 3-FLAG, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20 native blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: Veh 3-FLAG, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70 native blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: Veh 3-FLAG, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>PINK1 Ponceau </span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: Veh 3-FLAG, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM40 Ponceau </span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: Veh 3-FLAG, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM20 Ponceau</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: Veh 3-FLAG, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>TOM70 Ponceau</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 3-4: Veh 3-FLAG, Lane 5-6: WT hPINK1 with TOM-complex, Lane 7-8: KI hPINK1 with TOM-complex</span></p>
<p><strong><span>Supplementary Figure 14C</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>Suppl14C_aPINK1.scn: Western blot for test-expression of N-terminally truncated PINK1 constructs</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1-2: total and elution fraction of His-Z-PINK1 144-581; Lane 3-4: total and elution fraction of His-Z-PINK1 152-581; Lane 5-6: total and elution fraction of His-Z-PINK1 65-581; Lane 7-8: total and elution fraction of His-Z-PINK1 71-581; Lane 9-10: total and elution fraction of His-Z-PINK1 92-581; Lane 11-12: total and elution fraction of His-Z-PINK1 95-581; Lane 13-15: total and elution fraction of His-Z-PINK1 104-581; Lane 15-16: total and elution fraction of His-Z-PINK1 98-581; Lane 17-18: total and elution fraction of His-Z-PINK1 107-581; Lane 19-20: total and elution fraction of His-Z-PINK1 110-581; Lane 21-22: total and elution fraction of His-Z-PINK1 20-581; Lane 23-24: total and elution fraction of His-Z-PINK1 47-581; Lane 26: Marker.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>Suppl14C_aPINK1_color.scn: Colorimetric image of Western blot </span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>Suppl14C_Coomassie.scn &ndash; Coomassie stained SDS gel </span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Marker; Lane 2-3: total and elution fraction of His-Z-PINK1 144-581; Lane 4-5: total and elution fraction of His-Z-PINK1 152-581; Lane 6-7: total and elution fraction of His-Z-PINK1 65-581; Lane 8-9: total and elution fraction of His-Z-PINK1 71-581; Lane 10-11: total and elution fraction of His-Z-PINK1 92-581; Lane 12-13: total and elution fraction of His-Z-PINK1 95-581; Lane 14-15: total and elution fraction of His-Z-PINK1 104-581; Lane 16-17: total and elution fraction of His-Z-PINK1 98-581; Lane 18-19: total and elution fraction of His-Z-PINK1 107-581; Lane 20-21: total and elution fraction of His-Z-PINK1 110-581; Lane 22-23: total and elution fraction of His-Z-PINK1 20-581; Lane 24-25 total and elution fraction of His-Z-PINK1 47-581; Lane 26: Marker.</span></p>
<p><span>&nbsp;</span></p>
<p><strong><span>&nbsp;</span></strong></p>
<p><strong><span>&nbsp;</span></strong></p>
<p><strong><span>Supplementary Figure 14D</span></strong></p>
<p><strong><span>&nbsp;</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>Suppl14D_aHis.scn Western blot for test-expression of PINK1 constructs: WT, PINK1 insertion I replacement by PhPINK1 or PEAK1 sequence</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Marker; Lane 2-3: total and elution fraction of His-Z-PINK1 WT 1-581; Lane 4-5: total and elution fraction of His-Z-PINK1 WT 71-581; Lane 6-7: total and elution fraction of His-Z-PINK1 WT 104-581; Lane 8-9: total and elution fraction of His-Z-PINK1 WT 144-581; Lane 10-11: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK11-581; Lane 12-13: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK1 71-581; Lane 14-15: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK1 104-581; Lane 16-17: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK1 144-581; Lane 18-19: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 1-581; Lane 20-21: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 71-581; Lane 22-23: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 104-581; Lane 24-25: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 144-581; Lane 26: Marker.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>Suppl14D_aHis-color.scn: Colorimetric image of Western blot</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>Suppl14D_Coomassie.scn - Coomassie stained SDS gel </span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: Marker; Lane 2-3: total and elution fraction of His-Z-PINK1 WT 1-581; Lane 4-5: total and elution fraction of His-Z-PINK1 WT 71-581; Lane 6-7: total and elution fraction of His-Z-PINK1 WT 104-581; Lane 8-9: total and elution fraction of His-Z-PINK1 WT 144-581; Lane 10-11: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK11-581; Lane 12-13: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK1 71-581; Lane 14-15: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK1 104-581; Lane 16-17: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PhPINK1 144-581; Lane 18-19: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 1-581; Lane 20-21: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 71-581; Lane 22-23: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 104-581; Lane 24-25: total and elution fraction of His-Z-PINK1 &Delta;Ins1 PEAK1 144-581; Lane 26: Marker.</span></p>
<p><span>&nbsp;</span></p>
<p><span>&nbsp;</span></p>
<p><strong><span>Supplementary Figure 15A</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15A TOM6 blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 2: Input TOM6-HA (tag at C-terminus), Lane 3: Input HA-TOM6 (tag at N-terminus), Lane 4: IP TOM6-HA (tag at C-terminus), Lane 5: IP HA-TOM6 (tag at N-terminus)</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15A HA blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 2: Input TOM6-HA (tag at C-terminus), Lane 3: Input HA-TOM6 (tag at N-terminus), Lane 4: IP TOM6-HA (tag at C-terminus), Lane 5: IP HA-TOM6 (tag at N-terminus)</span></p>
<p><strong><span>Supplementary Figure 15B</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15B TOM6 blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Left blot:</span></p>
<p><span>Lane 1: marker, Lane 2: PINK1-TOMcomplex expressed in yeast mitochondria, Lane 3: PINK1-TOMcomplex minus TOM6 expressed in yeast mitochondria.</span></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Right blot:</span></p>
<p><span>Lane 1: marker, Lane 2: Uninduced PINK1-TOMcomplex expressed in yeast, Lane 3: Induced PINK1-TOMcomplex expressed in yeast.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15B TOM6 mito Ponceau</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Left blot:</span></p>
<p><span>Lane 1: marker, Lane 2: PINK1-TOMcomplex expressed in yeast mitochondria, Lane 3: PINK1-TOMcomplex minus TOM6 expressed in yeast mitochondria.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15B TOM6 whole Ponceau</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Right blot:</span></p>
<p><span>Lane 1: marker, Lane 2: Uninduced PINK1-TOMcomplex expressed in yeast, Lane 3: Induced PINK1-TOMcomplex expressed in yeast.</span></p>
<p><strong><span>&nbsp;</span></strong></p>
<p><strong><span>Supplementary Figure 15</span></strong></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15C TOM7 blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 2: Input TOM7-HA (tag at C-terminus), Lane 3: Input HA-TOM7 (tag at N-terminus), Lane 4: IP TOM7-HA (tag at C-terminus), Lane 5: IP HA-TOM7 (tag at N-terminus)</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15C HA blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Lane 1: marker, Lane 2: Input TOM7-HA (tag at C-terminus), Lane 3: Input HA-TOM7 (tag at N-terminus), Lane 4: IP TOM7-HA (tag at C-terminus), Lane 5: IP HA-TOM7 (tag at N-terminus)</span></p>
<p><strong><span>Supplementary Figure 15D</span></strong></p>
<p><span>&nbsp;</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15D TOM7 blot</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Left blot:</span></p>
<p><span>Lane 1: marker, Lane 2: PINK1-TOMcomplex expressed in yeast mitochondria, Lane 3: PINK1-TOMcomplex minus TOM7 expressed in yeast mitochondria.</span></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Right blot:</span></p>
<p><span>Lane 1: marker, Lane 2: Uninduced PINK1-TOMcomplex expressed in yeast, Lane 3: Induced PINK1-TOMcomplex expressed in yeast.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15D TOM7 mito Ponceau</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Left blot:</span></p>
<p><span>Lane 1: marker, Lane 2: PINK1-TOMcomplex expressed in yeast mitochondria, Lane 3: PINK1-TOMcomplex minus TOM7 expressed in yeast mitochondria.</span></p>
<p><span><span>&middot;<span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><strong><span>15D TOM7 whole Ponceau</span></strong></p>
<p><span><span>o<span>&nbsp;&nbsp; </span></span></span><span>Right blot:</span></p>
<p><span>Lane 1: marker, Lane 2: Uninduced PINK1-TOMcomplex expressed in yeast, Lane 3: Induced PINK1-TOMcomplex expressed in yeast.</span></p>",Image,2024,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Raimi, Olawale
Ojha, Hina
Ehses, Kenneth
Dederer, Verena
Lange, Sven
Rivera, Cristian Polo
Deegan, Tom D
Chen, Yinchen
Wightman, Melanie
Toth, Rachel
Labib, Karim P.M.
Mathea, Sebastian
Ranson, Neil
Fernandez-Busnadiego, Ruben
Muqit, Miratul",cc-by-4.0,,,,
87,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5037145890,Anna Bieber,0000-0001-5014-6620
88,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5045212954,Cristina Capitanio,0000-0002-5297-9156
89,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5066605298,Philipp S. Erdmann,0000-0001-8289-9133
90,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5076792820,Fabian Fiedler,
91,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5014597115,Florian Beck,0000-0003-3183-2953
92,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5101504331,Chia‐Wei Lee,0000-0002-8925-7421
93,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5047466909,Delong Li,0000-0003-1165-9137
94,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5059945365,Gerhard Hummer,0000-0001-7768-746X
95,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5023564164,Brenda A. Schulman,0000-0002-3083-1126
96,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5029559203,Wolfgang Baumeister,0000-0001-8154-8809
97,6607443,2022-06-02T16:14:10.758681+00:00,10.5281/zenodo.6607443,"Tabular datasets for ""In situ structural analysis reveals membrane shape transitions during autophagosome formation""",<p>Tabular source data for all plots in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot;. The article is available at https://doi.org/10.1101/2022.05.02.490291. The naming of the sheets in the .xlsx files corresponds to the figure number and panel.</p>,Dataset,2022-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Bieber, Anna
Capitanio, Cristina
Erdmann, Philipp S
Fiedler, Fabian
Beck, Florian
Lee, Chia-Wei
Li, Delong
Hummer, Gerhard
Schulman, Brenda A
Baumeister, Wolfgang
Wilfling, Florian",cc-by-4.0,W4393795105,A5006303094,Florian Wilfling,0000-0002-6559-7261
98,4649457,2021-03-31T01:10:57.795434+00:00,10.5281/zenodo.4649457,ASAP and Our Path to Open Access,"<p>Presentation on initial open science policies and philosophy of the Aligning Science Across Parkinson&#39;s (ASAP) initiative&nbsp;given at the National Academy of Sciences Engineering and Medicine during a virtual public workshop on developing a toolkit for fostering open science practices&nbsp;in conjunction with the Fall 2020 meeting of the&nbsp;<a href=""https://www.nationalacademies.org/our-work/roundtable-on-aligning-incentives-for-open-science?utm_source=BRDI&amp;utm_campaign=9654e8a95e-EMAIL_CAMPAIGN_2017_08_15_COPY_01&amp;utm_medium=email&amp;utm_term=0_5b187d867a-9654e8a95e-"">Roundtable on Aligning Incentives for Open Science</a>.&nbsp;</p>",Presentation,2020-11-05 00:00:00,personal,Ekemini Riley,cc-by-4.0,,,,
99,11077189,2024-05-23T19:23:12.476365+00:00,10.5281/zenodo.11077189,"Data to accompany the outlier-waveform-detection Github repository (internal globus pallidus, GPi)","<p>This repository contains data based on neuronal recordings from two monkeys (G and I, in the pre- and post-MPTP states) that serve as input to the code provided at <a href=""https://github.com/turner-lab-pitt/outlier-waveform-detection"">https://github.com/turner-lab-pitt/outlier-waveform-detection</a>.&nbsp;Text files located within that Github repository provide detailed instructions on how these data may be used with that code.&nbsp; As described in those text files, extra data are provided for Monkey G, in the pre-MPTP state.</p>
<p>The data-description.txt file provides detailed information regarding the contents of each zipped tar archive. Briefly, the most important components of the files are the ""snips"" (individual spike waveforms) from the two monkeys and MPTP states, as extracted for each of a series of single sorted units from the internal globus pallidus (GPi).&nbsp; The additional G-Pre data provides examples of the high-pass filtered voltage signals from which these snips were extracted.&nbsp; All data are stored in the Matlab .mat format.</p>
<p>All zipped files can be decompressed with 7-zip: <a href=""https://www.7-zip.org/"" target=""_blank"" rel=""noopener"">https://www.7-zip.org/</a></p>
<p>These data and the associated Github code were used for analyses reported in an in-preparation manuscript (Kase et al., ""Movement-related activity in the internal globus pallidus of the parkinsonian macaque""), and also with a preprint that is currently under review:</p>
<div>
<div>Detecting rhythmic spiking through the power spectra of point process model residuals</div>
</div>
<div>Karin M. Cox, Daisuke Kase, Taieb Znati, Robert S. Turner</div>
<div>bioRxiv 2023.09.08.556120; doi: <a href=""https://doi.org/10.1101/2023.09.08.556120"" target=""_blank"" rel=""noopener"">https://doi.org/10.1101/2023.09.08.556120</a></div>
<div>&nbsp;</div>
<p>This research was funded in part by Aligning Science Across Parkinson's [ASAP-020519] through the Michael J. Fox Foundation for Parkinson's Research (MJFF). For the purpose of open access, the authors have applied a Creative Commons Attribution 4.0 International (CC BY) public copyright license to this dataset.&nbsp;</p>",Dataset,2024-05-05 00:00:00,"personal
personal
personal","Cox, Karin
Kase, Daisuke
Turner, Robert",cc-by-4.0,,,,
100,8144253,2023-07-13T15:44:57.236450+00:00,10.5281/zenodo.8144253,Enteric neuron and macrophage quantification following T cell depletion,"<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub>. Data includes three conditions: isotype control, anti-CD4, and anti-CD8 T cell depleting antibodies.</p>

<p>Enteric neuron (ANNA1<sup>+</sup>), macrophage density (IBA1<sup>+</sup>), tyrosine hydroxylase (TH<sup>+</sup>) neuron, TH<span><sup>+</sup>&nbsp;</span>area and mean fluorescence intensity in the myenteric and submucosal plexus of the ileum were&nbsp;quantified.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393667704,A5012875579,Francesca Garretti,0000-0002-6609-8034
101,8144253,2023-07-13T15:44:57.236450+00:00,10.5281/zenodo.8144253,Enteric neuron and macrophage quantification following T cell depletion,"<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub>. Data includes three conditions: isotype control, anti-CD4, and anti-CD8 T cell depleting antibodies.</p>

<p>Enteric neuron (ANNA1<sup>+</sup>), macrophage density (IBA1<sup>+</sup>), tyrosine hydroxylase (TH<sup>+</sup>) neuron, TH<span><sup>+</sup>&nbsp;</span>area and mean fluorescence intensity in the myenteric and submucosal plexus of the ileum were&nbsp;quantified.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393667704,A5084707089,Connor Monahan,0000-0003-3245-6187
102,8144253,2023-07-13T15:44:57.236450+00:00,10.5281/zenodo.8144253,Enteric neuron and macrophage quantification following T cell depletion,"<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub>. Data includes three conditions: isotype control, anti-CD4, and anti-CD8 T cell depleting antibodies.</p>

<p>Enteric neuron (ANNA1<sup>+</sup>), macrophage density (IBA1<sup>+</sup>), tyrosine hydroxylase (TH<sup>+</sup>) neuron, TH<span><sup>+</sup>&nbsp;</span>area and mean fluorescence intensity in the myenteric and submucosal plexus of the ileum were&nbsp;quantified.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393667704,A5026787858,David Sulzer,0000-0001-7632-0439
103,8144253,2023-07-13T15:44:57.236450+00:00,10.5281/zenodo.8144253,Enteric neuron and macrophage quantification following T cell depletion,"<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub>. Data includes three conditions: isotype control, anti-CD4, and anti-CD8 T cell depleting antibodies.</p>

<p>Enteric neuron (ANNA1<sup>+</sup>), macrophage density (IBA1<sup>+</sup>), tyrosine hydroxylase (TH<sup>+</sup>) neuron, TH<span><sup>+</sup>&nbsp;</span>area and mean fluorescence intensity in the myenteric and submucosal plexus of the ileum were&nbsp;quantified.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393667704,A5085315691,Dritan Agalliu,0000-0002-5375-4143
104,10928257,2024-04-12T17:35:25.345791+00:00,10.5281/zenodo.10928257,Reward perseveration is shaped by GABAA-mediated dopamine pauses: Behavior Hardware 3D printing,"<p>STL files to 3D print various behavior hardware components.</p>
<p>This behavior hardware setup was used to collect the data in Fig 2-4 and Ext. Fig 3-5 of the publication ""Reward perseveration is shaped by GABAA-mediated dopamine pauses"".</p>",Other,2024-04-04 00:00:00,"personal
personal
personal","Burwell, Sasha
Weaver, Isaac
Tadross, Michael",cc-by-4.0,,,,
105,10162265,2023-11-20T22:38:17.657991+00:00,10.5281/zenodo.10162265,GABAergic regulation of striatal spiny projection neuron excitability depends upon their activity state: NEURON + Python model of striatal projection neurons,"<p>This repository contains a NEURON + Python model of striatal projection neurons (or SPNs) designed to simulate the interaction between GABAergic and glutamatergic synaptic inputs.</p>
<p>These simulations are part of the manuscript: </p>
<p>Day M., Belal M., Surmeier W. C., Melendez A., Wokosin, D., Tkatch T., Clarke V. R. J. and Surmeier D. J.&nbsp; GABAergic regulation of striatal spiny projection neurons depends upon their activity state (2024). PLoS Biol 22(1): e3002483. <a href=""https://doi.org/10.1371/journal.pbio.3002483"">https://doi.org/10.1371/journal.pbio.3002483</a></p>
<p>The simulations run in the Jupyter Notebook environment. The readme file should contain all the relevant information necessary to reproduce all the modelling figures in the manuscript. Simulations relating to individual figure panels are clearly labelled (e.g. Fig5_BC.ipynb).</p>
<p>Post analyses and final figure outputs were generated in R. The code to reproduce this part of the manuscript is in the folder 'R analysis'. Again, the relevant files are clearly labelled (i.e. Fig5_BC.R). Graphical output from the R code is in the form of svg files which were subsequently used to make the final version of the figures in Adobe Illustrator 2023/2024.</p>
<p>The relevant figures from the ms are: Fig.5-8 and S2-4.</p>",Computational notebook,2023-11-20 00:00:00,"personal
personal
personal","Clarke, Vernon R.J.
Surmeier, William C.
Surmeier, D. James",cc-by-4.0,,,,
106,8017150,2023-06-08T11:01:22.757737+00:00,10.5281/zenodo.8017150,Genome-wide determinants of mortality and motor progression in Parkinson's disease: Supplementary Materials,<p>Supplementary Materials for&nbsp;&quot;Genome-wide determinants of mortality and clinical progression in Parkinson&rsquo;s disease&quot;.</p>,Journal article,2023-06-08 00:00:00,"personal
personal","Tan, Manuela
Morris, Huw",cc-by-4.0,W4379919285,A5046721666,Manuela Tan,0000-0001-5835-669X
107,8017150,2023-06-08T11:01:22.757737+00:00,10.5281/zenodo.8017150,Genome-wide determinants of mortality and motor progression in Parkinson's disease: Supplementary Materials,<p>Supplementary Materials for&nbsp;&quot;Genome-wide determinants of mortality and clinical progression in Parkinson&rsquo;s disease&quot;.</p>,Journal article,2023-06-08 00:00:00,"personal
personal","Tan, Manuela
Morris, Huw",cc-by-4.0,W4379919285,A5082416184,Huw R. Morris,0000-0002-5473-3774
108,10471514,2024-01-08T17:19:00.370609+00:00,10.5281/zenodo.10471514,Development of LRRK2 designed ankyrin-repeat proteins,"<p><span>Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinson&rsquo;s disease (PD) has led to intense interest in determining its cellular function. However, small-molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase itself. </span></p>",Dataset,2024-01-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Dederer, Verena
Sanz Murillo, Marta
Karasmanis, Eva P
Mathea, Sebastian
Leschziner, Andres E
Reck-Peterson, Samara L
Knapp, Stefan",cc-by-4.0,W4393708165,A5019965194,Verena Dederer,0000-0002-7877-4706
109,10471514,2024-01-08T17:19:00.370609+00:00,10.5281/zenodo.10471514,Development of LRRK2 designed ankyrin-repeat proteins,"<p><span>Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinson&rsquo;s disease (PD) has led to intense interest in determining its cellular function. However, small-molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase itself. </span></p>",Dataset,2024-01-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Dederer, Verena
Sanz Murillo, Marta
Karasmanis, Eva P
Mathea, Sebastian
Leschziner, Andres E
Reck-Peterson, Samara L
Knapp, Stefan",cc-by-4.0,W4393708165,A5053245720,Marta Sanz Murillo,0000-0002-6175-9315
110,10471514,2024-01-08T17:19:00.370609+00:00,10.5281/zenodo.10471514,Development of LRRK2 designed ankyrin-repeat proteins,"<p><span>Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinson&rsquo;s disease (PD) has led to intense interest in determining its cellular function. However, small-molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase itself. </span></p>",Dataset,2024-01-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Dederer, Verena
Sanz Murillo, Marta
Karasmanis, Eva P
Mathea, Sebastian
Leschziner, Andres E
Reck-Peterson, Samara L
Knapp, Stefan",cc-by-4.0,W4393708165,A5076988745,Eva Karasmanis,0000-0002-0139-0210
111,10471514,2024-01-08T17:19:00.370609+00:00,10.5281/zenodo.10471514,Development of LRRK2 designed ankyrin-repeat proteins,"<p><span>Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinson&rsquo;s disease (PD) has led to intense interest in determining its cellular function. However, small-molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase itself. </span></p>",Dataset,2024-01-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Dederer, Verena
Sanz Murillo, Marta
Karasmanis, Eva P
Mathea, Sebastian
Leschziner, Andres E
Reck-Peterson, Samara L
Knapp, Stefan",cc-by-4.0,W4393708165,A5042127936,Sebastian Mathea,0000-0001-8500-4569
112,10471514,2024-01-08T17:19:00.370609+00:00,10.5281/zenodo.10471514,Development of LRRK2 designed ankyrin-repeat proteins,"<p><span>Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinson&rsquo;s disease (PD) has led to intense interest in determining its cellular function. However, small-molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase itself. </span></p>",Dataset,2024-01-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Dederer, Verena
Sanz Murillo, Marta
Karasmanis, Eva P
Mathea, Sebastian
Leschziner, Andres E
Reck-Peterson, Samara L
Knapp, Stefan",cc-by-4.0,W4393708165,A5011173483,Andres E. Leschziner,0000-0002-7732-7023
113,10471514,2024-01-08T17:19:00.370609+00:00,10.5281/zenodo.10471514,Development of LRRK2 designed ankyrin-repeat proteins,"<p><span>Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinson&rsquo;s disease (PD) has led to intense interest in determining its cellular function. However, small-molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase itself. </span></p>",Dataset,2024-01-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Dederer, Verena
Sanz Murillo, Marta
Karasmanis, Eva P
Mathea, Sebastian
Leschziner, Andres E
Reck-Peterson, Samara L
Knapp, Stefan",cc-by-4.0,W4393708165,A5021023250,Samara L. Reck‐Peterson,0000-0002-1553-465X
114,10471514,2024-01-08T17:19:00.370609+00:00,10.5281/zenodo.10471514,Development of LRRK2 designed ankyrin-repeat proteins,"<p><span>Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinson&rsquo;s disease (PD) has led to intense interest in determining its cellular function. However, small-molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase itself. </span></p>",Dataset,2024-01-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Dederer, Verena
Sanz Murillo, Marta
Karasmanis, Eva P
Mathea, Sebastian
Leschziner, Andres E
Reck-Peterson, Samara L
Knapp, Stefan",cc-by-4.0,W4393708165,A5013336817,Stefan Knapp,0000-0001-5995-6494
115,10850897,2024-05-28T18:52:33.348635+00:00,10.5281/zenodo.10850897,Data and Images for Tonic dendritic GABA release by substantia nigra dopaminergic neurons,"<p>Figure1_data.xlsx</p>
<p>Numerical data for the charts in Figure 1C &nbsp;and Figure 1E</p>
<p><br>Figure1A_GP.tif</p>
<p>Fluorescent image (red channel, Chronos) for Figure 1A.&nbsp;</p>
<p><br>Figure2_data.xlsx</p>
<p>Numerical data for the charts in Figure 2B and Figure 2C</p>
<p><br>Figure3_data.xlsx</p>
<p>Numerical data for the charts in Figure 3A, 3B, and 3C.</p>
<p><br>Figure4_data.xlsx</p>
<p>Numerical data for the charts in Figure 4A and 4B.</p>
<p><br>Figure5_data.xlsx</p>
<p>Numerical data for the charts in Figure 5B and 5C.</p>
<p><br>Figure6_data.xlsx</p>
<p>Numerical data for the charts in Figure 6D, 6E, 6F, 6G and 6H.</p>
<p>&nbsp;</p>
<p>Figure6A_ALDH_Positive.tif</p>
<p>DAT-Cre positive, ALDH1A1 positive axons of SNc neurons in Rostral SNr.&nbsp;</p>
<p><br>Figure6A_ALDH_Negative.tif</p>
<p>DAT-Cre positive, ALDH1A1 negative axons of SNc neurons in Rostral SNr.</p>
<p><br>Figure6B_ALDH_Positive.tif</p>
<p>DAT-Cre positive, ALDH1A1 positive axons of SNc neurons in Caudal SNr.&nbsp;</p>
<p><br>Figure6B_ALDH_Negative.tif</p>
<p>DAT-Cre positive, ALDH1A1 negative axons of SNc neurons in Caudal SNr.</p>
<p><br>Figure6C_shRNA.tif</p>
<p>Fluorescent image (red channel: ALDH_shRNA) for Figure 6C.</p>
<p><br>Figure7_data.xlsx</p>
<p>Numerical data for the charts in Figure 7D and 7E.</p>
<p><br>Figure7A_10x.tif</p>
<p>Confocal image (red channel: PSAM_FusionRed; green channel: anti-TH) for Figure 7A.</p>
<p><br>Figure7B_60x.tif</p>
<p>Confocal image (red channel: PSAM_FusionRed; green channel: anti-TH) for Figure 7B.&nbsp;</p>
<p><br>Figure8_data.xlsx</p>
<p>Numerical data for the charts in Figure 8A and 8B.&nbsp;</p>
<p>&nbsp;</p>
<p>Figure_S1_data.xlsx</p>
<p>Numerical data for the chart in Figure S1</p>
<p><br>Figure_S2_data.xlsx</p>
<p>Numerical data &nbsp;for charts in Figure S2 C - E</p>",Dataset,2024-03-21 00:00:00,personal,"Simmons, DeNard",cc-by-4.0,,,,
116,7149282,2022-10-05T15:18:52.673096+00:00,10.5281/zenodo.7149282,Mitochondria morphology quantification datasheet of  different MIGA2 expressing cells,"<p>Mitochondria morphology quantification datasheet of different MIGA2 constructs expressing Hela cells: WT, MIGA2 KO, MIGA2 KO cells transfected with WT MIGA2, MIGA2&nbsp;KO cells transfected with MIGA2 mutants (M1, M2, M3).</p>",Dataset,2022-10-05 00:00:00,personal,Zhouping Hong,cc-by-4.0,W4393792867,A5072197894,Zhouping Hong,0000-0002-8513-3288
117,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5022357653,Enrico Zampese,0000-0002-8851-2566
118,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5044172289,David L. Wokosin,
119,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5102639210,Patricia Gonzales Rodriguez,
120,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5111645731,Jaime N. Guzmán,0000-0002-7142-8384
121,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5005081394,Tatiana Tkatch,0000-0001-6626-7435
122,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5009047210,Jyothisri Kondapalli,
123,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5110964195,William C. Surmeier,
124,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5091095249,Karis B. D’Alessandro,0000-0003-1572-1321
125,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5014388603,Diego De Stefani,0000-0003-3796-8907
126,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5027748782,Rosario Rizzuto,0000-0001-7044-5097
127,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5009491639,Masamitsu Iino,0000-0001-6426-4206
128,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5075550603,Jeffery D. Molkentin,0000-0002-3558-6529
129,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5046518034,Navdeep S. Chandel,0000-0001-7208-3886
130,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5081897750,Paul T. Schumacker,0000-0001-9591-2034
131,6949450,2022-08-08T20:48:31.435658+00:00,10.5281/zenodo.6949450,"Source data for ""Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons""","<p><strong>Fig.1Aa-c.tif</strong></p>

<p>2PLSM images (Fura-2 filled neuron) used for the reconstruction in Fig.1A</p>

<p>&nbsp;</p>

<p><strong>Fig1CDJ.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 1C, Fig.1D, Fig.1J</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1F_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1F</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1G_CRT.tif</strong></p>

<p>Confocal image (magenta channel, anti-CRT immunostaining) for Fig. 1G</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_GCEPIA1er.tif</strong></p>

<p>Confocal image (green channel, G-CEPIA1er) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig.1H_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 1H</p>

<p>&nbsp;</p>

<p><strong>Fig. 2B_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig.2B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2B</p>

<p>&nbsp;</p>

<p><strong>Fig. 2C_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig.2C_COXIV.tif</strong></p>

<p>Confocal image (magenta channel, anti-COXIV immunostaining) for Fig. 2C</p>

<p>&nbsp;</p>

<p><strong>Fig. 2D_mitoGCaMP6.tif</strong></p>

<p>Confocal image (green channel, mito-GCaMP6) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2D_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig. 2D</p>

<p>&nbsp;</p>

<p><strong>Fig.2FGJL.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 2F, Fig.2G, Fig.2J, Fig.2L</p>

<p>&nbsp;</p>

<p><strong>Fig.3BDE.xlsx</strong></p>

<p>Numerical data for the charts in Fig. 3B, Fig.3D, Fig.3E</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_Alexa.tif</strong></p>

<p>MAX Projection of z-stack of 2PLSM images (magenta channel, Alexa 594 dye) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_mitoGCaMP6.tif</strong></p>

<p>MAX Projection of&nbsp;z-stack of 2PLSM images (green channel, mito-GCaMP6) used to generate Fig.3C top panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_dendritic_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom left panel</p>

<p>&nbsp;</p>

<p><strong>Fig.3C_inset_soma_mitoGCaMP6.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.3C bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig. 4A_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig.4A_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4A</p>

<p>&nbsp;</p>

<p><strong>Fig. 4B_PercevalHR.tif</strong></p>

<p>Confocal image (green channel, PercevalHR) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4B_TH.tif</strong></p>

<p>Confocal image (blue channel, anti-TH immunostaining) for Fig.4B</p>

<p>&nbsp;</p>

<p><strong>Fig.4G.xlsx</strong></p>

<p>Numerical data for the charts in Fig.4G</p>

<p>&nbsp;</p>

<p><strong>Fig.5BDFHI.xlsx</strong></p>

<p>Numerical data for the charts in Fig.5B, Fig.5D, Fig.5F, Fig.5H, Fig.5I</p>

<p>&nbsp;</p>

<p><strong>Fig.6ADEFJKLN.xlsx</strong></p>

<p>Numerical data for the charts in Fig.6A, Fig.6D, Fig.6E, Fig.6F, Fig.6J, Fig.6K, Fig.6L, Fig.6N</p>

<p>&nbsp;</p>

<p><strong>Fig.6H_mitoroGFP.tif</strong></p>

<p>2PLSM image (green channel, mito-roGFP) for Fig.6H</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_MCU-KO.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M right side</p>

<p>&nbsp;</p>

<p><strong>Fig.6M_wildtype.tif</strong></p>

<p>Combined EM micrographs used to generate Fig. 6M left side</p>

<p>&nbsp;</p>

<p><strong>Fig.7CEFG.xlsx</strong></p>

<p>Numerical data for the charts in Fig.7C, Fig.7E, Fig.7F, Fig.7G</p>

<p>&nbsp;</p>

<p><strong>Fig.8CEHJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.8C, Fig.8E, Fig.8H, Fig.8J, Fig.8K</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_bottom.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1A_top.tif</strong></p>

<p>2PLSM image (green channel, G-CEPIA1er) for Fig.S1A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S1B.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S1B</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2A_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2A bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C middle panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_MAX.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C top panel (high Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2C_min.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2C bottom panel (low Ca2+)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_baseline.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom left panel (baseline)</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_end.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom right panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2E_peak.tif</strong></p>

<p>2PLSM image (green channel, mito-GCaMP6) for Fig.S2E bottom center panel</p>

<p>&nbsp;</p>

<p><strong>Fig.S2F.xlsx</strong></p>

<p>Numerical data for the chart in Fig.S2F</p>

<p>&nbsp;</p>

<p><strong>Fig.S3ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S3A, Fig.S3B, Fig.S3C</p>

<p>&nbsp;</p>

<p><strong>Fig.S4CD.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S4C, Fig.S4D</p>

<p>&nbsp;</p>

<p><strong>Fig.S5ABC.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S5A, Fig.S5B, Fig.S5C</p>

<p>&nbsp;</p>

<p><strong>Fig.S7A.tif</strong></p>

<p>2PLSM image (green channel, GCaMP6) for Fig.S7A</p>

<p>&nbsp;</p>

<p><strong>Fig.S7CEFGH.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S7C, Fig.S7E, Fig.S7F, Fig.S7G, Fig.S7H</p>

<p>&nbsp;</p>

<p><strong>Fig.S8ABCDEF.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S8A, Fig.S8B, Fig.S8C, Fig.S8D, Fig.S8E, Fig.S8F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9AHIJK.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S9A, Fig.S9H, Fig.S9I, Fig.S9J, Fig.S9K</p>

<p>&nbsp;</p>

<p><strong>Fig.S9B_wildtype_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9B</p>

<p>&nbsp;</p>

<p><strong>Fig.S9C_MCU-KO_DLStr.tif</strong></p>

<p>Confocal image of dorso-laterateral striatum in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9C</p>

<p>&nbsp;</p>

<p><strong>Fig.S9D_wildtype_SN.tif</strong></p>

<p>Confocal image of midbrain in wildtype mouse (red channel, anti-TH immunostaining) for Fig.S9D</p>

<p>&nbsp;</p>

<p><strong>Fig.S9E_MCU-KO_SN.tif</strong></p>

<p>Confocal image of midbrain in MCU-KO mouse (red channel, anti-TH immunostaining) for Fig.S9E</p>

<p>&nbsp;</p>

<p><strong>Fig.S9F_wildtype_openfield.png</strong></p>

<p>Open field path tracked for wildtype mouse for Fig.S9F</p>

<p>&nbsp;</p>

<p><strong>Fig.S9G_MCU-KO_openfield.png</strong></p>

<p>Open field path tracked for MCU-KO mouse for Fig.S9G</p>

<p>&nbsp;</p>

<p><strong>Fig.S10A.xlsx</strong></p>

<p>Numerical data for the charts in Fig.S10A</p>",Dataset,2022-08-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Zampese, Enrico
Wokosin, David L.
Gonzales Rodriguez, Patricia
Guzman, Jaime N.
Tkatch, Tatiana
Kondapalli, Jyothisri
Surmeier, William C.
D'Alessandro, Karis B.
De Stefani, Diego
Rizzuto, Rosario
Iino, Masamitsu
Molkentin, Jeffery D.
Chandel, Navdeep S.
Schumacker, Paul T.
Surmeier, D. James",cc-by-4.0,W4393656754,A5033742239,D. James Surmeier,0000-0002-6376-5225
132,10819039,2024-05-31T18:29:26.203210+00:00,10.5281/zenodo.10819039,R functions and scripts for Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,<p>Reusable R functions and scripts for general data analysis and visualizations.</p>,Software,2024-03-14 00:00:00,personal,"Margolis, Elyssa",cc-by-4.0,,,,
133,10056244,2023-10-30T23:32:40.897221+00:00,10.5281/zenodo.10056244,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,"<p>The unc-51-like kinase protein kinase complex (ULK1C) and the class III phosphatidylinositol (PI) 3-kinase complex I (PI3KC3-C1) are the most upstream and central players in the initiation of macroautophagy in mammals. We found a direct physical interaction between the two complexes. The cryo-EM structures of the human ULK1C core and PI3KC3-C1 were determined at amino acid residue-level resolution, and used to interpret a moderate resolution structure of the ULK1C:PI3KC3-C1 supercomplex. The two complexes co-assemble through extensive contacts between the FIP200 scaffold subunit of ULK1C and the VPS15 pseudokinase subunit of PI3KC3-C1. The presence of PI3KC3-C1 induces a rearrangement of ULK1C from a FIP200:ATG13:ULK1 2:1:1 to a 2:2:2 stoichiometry by dislocating part of the ATG13 intrinsically disordered region (ATG13IDR) from an inhibitory site on the dimeric FIP200 scaffold. This suggests a structural mechanism for the initiation of autophagy through PI3KC3-C1-induced dimerization of ULK1 as bound to FIP200, followed by an activating trans-autophosphorylation of ULK1.</p>",Preprint,2023-06-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Chen, Minghao
Ren, Xuefeng
Nguyen, Thanh Ngoc
Khuu, Grace
Cook, Annan
Lazarou, Michael
Hurley, James",cc-by-4.0,,,,
134,7254686,2022-10-26T17:02:19.984345+00:00,10.5281/zenodo.7254686,Jensen_etal_2022_molecular_dynamics_simulation_data,"<p>Full molecular dynamics simulation data set accompanying Jensen et al, 2022, containing (i) representative coordinates and measurements described therein, (ii) simulation trajectories, and (iii) GROMACS input files.</p>",Dataset,2022-05-02 00:00:00,"personal
personal","Shanlin Rao
Gerhard Hummer",cc-by-4.0,W4393719472,A5028861095,Shanlin Rao,0000-0003-4892-5523
135,7254686,2022-10-26T17:02:19.984345+00:00,10.5281/zenodo.7254686,Jensen_etal_2022_molecular_dynamics_simulation_data,"<p>Full molecular dynamics simulation data set accompanying Jensen et al, 2022, containing (i) representative coordinates and measurements described therein, (ii) simulation trajectories, and (iii) GROMACS input files.</p>",Dataset,2022-05-02 00:00:00,"personal
personal","Shanlin Rao
Gerhard Hummer",cc-by-4.0,W4393719472,A5059945365,Gerhard Hummer,0000-0001-7768-746X
136,7882382,2023-05-01T04:54:03.630622+00:00,10.5281/zenodo.7882382,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 3 - Neurite outgrowth dataset. Comparing neurite outgrowth at Day1 and 15 post-seeding cortical neural progenitors.&nbsp;</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal","Gautam Wali
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4393803522,A5022317877,Gautam Wali,0000-0003-2961-3954
137,7882382,2023-05-01T04:54:03.630622+00:00,10.5281/zenodo.7882382,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 3 - Neurite outgrowth dataset. Comparing neurite outgrowth at Day1 and 15 post-seeding cortical neural progenitors.&nbsp;</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal","Gautam Wali
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4393803522,A5005036101,Dad Abu-Bonsrah,0000-0002-2687-3526
138,7882382,2023-05-01T04:54:03.630622+00:00,10.5281/zenodo.7882382,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 3 - Neurite outgrowth dataset. Comparing neurite outgrowth at Day1 and 15 post-seeding cortical neural progenitors.&nbsp;</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal","Gautam Wali
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4393803522,A5083016310,Deniz Kirik,0000-0002-1360-1265
139,7882382,2023-05-01T04:54:03.630622+00:00,10.5281/zenodo.7882382,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 3 - Neurite outgrowth dataset. Comparing neurite outgrowth at Day1 and 15 post-seeding cortical neural progenitors.&nbsp;</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal","Gautam Wali
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4393803522,A5044118193,Clare L. Parish,0000-0001-8212-9884
140,7882382,2023-05-01T04:54:03.630622+00:00,10.5281/zenodo.7882382,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 3 - Neurite outgrowth dataset. Comparing neurite outgrowth at Day1 and 15 post-seeding cortical neural progenitors.&nbsp;</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal","Gautam Wali
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4393803522,A5045037139,Carolyn M. Sue,0000-0003-1255-3617
141,10268773,2023-12-06T02:56:24.721935+00:00,10.5281/zenodo.10268773,Nigrostriatal Tau Pathology in parkinsonism and Parkinson's disease,,Dataset,2023-12-05 00:00:00,"personal
personal
personal","Scott Muller
Yaping Chu
Jeffrey Kordower",cc-by-4.0,W4393757336,A5086806840,Scott Muller,0000-0002-5379-1331
142,10268773,2023-12-06T02:56:24.721935+00:00,10.5281/zenodo.10268773,Nigrostriatal Tau Pathology in parkinsonism and Parkinson's disease,,Dataset,2023-12-05 00:00:00,"personal
personal
personal","Scott Muller
Yaping Chu
Jeffrey Kordower",cc-by-4.0,W4393757336,A5077753619,Yaping Chu,0000-0001-6573-9496
143,10268773,2023-12-06T02:56:24.721935+00:00,10.5281/zenodo.10268773,Nigrostriatal Tau Pathology in parkinsonism and Parkinson's disease,,Dataset,2023-12-05 00:00:00,"personal
personal
personal","Scott Muller
Yaping Chu
Jeffrey Kordower",cc-by-4.0,W4393757336,A5074765508,Jeffrey H. Kordower,0000-0001-8629-3294
144,10798584,2024-03-18T14:36:02.264400+00:00,10.5281/zenodo.10798584,Western Blot and Gel source data,,Image,2024-03-08 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
145,13332144,2024-10-09T15:56:11.254403+00:00,10.5281/zenodo.13332144,QC and WGS around the breakpoints of deletions in the compound heterozygous PRKN-deficient PD iPSC line FINi006-A (FI.CS.PRKNDex2/Dex5-7.@40),<p>BAM files from WGS on the regions of deletions in both <em>PRKN</em> gene alleles of the iPSC line (clone 18) derived using Sendai virus from PRKN 09/090 patient's fibroblasts&nbsp;&nbsp;</p>,Dataset,2024-08-16 00:00:00,"personal
personal
personal","Ovchinnikov, Dmitry
Jong, Sharon
Davis, Ryan",cc-by-4.0,,,,
146,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5046678361,Gregory P. Williams,0000-0001-9523-1781
147,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5052801583,Kaylin Muskat,
148,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5044515449,April Frazier,0000-0002-4722-7304
149,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5075915109,Yaqian Xu,0000-0001-5890-3446
150,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5063444034,José Mateus,0000-0002-1402-3452
151,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5083647614,Alba Grifoni,0000-0002-0369-1746
152,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5075614639,Ricardo da Silva Antunes,0000-0001-9785-5272
153,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5071431150,Daniela Weiskopf,0000-0003-2968-7371
154,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5067845430,Amy W. Amara,0000-0003-0762-9656
155,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5000374325,David G. Standaert,0000-0003-2921-8348
156,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535
157,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5006709022,Irene Litvan,0000-0002-3485-3445
158,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5037098776,Roy N. Alcalay,0000-0002-5717-4875
159,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5026787858,David Sulzer,0000-0001-7632-0439
160,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002
161,6426039,2022-04-08T20:02:03.202043+00:00,10.5281/zenodo.6426039,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS (2/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 2/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393784486,A5010966529,Alessandro Sette,0000-0001-7013-2250
162,5387892,2021-09-02T17:26:57.886602+00:00,10.5281/zenodo.5387892,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy Raw GUV Data,<p>Raw GUV data of fluorescent&nbsp;protein imaged on a&nbsp;Nikon A1 confocal microscope with a 63 &times; Plan 359 Apochromat 1.4 NA objective. Three biological replicates were performed for each experimental 360 condition. Identical laser power and gain settings were used during the course of all conditions.</p>,Dataset,2021-09-02 00:00:00,"personal
personal
personal","Chunmei Chang
Lisa Strong
James H Hurley",cc-by-4.0,W4393449518,A5002623700,Chunmei Chang,0000-0002-5607-7985
163,5387892,2021-09-02T17:26:57.886602+00:00,10.5281/zenodo.5387892,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy Raw GUV Data,<p>Raw GUV data of fluorescent&nbsp;protein imaged on a&nbsp;Nikon A1 confocal microscope with a 63 &times; Plan 359 Apochromat 1.4 NA objective. Three biological replicates were performed for each experimental 360 condition. Identical laser power and gain settings were used during the course of all conditions.</p>,Dataset,2021-09-02 00:00:00,"personal
personal
personal","Chunmei Chang
Lisa Strong
James H Hurley",cc-by-4.0,W4393449518,A5071900726,Lisa Strong,0000-0002-4293-8131
164,5387892,2021-09-02T17:26:57.886602+00:00,10.5281/zenodo.5387892,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy Raw GUV Data,<p>Raw GUV data of fluorescent&nbsp;protein imaged on a&nbsp;Nikon A1 confocal microscope with a 63 &times; Plan 359 Apochromat 1.4 NA objective. Three biological replicates were performed for each experimental 360 condition. Identical laser power and gain settings were used during the course of all conditions.</p>,Dataset,2021-09-02 00:00:00,"personal
personal
personal","Chunmei Chang
Lisa Strong
James H Hurley",cc-by-4.0,W4393449518,A5061450716,James H. Hurley,0000-0001-5054-5445
165,7153493,2022-10-06T16:25:14.690619+00:00,10.5281/zenodo.7153493,Script for the spike numbers in LRRK2 KI mice,"<p>The script determines the number of spikes for each current injected step in the manuscript titled <strong>R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations by Xenias et al</strong>. In addition, various parameters such as the threshold, maximum firing, rheobase, dy/dt, and FWHM are determined.</p>",Software,2022-10-06 00:00:00,personal,"Harry Xenias, Savio Chan, Loukia Parisiadou",cc-by-4.0,,,,
166,8017385,2023-06-08T12:06:06.581415+00:00,10.5281/zenodo.8017385,Genome-wide determinants of mortality and clinical progression in Parkinson's disease - Summary statistics,<p>Summary statistics from &quot;Genome-wide determinants of mortality and clinical progression in Parkinson&rsquo;s disease&quot;.</p>,Dataset,2022-07-10 00:00:00,"personal
personal","Tan, Manuela
Morris, Huw",cc-by-4.0,W4393731976,A5046721666,Manuela Tan,0000-0001-5835-669X
167,8017385,2023-06-08T12:06:06.581415+00:00,10.5281/zenodo.8017385,Genome-wide determinants of mortality and clinical progression in Parkinson's disease - Summary statistics,<p>Summary statistics from &quot;Genome-wide determinants of mortality and clinical progression in Parkinson&rsquo;s disease&quot;.</p>,Dataset,2022-07-10 00:00:00,"personal
personal","Tan, Manuela
Morris, Huw",cc-by-4.0,W4393731976,A5082416184,Huw R. Morris,0000-0002-5473-3774
168,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5054612290,Mai-Anh Vu,0000-0003-4766-1159
169,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5103158780,Eleanor Brown,0000-0001-9564-9213
170,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5093284830,Christian A. Noggle,0009-0003-0225-3677
171,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5101797192,Zicheng Zhang,0000-0002-7247-7938
172,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5004348674,Kevin J. Monk,0000-0003-2055-2614
173,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5085666638,Safa Bouabid,0000-0003-4184-3795
174,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5020594160,Ian G. Davison,0000-0003-0998-7676
175,10473960,2024-01-09T12:20:17.734017+00:00,10.5281/zenodo.10473960,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior: resources and main figure data","<p><strong>Summary:</strong></p>
<p>Neural population dynamics relevant for behavior vary over multiple spatial and temporal scales across 3-dimensional volumes. Current optical approaches lack the spatial coverage and resolution necessary to measure and manipulate naturally occurring patterns of large-scale, distributed dynamics within and across deep brain regions such as the striatum. We designed a new micro-fiber array approach capable of chronically measuring and optogenetically manipulating local dynamics across over 100 targeted locations simultaneously in head-fixed and freely moving mice. We developed a semi-automated micro-CT based strategy to precisely localize positions of each optical fiber. This highly-customizable approach enables investigation of multi-scale spatial and temporal patterns of cell-type and neurotransmitter specific signals over arbitrary 3-D volumes at a spatial resolution and coverage previously inaccessible. We applied this method to resolve rapid dopamine release dynamics across the striatum volume which revealed distinct, modality specific spatiotemporal patterns in response to salient sensory stimuli extending over millimeters of tissue. Targeted optogenetics through our fiber arrays enabled flexible control of neural signaling on multiple spatial scales, better matching endogenous signaling patterns, and spatial localization of behavioral function across large circuits.&nbsp;</p>
<p><strong>Files included:&nbsp;</strong></p>
<ul>
<li>Vu, M-A. et al. (2023) - Key Resources Table.xlsx -- key resources used in this study</li>
<li>README_figure_data_and_analysis.txt --a description of the organization of the files within this repository</li>
<li>README_preprocessing_code.txt -- details about the preprocessing pipeline (including registration and localization pipelines) and annotation of the preprocessed data structure</li>
<li>preprocessing_code.zip -- contains all the preprocessing code</li>
<li>Fig01.zip -- preprocessed data and analysis code for main Figure 1</li>
<li>Fig03.zip -- preprocessed&nbsp;data and analysis code for main Figure 3</li>
<li>Fig04.zip -- preprocessed&nbsp;data and analysis code for main Figure 4</li>
<li>Fig05.zip -- preprocessed&nbsp;data and analysis code for main Figure 5</li>
<li>Fig06.zip -- preprocessed&nbsp;data and analysis code for main Figure 6</li>
<li>Fig07.zip -- preprocessed&nbsp;data and analysis code for main Figure 7</li>
<li>SuppFig01.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 1</li>
<li>SuppFig02.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 2</li>
<li>SuppFig03.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 3</li>
<li>SuppFig04.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 4</li>
<li>SuppFig05.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 5</li>
<li>SuppFig06.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 6</li>
<li>SuppFig07.zip -- preprocessed&nbsp;data and analysis code for supplemental Figure 7</li>
</ul>
<p>Each .zip file contains a folder corresponding to a figure. &nbsp;Within each figure folder will be a folder corresponding to the letter (e.g., A, B, C) of the panel within the figure. In addition to the panel folders, when applicable, there may also be a folder containing general-use functions or scripts, or interim results .mat files, that are called by the scripts within the subfolders. In each subfolder there will be 3 things:</p>
<ol>
<li>a folder of preprocessed data (see README_preprocessing_code.txt)</li>
<li>a folder of the analysis scripts that analyzed the preprocessed data and generated the figure</li>
<li>a README text file detailing the contents of both folders and the analysis workflow.</li>
</ol>
<p>&nbsp;</p>",Dataset,2024-01-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Vu, Mai-Anh
Brown, Eleanor
Noggle, Christian
Zhang, Zicheng
Monk, Kevin
Bouabid, Safa
Davison, Ian
Howe, Mark",cc-by-4.0,W4393783195,A5003078833,Mark W. Howe,0000-0002-6865-5084
176,10819073,2024-05-09T18:04:11.699586+00:00,10.5281/zenodo.10819073,Photometry Data Analysis for Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,<p>A set of Matlab files to analyze photometry data. These files were developed in the lab of Anatol Kreitzer at UCSF and shared with the community by Didi Mamaligas.</p>,Software,2024-03-14 00:00:00,"personal
personal","Kreitzer, Anatol
Mamaligas, Aphroditi",cc-by-4.0,,,,
177,11153955,2024-05-22T16:04:36.328410+00:00,10.5281/zenodo.11153955,"Tabular datasets for for Morrone Parfitt, G., Coccia, E., Goldman, C. et al. Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson's disease model. Nat Commun 15, 447 (2024). https://doi.org/10.1038/s41467-024-44732-2",,Dataset,2024-05-08 00:00:00,"personal
personal","Morrone Barbat Parfitt, Gustavo
Blanchard, Joel",cc-by-4.0,,,,
178,7871982,2023-04-27T19:12:49.695408+00:00,10.5281/zenodo.7871982,Azcorra2023 - Fiber photometry recordings (pre-processed to get DF/F),"<p>Pre-processed raw data from fiber photometry recordings of different subtypes (Vglut2+, Calb1+, Anxa1+ and Aldh1a1+ as well as&nbsp;DAT+) SNc dopamine neurons labelled with GCaMP6f, as used in Azcorra et al. Nat Neuro 2023. This dataset has been pre-processed to calculate DF/F from the raw data (see below for code and raw data), which are then normalized from 0 to 1 (un-normalized DF/F data can be recovered using the &#39;norm&#39; value included in the dataset).&nbsp;This dataset also includes metadata for each recording&nbsp;(recording location, mouse sex...).&nbsp;</p>

<p>The code used to generate this pre-processed data from raw data is available on GitHub (<a href=""https://github.com/DombeckLab/Azcorra2023/releases/tag/Azcorra2023"">https://github.com/DombeckLab/Azcorra2023/releases/tag/Azcorra2023</a>) and Zenodo (DOI: 10.5281/zenodo.7872052, <a href=""https://zenodo.org/record/7872052"">https://zenodo.org/record/7872052</a>). The original raw data has been deposited on Zenodo (DOI:&nbsp;10.5281/zenodo.7871634,&nbsp;<a href=""https://zenodo.org/record/7871634"">https://zenodo.org/record/7871634</a>).&nbsp;The code necessary to analyze this data and generate the figures shown in the manuscript is is found in that same GitHub repository as the pre-processing code above.</p>",Dataset,2023-04-27 00:00:00,personal,"Azcorra, Maite",cc-by-4.0,W4393725102,A5053163008,Maite Azcorra,0000-0002-2919-3825
179,10896364,2024-03-30T03:32:54.347106+00:00,10.5281/zenodo.10896364,Figure 7. Pacer expression promotes formation of WIPI2 puncta upon depolarization [FINAL],,Dataset,2023-03-29 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
180,8139563,2023-07-12T15:04:35.357972+00:00,10.5281/zenodo.8139563,AMCalejandro/LID-CPH: V3 Release,<p>New release after update on post meta-analysis QC steps</p>,Software,2023-07-12 00:00:00,personal,Alejandro Martinez,other-open,,,,
181,13381067,2024-08-27T17:39:09.786555+00:00,10.5281/zenodo.13381067,"Code related to manuscript: Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of a-synuclein inclusions","<p>Code for plotting graphs within Figure panels in Lam, Ndayisaba et al 2024.</p>
<p>Key Resources Table and tabular data can be found at: doi:10.5281/zenodo.12549027</p>
<p>&nbsp;</p>",Computational notebook,2024-08-27 00:00:00,"personal
personal
personal","Lam, Isabel
Ndayisaba, Alain
Khurana, Vikram",cc-by-4.0,,,,
182,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5066628008,Felix Kraus,0000-0002-3757-541X
183,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5042803666,Ellen A. Goodall,0000-0001-9876-5973
184,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5035241621,Ian R. Smith,0000-0002-4966-9333
185,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5054007595,Yizhi Jiang,0000-0001-9016-1104
186,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5023479457,Julia C. Paoli,0000-0001-8266-1766
187,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5111159974,Frank Adolf,
188,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5000219280,Jiuchun Zhang,
189,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5026734370,João A. Paulo,0000-0002-4291-413X
190,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5023564164,Brenda A. Schulman,0000-0002-3083-1126
191,7803294,2023-04-05T19:41:58.861004+00:00,10.5281/zenodo.7803294,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,"<p>The protein kinase PINK1 and ubiquitin ligase Parkin promote removal of damaged mitochondria via a feed-forward mechanism involving ubiquitin (Ub) phosphorylation, Parkin activation, and ubiquitylation of mitochondrial outer membrane proteins to support recruitment of mitophagy receptors. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early-onset parkinsonian-pyramidal syndrome. Previous studies have proposed a role for FBXO7 in promoting Parkin-dependent mitophagy. Here, we systematically examine the involvement of FBXO7 in depolarization-dependent mitophagy in the well-established HeLa and induced-neurons cell systems. We find that FBXO7<sup>-/-</sup> cells have no demonstrable defect in: 1) kinetics of pUb accumulation, 2) pUb puncta on mitochondria by super-resolution imaging, 3) recruitment of Parkin and autophagy machinery to damaged mitochondria, 4) mitophagic flux, and 5) mitochondrial clearance as quantified by global proteomics. Moreover, global proteomics of neurogenesis in the absence of FBXO7 reveals no obvious alterations in mitochondria or other organelles. These results argue against a general role for FBXO7 in Parkin-dependent mitophagy and point to the need for additional studies to define how FBXO7 mutations promote parkinsonian-pyramidal syndrome. &nbsp;&nbsp;</p>",Dataset,2022-10-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Kraus, Felix
Goodall, Ellen A.
Smith, Ian R.
Jiang, Yizhi
Paoli, Julia C.
Adolf, Frank
Zhang, Jiuchun
Paulo, Joao A.
Schulman, Brenda A.
Harper, J. Wade",cc-by-4.0,W4393670743,A5047746208,J. Wade Harper,0000-0002-6944-7236
192,10456840,2024-01-11T15:23:31.066078+00:00,10.5281/zenodo.10456840,Macaque Stereotax,,Dataset,2024-01-03 00:00:00,organizational,University of Pittsburgh,cc-by-4.0,W4393832164,A5094337852,University of Pittsburgh,
193,11519152,2024-07-09T16:22:29.551376+00:00,10.5281/zenodo.11519152,Endogenous LRRK2 and PINK1 function in parallel signalling pathways regulating ciliogenesis in the brain in vivo,<p>Raw data for Figure 5</p>,Dataset,2024-06-07 00:00:00,personal,"Bagnoli, Enrico",cc-by-4.0,,,,
194,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5054743790,Miguel R. Chuapoco,0000-0001-5397-996X
195,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5038007344,Nicholas C. Flytzanis,0000-0002-7921-9392
196,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5039431916,Nick Goeden,
197,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5028809809,J. Christopher Octeau,0000-0001-6462-9439
198,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5077285514,Kristina M. Roxas,0009-0004-7462-0154
199,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5068542583,Ken Y. Chan,0000-0002-8853-5186
200,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5036676609,J Scherrer,0009-0008-8040-4860
201,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5018958986,Janet Winchester,
202,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5033121696,Roy J. Blackburn,
203,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5057677268,Lillian Campos,0000-0003-0839-0288
204,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5068243350,Kwun Nok Mimi Man,0000-0002-0132-9129
205,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5076380977,Junqing Sun,
206,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5103159490,Xinhong Chen,0000-0003-0408-0813
207,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5065342764,Arthur Lefèvre,0000-0003-2847-0859
208,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5107946983,Vikram Pal Singh,0000-0002-1593-9796
209,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5044178593,Cynthia M. Arokiaraj,0000-0003-3201-9868
210,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5017919522,Timothy F. Shay,0000-0001-6591-3271
211,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5018653405,Julia Vendemiatti,0000-0002-6547-9601
212,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5029757025,Min Jee Jang,0000-0002-1536-7177
213,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5053088872,John K. Mich,0000-0002-1626-1139
214,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5056483082,Yeme Bishaw,
215,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5061805152,Bryan B. Gore,0000-0003-1721-4235
216,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5080318812,Victoria Omstead,0000-0002-3796-970X
217,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5006766567,Naz Taskin,0009-0003-2417-8428
218,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5008277955,Natalie Weed,0000-0003-0891-0327
219,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5013070422,Jonathan T. Ting,0000-0001-8266-0392
220,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5081532552,Cory T. Miller,0000-0001-8345-2720
221,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5014515859,Benjamin E. Deverman,0000-0002-6223-9303
222,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5053346018,James Pickel,0000-0002-3617-3072
223,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5080490976,Lin Tian,0000-0001-7012-6926
224,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5101580701,Andrew S. Fox,0000-0003-0695-3323
225,8381383,2023-09-26T21:42:49.381217+00:00,10.5281/zenodo.8381383,Next-generation sequencing of AAV.CAP-Mac from Chuapoco et al. (2023) Nature Nanotechnology,"<p>Dataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication:</p>

<p>Chuapoco, M.R., Flytzanis, N.C., Goeden, N.&nbsp;<em>et al.</em>&nbsp;Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.&nbsp;<em>Nat. Nanotechnol.</em>&nbsp;(2023). https://doi.org/10.1038/s41565-023-01419-x</p>",Dataset,2023-09-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Chuapoco, Miguel R.
Flytzanis, Nicholas C.
Goeden, Nick
Octeau, J. Christopher
Roxas, Kristina M.
Chan, Ken Y.
Scherrer, Jon
Winchester, Janet
Blackburn, Roy J.
Campos, Lillian J.
Man, Kwun Nok Mimi
Sun, Junqing
Chen, Xinhong
Lefevre, Arthur
Singh, Vikram Pal
Arokiaraj, Cynthia M.
Shay, Timothy F.
Vendemiatti, Julia
Jang, Min J.
Mich, John
Bishaw, Yeme
Gore, Bryan
Omstead, Victoria
Taskin, Naz
Weed, Natalie
Ting, Jonathan
Miller, Cory T.
Deverman, Benjamin E.
Pickel, James
Tian, Lin
Fox, Andrew S.
Gradinaru, Viviana",cc-by-4.0,W4393500898,A5050240445,Viviana Gradinaru,0000-0001-5868-348X
226,13251243,2024-08-07T02:40:02.533221+00:00,10.5281/zenodo.13251243,Data from: Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p>
<p><span>Fig. 1 Mouse &alpha;-syn fibrils are structurally similar to human E46K-mutated and MSA-amplified &alpha;-syn fibrils</span></p>
<p><span>Chemical structure and binding curves of ThT (J), Nile Red (K), and FSB (L) to mouse and human sonicated &alpha;-syn fibrils (average radii: 16.68&plusmn;1.44 nm and 15.14&plusmn;4.02 nm, respectively). Data points indicate means from three independent experiments and error bars are S.E.M.&nbsp; ****p&lt;0.0001 and ***p&lt;0.01 from 2-tailed t-tests. </span></p>
<p><span>Fig. 2 Distinct &beta;-fold stacking arrangements in mouse &alpha;-syn fibrils contribute to low tensile strength and resilience</span></p>
<p><span>(C) Representation of proposed model of fibril fragmentation for tensile strength estimation used to simulate the MMGBSA energy of &alpha;-syn fibrils rupture and group analysis of MMGBSA energy required to disrupt a stack of six rungs. Error bars represent S.D. from 100 independent simulations. (D) Group comparison of fibril breakage under sonication conditions shown as the percent of size population of 10-100 nm (e.g., short fibrils) at 0, 2, and 30 minutes, measured by DLS. Error bars indicate S.E.M of three independent experiments with 30 acquisition measurements corresponding to each experiment. (E) Filter-trap slot-blot analysis of sonicated fibrils (i.e., PFFs) exposed to different concentrations of guanidinium chloride (GuHCl), and then remaining fibrils detected with the fibril-selective antibody MJFR14-6-4-2. Error bars indicate S.E.M from three independent experiments. (F) DLS analysis of PFFs after incubation with GuHCL. Error bars indicate S.E.M of three independent experiments with 10 acquisition measurements for each biological sample. Curves in (E) and (F) show asymmetric sigmoidal models with a goodness of fit &gt;0.96, and&nbsp; **p&lt;0.01, **p&lt;0.001, ****p &lt; 0.0001 from unpaired 2-tailed t-tests.</span></p>
<p><br><br></p>
<p><span>Fig. 3 Mouse &alpha;-syn fibrils fail to elicit robust cytokine and lysosome damage in macrophages </span></p>
<p><span>(B) Internalized Alexa-647-PFFs (%area) inside cells and (C) % of LAMP1-positive vesicles positive for PFFs. Each data point represents the means of cells analyzed from at least eight images from three independent experiments. (D) ELISA analysis of the extracellular IL-6 and (E) CCL5 from MDM cultures treated with PFFs (1 &mu;g/mL) for 3 and 24 hours. Each data point represents the mean from two technical replicates from four independent experiments. (F) % of Gal3-positive vesicles calculated per mm&sup2; of cell surface area in PFF-treated MDM cultures after 24 hours of incubation and (G) % of Gal3-positive vesicles also positive for DQ-PFFs after 48 hours of PFF incubation. Data points show the mean values from cells imaged across three independent experiments with at least eight images analyzed per group. (H) Representative images of Gal3 immunostaining after 24-hours treatment with Alexa-647- or DQ- labeled PFFs. Orthogonal views of sequential z-stacks are shown. Side left image = x,y plane, side right image = y,z plane; top image = x,z plane. Scale bar is 5 um. Error bars represent S.E.M and&nbsp; ***p&lt;0.001, *p&lt;0.05 and ns for not significant from unpaired 2-tailed t-tests (panels B, C, F, G) or from Tukey&rsquo;s post-hoc test after ANOVA (panels D,E). </span></p>
<p><span>Fig. 4. Mouse and human &alpha;-syn fibril uptake in neurons is similar and clathrin-dependent</span></p>
<p><span>(A) Time-dependent dynamics of pHrodo-labeled mouse or human PFF (1 &micro;g/mL) internalization over 24 hours into human-PAC-wt-SNCA<sup>+/+</sup>/Snca<sup>-/- </sup>hippocampal primary neuronal cultures at DIV7, with normalized pHrodo-channel intensity to DAPI counts at the indicated time point. Each dot represents mean values from four images each from three independent neuronal cultures.&nbsp;</span><span>(D)&nbsp; Alexa-568 intensity in dopaminergic neurons and (E) intensity exclusively in the perinuclear area 8 hours post PFF incubation. Each dot represents the mean value of one image with at least 20 images collected from three independent experiments. (F) Calculated uptake of pHrodo-labeled &alpha;-syn PFFs at 24 hours in the presence of endocytosis inhibitors with signals normalized to vehicle only controls. Each dot in panel F represents the mean value of four images evaluated per condition from three independent experiments. Error bars for each group analysis represent S.E.M., and ns is not-significant from 2-tailed t tests.</span></p>
<p><span>Fig. 5. Mouse &alpha;-syn fibrils pathology propagation is more efficient than human &alpha;-syn in primary neurons.&nbsp;</span></p>
<p><span>(A) Levels of pS129-&alpha;-syn signal assessed relative to the number of neurons in the corresponding cultures cultured from human-PAC-wt-SNCA<sup>+/+</sup>/Snca<sup>-/- </sup>hippocampal primary neuron culture treated with 1 &micro;g/mL of &alpha;-syn PFFs for 14 days, or equivalent amounts of monomer as indicated, and stained against pS129-&alpha;-syn, Tau and NeuN. (B) To ensure the specificity of pS129-&alpha;-syn signals, control groups show the lack of signal in neurons cultured from Snca<sup>-/- </sup>mice following 14 days of incubation with &alpha;-syn PFFs or monomer as shown.&nbsp;(D) Abundance of distinct pS129-&alpha;-syn signals in cell bodies or neuritic morphology in neuronal cells treated with 1 &micro;g/mL of mouse or human &alpha;-syn PFFs. (E) Proportion of pS129-&alpha;-syn occupancy in cell body and neurites in primary hippocampal cultures incubated with mouse or human &alpha;-syn PFFs for 14 days. (F) ELISA quantification of &alpha;-syn aggregate levels in cell lysates from human-PAC-wt-SNCA<sup>+/+</sup>/Snca<sup>-/- </sup>&nbsp;or Snca<sup>-/- </sup>neuronal cultures treated with fibril PFFs or monomeric protein for 14 days. (G) Group analysis of NeuN-positive nuclei abundance normalized to DAPI count. Each data point in a group in the graphs represents the mean of signal from an individual litter with two technical replicates per litter and at least 25 images analyzed for each replicate, with error bars indicating S.E.M. Significance was determined by 2-tailed t-tests; **p&lt;0.001, ****p &lt; 0.0001, ns for not significant.</span></p>
<p><span>Fig. 6. Mouse PFF induced &alpha;-syn pathology spreads through the mouse brain to seed human &alpha;-syn pathology more efficiently than human &alpha;-syn PFFs</span></p>
<p><span>(B) Group analysis of &alpha;-syn pathology propagation ratio to contralateral side in piriform cortex, (C) thalamus, and (D) dorsal striatum, quantified as proportion of pSyn neuronal inclusion spread between Ipsi and Contr. areas. (E) Analysis of pS129-&alpha;-syn pathology near the injection site within the ipsilateral dorsal striatum. Each data point (n=5 per group) in group analysis plots represents the mean of the signal from 20-25 sections from an individual animal, and error bars indicate S.E.M. Significance was determined by 2-tailed t-tests; *p&lt;0.05, ns for not significant</span>.</p>
<p><span>Fig. 7. Recruitment of human &alpha;-syn monomer into mouse PFFs leads to the generation of mouse-like fibrils.</span></p>
<p><span>(A) Representative aggregation assays showing mouse and human PFF-templated aggregation with human &alpha;-syn monomer, with (B) the calculated lag phase. Data points represent normalized ThT fluorescence from three independent experiments with error bars indicating S.E.M. (C) Representative filter-trap slot-blot membranes stained with MJFR14-6-4-2 &alpha;-syn aggregate-specific antibodies for the detection of aggregated &alpha;-syn in corroboration of aggregation kinetics without amyloid dyes.&nbsp;</span><span>&nbsp;(E) Group analysis of ThT binding (fluorescence units, F.U.) from chimeric or homogenous-sequence extracted, monomer-free, sonicated &alpha;-syn fibril (PFF) products, as well as (F) Nile Red binding. Each data point in panels E and F represents a mean from an individual experiment measured in duplicate with three independent experiments.E<a name=""_Hlk173655145""></a>rror bars indicate S.E.M.,&nbsp; **p&lt;0.01, from a 2-tailed t-test, and ***p&lt;0.001 from Tukey&rsquo;s post-hoc test after ANOVA. </span></p>
<p>fig. S2. High resolution estimation of the cryo-EM map of mouse and human recombinant &alpha;-syn fibrils</p>
<p>Fourier shell correlation (FSC) resolution estimation and validation for the 3D reconstruction of the cryo-EM collected images of procured&nbsp; mouse fibrils generated by Duke (a) and EPFL (b) research groups. (c) FSC estimation plot of human &alpha;-syn fibrils collected and generated at Duke University.</p>
<p>&nbsp;</p>
<p>fig. S7. Generation and validation of mouse and human &alpha;-syn PFFs</p>
<p>(c) Group analysis of the size population proportions of sonicated mouse and human &alpha;-syn preparations, (e) representative average radii of human &alpha;-syn,(f) UV absorbance spectra and (g) coefficient extinction adjusted concentration. Each data point or S.E.M in panel c, e and g are extracted from a single acquisition from three independent experiments with ten measurements analyzed per group. Each dot in panel f is the mean of two technical replicates from three independent batches. Significance was assessed via 2-tailed t-tests with ns for not significant.</p>
<p>&nbsp;</p>
<p>fig. S9. Mouse &alpha;-syn PFFs are highly susceptible to sarkosyl denaturation.</p>
<p>(a) Filter-trap slot-blot analysis of sonicated fibrils (PFFs) exposed to different concentrations of sarkosyl (left) and the remaining fibrils detected with the fibril-selective antibody MJFR14-6-4-2 in a dose-response curve (middle), with group analysis between two PFF variants at 1% Sarkosyl compared (right). Error bars indicate S.E.M from three independent experiments. (b) DLS analysis of sonicated fibrils (PFFs) exposed to sarkosyl concentrations in a dose-response curve. Error bars indicate S.E.M of three independent experiments with 10 acquisition measurements for each biological sample.&nbsp; *p&lt;0.05 from unpaired 2-tailed t-tests.</p>
<p>&nbsp;</p>
<p>fig. S11. Evaluation of &alpha;-syn aggregation ELISA using control recombinant mouse and human &alpha;-syn fibril PFFs.</p>
<p>Standard curves generated from mouse and human PFFs in a pan-&alpha;-syn aggregate-specific ELISA. The ELISA approach was utilized to quantify the level of aggregates present in lysates derived from the neuronal cultures. The standard curve, along with the indicated goodness of fit and corresponding r&sup2; values, provides reliable measures at physiological ranges. Each data point represents the mean from three technical replicates from two independent experiments with errors bars indicating S.E.M.</p>
<p>&nbsp;</p>
<p>fig. S9. Evaluation of &alpha;-syn ELISA using control recombinant mouse and human &alpha;-syn fibril PFFs</p>
<p>Standard curve generated from mouse and human PFFs in a pan-&alpha;-syn aggregate ELISA. The ELISA was utilized to quantify the level of aggregates present in the cell lysates. The standard curve, along with the indicated goodness of fit and corresponding r&sup2; values, provides a reliable measure for interpreting the results. Each data point represents the mean from three technical replicates from two independent experiments with errors bars indicating S.E.M.</p>
<p>&nbsp;</p>
<p>fig. S12. Elevated p-S129-&alpha;-syn levels in iPSC-derived dopaminergic neurons following treatment with mouse &alpha;-syn PFFs</p>
<p>(b) Levels of pS129-&alpha;-syn in the &beta;-III-tubulin area in iPSC-derived DA neurons after 7 days of treatment with 10 &mu;g/mL of PFFs or control. (c) The quantity of pS129-&alpha;-syn puncta relative to the &beta;-III-tubulin area measured in each image and compared across conditions. (d) Proportion of abundance of pS129-&alpha;-syn puncta localized in cell bodies and neurites in group analysis between mouse and human &alpha;-syn PFF treatments. Each data point in c and d represent the mean value of the images from one well (n=4) and errors bars indicate S.E.M with **p&lt;0.01 from 2-tailed t-tests.&nbsp;</p>
<p>&nbsp;</p>
<p>fig. S13. Evaluation of kinetic properties in aggregation assays with cross-seeded chimeric fibrils show that the chimeric fibrils largely replicate the functional properties of their parental seeds, despite different amino acid sequences between the fibril preparations.</p>
<p>(a) Representative RT-QuIC (real-time quaking induced)&nbsp; assays of normalized relative fluorescence values (RFUs) with mouse monomer templating on different PFF seeds in the creation of new fibrils. The lack of formation of spontaneous fibrils (gray color, no PFFs added &ldquo;no template&rdquo;) indicate that spontaneous aggregation is not occurring under the given aggregation conditions within the specified timeframes. Line graphs show corresponding lag in amplification (in hours, or time to initial fluorescence threshold) of the different reactions combined with different PFF concentrations added and analyzed to a linear regression model. Data points represent normalized ThT fluorescence to their maximal fluorescence in the individual reactions, accounting for differential ThT binding to different fibril structures. (b) Comparable reactions as above but with human instead of mouse monomer templating with the indicated PFF seed. &nbsp;</p>
<p>&nbsp;</p>",Dataset,2024-08-06 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Sokratian, Arpine
West, Andrew
Zhou, Ye
Tatli, Meltem
Burbidge, Kevin J.
Perera, Lalith
Lashuel, Hilal
Bartesaghi, Alberto
Borgnia, Mario",cc-by-4.0,,,,
227,10714316,2024-02-27T02:43:16.825693+00:00,10.5281/zenodo.10714316,RAB3 phosphorylation by pathogenic LRRK2 impairs  trafficking of synaptic vesicle precursors,"<p>Gain-of-function mutations in the <em>LRRK2 </em>gene cause Parkinson&rsquo;s disease (PD), characterized by debilitating motor and non-motor symptoms. Increased phosphorylation of a subset of RAB GTPases by LRRK2 is implicated in PD pathogenesis. We find that increased phosphorylation of RAB3A, a cardinal synaptic vesicle precursor (SVP) protein, disrupts anterograde axonal transport of SVPs in iPSC-derived human neurons (iNeurons) expressing hyperactive <em>LRRK2</em>-p.R1441H. Knockout of the opposing protein phosphatase 1H (<em>PPM1H</em>) in iNeurons phenocopies this effect. In these models, the compartmental distribution of synaptic proteins is altered; synaptophysin and synaptobrevin-2 become sequestered in the neuronal soma with decreased delivery to presynaptic sites along the axon. We find that RAB3A phosphorylation disrupts binding to the motor adapter MADD, potentially preventing formation of the RAB3A-MADD-KIF1A/1B&beta; complex driving anterograde SVP transport. RAB3A hyperphosphorylation also disrupts interactions with RAB3GAP and RAB-GDI1. Our results reveal a mechanism by which pathogenic hyperactive LRRK2 may contribute to the altered synaptic homeostasis associated with characteristic non-motor and cognitive manifestations of PD.</p>",Journal article,2024,"personal
personal
personal","Dou, Dan
Aiken, Jayne
Holzbaur, Erika L.F.",cc-by-4.0,,,,
228,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5034575260,Reem Abdel-Haq,0000-0002-7418-5736
229,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513
230,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5017206227,Johannes C. M. Schlachetzki,0000-0002-7801-9743
231,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5082378291,Joseph C. Boktor,0000-0003-2456-1913
232,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5014061199,Thaisa M. Cantu-Jungles,0000-0001-8928-9717
233,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5064324943,Taren Thron,0000-0001-9577-2617
234,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5103166723,Mengying Zhang,0000-0003-0674-9437
235,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5025238358,John W. Bostick,0000-0001-8925-2447
236,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5023642382,Tahmineh Khazaei,0000-0002-4743-2383
237,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5008275014,Sujatha Chilakala,0000-0003-1581-3381
238,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5027763981,Lívia H. Morais,0000-0002-5738-2658
239,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5087126302,Greg Humphrey,
240,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5002619544,Ali Keshavarzian,0000-0002-7969-3369
241,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5089760163,Bruce R. Hamaker,0000-0001-6591-942X
242,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5022615394,Jonathan E. Katz,0000-0001-8175-790X
243,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5014506392,Matt Thomson,0000-0003-1021-1234
244,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5033881627,Rob Knight,0000-0002-0975-9019
245,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5039839135,Christopher K. Glass,0000-0003-4344-3592
246,6377704,2022-06-28T19:17:11.761504+00:00,10.5281/zenodo.6377704,A prebiotic diet modulates microglia response and motor deficits in α-synuclein overexpressing mice,"<p>Parkinson&rsquo;s disease (PD) is a movement disorder characterized by neuroinflammation, &alpha;-&nbsp;synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in &alpha;-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces &alpha;-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for&nbsp;neuroinflammation and PD.</p>",Journal article,2022-07-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Reem Abdel-haq
Sarkis Mazmanian
Johannes C.M. Schlachetzki
Joseph C. Boktor
Thaisa M. Cantu-Jungles
Taren Thron
Mengying Zhang
John W. Bostick
Tahmineh Khazaei
Sujatha Chilakala
Livia H. Morais
Greg Humphrey
Ali Keshavarzian
Bruce R. Hamaker
Jonathan E. Katz
Matt Thomson
Rob Knight
Christopher K. Glass
Viviana Gradinaru",cc-by-4.0,W4283697908,A5050240445,Viviana Gradinaru,0000-0001-5868-348X
247,7871634,2023-04-28T17:47:01.720676+00:00,10.5281/zenodo.7871634,Azcorra2023 - Raw fiber photometry recordings,"<p>Raw data from fiber photometry recordings of different subtypes (Vglut2+, Calb1+, Anxa1+ and Aldh1a1+ as well as&nbsp;DAT+) SNc dopamine neurons labelled with GCaMP6f, as used in Azcorra et al. Nat Neuro 2023. Metadata for these recordings (recording location, mouse sex...) can be found in the pre-processed dataset (see below).</p>

<p>The code used to pre-processed this data to get DF/F&nbsp;is available on GitHub (<a href=""https://github.com/DombeckLab/Azcorra2023/releases/tag/Azcorra2023"">https://github.com/DombeckLab/Azcorra2023/releases/tag/Azcorra2023</a>) and Zenodo (DOI: 10.5281/zenodo.7872052, <a href=""https://zenodo.org/record/7872052"">https://zenodo.org/record/7872052</a>). We have also made the pre-processed data available on Zenodo (DOI: 10.5281/zenodo.7871982, <a href=""https://zenodo.org/record/7871982"">https://zenodo.org/record/7871982</a>). The code necessary to analyze this data and generate the figures shown in the manuscript is is found in that same GitHub repository as the pre-processing code above.</p>",Dataset,2023-04-27 00:00:00,personal,"Azcorra, Maite",cc-by-4.0,W4394049292,A5053163008,Maite Azcorra,0000-0002-2919-3825
248,6463635,2022-05-09T21:32:13.693633+00:00,10.5281/zenodo.6463635,Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules,"<p>This dataset&nbsp;includes all of the tabular data used in the figures in the article. Original article is available at:&nbsp;https://doi.org/10.1101/2022.01.21.477284</p>

<p>Leucine Rich Repeat Kinase 2 (<em>LRRK2</em>) is one of the most commonly mutated genes in familial Parkinson&rsquo;s Disease (PD). Under some circumstances, LRRK2 co-localizes with microtubules in cells, an association enhanced by PD mutations. We report a cryo-electron microscopy structure of the catalytic half of LRRK2, containing its kinase, which is in a closed conformation, and GTPase domains, bound to microtubules. We also report a structure of the catalytic half of LRRK1, which is closely related to LRRK2, but is not linked to PD. LRRK1&rsquo;s structure is similar to LRRK2, but LRRK1 does not interact with microtubules. Guided by these structures, we identify amino acids in LRRK2&rsquo;s GTPase domain that mediate microtubule binding; mutating them disrupts microtubule binding in vitro and in cells, without affecting LRRK2&rsquo;s kinase activity. Our results have implications for the design of therapeutic LRRK2 kinase inhibitors.</p>",Dataset,2022-01-22 00:00:00,"personal
personal
personal
personal
personal
personal","Snead, David M.
Matyszewski, Mariusz
Dickey, Andrea M.
Lin, Yu Xuan
Leschziner, Andres E.
Reck-Peterson, Samara L.",cc-by-4.0,W4393839564,A5021363544,David Snead,0000-0001-7839-452X
249,6463635,2022-05-09T21:32:13.693633+00:00,10.5281/zenodo.6463635,Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules,"<p>This dataset&nbsp;includes all of the tabular data used in the figures in the article. Original article is available at:&nbsp;https://doi.org/10.1101/2022.01.21.477284</p>

<p>Leucine Rich Repeat Kinase 2 (<em>LRRK2</em>) is one of the most commonly mutated genes in familial Parkinson&rsquo;s Disease (PD). Under some circumstances, LRRK2 co-localizes with microtubules in cells, an association enhanced by PD mutations. We report a cryo-electron microscopy structure of the catalytic half of LRRK2, containing its kinase, which is in a closed conformation, and GTPase domains, bound to microtubules. We also report a structure of the catalytic half of LRRK1, which is closely related to LRRK2, but is not linked to PD. LRRK1&rsquo;s structure is similar to LRRK2, but LRRK1 does not interact with microtubules. Guided by these structures, we identify amino acids in LRRK2&rsquo;s GTPase domain that mediate microtubule binding; mutating them disrupts microtubule binding in vitro and in cells, without affecting LRRK2&rsquo;s kinase activity. Our results have implications for the design of therapeutic LRRK2 kinase inhibitors.</p>",Dataset,2022-01-22 00:00:00,"personal
personal
personal
personal
personal
personal","Snead, David M.
Matyszewski, Mariusz
Dickey, Andrea M.
Lin, Yu Xuan
Leschziner, Andres E.
Reck-Peterson, Samara L.",cc-by-4.0,W4393839564,A5084097252,Mariusz Matyszewski,0000-0003-1033-9270
250,6463635,2022-05-09T21:32:13.693633+00:00,10.5281/zenodo.6463635,Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules,"<p>This dataset&nbsp;includes all of the tabular data used in the figures in the article. Original article is available at:&nbsp;https://doi.org/10.1101/2022.01.21.477284</p>

<p>Leucine Rich Repeat Kinase 2 (<em>LRRK2</em>) is one of the most commonly mutated genes in familial Parkinson&rsquo;s Disease (PD). Under some circumstances, LRRK2 co-localizes with microtubules in cells, an association enhanced by PD mutations. We report a cryo-electron microscopy structure of the catalytic half of LRRK2, containing its kinase, which is in a closed conformation, and GTPase domains, bound to microtubules. We also report a structure of the catalytic half of LRRK1, which is closely related to LRRK2, but is not linked to PD. LRRK1&rsquo;s structure is similar to LRRK2, but LRRK1 does not interact with microtubules. Guided by these structures, we identify amino acids in LRRK2&rsquo;s GTPase domain that mediate microtubule binding; mutating them disrupts microtubule binding in vitro and in cells, without affecting LRRK2&rsquo;s kinase activity. Our results have implications for the design of therapeutic LRRK2 kinase inhibitors.</p>",Dataset,2022-01-22 00:00:00,"personal
personal
personal
personal
personal
personal","Snead, David M.
Matyszewski, Mariusz
Dickey, Andrea M.
Lin, Yu Xuan
Leschziner, Andres E.
Reck-Peterson, Samara L.",cc-by-4.0,W4393839564,A5057238552,Andrea M. Dickey,0000-0001-8725-0982
251,6463635,2022-05-09T21:32:13.693633+00:00,10.5281/zenodo.6463635,Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules,"<p>This dataset&nbsp;includes all of the tabular data used in the figures in the article. Original article is available at:&nbsp;https://doi.org/10.1101/2022.01.21.477284</p>

<p>Leucine Rich Repeat Kinase 2 (<em>LRRK2</em>) is one of the most commonly mutated genes in familial Parkinson&rsquo;s Disease (PD). Under some circumstances, LRRK2 co-localizes with microtubules in cells, an association enhanced by PD mutations. We report a cryo-electron microscopy structure of the catalytic half of LRRK2, containing its kinase, which is in a closed conformation, and GTPase domains, bound to microtubules. We also report a structure of the catalytic half of LRRK1, which is closely related to LRRK2, but is not linked to PD. LRRK1&rsquo;s structure is similar to LRRK2, but LRRK1 does not interact with microtubules. Guided by these structures, we identify amino acids in LRRK2&rsquo;s GTPase domain that mediate microtubule binding; mutating them disrupts microtubule binding in vitro and in cells, without affecting LRRK2&rsquo;s kinase activity. Our results have implications for the design of therapeutic LRRK2 kinase inhibitors.</p>",Dataset,2022-01-22 00:00:00,"personal
personal
personal
personal
personal
personal","Snead, David M.
Matyszewski, Mariusz
Dickey, Andrea M.
Lin, Yu Xuan
Leschziner, Andres E.
Reck-Peterson, Samara L.",cc-by-4.0,W4393839564,A5044141143,Yu Xuan Lin,0000-0002-1016-4776
252,6463635,2022-05-09T21:32:13.693633+00:00,10.5281/zenodo.6463635,Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules,"<p>This dataset&nbsp;includes all of the tabular data used in the figures in the article. Original article is available at:&nbsp;https://doi.org/10.1101/2022.01.21.477284</p>

<p>Leucine Rich Repeat Kinase 2 (<em>LRRK2</em>) is one of the most commonly mutated genes in familial Parkinson&rsquo;s Disease (PD). Under some circumstances, LRRK2 co-localizes with microtubules in cells, an association enhanced by PD mutations. We report a cryo-electron microscopy structure of the catalytic half of LRRK2, containing its kinase, which is in a closed conformation, and GTPase domains, bound to microtubules. We also report a structure of the catalytic half of LRRK1, which is closely related to LRRK2, but is not linked to PD. LRRK1&rsquo;s structure is similar to LRRK2, but LRRK1 does not interact with microtubules. Guided by these structures, we identify amino acids in LRRK2&rsquo;s GTPase domain that mediate microtubule binding; mutating them disrupts microtubule binding in vitro and in cells, without affecting LRRK2&rsquo;s kinase activity. Our results have implications for the design of therapeutic LRRK2 kinase inhibitors.</p>",Dataset,2022-01-22 00:00:00,"personal
personal
personal
personal
personal
personal","Snead, David M.
Matyszewski, Mariusz
Dickey, Andrea M.
Lin, Yu Xuan
Leschziner, Andres E.
Reck-Peterson, Samara L.",cc-by-4.0,W4393839564,A5011173483,Andres E. Leschziner,0000-0002-7732-7023
253,6463635,2022-05-09T21:32:13.693633+00:00,10.5281/zenodo.6463635,Structural basis for Parkinson's Disease-linked LRRK2's binding to microtubules,"<p>This dataset&nbsp;includes all of the tabular data used in the figures in the article. Original article is available at:&nbsp;https://doi.org/10.1101/2022.01.21.477284</p>

<p>Leucine Rich Repeat Kinase 2 (<em>LRRK2</em>) is one of the most commonly mutated genes in familial Parkinson&rsquo;s Disease (PD). Under some circumstances, LRRK2 co-localizes with microtubules in cells, an association enhanced by PD mutations. We report a cryo-electron microscopy structure of the catalytic half of LRRK2, containing its kinase, which is in a closed conformation, and GTPase domains, bound to microtubules. We also report a structure of the catalytic half of LRRK1, which is closely related to LRRK2, but is not linked to PD. LRRK1&rsquo;s structure is similar to LRRK2, but LRRK1 does not interact with microtubules. Guided by these structures, we identify amino acids in LRRK2&rsquo;s GTPase domain that mediate microtubule binding; mutating them disrupts microtubule binding in vitro and in cells, without affecting LRRK2&rsquo;s kinase activity. Our results have implications for the design of therapeutic LRRK2 kinase inhibitors.</p>",Dataset,2022-01-22 00:00:00,"personal
personal
personal
personal
personal
personal","Snead, David M.
Matyszewski, Mariusz
Dickey, Andrea M.
Lin, Yu Xuan
Leschziner, Andres E.
Reck-Peterson, Samara L.",cc-by-4.0,W4393839564,A5021023250,Samara L. Reck‐Peterson,0000-0002-1553-465X
254,10443508,2023-12-29T22:51:27.626258+00:00,10.5281/zenodo.10443508,aSyn isoforms,,Dataset,2023-12-29 00:00:00,"personal
personal
personal
personal","Röntgen, Alexander
Toprakcioglu, Zenon
Tomkins, James
Vendruscolo, Michele",cc-by-4.0,W4393728825,A5011976831,Alexander Röntgen,0000-0002-0500-4815
255,10443508,2023-12-29T22:51:27.626258+00:00,10.5281/zenodo.10443508,aSyn isoforms,,Dataset,2023-12-29 00:00:00,"personal
personal
personal
personal","Röntgen, Alexander
Toprakcioglu, Zenon
Tomkins, James
Vendruscolo, Michele",cc-by-4.0,W4393728825,A5006932685,Zenon Toprakcioglu,0000-0003-1964-8432
256,10443508,2023-12-29T22:51:27.626258+00:00,10.5281/zenodo.10443508,aSyn isoforms,,Dataset,2023-12-29 00:00:00,"personal
personal
personal
personal","Röntgen, Alexander
Toprakcioglu, Zenon
Tomkins, James
Vendruscolo, Michele",cc-by-4.0,W4393728825,A5033209539,James E. Tomkins,0000-0003-3010-6634
257,10443508,2023-12-29T22:51:27.626258+00:00,10.5281/zenodo.10443508,aSyn isoforms,,Dataset,2023-12-29 00:00:00,"personal
personal
personal
personal","Röntgen, Alexander
Toprakcioglu, Zenon
Tomkins, James
Vendruscolo, Michele",cc-by-4.0,W4393728825,A5038452125,Michele Vendruscolo,0000-0002-3616-1610
258,7153552,2022-10-06T17:05:09.102820+00:00,10.5281/zenodo.7153552,Tabular data of fast-scanning voltammetry and physiology experiments in LRRK2 KI mice,"<p>The tabular data of fast-scanning cyclic voltammetry and physiology experiments from manuscript: &quot;R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations.&quot; by Xenias et al.&nbsp;</p>",Dataset,2022-10-06 00:00:00,personal,"Harry Xenias, Savio Chan, Loukia Parisiadou",cc-by-4.0,W4393459338,A5113158508,Savio Chan Harry Xenias,
259,8384724,2023-10-01T00:56:32.152881+00:00,10.5281/zenodo.8384724,HPLC Data associated with PI3KC3-C1 activation paper,<p>HPLC data of bound nucleotides and nucleotide standards</p>,Dataset,2023-09-28 00:00:00,personal,Annan Cook,cc-by-4.0,W4393660207,A5054466750,Annan SI Cook,0000-0001-6415-9107
260,7349256,2022-11-23T03:02:03.009326+00:00,10.5281/zenodo.7349256,CX3CR1cre_IABflox_stereology,"<p>This dataset contains&nbsp;stereological quantification&nbsp;of tyrosine hydroxylase positive neurons in the substantia nigra pars compacta of AAV2-SYN transduced CX3CR1 Cre/+ or CX3CR1 Cre/+ IAB fl/fl mice. Brans were collected at 6 months post-transduction, labelled with anti-TH antibodies, and quantified using a brightfield microscope and Stereoinvestigator software.</p>",Dataset,2022-11-23 00:00:00,personal,"Schonhoff, Aubrey M",cc-by-4.0,W4393847496,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
261,6539372,2022-05-11T14:27:54.764149+00:00,10.5281/zenodo.6539372,"R scripts for Park et al, 2022","<p>R scripts used to analyze all proteomics data including whole cell, Endo-IP, Lyso-IP, TOMAHAQ, and SIM data</p>",Workflow,2022-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Hankum Park
Qing Yu
Frances V. Hundley
Katherine Overmyer
Lia Serrano
Joao A. Paulo
Julia C. Paoli
Sharan Swarup
Joshua J. Coon
Steven P. Gygi
J. Wade Harper",cc-by-4.0,,,,
262,5137374,2021-07-26T11:19:18.328961+00:00,10.5281/zenodo.5137374,huw-morris-lab/dementia_GWAS_replication: Submission version - dementia_GWAS_replication,<p>Response to Liu et al. (2021) paper for GWAS of PD dementia</p>,Software,2021-07-26 00:00:00,"personal
personal","Manuela Tan
huw101",other-open,W3210252385,A5046721666,Manuela Tan,0000-0001-5835-669X
263,5137374,2021-07-26T11:19:18.328961+00:00,10.5281/zenodo.5137374,huw-morris-lab/dementia_GWAS_replication: Submission version - dementia_GWAS_replication,<p>Response to Liu et al. (2021) paper for GWAS of PD dementia</p>,Software,2021-07-26 00:00:00,"personal
personal","Manuela Tan
huw101",other-open,W3210252385,A5046047343,huw,
264,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5091287609,Pascale Baden,
265,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5100614696,María José Pérez,0000-0001-8842-4286
266,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5021231719,Stefanie Kalb,
267,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5002880244,Hariam Raji,0000-0002-2705-8857
268,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5014496858,M. E. Banegas Illescas,0000-0003-0198-1106
269,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5082836367,Claudio Giuliano,0000-0003-1600-544X
270,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5078024953,Federico Bertoli,0000-0001-5600-1190
271,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5032912195,Marvin Oldrati,0000-0001-6205-3042
272,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5023721480,Alessandra Maria Calogero,0000-0003-2262-4992
273,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5012729392,Graziella Cappelletti,0000-0003-0903-5392
274,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5004204996,Kathrin Brockmann,0000-0002-7515-8596
275,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5067744605,Thomas Gasser,0000-0002-1069-1146
276,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966
277,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5023707841,Cristina Ugalde,0000-0002-9742-1877
278,6518518,2022-05-09T15:16:01.929316+00:00,10.21203/rs.3.rs-1521848/v1,"Glucocerebrosidase, a Parkinson´s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function","<p>Raw data files used for the manuscript &quot;Glucocerebrosidase, a Parkinson&acute;s disease-associated protein, is imported into mitochondria and regulates complex I assembly and function&quot;&nbsp;<a href=""https://www.researchsquare.com/article/rs-1521848/v1"">https://www.researchsquare.com/article/rs-1521848/v1</a></p>

<p>&nbsp;</p>",Preprint,2022-05-04 00:00:00,personal,Michela Deleidi,cc-by-4.0,W4225270111,A5056933907,Michela Deleidi,0000-0003-0357-0124
279,7346957,2022-11-22T10:38:15.639108+00:00,10.5281/zenodo.7346957,katiekellyucl/W-PPI-NA-NSL-complex: v1.0.0. W-PPI-NA/NSL_complex,<p>No description provided.</p>,Software,2022-11-22 00:00:00,personal,katiekellyucl,other-open,,,,
280,7991560,2023-05-31T16:14:16.083731+00:00,10.5281/zenodo.7991560,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,<p>FISH image quantification and pSTAT1-Y701 analysis of fig.4 &nbsp;</p>,Dataset,2023-04-24 00:00:00,personal,Benjamin Hobson,cc-by-4.0,W4393805477,A5072833710,Benjamin D. Hobson,0000-0002-2745-5318
281,5854954,2022-01-15T23:02:04.152597+00:00,10.5281/zenodo.5854954,filfinder: Machine Learning based Filament Finder for Leginon,"<p>filfinder v1.0.0 release as used in &quot;Structural basis for Parkinson&#39;s Disease-linked LRRK2&#39;s binding to microtubules&quot; by Snead DM, Matyszewski M, Dickey AM et al. Preprint available at:&nbsp;https://doi.org/10.1101/2022.01.21.477284</p>

<p>Github:&nbsp;https://github.com/matyszm/filfinder</p>

<p>This is a Leginon plugin to help automate data collection on non-uniform samples, primarily filamentous complexes. Specifically, this was designed in mind for collecting data on LRRK2 filaments bound to microtubules using lacey grids rather than the usual UltrAuFoil or Quantifoil grids with equally spaced holes. This plug-in works on the hole level magnification, where it can select multiple imaging areas with filaments, as well as suggest an area to put down a focus target that contains enough carbon to properly focus.</p>",Software,2022-01-15 00:00:00,personal,Mariusz Matyszewski,other-open,,,,
282,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5046678361,Gregory P. Williams,0000-0001-9523-1781
283,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5052801583,Kaylin Muskat,
284,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5044515449,April Frazier,0000-0002-4722-7304
285,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5075915109,Yaqian Xu,0000-0001-5890-3446
286,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5063444034,José Mateus,0000-0002-1402-3452
287,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5083647614,Alba Grifoni,0000-0002-0369-1746
288,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5075614639,Ricardo da Silva Antunes,0000-0001-9785-5272
289,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5071431150,Daniela Weiskopf,0000-0003-2968-7371
290,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5067845430,Amy W. Amara,0000-0003-0762-9656
291,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5000374325,David G. Standaert,0000-0003-2921-8348
292,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535
293,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5006709022,Irene Litvan,0000-0002-3485-3445
294,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5037098776,Roy N. Alcalay,0000-0002-5717-4875
295,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5026787858,David Sulzer,0000-0001-7632-0439
296,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002
297,6425937,2022-04-08T19:14:26.747142+00:00,10.5281/zenodo.6425937,Unaltered T cell responses to common antigens in individuals with Parkinson's disease--AIM Assay FCS Data (1/3),"<p>FCS files pertaining to the AIM analysis described and included in &quot;Unaltered T cell responses to common antigens in individuals with Parkinson&#39;s disease&quot;. Part 1/3 of dataset, data key can be found in within 3/3 upload.</p>",Dataset,2022-04-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Gregory P. Williams
Kaylin Muskat
April Frazier
Yaqian Xu
José Mateus
Alba Grifoni
Ricardo da Silva Antunes
Daniela Weiskopf
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-4.0,W4393764228,A5010966529,Alessandro Sette,0000-0001-7013-2250
298,8144320,2023-07-13T15:54:29.491739+00:00,10.5281/zenodo.8144320,Gastrointestinal transit time,"<p>GI Transit time for a-synuclein<sub>32-46</sub>, CFA-only, PBS immunized HLA mice. GI transit time for a-synuclein<sub>32-46</sub> immunized HLA mice with T cell depletions are included. Corresponds to Figures 2 and 6</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531408,A5012875579,Francesca Garretti,0000-0002-6609-8034
299,8144320,2023-07-13T15:54:29.491739+00:00,10.5281/zenodo.8144320,Gastrointestinal transit time,"<p>GI Transit time for a-synuclein<sub>32-46</sub>, CFA-only, PBS immunized HLA mice. GI transit time for a-synuclein<sub>32-46</sub> immunized HLA mice with T cell depletions are included. Corresponds to Figures 2 and 6</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531408,A5084707089,Connor Monahan,0000-0003-3245-6187
300,8144320,2023-07-13T15:54:29.491739+00:00,10.5281/zenodo.8144320,Gastrointestinal transit time,"<p>GI Transit time for a-synuclein<sub>32-46</sub>, CFA-only, PBS immunized HLA mice. GI transit time for a-synuclein<sub>32-46</sub> immunized HLA mice with T cell depletions are included. Corresponds to Figures 2 and 6</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531408,A5026787858,David Sulzer,0000-0001-7632-0439
301,8144320,2023-07-13T15:54:29.491739+00:00,10.5281/zenodo.8144320,Gastrointestinal transit time,"<p>GI Transit time for a-synuclein<sub>32-46</sub>, CFA-only, PBS immunized HLA mice. GI transit time for a-synuclein<sub>32-46</sub> immunized HLA mice with T cell depletions are included. Corresponds to Figures 2 and 6</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531408,A5085315691,Dritan Agalliu,0000-0002-5375-4143
302,8144337,2023-07-13T15:57:27.057863+00:00,10.5281/zenodo.8144337,Weight changes,"<p>Weight changes in a-syn<sub>32-46</sub>, CFA-only, PBS immunized HLA mice and a-syn<sub>32-46</sub>-immunized HLA mice with T cell depletion.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393543659,A5012875579,Francesca Garretti,0000-0002-6609-8034
303,8144337,2023-07-13T15:57:27.057863+00:00,10.5281/zenodo.8144337,Weight changes,"<p>Weight changes in a-syn<sub>32-46</sub>, CFA-only, PBS immunized HLA mice and a-syn<sub>32-46</sub>-immunized HLA mice with T cell depletion.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393543659,A5084707089,Connor Monahan,0000-0003-3245-6187
304,8144337,2023-07-13T15:57:27.057863+00:00,10.5281/zenodo.8144337,Weight changes,"<p>Weight changes in a-syn<sub>32-46</sub>, CFA-only, PBS immunized HLA mice and a-syn<sub>32-46</sub>-immunized HLA mice with T cell depletion.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393543659,A5026787858,David Sulzer,0000-0001-7632-0439
305,8144337,2023-07-13T15:57:27.057863+00:00,10.5281/zenodo.8144337,Weight changes,"<p>Weight changes in a-syn<sub>32-46</sub>, CFA-only, PBS immunized HLA mice and a-syn<sub>32-46</sub>-immunized HLA mice with T cell depletion.</p>",Dataset,2023-07-13 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393543659,A5085315691,Dritan Agalliu,0000-0002-5375-4143
306,10079840,2023-11-07T20:06:05.317284+00:00,10.5281/zenodo.10079840,Turek Laboratory Sleep-Wake Dataset and R Code for Analysis,<p>Sleep-wake dataset for MCI-Park mice and R code used for statistical analysis.&nbsp;</p>,Dataset,2023-11-07 00:00:00,"personal
personal","Summa, Keith
Lin, Xuanyi",cc-by-4.0,W4393727289,A5026205750,Keith C. Summa,0000-0001-9541-8458
307,10079840,2023-11-07T20:06:05.317284+00:00,10.5281/zenodo.10079840,Turek Laboratory Sleep-Wake Dataset and R Code for Analysis,<p>Sleep-wake dataset for MCI-Park mice and R code used for statistical analysis.&nbsp;</p>,Dataset,2023-11-07 00:00:00,"personal
personal","Summa, Keith
Lin, Xuanyi",cc-by-4.0,W4393727289,A5063198364,Xuanyi Lin,0000-0001-5486-1058
308,10976403,2024-04-16T16:42:18.419206+00:00,10.5281/zenodo.10976403,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,"<p>Growing evidence indicates that persons living with Parkinson disease (PD), have a unique composition of indigenous gut microbes. Given the long prodromal or pre-diagnosed period, longitudinal studies of the human and rodent gut microbiome prior to symptomatic onset and for the duration of the disease period are currently lacking. PD is characterized in part by accumulation of the protein &alpha;-synuclein (&alpha;-syn) into insoluble aggregates, in both the central and enteric nervous systems. As such, a number of experimental rodent and non-human primate models of &alpha;-syn overexpression recapitulate some of hallmark pathophysiologies of PD. These animal models provide an opportunity to assess how the gut microbiome changes with age under disease relevant conditions. Here, we used a transgenic mouse strain, the Thy1-hSYN &ldquo;line 61&rdquo; mice which over express wild-type human &alpha;-syn to test how the gut microbiome composition responds in this model of PD pathology during aging. Using shotgun metagenomics, we find significant, age and genotype dependent bacterial taxa that become altered over age. We reveal that &alpha;-syn overexpression can drive alterations to the gut microbiome composition and suggest that it limits the expansion of diversity through age. Given emerging data on potential contributions of the gut microbiome to PD pathologies, our data provide an experimental foundation to understand how the PD-associated microbiome may arise as a trigger or co-pathology to disease.</p>",Dataset,2024-04-16 00:00:00,"personal
personal
personal
personal
personal
personal","Sampson, Timothy
Wallen, Zachary
Won, Woong-Jai
Standaert, David
Payami, Haydeh
Harms, Ashley",cc-by-4.0,,,,
309,8384826,2023-10-01T00:57:23.240833+00:00,10.5281/zenodo.8384826,Electrospray ionization mass spectra of PI3KC3-C1 bound nucleotides,<p>Raw data file of GTP mass spectra from publication.</p>,Dataset,2023-09-28 00:00:00,personal,"Cook, Annan",cc-by-4.0,W4394054992,A5054466750,Annan SI Cook,0000-0001-6415-9107
310,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5050542211,Sherilyn Junelle Recinto,0000-0001-9632-1201
311,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5091470177,Shobina Premachandran,0009-0002-0672-1362
312,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5066311857,Sriparna Mukherjee,0000-0002-1299-4343
313,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5083549654,Adam MacDonald,0000-0002-6470-1186
314,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5090736279,Moein Yaqubi,0000-0001-7299-5930
315,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5007887366,Samantha Gruenheid,0000-0002-0908-6715
316,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5024580674,Louis‐Éric Trudeau,0000-0003-4684-1377
317,8231678,2023-08-10T03:13:14.846504+00:00,10.5281/zenodo.8231678,Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice,"<p>The enteric nervous system (ENS) comprises a complex network of neurons whereby a subset appears to be dopaminergic, although the characteristics, roles, and implications in disease are less understood. Most investigations relating to enteric dopamine (DA) neurons rely on immunoreactivity to tyrosine hydroxylase (TH) - a rate-limiting enzyme in the production of DA. However, TH immunoreactivity is likely to provide an incomplete picture given previous work has showed that some DA neurons contain little if any TH and its levels tend to be decreased in response to cellular stress. The study herein provides a comprehensive characterization of DA neurons in the gut using a well-accepted reporter mouse line, expressing a fluorescent protein under control of the DA transporter (DAT) promoter. Our findings confirm a unique localization of DA neurons in the gut and unveil the discrete subtypes of DA neurons in this organ, which we characterized using both immunofluorescence and single-cell transcriptomics, validated by&nbsp;<em>in situ</em>hybridization. We observed distinct subtypes of DAT neurons expressing co-transmitters and modulators across both plexuses; some of them likely co-releasing acetylcholine, and a smaller population likely releasing nitric oxide; while others were positive for a slew of canonical DA markers. Interestingly, we uncovered a seemingly novel population of DA neurons unique to the ENS which were ChAT/DAT-positive neurons and characterised by the expression of&nbsp;<em>Th</em>,&nbsp;<em>Grp</em>,<em>Calcb</em>&nbsp;and<em>&nbsp;Sst</em>. Given the clear heterogeneity of DAergic gut neurons, further investigation is warranted to define their functional signatures&nbsp;and discover any inherent vulnerabilities in disease.&nbsp;&nbsp;</p>",Dataset,2023-08-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Recinto, Sherilyn Junelle
Premachandran, Shobina
Mukherjee, Sriparna
MacDonald, Adam
Yaqubi, Moein
Gruenheid, Samantha
Trudeau, Louis-Eric
Stratton, Jo Anne",cc-by-4.0,W4393573076,A5074478086,Jo Anne Stratton,0000-0002-1205-1353
318,13384532,2024-09-17T14:03:42.876454+00:00,10.5281/zenodo.13384532,MatLab Code and Source Data for Analyzing Reach-related Single Unit Activity in the Internal Segment of the Globus Pallidus in Parkinsonian Macaque,<p>This dataset contains source data stored in non-proprietary format and MatLab code prepared for publishing our study regarding the movement-related activity in the internal globus pallidus of the parkinsonian macaque.</p>,Other,2024-08-28 00:00:00,"personal
personal","Kase, Daisuke
Turner, Robert S.",cc-by-4.0,,,,
319,7360296,2022-11-25T09:24:33.193300+00:00,10.5281/zenodo.7360296,Sex-specific microglial responses to glucocerebrosidase inhibition,"<p>Morpho-dynamic&nbsp;analysis occurring in primary cells derived from female and male mice in response to proinflammatory stimulations and glucocerebrosidase inhibition.&nbsp;The work was supported by the EU Joint Programme - Neurodegenerative Disease Research (JPND) project GBA-PaCTS.</p>

<p>Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).</p>",Dataset,2022-11-25 00:00:00,"personal
personal
personal","Electra Brunialti
Alessandro Maria Villa
Paolo Ciana",cc-by-4.0,W4393799485,A5003538295,Electra Brunialti,0000-0002-0247-3819
320,7360296,2022-11-25T09:24:33.193300+00:00,10.5281/zenodo.7360296,Sex-specific microglial responses to glucocerebrosidase inhibition,"<p>Morpho-dynamic&nbsp;analysis occurring in primary cells derived from female and male mice in response to proinflammatory stimulations and glucocerebrosidase inhibition.&nbsp;The work was supported by the EU Joint Programme - Neurodegenerative Disease Research (JPND) project GBA-PaCTS.</p>

<p>Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).</p>",Dataset,2022-11-25 00:00:00,"personal
personal
personal","Electra Brunialti
Alessandro Maria Villa
Paolo Ciana",cc-by-4.0,W4393799485,A5016070892,Alessandro Villa,0000-0002-7445-916X
321,7360296,2022-11-25T09:24:33.193300+00:00,10.5281/zenodo.7360296,Sex-specific microglial responses to glucocerebrosidase inhibition,"<p>Morpho-dynamic&nbsp;analysis occurring in primary cells derived from female and male mice in response to proinflammatory stimulations and glucocerebrosidase inhibition.&nbsp;The work was supported by the EU Joint Programme - Neurodegenerative Disease Research (JPND) project GBA-PaCTS.</p>

<p>Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).</p>",Dataset,2022-11-25 00:00:00,"personal
personal
personal","Electra Brunialti
Alessandro Maria Villa
Paolo Ciana",cc-by-4.0,W4393799485,A5052037610,Paolo Ciana,0000-0001-5771-5638
322,13755496,2024-09-17T14:05:01.414303+00:00,10.5281/zenodo.13755496,Global Parkinson's Genetics Program Data Release 8,"<p>In September 2024, GP2 announced the eighth data release on the Terra and the Verily&reg; Workbench platforms in collaboration with AMP&reg; PD. This release includes 5,481 additional whole genome sequences and 10,454 clinical exome sequences. Additional genotyping will be provided in the following release.</p>
<ul>
<li>
<p>The whole genome sequencing (WGS) data now consists of a total of 7,734 sequenced participants (6,113 PD cases, 617 Controls, and 1,004 &lsquo;Other&rsquo; phenotypes).</p>
</li>
<ul>
<li>
<p>When removing the locally-restricted samples, these now consist of 4,713 participants (4,098 PD cases, 390 Controls, and 225 &lsquo;Other&rsquo; phenotypes).</p>
</li>
<li>
<p>Of note, cases recruited via the Monogenic network are coded as &lsquo;Other&rsquo;</p>
</li>
</ul>
<li>
<p>Additionally, included in this WGS release is a partial release of whole genome sequences from two AMP-PD cohorts (BioFind and PPMI) that have been joint-called with GP2 WGS. Released samples can be linked back to the original AMP-PD IDs through an ID crosswalk file included with the release.</p>
</li>
<li>
<p>This release also includes 10,454 joint-called clinical exome sequencing (CES) participants from the Parkinson&rsquo;s Foundation.</p>
</li>
<li>This release includes a total of 62,087 individuals who have core clinical data available. Among these, 16,800 individuals have deep clinical phenotyping and genetic data available</li>
</ul>
<p>---</p>
<p>Please see the accompanying blog for further description of this release. To obtain data access, please see&nbsp;<a href=""https://amp-pd.org/researchers/data-use-agreement"">https://amp-pd.org/researchers/data-use-agreement</a>. For any publications using data from this release, please reference the DOI number and the following statement: ""<em>Data (DOI <strong>10.5281/zenodo.13755496</strong>, release 8) used in the preparation of this article were obtained from the Global Parkinson&rsquo;s Genetics Program (GP2).""</em></p>",Dataset,2024-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Leonard, Hampton
Nalls, Mike
Vitale, Dan
Koretsky, Mat
Levine, Kristin
Makarious, Mary
Fang, Zih-Hua
Jones, Lietsel
Solle, J",cc-by-4.0,,,,
323,13169485,2024-08-02T12:39:18.602342+00:00,10.5281/zenodo.13169485,"Splicing accuracy varies across human introns, tissues, age and disease","<p>Alternative splicing impacts most multi-exonic human genes. Inaccuracies during this process may have an important role in ageing and disease. Here, we investigated splicing accuracy using RNA-sequencing data from &gt;14K control samples and 40 human body sites, focusing on split reads partially mapping to known transcripts in annotation. We show that splicing inaccuracies occur at different rates across introns and tissues and are primarily affected by the abundance of core components of the spliceosome assembly and its regulators. Using publicly available data from RNA-knockdowns and CLIP-seq binding sites of numerous spliceosomal components and related regulators, we demonstrated the importance of RNA-binding proteins in splicing accuracy. We found that age is positively correlated with a global decline in splicing fidelity, mostly affecting genes implicated in neurodegenerative diseases. We found further support for the latter by observing a genome-wide increase in splicing inaccuracies in samples affected with Alzheimer's disease as compared to neurologically normal individuals. This in-depth characterisation of splicing has important implications for our understanding of the role of inaccuracies in ageing and human disease, particularly in neurodegenerative disorders.</p>",Dataset,2023-03-31 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","García-Ruiz, S
Zhang, D
Gustavsson, E K
Rocamora-Perez, G
Grant-Peters, M
Fairbrother-Browne, A
Reynolds, R H
Brenton, J W
Gil-Martínez, A L
Chen, Z
Botia, JA
Guelfi, S
Collado-Torres, L
Ryten, M",cc-by-4.0,,,,
324,7706957,2023-03-08T00:52:01.129351+00:00,10.5281/zenodo.7706957,Tmem119Cre_TdTomato_flox_test,"<p>This dataset contains recombination data of Tmem119 CreERT2/+ TdTomato&nbsp;fl/fl mice injected with tamoxifen or corn oil as a control. Six weeks after tamoxifen, tdTomato expression was assayed via flow cytometry.</p>",Dataset,2023-03-08 00:00:00,personal,Aubrey Schonhoff,cc-by-4.0,W4393515632,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
325,10396372,2024-01-16T11:37:31.439850+00:00,10.5281/zenodo.10396372,Simulation of artificial fast scan cyclic voltammetry artifacts on electrophysiological recordings,"<p>Data for simulating fast scan cyclic voltammetry artifacts onto electrophysiology recording and validation.</p>
<p>Code provided on github https://github.com/hschwerdt/fscvartifactcreation/</p>",Software,2023-12-17 00:00:00,"personal
personal","Schwerdt, Helen
Amjad, Usamma",cc-by-4.0,,,,
326,10470982,2024-03-18T14:37:08.498886+00:00,10.5281/zenodo.10470982,Polarisation camera dSTORM datasets of actin in fixed HeLa cells labeled with phalloidin-Alexa Fluor 488,"<p>Polarisation camera dSTORM dataset of the actin of fixed HeLa cells labeled with phalloidin-Alexa Fluor 488.</p>
<p><strong>Image acquisition was performed as follows:</strong></p>
<p>Imaging was performed on a widefield microscope equipped with a polarisation camera (CS505MUP, Thorlabs). The sample was excited using a 488 nm laser at quasi-TIRF, with a measured power density at the image plane of <span>5.04 kW/cm^2</span>. A single long-pass dichroic (Di02-R488, Semrock) was used to seperate fluorescence from the excitation. The emission was filtered using a long-pass (BLP01-488R, Semrock) and a bandpass filter (FF01-582/64, Semrock) before detection. An exposure time of 30 ms was used.</p>
<p><strong>Samples were prepared as follows:</strong></p>
<p><span>Cell culture: </span>HeLa TDS cells were cultured in DMEM (Gibco, Invitrogen) supplemented with 10 % Fetal Bovine Serum (FBS, Life Technologies), 1 % penicillin/streptomycin (Life Technologies), and 1 % glutamine (Life Technologies) at 37 &deg;C + 5 % CO_2. Cells were periodically tested for mycoplasma contamination and passaged 3 times per week. Cells were plated at low density on high-precision glass coverslips (MatTek, P35G-0.170-14-C) 1 day prior to fixation for dSTORM experiments.</p>
<p><span>Labeling:</span> Cells were simultaneously fixed and permeabilized in cytoskeleton buffer (CBS, 10 mM MES, 138 mM KCl, 3 mM MgCl_2, 2 mM EGTA, 4.5 % sucrose w/v, pH 7.4), + 4 % paraformaldehyde (PFA) and 0.2 % Triton for 6 minutes at 37 &deg;C, and further fixed in CBS + 4 % PFA for 14 minutes at 37 &deg;C. Post-fixation, cells were washed x3 in PBST (PBS supplemented with 0.1 % Tween) and permeabilized a second time in PBS + 0.5 % Triton for 5 minutes at room temperature. The samples were then washed 3 times in PBST and blocked for 30 minutes in 5 % BSA. Cells were washed x3 in PBST and then incubated with Alexa Fluor&trade; 488 Phalloidin (A12379, Invitrogen, 1:50 in PBS) for 1 h in the dark, followed by x2 washes in PBS. Prior to dSTORM imaging, PBS was replaced with dSTORM imaging buffer (base buffer consisting of 0.56 M glucose, 50 mM Tris (pH 8.5), and 10 mM NaCl supplemented with 5 U/mL pyranose oxidase (Sigma, P4234), 10 mM cysteamine (Sigma, 30070), 40 &micro;g/mL catalase (Sigma, C100) and 2 mM cyclooctatetraene (Sigma, 138924).</p>",Dataset,2024-03-01 00:00:00,personal,"Bruggeman, Ezra",cc-by-4.0,,,,
327,10470795,2024-03-21T20:25:43.449427+00:00,10.5281/zenodo.10470795,Polarisation camera TAB-PAINT dataset of alpha-synuclein fibrils using Nile red,"<p>Alpha-synuclein fibrils were deposited on PLL-coated and argon plasma-cleaned coverslides. A low concentration of Nile Red (~1 nM) was added for PAINT imaging, and fluorescent beads for post-acquisition drift correction.</p>
<p>The data was collected on a fluorescence microscope (Eclipse Ti-U, Nikon) with a polarisation camera (CS505MUP, Thorlabs). The molecules were excited with a 515 nm laser using epi-illumination with a measured power density at the sample plane of 6.08 kW/cm^2. An exposure time of 50 ms was used. The following filters were used: dichroic (Di03-R514-t1, Semrock) and emission filter (FF01-515/LP and FF01-650/200, Semrock). A 60x oil-immersion objective (Plan Apo, 60xA/1.40 Oil, DIC H, inf/0.17 WD 0.21, Nikon) was used for detection.</p>",Dataset,2024-01-08 00:00:00,personal,"Bruggeman, Ezra",cc-by-4.0,,,,
328,10732697,2024-03-21T20:25:11.913184+00:00,10.5281/zenodo.10732697,Polarisation camera dSTORM datasets of actin in fixed HeLa cells labeled with phalloidin-Alexa Fluor 647,"<p>Polarisation camera dSTORM dataset of the actin of fixed HeLa cells labeled with phalloidin-Alexa Fluor 647.</p>
<p><strong>Image acquisition was performed as follows:</strong></p>
<p>Imaging was performed on a widefield microscope equipped with a polarisation camera (CS505MUP, Thorlabs). The sample was excited using a 638 nm laser at quasi-TIRF, with a measured power density at the image plane of 3.51 kW/cm^2. A multiband dichroic (Di03-R405/488/561/635-t1, Semrock) was used to seperate fluorescence from the excitation. The emission was filtered using a long-pass filter (BLP01-635R, Semrock) before detection. An exposure time of 30 ms was used.</p>
<p><strong>Samples were prepared as follows:</strong></p>
<p>Cell culture: HeLa TDS cells were cultured in DMEM (Gibco, Invitrogen) supplemented with 10 % Fetal Bovine Serum (FBS, Life Technologies), 1 % penicillin/streptomycin (Life Technologies), and 1 % glutamine (Life Technologies) at 37 &deg;C + 5 % CO_2. Cells were periodically tested for mycoplasma contamination and passaged 3 times per week. Cells were plated at low density on high-precision glass coverslips (MatTek, P35G-0.170-14-C) 1 day prior to fixation for dSTORM experiments.</p>
<p>Labeling: Cells were simultaneously fixed and permeabilized in cytoskeleton buffer (CBS, 10 mM MES, 138 mM KCl, 3 mM MgCl_2, 2 mM EGTA, 4.5 % sucrose w/v, pH 7.4), + 4 % paraformaldehyde (PFA) and 0.2 % Triton for 6 minutes at 37 &deg;C, and further fixed in CBS + 4 % PFA for 14 minutes at 37 &deg;C. Post-fixation, cells were washed x3 in PBST (PBS supplemented with 0.1 % Tween) and permeabilized a second time in PBS + 0.5 % Triton for 5 minutes at room temperature. The samples were then washed 3 times in PBST and blocked for 30 minutes in 5 % BSA. Cells were washed x3 in PBST and then incubated with Alexa Fluor&trade; 647 Phalloidin (A22287, Invitrogen, 1:50 in PBS) for 1 h in the dark, followed by x2 washes in PBS. Prior to dSTORM imaging, PBS was replaced with dSTORM imaging buffer (base buffer consisting of 0.56 M glucose, 50 mM Tris (pH 8.5), and 10 mM NaCl supplemented with 5 U/mL pyranose oxidase (Sigma, P4234), 10 mM cysteamine (Sigma, 30070), 40 &micro;g/mL catalase (Sigma, C100) and 2 mM cyclooctatetraene (Sigma, 138924).</p>",Dataset,2024-03-01 00:00:00,personal,"Bruggeman, Ezra",cc-by-4.0,,,,
329,7352495,2022-11-24T00:20:41.095716+00:00,10.5281/zenodo.7352495,"CX3CR1 CreERT2 TdTomato Fatemap Recombination for brain, meninges, and blood","<p>These files contain quantification of recombination efficiency in tamoxifen-injected CX3CR1 CreERT2 TdTomato mice. The blood data was acquired longitudinally over six weeks, whereas the brain and meninges data were acquired at the end of the six weeks. Workspace files are included to demonstrate gating and quantification.</p>",Dataset,2022-11-23 00:00:00,personal,"Schonhoff, Aubrey M",cc-by-4.0,W4393671463,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
330,11126860,2024-06-26T15:10:00.102270+00:00,10.5281/zenodo.11126860,Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease,"<p><strong>Abstract: </strong>We address an unmet challenge in Parkinson&rsquo;s disease: the lack of biomarkers to identify the right patients for the right therapy, which is a main reason clinical trials for disease modifying treatments have all failed. The gut microbiome is a new target for treatment of neurodegenerative diseases. Our aim was to develop microbiome-based biomarkers to guide patient selection for microbiome-based clinical trials. We used microbial taxa that are robustly associated with PD across studies and at high significance as dysbiotic features of PD. &nbsp;Using individual-level taxonomic relative abundance data, we classified patients according to their dysbiotic features, effectively defining microbiome-based subtypes of PD. &nbsp;We show that not all persons with PD have a dysbiotic microbiome, and not all dysbiotic PD microbiomes have the same features. Grounded in robust and reproducible data from differential abundance studies, we propose an intuitive and easily modifiable method to identify the optimal candidates for microbiome-based clinical trials, and subsequently, for treatments that are personalized for each individual&rsquo;s dysbiotic features. We demonstrate the method for PD. The concept, and the method, is generalizable for any disease with a microbiome component.</p>
<p><strong>Zenodo</strong>&nbsp;<strong>content: </strong>In this Zenodo archive we provide (a) the method described step by step, which can be implemented in Microsoft Excel (we used v.16.84 (RRID:SCR_016137)&nbsp;<a href=""https://www.microsoft.com/en-gb/"">https://www.microsoft.com/en-gb/</a>) or in R (we used v4.3.3 (RRID:SCR_001905) <a title=""https://www.r-project.org/
Cmd+Click or tap to follow the link"" href=""https://www.r-project.org/"">https://www.r-project.org/</a>); and&nbsp;(b) data used to generate the results, tables and figures (except figure 2). Data for creating figure 2 can be found in source data&nbsp;(doi: 10.5281/zenodo.7246185) and the method is described by Wallen et al 2022&nbsp;(DOI:&nbsp;<u><a href=""https://doi.org/10.1038/s41467-022-34667-x"" target=""_blank"" rel=""noopener"">10.1038/s41467-022-34667-x</a></u>). All data used here were extracted from the original source data reported by<strong> </strong>Wallen et. al. 2022 (DOI:&nbsp;<u><a href=""https://doi.org/10.1038/s41467-022-34667-x"" target=""_blank"" rel=""noopener"">10.1038/s41467-022-34667-x</a></u>) which can be found on Zenodo (DOI: 10.5281/zenodo.7246185).</p>",Dataset,2024-05-30 00:00:00,"personal
personal
personal
personal","Payami, Haydeh
Sampson, Timothy R
Murchison, Charles F
Wallen, Zachary D",cc-by-4.0,,,,
331,13381181,2024-08-30T02:23:02.254602+00:00,10.5281/zenodo.13381181,"Dataset related to manuscript: Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of a-synuclein inclusions","<p>Key Resources Table and tabular data related to Lam, Ndayisaba et al 2024.</p>
<p>Code for generating graphs can be found at: doi:10.5281/zenodo.12574231 (version 1), doi:10.5281/zenodo.12574230 (all versions)</p>",Dataset,2024-08-27 00:00:00,"personal
personal
personal","Lam, Isabel
Ndayisaba, Alain
Khurana, Vikram",cc-by-4.0,,,,
332,7183678,2022-10-11T02:35:53.089060+00:00,10.5281/zenodo.7183678,Integrated multi-cohort analysis of the Parkinson's disease gut metagenome,"<p>Supplementary tables, and final code submission for Boktor et al. 2022</p>",Software,2022-10-11 00:00:00,personal,"Boktor, Joseph",cc-by-4.0,,,,
333,7799587,2023-06-20T17:14:43.579663+00:00,10.5281/zenodo.7799587,Western blot quantification dataset for Structure of LRRK1 and mechanisms of  autoinhibition and activation,<p>Tabular data corresponding to Western blots.&nbsp;</p>,Dataset,2023-04-04 00:00:00,"personal
personal","Abrisch, Robert
Dickey, Andrea",cc-by-4.0,W4394044542,A5086277887,Robert G. Abrisch,0000-0002-4231-9971
334,7799587,2023-06-20T17:14:43.579663+00:00,10.5281/zenodo.7799587,Western blot quantification dataset for Structure of LRRK1 and mechanisms of  autoinhibition and activation,<p>Tabular data corresponding to Western blots.&nbsp;</p>,Dataset,2023-04-04 00:00:00,"personal
personal","Abrisch, Robert
Dickey, Andrea",cc-by-4.0,W4394044542,A5057238552,Andrea M. Dickey,0000-0001-8725-0982
335,13855996,2024-09-30T18:02:49.851312+00:00,10.5281/zenodo.13855996,"Nielsen and Ford, 2024 - Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and L-DOPA-induced dyskinetic behaviors","<p>Dataset for: Nielsen and Ford, 2024 - Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and L-DOPA-induced dyskinetic behaviors</p>",Dataset,2024,"personal
personal","Beatriz E. Nielsen
Christopher P. Ford",cc-by-4.0,,,,
336,11585274,2024-06-12T20:40:31.588835+00:00,10.5281/zenodo.11585274,ASAP CRN Postmortem-Derived Brain Sequencing Collection,"<p>We're excited to announce the availability of the Version 1.0.0 data release on the CRN Cloud! In this release, we have expanded data collections with contributions from Team Scherzer. Furthermore, we've updated the Postmortem-derived Brain Sequencing Collection by integrating this team&rsquo;s data into the harmonized subset. This curated subset now contains data from a total of 156 subjects from 4 CRN Teams and is organized across common data elements.</p>
<p>The current data collections represent the minimum viable product and are being expanded as additional data is uploaded into the CRN Cloud. When complete, the collection will provide data generated from 1,800+ samples using proteomics, transcriptomics, and sequencing (single-nucleus RNAseq, single-cell RNAseq, bulk RNA-seq, ATAC-seq, long read WGS, and single-nucleus multiome sequencing (paired snRNAseq, snATACseq)) techniques.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>",Dataset,2024-06-25 00:00:00,"personal
personal
personal
personal","Zhang, Le
Bras, Jose
Gale Hammell, Molly
Scherzer, Clemens",cc-by-4.0,,,,
337,12684329,2024-07-08T10:10:43.140600+00:00,10.5281/zenodo.12684329,A fluid-walled microfluidic platform for human neuron microcircuits and directed axotomy,"<p><strong>ABSTRACT</strong></p>
<div>
<p>In our brains, different neurons make appropriate connections; however, there remain few in vitro models of such circuits. We use an open microfluidic approach to build and study neuronal circuits in vitro in ways that fit easily into existing bio-medical workflows. Dumbbell-shaped circuits are built in minutes in standard Petri dishes; the aqueous phase is confined by fluid walls &ndash; interfaces between cell-growth medium and an immiscible fluorocarbon, FC40. Conditions are established that ensure post-mitotic neurons derived from human induced pluripotent stem cells (iPSCs) plated in one chamber of a dumbbell remain where deposited. After seeding cortical neurons on one side, axons grow through the connecting conduit to ramify amongst striatal neurons on the other &ndash; an arrangement mimicking unidirectional cortico-striatal connectivity. We also develop a moderate-throughput non-contact axotomy assay. Cortical axons in conduits are severed by a media jet; then, brain-derived neurotrophic factor and striatal neurons in distal chambers promote axon regeneration. As additional conduits and chambers are easily added, this opens up the possibility of mimicking complex neuronal networks, and screening drugs for their effects on connectivity.</p>
<p>&nbsp;</p>
</div>
<p><strong>FILE DESCRIPTIONS</strong></p>
<p>Source Data.xlsx: Tabular datasets plotted on Main Figures 2, 3 and 6, and Supplementary Figures 1 and 2.</p>
<p>Key Resources Table.xlsx: Table containing details on the key resources (antibodies, cell lines, virus strains, software, code, and protocols) used in this study.</p>",Dataset,2024-07-08 00:00:00,"personal
personal
personal
personal
personal","Nebuloni, Federico
Do, Qyen B.
Cook, Peter R.
Walsh, Edmond J.
Wade-Martins, Richard",cc-by-4.0,,,,
338,10222976,2023-12-19T15:58:11.037816+00:00,10.5281/zenodo.10222976,"Clinical datasets related DeNoPa olfaction, cerebrospinal fluid readouts and alpha-synuclein seeding aggregation assay","<p>These dataset files are associated with the manuscript:&nbsp;</p>
<p>Mollenhauer B*, Li J*, Schade S, Weber S, Trenkwalder C, Concha-Marambio L, Tomlinson JJ, aSCENT-PD Investigators and Schlossmacher MG. <em>Persistent Hyposmia as Surrogate for alpha-Synuclein-Linked Brain Pathology.&nbsp;</em>Submitted 2023</p>
<p>3 files:</p>
<p>Data dictionary.csv</p>
<p>Baseline_cut.csv</p>
<p>Time_cut.csv</p>
<p>The file ""Data dictionary.csv"" contains description of the two data files and the variables within.</p>
<p>Clinical data used for this study is from the DeNoPa Cohort, led by Dr. Brit Mollenhauer, Department of Neurology, University of Goettingen, Kassel, Germany and the Paracelsus-Elena-Klinik. See references below for additional details.</p>
<p>Mollenhauer B, Trautmann E, Sixel-D&ouml;ring F, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Focke NK, Kumar KR, Lohmann K, Klein C, Schlossmacher MG, Kohnen R, Friede T, Trenkwalder C; DeNoPa Study Group. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology. 2013 Oct 1;81(14):1226-34. doi: 10.1212/WNL.0b013e3182a6cbd5</p>
<p>Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, Ma Y, Starke M, Ebentheuer J, Sixel-D&ouml;ring F, Muntean ML, Schade S, Trenkwalder C, Soto C, Mollenhauer B. Accurate Detection of &alpha;-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. Mov Disord. 2023 Apr;38(4):567-578. doi: 10.1002/mds.29329</p>",Dataset,2023-12-19 00:00:00,"personal
personal
personal","Li, Juan
Mollenhauer, Brit
Schlossmacher, Michael",cc-by-4.0,W4393774069,A5002039998,Juan Li,0000-0003-1565-2477
339,10222976,2023-12-19T15:58:11.037816+00:00,10.5281/zenodo.10222976,"Clinical datasets related DeNoPa olfaction, cerebrospinal fluid readouts and alpha-synuclein seeding aggregation assay","<p>These dataset files are associated with the manuscript:&nbsp;</p>
<p>Mollenhauer B*, Li J*, Schade S, Weber S, Trenkwalder C, Concha-Marambio L, Tomlinson JJ, aSCENT-PD Investigators and Schlossmacher MG. <em>Persistent Hyposmia as Surrogate for alpha-Synuclein-Linked Brain Pathology.&nbsp;</em>Submitted 2023</p>
<p>3 files:</p>
<p>Data dictionary.csv</p>
<p>Baseline_cut.csv</p>
<p>Time_cut.csv</p>
<p>The file ""Data dictionary.csv"" contains description of the two data files and the variables within.</p>
<p>Clinical data used for this study is from the DeNoPa Cohort, led by Dr. Brit Mollenhauer, Department of Neurology, University of Goettingen, Kassel, Germany and the Paracelsus-Elena-Klinik. See references below for additional details.</p>
<p>Mollenhauer B, Trautmann E, Sixel-D&ouml;ring F, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Focke NK, Kumar KR, Lohmann K, Klein C, Schlossmacher MG, Kohnen R, Friede T, Trenkwalder C; DeNoPa Study Group. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology. 2013 Oct 1;81(14):1226-34. doi: 10.1212/WNL.0b013e3182a6cbd5</p>
<p>Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, Ma Y, Starke M, Ebentheuer J, Sixel-D&ouml;ring F, Muntean ML, Schade S, Trenkwalder C, Soto C, Mollenhauer B. Accurate Detection of &alpha;-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. Mov Disord. 2023 Apr;38(4):567-578. doi: 10.1002/mds.29329</p>",Dataset,2023-12-19 00:00:00,"personal
personal
personal","Li, Juan
Mollenhauer, Brit
Schlossmacher, Michael",cc-by-4.0,W4393774069,A5082185657,Brit Mollenhauer,0000-0001-8437-3645
340,10222976,2023-12-19T15:58:11.037816+00:00,10.5281/zenodo.10222976,"Clinical datasets related DeNoPa olfaction, cerebrospinal fluid readouts and alpha-synuclein seeding aggregation assay","<p>These dataset files are associated with the manuscript:&nbsp;</p>
<p>Mollenhauer B*, Li J*, Schade S, Weber S, Trenkwalder C, Concha-Marambio L, Tomlinson JJ, aSCENT-PD Investigators and Schlossmacher MG. <em>Persistent Hyposmia as Surrogate for alpha-Synuclein-Linked Brain Pathology.&nbsp;</em>Submitted 2023</p>
<p>3 files:</p>
<p>Data dictionary.csv</p>
<p>Baseline_cut.csv</p>
<p>Time_cut.csv</p>
<p>The file ""Data dictionary.csv"" contains description of the two data files and the variables within.</p>
<p>Clinical data used for this study is from the DeNoPa Cohort, led by Dr. Brit Mollenhauer, Department of Neurology, University of Goettingen, Kassel, Germany and the Paracelsus-Elena-Klinik. See references below for additional details.</p>
<p>Mollenhauer B, Trautmann E, Sixel-D&ouml;ring F, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Focke NK, Kumar KR, Lohmann K, Klein C, Schlossmacher MG, Kohnen R, Friede T, Trenkwalder C; DeNoPa Study Group. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology. 2013 Oct 1;81(14):1226-34. doi: 10.1212/WNL.0b013e3182a6cbd5</p>
<p>Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, Ma Y, Starke M, Ebentheuer J, Sixel-D&ouml;ring F, Muntean ML, Schade S, Trenkwalder C, Soto C, Mollenhauer B. Accurate Detection of &alpha;-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. Mov Disord. 2023 Apr;38(4):567-578. doi: 10.1002/mds.29329</p>",Dataset,2023-12-19 00:00:00,"personal
personal
personal","Li, Juan
Mollenhauer, Brit
Schlossmacher, Michael",cc-by-4.0,W4393774069,A5000268173,Michael G. Schlossmacher,0000-0002-0394-0300
341,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5039704196,Odetta Antico,0000-0002-7325-3303
342,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5050948158,Alban Ordureau,0000-0002-4924-8520
343,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5103155091,Michael Stevens,0000-0001-8105-6302
344,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5081374585,François Singh,0000-0002-1696-9815
345,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566
346,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5013433142,Marek Gierliński,0000-0001-9149-3514
347,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5054977583,Erica Barini,0000-0002-3093-4053
348,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5081090599,Mollie L. Rickwood,0000-0002-3715-8915
349,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5027617773,Alan R. Prescott,0000-0002-0747-7317
350,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5067524265,Rachel Toth,0000-0002-1337-0612
351,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5001971427,Ian G. Ganley,0000-0003-1481-9407
352,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5047746208,J. Wade Harper,0000-0002-6944-7236
353,5163706,2021-08-10T13:03:25.260071+00:00,10.5281/zenodo.5163706,Global ubiquitylation analysis of mitochondria  in primary neurons identifies endogenous Parkin targets following activation of PINK1,"<p>&nbsp;How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by&nbsp;mitophagy is largely based on cell lines with few studies in neurons. Herein we have&nbsp;undertaken proteomic analysis of mitochondria from mouse neurons to identify&nbsp;ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron&nbsp;datasets revealed a subset of 49 PINK1 activation-dependent diGLY sites in 22 proteins&nbsp;conserved across mouse and human systems. We employ reconstitution assays to&nbsp;demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of&nbsp;cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin&nbsp;independent ubiquitylation indicating the presence of alternate ubiquitin E3 ligase&nbsp;&nbsp;pathways that are activated by mitochondrial depolarisation in neurons. Finally we have&nbsp;developed an online resource to search for ubiquitin sites and enzymes in mitochondria of&nbsp;neurons, MitoNUb. These findings will aid future studies to understand Parkin activation&nbsp;in neuronal subtypes.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1C: Immunoblots for PINK1 signaling in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>Figure1C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure1C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure1C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>Figure1C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>Figure1C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>Figure1C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S10A, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 4A: Immunoblots for time-course of Parkin-dependent substrates in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4A_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4A_ CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_CPT1</strong><strong>a</strong><strong>.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4A_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4A_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4A_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p><strong>Figure 4B: Immunoblots for validation of Parkin-dependent substrates in PARKIN WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure4B_CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li>(bottom blot)<strong>&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure4B_ CPT1a.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li>(top blot)<strong>&nbsp;&nbsp;Figure4B_INPUT_CPT1a_CISD1.tif</strong>&nbsp;( (INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure4B_Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure4B_INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure4B_UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure4B_INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5A: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in PINK1 WT and KO mouse embryonic fibroblasts.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>Figure5A_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5A_ CPT1a.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>Figure5A_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>Figure5A_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>Figure5A_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>Figure5A_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>Figure5A_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>Figure5A_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure5A_Ubiquitin.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure5A_UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (CPT1&alpha;) shown in&nbsp;<strong>Figure5B_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<ul>
	<li>Miro1 shown in&nbsp;<strong>Figure5B_Miro1_800nm.tif</strong></li>
	<li>Flag-Ub (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_Flag_800nm</strong><strong>.tif</strong></li>
	<li>His (Miro1) shown in&nbsp;<strong>Figure5B_ Miro1</strong><strong>_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure 5C: Immunoblots for time-course of CPT1</strong><strong>&alpha;</strong><strong>&nbsp;ubiquitylation in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>CPT1&alpha;&nbsp;shown in top blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>Flag-Ub shown in bottom blot:&nbsp;<strong>Figure5C_Flag_CPT1</strong><strong>&alpha;_800nm</strong><strong>.tif</strong></li>
	<li>His shown in&nbsp;<strong>Figure5C_ CPT1&nbsp;</strong><strong>&alpha;_His_800nm</strong><strong>.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3A: Immunoblots for PINK1 signaling in C57BL/6J neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3A_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3A_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3A_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3A_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3A_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3A_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3A_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4A, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser111 Rab8A and Phospho-Ser65 Parkin also shown in&nbsp;<strong>FigureS3A_ParkinPSer65_Rab8APSer111.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3B: Immunoblots for comparison of Halo-multiDSK and Halo-TUBE in&nbsp;&nbsp;C57BL/6J neurons.</strong></p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S9)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S3C: Immunoblots for PINK1 signaling in Parkin WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS3C_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS3C_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS3C_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS3C_PINK1.tif&nbsp;</strong>(immunoprecipitation)</li>
	<li>Rab8A shown in&nbsp;<strong>FigureS3C_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS3C_Rab8APSer111.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS3C_ Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS3C_ UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_4B, Halo-multiDSK pull-down)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S4: Immunoblots for PINK-Parkin signaling in VPS35 D620N mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS4_GAPDH.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS4_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS4_ParkinPSer65.tif</strong></li>
	<li>Rab8A shown in&nbsp;<strong>FigureS4_Rab8A.tif</strong></li>
	<li>Phospho-Ser111 Rab8A shown in&nbsp;<strong>FigureS4_Rab8APSer111.tif</strong></li>
	<li>CISD1 shown in&nbsp;<strong>FigureS4_ CISD1.tif&nbsp;</strong>(Halo-UBQLN1 pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS4_ UbiquitinPSer65.tif</strong>&nbsp;(Halo-UBQLN1 pull-down)</li>
	<li>VPS35 shown in&nbsp;<strong>FigureS4_VPS35.tif</strong></li>
</ul>

<p>Scan of Memcode shown in&nbsp;<strong>FigureS4_Memcode.tif</strong></p>

<p>&nbsp;</p>

<p><strong>Figure S6: Immunoblots for biochemical analysis in C56BL/6J mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS6_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS6_ UbiquitinPSer65.tif&nbsp;</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S8: Immunoblots for biochemical analysis in PINK1 WT and KO mouse cortical neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>GAPDH shown in&nbsp;<strong>FigureS8_GAPDH.tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS8_ UbiquitinPSer65.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S9: Immunoblots for biochemical analysis of ubiquitylated target in C56BL/6J mouse cortical neurons.</strong></p>

<p>Membrane-enriched lysate subjected to ubiquitin capture using UBQLN1(TUBE), multiDSK and mutant multiDSK pull-down&nbsp;(Illustration of sample loading in figures FigureS9_ACSL6,_MFN2, _UbiquitinPSer65, _NAV1.7).</p>

<p>Scans of X-ray film:</p>

<ul>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS9_S3_Ubiquitin.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS9_S3_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for Figure_S3B)</li>
	<li>ABCD3 shown in&nbsp;<strong>FigureS9_ABCD3.tif</strong></li>
	<li>ACSL1shown in&nbsp;<strong>FigureS9_ ACSL1.tif</strong></li>
	<li>ACSL6 shown in&nbsp;<strong>FigureS9_ACSL6.tif</strong></li>
	<li>AGPAT5 shown in&nbsp;<strong>FigureS9_AGPAT5.tif</strong></li>
	<li>ARHGAP33 shown in&nbsp;<strong>FigureS9_ARHGAP33.tif</strong></li>
	<li>ATAD1 shown in&nbsp;<strong>FigureS9_ATAD1.tif</strong></li>
	<li>CAD shown in&nbsp;<strong>FigureS9_ CAD.tif</strong></li>
	<li>CAMK2A shown in&nbsp;<strong>FigureS9_CAMK2A.tif</strong></li>
	<li>CAMK2B shown in&nbsp;<strong>FigureS9_CAMK2B.tif</strong></li>
	<li>CDK16 shown in&nbsp;<strong>FigureS9_CDK16.tif</strong></li>
	<li>CISD1shown in&nbsp;<strong>FigureS9_CISD1.tif</strong></li>
	<li>CNN3 shown in<strong>&nbsp;FigureS9_CNN3.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS9_ CPT1A.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS9_CYB5B.tif</strong></li>
	<li>CYB5R3 shown in&nbsp;<strong>FigureS9_CYB5R3.tif</strong></li>
	<li>DCAKD shown in&nbsp;<strong>FigureS9_DCAKD.tif</strong></li>
	<li>DCAMKL2 shown in&nbsp;<strong>FigureS9_DCAMKL2.tif</strong></li>
	<li>FAM213A shown in&nbsp;<strong>FigureS9_FAM213A.tif</strong></li>
	<li>FBXO41 shown in&nbsp;<strong>FigureS9_FBXO41.tif</strong></li>
	<li>GK shown in&nbsp;<strong>FigureS9_GK.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS9_HK1.tif</strong></li>
	<li>HSDL1&nbsp;shown in&nbsp;<strong>FigureS9_HSDL1.tif</strong></li>
	<li>MAO-A shown in&nbsp;<strong>FigureS9_MAOA.tif</strong></li>
	<li>MAO-B shown in&nbsp;<strong>FigureS9_MAOB.tif</strong></li>
	<li>MAPRE2 shown in&nbsp;<strong>FigureS9_MAPRE2.tif</strong></li>
	<li>MARC2 shown in&nbsp;<strong>FigureS9_MARC2.tif</strong></li>
	<li>MFN1 shown in&nbsp;<strong>FigureS9_MFN1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS9_MFN2.tif</strong></li>
	<li>NAV1.7 shown in&nbsp;<strong>FigureS9_NAV1.7.tif</strong></li>
	<li>P23 shown in&nbsp;<strong>FigureS9_p23.tif</strong></li>
	<li>PRKCG shown in&nbsp;<strong>FigureS9_PRKCG.tif</strong></li>
	<li>RAB5C shown in&nbsp;<strong>FigureS9_Rab5c.tif</strong></li>
	<li>RHOT2 shown in&nbsp;<strong>FigureS9_RHOT2.tif</strong></li>
	<li>RIMS4 shown in&nbsp;<strong>FigureS9_RIMS4.tif</strong></li>
	<li>RUFY3 shown in&nbsp;<strong>FigureS9_RUFY3.tif</strong></li>
	<li>SH3BP4 shown in&nbsp;<strong>FigureS9_SH3BP4.tif</strong></li>
	<li>SNX3 shown in&nbsp;<strong>FigureS9_SNX3.tif</strong></li>
	<li>TDRKH shown in&nbsp;<strong>FigureS9_TDRKH.tif</strong></li>
	<li>TOMM70 shown in&nbsp;<strong>FigureS9_TOMM70.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10A: Immunoblots for validation of Parkin-dependent substrates in PINK1 WT and KO neurons.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10A _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)

	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_CISD1.tif&nbsp;</strong>(INPUT)</li>
	</ul>
	</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10A _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_ CPT1A.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A _Ubiquitin.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)
	<ul>
		<li><strong>&nbsp;&nbsp;Figure S10A _INPUT_Ubiquitin.tif</strong>&nbsp;(INPUT)</li>
	</ul>
	</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure1C_ S10A_UbiquitinPSer65.tif&nbsp;</strong>(same blot used for FigureS1C, Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10A _INPUT_GAPDH.tif&nbsp;</strong>(INPUT)</li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S10B: Immunoblots for time-course of Parkin-dependent substrates in SH-SY5Y cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1 shown in&nbsp;<strong>Figure S10B _CISD1.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>Figure S10B _ CPT1A.tif</strong>&nbsp;(Halo-multiDSK pull-down)</li>
	<li>Ubiquitin shown in&nbsp;<strong>Figure S10B _Ubiquitin.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>Figure S10B _UbiquitinPSer65.tif&nbsp;</strong>(Halo-multiDSK pull-down)</li>
	<li>GAPDH Shown in&nbsp;<strong>Figure S10B _GAPDH.tif&nbsp;</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS10B_Parkin.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS10B_ParkinPSer65.tif</strong></li>
	<li>PINK1 shown in&nbsp;<strong>FigureS10B_PINK1.tif</strong></li>
	<li>OPA1 shown in&nbsp;<strong>FigureS10B_OPA1.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>Figure S11: Immunoblots for&nbsp;<em>in vitro</em>&nbsp;reconstitution assay in HeLa cells.</strong></p>

<p>Scans of X-ray film:</p>

<ul>
	<li>CISD1shown in&nbsp;<strong>FigureS11_CISD1.tif</strong></li>
	<li>CPT1&alpha;&nbsp;shown in&nbsp;<strong>FigureS11_ CPT1</strong><strong>a</strong><strong>.tif</strong></li>
	<li>CYB5B shown in&nbsp;<strong>FigureS11_CYB5B.tif</strong></li>
	<li>HK1 shown in&nbsp;<strong>FigureS11_HK1.tif</strong></li>
	<li>MFN2 shown in&nbsp;<strong>FigureS11_MFN2.tif</strong></li>
	<li>VDAC shown in&nbsp;<strong>FigureS11_VDAC.tif</strong></li>
	<li>Phospho-Ser65 Parkin shown in&nbsp;<strong>FigureS11_ParkinPSer65.tif</strong></li>
	<li>Parkin shown in&nbsp;<strong>FigureS11_Parkin.tif</strong></li>
	<li>Ubiquitin shown in&nbsp;<strong>FigureS11_Ubiquitin .tif</strong></li>
	<li>Phospho-Ser65 Ubiquitin shown in&nbsp;<strong>FigureS11_UbiquitinPSer65 .tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS12A: Purification of CPT1</strong><strong>&alpha; protein.</strong></p>

<ul>
	<li><strong>FigureS12A_</strong><strong>&nbsp;Akta_Purifier_Curves.txt</strong>.</li>
</ul>

<p>&nbsp;Tab delimited text of data from the AKTA system, plotted in figure S12A. Columns are laid out as volume/measured parameter &nbsp; &nbsp;for each parameter from the Akta. The columns plotted in figure S12A were mAU (columns A and B in excel) and fractions (columns M and N in excel).</p>

<ul>
	<li><strong>Figure_S12A_Coomassie_Gel.tif</strong>.&nbsp;</li>
</ul>

<p>Coomassie stained gels of fractions from the AKTA system in figure S12A.</p>

<p>Top: Left hand Coomassie gel, figure S12A</p>

<p>Bottom: Right hand Coomassie gel, figure S12A</p>

<p>&nbsp;</p>

<p><strong>FigureS12B-C: Purification of recombinant Parkin targets&nbsp;</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<ul>
	<li><strong>FigureS12B_Ub_Targets_High_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Left: Lane: 1: Mwt Marker, 2: Fam213A, 3: MAO-B, 4: CAMK2&alpha;,&nbsp;<strong>5: MAO-A (figure S12B)</strong>, 6: GST-MAPRE2, 7: MBP-CYB5R3, 8: MBP-CYB5B, 9: MBP-CYB5B, 10: SNX3, 11: His-SUMO-MAO-B, 12: GST-MAO-B, 13: 0.03125 ug BSA, 14: 0.0625 ug BSA, 15: 0.125 ug BSA, 16: 0.25 ug BSA, 17: 0.5 ug BSA, 18: 1 ug BSA</p>

<p>Right: Lane: 1: Mwt Marker, 2: GST-MAO-A, 3: GST-FAM213A,&nbsp;<strong>4: MBP-CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(figure S12B)</strong>, 5: GST-TDRKH, 6: MBP-CPT1&alpha;, 7: MBP-CYB5B, 8: CAMK2&beta;, 9:, 10: His-SUMO-MAO-B, 11: GST-MAO-B, 12: 0.03125 ug BSA, 13: 0.0625 ug BSA, 14: 0.125 ug BSA, 15: 0.25 ug BSA, 16: 0.5 ug BSA, 17: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12B_Ub_Targets_Low_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets alongside a BSA curve.</p>

<p>Lane: 1: Mwt Marker,&nbsp;<strong>2: GST-Miro1 (figure S12B</strong>), 3: His-SUMO-Fam213A, 4: His-SUMO-MAPRE2, 5: His-SUMO-MAO-A, 6: His-SUMO-MAO-B, 7: His-SUMO-SNX26, 8: His-SNX3, 9: His-MAPRE2, 10: GST-FAM213A, 11: His-SUMO-CAMK2&alpha;, 12: His-SUMO-CAMK2&beta;, 13: GST-FAM213A, 14: 0.03125 ug BSA, 15: 0.0625 ug BSA, 16: 0.125 ug BSA, 17: 0.25 ug BSA, 18: 0.5 ug BSA, 19: 1 ug BSA</p>

<p>&nbsp;</p>

<ul>
	<li><strong>Figure_S12C_Ub_Targets_800nm.tif</strong></li>
</ul>

<p>Coomassie stained gels of the parkin targets in duplicate alongside a BSA curve.</p>

<p>Top: Lane: 1: Mwt Marker,&nbsp;<strong>2+3: ACSL1 45-end (Figure S12C)</strong>,&nbsp;<strong>4+5: SNX3 (Figure S12C),</strong>&nbsp;6+7: MFN1, 8+9: MFN2, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Middle: Lane: 1: Mwt Marker, 2+3: CAMK2&alpha;,&nbsp;<strong>4+5: CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S12C)</strong>, 6+7: MAO-A,&nbsp;<strong>8+9: MAO-B (Figure S12C)</strong>, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>Bottom: Lane: 1: Mwt Marker, 2+3: SRCIN, 4+5: His-MAPRE2, 6+7:&nbsp;<strong>FAM213A (Figure S12C)</strong>, 8+9: CISD1, 10+11: 0.125 ug BSA, 12+13: 0.25 ug BSA, 14+15: 0.5 ug BSA, 16+17: 1 ug BSA</p>

<p>&nbsp;</p>

<p><strong>FigureS13-S14: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of X-ray film:</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_a6His_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B</strong>), 2:&nbsp;&nbsp;<strong>MAO-B (Figure S13A</strong>), 3: MAPRE2, 4:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong></p>

<p>Top: 1:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 2: Miro1, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aFLAG_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2:&nbsp;<strong>CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C),</strong>&nbsp;3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D)</strong>, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_05m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1: FAM213A, 2: MAPRE2, 3: MAO-A</p>

<p>Top: 1: MAO-B, 2<strong>: CAMK2</strong><strong>&alpha;</strong><strong>&nbsp;(Figure S14C)</strong>, 3:&nbsp;<strong>CAMK2</strong><strong>&beta;</strong><strong>&nbsp;(Figure S14D</strong>), 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<ul>
	<li><strong>FigureS13A-B_S14C-D_aTarget_06m00s_Film.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes from left to right:</p>

<p>Top: 1:&nbsp;<strong>FAM213A (Figure S13B)</strong>, 2: MAPRE2, 3:&nbsp;<strong>MAO-A (Figure S13A)</strong></p>

<p>Top: 1:&nbsp;<strong>MAO-B (Figure S13A)</strong>, 2: CAMK2&alpha;, 3: CAMK2&beta;, 4: Miro1&nbsp;&nbsp;</p>

<p>&nbsp;</p>

<p><strong>FigureS13C: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>ACSL1 shown in&nbsp;<strong>FigureS13C_ACSL1_800nm.tif</strong></li>
	<li>Flag-Ub (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_Flag_800nm.tif</strong></li>
	<li>His (ACSL1) shown in&nbsp;<strong>Figure_S13C_ACSL1_His_800nm.tif</strong></li>
</ul>

<p>&nbsp;</p>

<p><strong>FigureS14B: Immunoblots for validation of Parkin-dependent substrates in<em>&nbsp;in vitro&nbsp;</em>studies.</strong></p>

<p>Blots shown in the paper are highlighted in bold.</p>

<p>Scans of Western blots (LI-COR):</p>

<ul>
	<li>SNX3 shown in&nbsp;<strong>FigureS14B_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right:&nbsp;<strong>SNX3 (Figure S14B</strong>), FAM213A, Miro1, Miro1</p>

<ul>
	<li>Flag-Ub (SNX3) shown in&nbsp;<strong>Figure_S14B_Flag_SNX3_800nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4:WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: Miro1, FAM213A, Miro1,&nbsp;<strong>SNX3 (Figure S14B)</strong></p>

<ul>
	<li>His (SNX3) shown in&nbsp;<strong>Figure_S14B_His_SNX3_700nm.tif</strong></li>
</ul>

<p>Gel loading: lanes: 1+2: &ndash; PINK1, 3+4: WT PINK1, 5+6: KD PINK1</p>

<p>Membranes, left to right: CPT1&alpha;, MFN1,&nbsp;<strong>SNX3 (Figure S14B)</strong>, FAM213A</p>

<p>&nbsp;</p>

<p><strong>FigureS1: Immunocytochemistry of mouse cortical neurons.</strong></p>

<ul>
	<li><strong>FigureS1_TILE_maximun intensity projection.tif</strong></li>
</ul>

<p>Original acquisition: MAP2 neuronal marker (green-488); GFAP astrocytic marker (red-594); Hoechst nuclear marker (blue 361/497).&nbsp;</p>

<ul>
	<li><strong>FigureS1MGB (RGB).tif</strong></li>
</ul>

<p>Modified from FigureS1_TILE_maximun intensity projection.tif: MAP2 (green); GFAP (magenta); Hoechst (blue).</p>

<p>&nbsp;</p>

<p><strong>Table for Fig1DE.xlsx</strong></p>

<p>Numerical data for the charts shown in Figure1D and Figure1E.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1A.xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for quantification of Map2 and GFAP in mouse cortical neurons shown in FigureS1A.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS1B (Cortical neurons_DIA_Report).xlsx</strong></p>

<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Numerical data for DIA proteomic analysis of AO and DMSO treated cortical neurons shown in FigureS1B.</p>

<p>&nbsp;</p>

<p><strong>Table for FigS2B_C_Oxygraph.xlsx</strong></p>

<p>Numerical data for the charts shown in FigureS2B and FigureS2C.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3A.xlsx</strong></p>

<p>Numerical data for total protein abundance in PINK1 WT and KO shown in Figure3A.</p>

<p>&nbsp;</p>

<p><strong>Table for Fig3B.xlsx</strong></p>

<p>Numerical data of abundance of phosphorylated-Ser65 or Ser57&nbsp;&nbsp;shown in Figure3B.</p>",Dataset,2021-08-05 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Odetta Antico
Alban Ordureau
Michael Stevens
Francois Singh
Raja S. Nirujogi
Marek Gierlinski
Erica Barini
Mollie L. Rickwood
Alan Prescott
Rachel Toth
Ian G. Ganley
J. Wade Harper
Miratul M. K. Muqit",cc-by-4.0,W4393768369,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404
354,12191805,2024-07-09T13:57:19.922867+00:00,10.5281/zenodo.12191805,"Data from ""SynBot: An open-source image analysis software for automated quantification of synapses""","<p>Primary image datasets and associated tables from the paper ""SynBot: An open-source image analysis software for automated quantification of synapses"".&nbsp;</p>",Dataset,2024-06-20 00:00:00,personal,"Savage, Justin",cc-by-4.0,,,,
355,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5036096692,Herschel S. Dhekne,0000-0002-2240-1230
356,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5029388712,Francesca Tonelli,0000-0002-4600-6630
357,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5071273941,Wondwossen M Yeshaw,0000-0002-3134-3458
358,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5085896336,Claire Y Chiang,0000-0002-0999-9856
359,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5111161388,Limouse Charles,
360,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5094360736,Jaimon Ebsy,
361,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5109698968,Purlyte Elena,
362,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5111163736,Alessi Dario R,
363,7659210,2023-02-26T06:22:12.553794+00:00,10.5281/zenodo.7659210,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the figure 1 of the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot;&nbsp;</strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;</p>

<p>These include&nbsp;</p>

<p>- data (annotated .tiff exports) from Metamorph acquired spinning disk confocal microscope</p>

<p>- sequencing data as fastq files .gz files from Hiseq or Miseq next generation sequencing,&nbsp;&nbsp;</p>

<p>- graphs made using GraphPad Prism&nbsp;(.pzf files).</p>

<p>- flow cytometry .fcs files and workspace files</p>

<p>-&nbsp;<a href=""https://zenodo.org/api/files/de4d1da1-785a-4f55-a542-876647a2a5ad/Figure%201-%20file%20names%20legend.xlsx"">Figure 1- file names legend.xlsx</a>&nbsp;excel sheet explaining the details</p>",Dataset,2023-06-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Dhekne, Herschel Shrikant
Tonelli, Francesca
Yeshaw, Wondwossen M
Chiang, Claire Y
Limouse Charles
Jaimon Ebsy
Purlyte Elena
Alessi Dario R
Pfeffer Suzanne R",cc-by-4.0,W4393876811,A5113165099,Pfeffer Suzanne R,
364,10791354,2024-03-21T20:25:07.265032+00:00,10.5281/zenodo.10791354,Figure 1: autophagy flux in RUBCN KOs [FINAL],,Dataset,2024-03-07 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
365,7577446,2023-01-30T21:29:48.917542+00:00,10.5281/zenodo.7577446,Alpha-synuclein ColabFold modeling,<p>ColabFold modeling of wild-type human alpha-synuclein and a variant carrying a Ser129Asp mutation</p>,Dataset,2022-12-23 00:00:00,personal,"Boyer, Nicholas P.",cc-by-4.0,W4393751682,A5090021123,Nicholas P. Boyer,0000-0001-8283-1710
366,8253811,2023-08-16T23:15:53.464655+00:00,10.5281/zenodo.8253811,ASAP Columbia PBMC FACS Report,<p>Columbia PBMC FACS&nbsp;Report (n=77) generated by ASAP Team Chen at MGH/HMS</p>,Dataset,2023-08-16 00:00:00,"personal
personal","Shi, Leilei
Peng, Weiyi",cc-by-4.0,W4393747115,A5004225770,Leilei Shi,0000-0002-9427-4357
367,8253811,2023-08-16T23:15:53.464655+00:00,10.5281/zenodo.8253811,ASAP Columbia PBMC FACS Report,<p>Columbia PBMC FACS&nbsp;Report (n=77) generated by ASAP Team Chen at MGH/HMS</p>,Dataset,2023-08-16 00:00:00,"personal
personal","Shi, Leilei
Peng, Weiyi",cc-by-4.0,W4393747115,A5071360122,Weiyi Peng,0000-0002-7785-6240
368,6477921,2022-04-22T14:14:23.235308+00:00,10.5281/zenodo.6477921,ipdgc/Colocalization-Pipeline: GP2 Hackathon Colocalization Pipeline,"<p>Code associated with Project 3: Colocalization pipeline from the 2021 GP2/IPDGC Hackathon and manuscript &quot;The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson&#39;s disease data&quot;.</p>",Software,2022-04-22 00:00:00,"personal
personal
personal
personal","devinachetty
Anni Moore
Konstantin Senkevich
paulandroide",other-open,,,,
369,10091730,2023-11-09T16:42:44.573367+00:00,10.5281/zenodo.10091730,Raw band intensity values for ATG3 WT or Mutants in vitro LC3 lipidation,"<p>Raw band intensity values used for the quantification of in vitro LC3 lipidation results (Fig4C) in Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore.</p>",Dataset,2023-11-09 00:00:00,personal,"Xuefeng, Ren",cc-by-4.0,W4393500945,A5041244181,Xuefeng Ren,0000-0002-4822-4316
370,10696967,2024-02-26T17:19:12.606315+00:00,10.5281/zenodo.10696967,Single cell allele specific expression processing pipeline,"<p>This pipeline is built as part of the ASAP project to take single nuclei data and a phased vcf file and, using that data, get allele specific expression information for the single nuclei data using STARSolo. It requires Java, nextflow, and Conda. Detailed running instructions are included.&nbsp;</p>",Software,2024-02-23 00:00:00,personal,"Simmons, Sean",mit,,,,
371,10951333,2024-04-10T17:42:59.345593+00:00,10.5281/zenodo.10951333,Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb,"<p>Data sets for;</p>
<p>Neither alpha-synuclein-preformed fibrils derived from patients with&nbsp;<em>GBA1</em> mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb</p>",Dataset,2024-04-09 00:00:00,personal,"Killinger, Bryan",cc-by-4.0,,,,
372,7352291,2022-11-23T18:09:28.516018+00:00,10.5281/zenodo.7352291,CD3_CD68_PD_midbrain_counts,<p>This file contains quantification of interactions between CD3+ and CD68+ cells in the perivascular space of PD or neurological control midbrains.</p>,Dataset,2022-11-23 00:00:00,personal,"Schonhoff, Aubrey M",cc-by-4.0,W4393487981,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
373,7149142,2022-10-05T14:43:53.460830+00:00,10.5281/zenodo.7149142,Lipid droplet quantification datasheet of different MIGA2 constructs expressing cells,"<p>Lipid droplet quantification datasheet of different MIGA2 constructs expressing Hela cells: WT, MIGA2 KO, MIGA2 KO cells transfected with WT MIGA2, MIGA2&nbsp;KO cells transfected with MIGA2 mutants.</p>",Dataset,2022-10-05 00:00:00,personal,Zhouping Hong,cc-by-4.0,W4394052775,A5072197894,Zhouping Hong,0000-0002-8513-3288
374,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5076988745,Eva Karasmanis,0000-0002-0139-0210
375,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5019965194,Verena Dederer,0000-0002-7877-4706
376,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5053245720,Marta Sanz Murillo,0000-0002-6175-9315
377,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5042127936,Sebastian Mathea,0000-0001-8500-4569
378,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5081790435,Kathryn M. Hatch,0000-0002-0680-3491
379,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5011173483,Andres E. Leschziner,0000-0002-7732-7023
380,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5021023250,Samara L. Reck‐Peterson,0000-0002-1553-465X
381,10530220,2024-01-19T02:56:06.227032+00:00,10.5281/zenodo.10530220,Figure 4 tabular data for the paper Development of LRRK2 designed ankyrin-repeat proteins,"<p>Figure 4 tabular data for</p>
<p>1) GFP-LRRK2 filamentation assay in HEK293T cells in the presence or absence of DARPin E11</p>
<p>2) westernblot analysis of pRab8/total GFP-Rab8 signal in the presence or absence of DARPin E11</p>
<p>Data stem from the paper &nbsp;""Development of LRRK2 designed ankyrin-repeat proteins"" and complement 10.5281/zenodo.10471514</p>",Dataset,2024-01-18 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Karasmanis, Eva
Dederer, Verena
Sanz-Murillo, Marta
Mathea, Sebastian
Hatch, Kathryn
Leschziner, Andres
Reck-Peterson, Samara
Knapp, Sebastian",cc-by-4.0,W4393785040,A5088907609,Sebastian Knapp,0000-0003-0025-3430
382,10703094,2024-02-26T00:52:23.555684+00:00,10.5281/zenodo.10703094,Data from: Inhibition of Indirect Pathway Activity Causes Abnormal Decision-Making In a Mouse Model of Impulse Control Disorder in Parkinson's Disease (preprint version),<p>Data from: Zhuang et al (2023) Inhibition of Indirect Pathway Activity Causes Abnormal Decision-Making In a Mouse Model of Impulse Control Disorder in Parkinson's Disease (Preprint Version).&nbsp;</p>,Dataset,2024-02-25 00:00:00,"personal
personal","Zhuang, Xiaowen
Nelson, Alexandra",cc-by-4.0,,,,
383,6587708,2022-05-27T15:56:42.104209+00:00,10.5281/zenodo.6587708,RHReynolds/neurodegen-psych-local-corr: v1.0,<p>Create release for Zenodo DOI generation.</p>,Software,2022-05-27 00:00:00,personal,Regina Hertfelder Reynolds,other-open,,,,
384,12531178,2024-08-14T19:57:46.885466+00:00,10.5281/zenodo.12531178,Single cell allele specific expression processing pipeline for long read data,"<p>This pipeline is built to take in long read single cell or single nucleus 10X data (ONT, PacBio, or MAS-Seq) and producing ASE specific counts at the gene or isoform level.</p>",Software,2024-06-25 00:00:00,personal,"Simmons, Sean",mit,,,,
385,11243617,2024-09-17T14:03:59.692076+00:00,10.5281/zenodo.11243617,VPS13B is localized at the interface between Golgi cisternae and is a functional partner of FAM177A1,"<p>Source Data For Main Figures 1-4 and Supplemental Figures 1-3</p>
<p>Tabular Data For Main Figure 1-3 and Supplemental Figure 3</p>
<p>Training Dataset for Main Figure 4 embedded in <a href=""../api/records/11243617/draft/files/Ilastik%20trained%20Data%20(Golgi%20reformation).ilp/content"" target=""_blank"" rel=""noopener noreferrer"">Ilastik trained Data (Golgi reformation).ilp</a> file that requires you to download ilastik software.</p>",Dataset,2024-05-22 00:00:00,personal,"Ugur, Berrak",cc-by-4.0,,,,
386,7709868,2023-03-09T01:00:41.404007+00:00,10.5281/zenodo.7709868,Tmem119_CreERT2_IAB_flox_IFNgamma_test,"<p>Tmem119 CreERT2/+ IAB fl/fl mice were dosed with i.p. tamoxifen. Six weeks after tamoxifen, mice were given IFN gamma. Three days later, microglial and BAM capacity to upregulate MHCII was assayed via flow cytometry.</p>",Dataset,2023-03-09 00:00:00,personal,Aubrey Schonhoff,cc-by-4.0,W4393440895,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
387,11060950,2024-04-25T09:52:18.535715+00:00,10.5281/zenodo.11060950,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system - AlphaFold models and Movie,"<p><strong>Loss of function mutations in PTEN-induced kinase 1 (PINK1) are a frequent cause of earlyonset Parkinson&rsquo;s disease (PD). Stabilisation of PINK1 at the Translocase of Outer Membrane&nbsp; (TOM) complex of damaged mitochondria is a critical step for its activation. To date the&nbsp; mechanism of how PINK1 is activated in the TOM complex is unclear. Herein we report co-expression of human PINK1 and all seven TOM subunits in Saccharomyces cerevisiae is&nbsp; sufficient for PINK1 activation. We use this reconstitution system to systematically assess the&nbsp; role of each TOM subunit towards PINK1 activation. We unambiguously demonstrate that the TOM20 and TOM70 receptor subunits are required for optimal PINK1 activation and map their sites of interaction with PINK1 using AlphaFold structural modelling and mutagenesis. We also demonstrate an essential role of the pore-containing subunit TOM40 and its structurally associated subunits TOM7 and TOM22 for PINK1 activation. These molecular findings will aid in the development of small molecule activators of PINK1 as a therapeutic strategy for PD.&nbsp;</strong></p>
<p><strong>Figure 3A and Supplementary Figure 6 AlphaFold models</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PINK1-TOM complex (PINK1, TOM20, TOM40, TOM22 and TOM7)</p>
<p>o&nbsp;&nbsp; Model1</p>
<p>o&nbsp;&nbsp; Model2</p>
<p>o&nbsp;&nbsp; Model3</p>
<p>o&nbsp;&nbsp; Model4</p>
<p>o&nbsp;&nbsp; Model5</p>
<p><strong>Figure 4A and Supplementary Figure 10 AlphaFold models</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PINK1-TOM70 complex</p>
<p>o&nbsp;&nbsp; Model1</p>
<p>o&nbsp;&nbsp; Model2</p>
<p>o&nbsp;&nbsp; Model3</p>
<p>o&nbsp;&nbsp; Model4</p>
<p>o&nbsp;&nbsp; Model5</p>",Model,2024,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Raimi, Olawale
Ojha, Hina
Ehses, Kenneth
Dederer, Verena
Lange, Sven
Rivera, Cristian Polo
Deegan, Tom D
Chen, Yinchen
Wightman, Melanie
Toth, Rachel
Labib, Karim P.M.
Mathea, Sebastian
Ranson, Neil
Fernandez-Busnadiego, Ruben
Muqit, Miratul",cc-by-4.0,,,,
388,10514256,2024-01-16T11:36:59.959539+00:00,10.5281/zenodo.10514256,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p>
<p><strong>Figure 1. &alpha;-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human &alpha;-synuclein in (C) duodenum (&alpha;-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (&alpha;-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (&alpha;-synuclein quantification in ng/mg of nodose tissue), from Snca&ndash;/&ndash; and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca&ndash;/&ndash; and SNCAA53T mice.&nbsp;</p>
<p><strong>Figure 3. Conditional human &alpha;-synuclein expression induces &alpha;-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p>
<p><strong>Figure 4. Conditional human &alpha;-synuclein expression in gut mucosal cells produces in &alpha;-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human &alpha;-synuclein protein in nodose ganglia of nontransgenic, Snca&ndash;/&ndash;, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca&ndash;/&ndash;, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca&ndash;/&ndash;, and SNCAbow mice.</p>
<p><strong>Figure 5. Vagotomy spares the nodose ganglia from &alpha;-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of &alpha;-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p>
<p>Epidemiological and histopathological findings have raised the possibility that misfolded &alpha;-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant &alpha;-synuclein fibrils to study gut-to-brain &alpha;-synuclein transfer, the possible origins of misfolded &alpha;-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express &alpha;-synuclein. Here, we employed mouse intestinal organoids expressing human &alpha;-synuclein to observe the transfer of &alpha;-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of &alpha;-synuclein. In mice expressing human &alpha;-synuclein, but no mouse &alpha;-synuclein, &alpha;-synuclein fibril-templating activity emerged in &alpha;-synuclein&ndash;seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human &alpha;-synuclein expression to intestinal epithelial cells, &alpha;-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of &alpha;-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of &alpha;-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar &alpha;-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2024-01-15 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Roger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4393521917,A5071278272,Andrew B. West,0000-0002-3034-4061
389,10514256,2024-01-16T11:36:59.959539+00:00,10.5281/zenodo.10514256,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p>
<p><strong>Figure 1. &alpha;-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human &alpha;-synuclein in (C) duodenum (&alpha;-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (&alpha;-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (&alpha;-synuclein quantification in ng/mg of nodose tissue), from Snca&ndash;/&ndash; and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca&ndash;/&ndash; and SNCAA53T mice.&nbsp;</p>
<p><strong>Figure 3. Conditional human &alpha;-synuclein expression induces &alpha;-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p>
<p><strong>Figure 4. Conditional human &alpha;-synuclein expression in gut mucosal cells produces in &alpha;-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human &alpha;-synuclein protein in nodose ganglia of nontransgenic, Snca&ndash;/&ndash;, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca&ndash;/&ndash;, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca&ndash;/&ndash;, and SNCAbow mice.</p>
<p><strong>Figure 5. Vagotomy spares the nodose ganglia from &alpha;-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of &alpha;-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p>
<p>Epidemiological and histopathological findings have raised the possibility that misfolded &alpha;-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant &alpha;-synuclein fibrils to study gut-to-brain &alpha;-synuclein transfer, the possible origins of misfolded &alpha;-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express &alpha;-synuclein. Here, we employed mouse intestinal organoids expressing human &alpha;-synuclein to observe the transfer of &alpha;-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of &alpha;-synuclein. In mice expressing human &alpha;-synuclein, but no mouse &alpha;-synuclein, &alpha;-synuclein fibril-templating activity emerged in &alpha;-synuclein&ndash;seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human &alpha;-synuclein expression to intestinal epithelial cells, &alpha;-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of &alpha;-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of &alpha;-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar &alpha;-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2024-01-15 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Roger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4393521917,A5109698060,Roger Liddle,
390,10514256,2024-01-16T11:36:59.959539+00:00,10.5281/zenodo.10514256,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p>
<p><strong>Figure 1. &alpha;-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human &alpha;-synuclein in (C) duodenum (&alpha;-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (&alpha;-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (&alpha;-synuclein quantification in ng/mg of nodose tissue), from Snca&ndash;/&ndash; and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca&ndash;/&ndash; and SNCAA53T mice.&nbsp;</p>
<p><strong>Figure 3. Conditional human &alpha;-synuclein expression induces &alpha;-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p>
<p><strong>Figure 4. Conditional human &alpha;-synuclein expression in gut mucosal cells produces in &alpha;-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human &alpha;-synuclein protein in nodose ganglia of nontransgenic, Snca&ndash;/&ndash;, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca&ndash;/&ndash;, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca&ndash;/&ndash;, and SNCAbow mice.</p>
<p><strong>Figure 5. Vagotomy spares the nodose ganglia from &alpha;-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of &alpha;-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p>
<p>Epidemiological and histopathological findings have raised the possibility that misfolded &alpha;-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant &alpha;-synuclein fibrils to study gut-to-brain &alpha;-synuclein transfer, the possible origins of misfolded &alpha;-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express &alpha;-synuclein. Here, we employed mouse intestinal organoids expressing human &alpha;-synuclein to observe the transfer of &alpha;-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of &alpha;-synuclein. In mice expressing human &alpha;-synuclein, but no mouse &alpha;-synuclein, &alpha;-synuclein fibril-templating activity emerged in &alpha;-synuclein&ndash;seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human &alpha;-synuclein expression to intestinal epithelial cells, &alpha;-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of &alpha;-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of &alpha;-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar &alpha;-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2024-01-15 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Roger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4393521917,A5072554284,Arpine Sokratian,0000-0001-6654-5773
391,10514256,2024-01-16T11:36:59.959539+00:00,10.5281/zenodo.10514256,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p>
<p><strong>Figure 1. &alpha;-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human &alpha;-synuclein in (C) duodenum (&alpha;-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (&alpha;-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (&alpha;-synuclein quantification in ng/mg of nodose tissue), from Snca&ndash;/&ndash; and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca&ndash;/&ndash; and SNCAA53T mice.&nbsp;</p>
<p><strong>Figure 3. Conditional human &alpha;-synuclein expression induces &alpha;-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p>
<p><strong>Figure 4. Conditional human &alpha;-synuclein expression in gut mucosal cells produces in &alpha;-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human &alpha;-synuclein protein in nodose ganglia of nontransgenic, Snca&ndash;/&ndash;, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca&ndash;/&ndash;, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca&ndash;/&ndash;, and SNCAbow mice.</p>
<p><strong>Figure 5. Vagotomy spares the nodose ganglia from &alpha;-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of &alpha;-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p>
<p>Epidemiological and histopathological findings have raised the possibility that misfolded &alpha;-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant &alpha;-synuclein fibrils to study gut-to-brain &alpha;-synuclein transfer, the possible origins of misfolded &alpha;-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express &alpha;-synuclein. Here, we employed mouse intestinal organoids expressing human &alpha;-synuclein to observe the transfer of &alpha;-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of &alpha;-synuclein. In mice expressing human &alpha;-synuclein, but no mouse &alpha;-synuclein, &alpha;-synuclein fibril-templating activity emerged in &alpha;-synuclein&ndash;seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human &alpha;-synuclein expression to intestinal epithelial cells, &alpha;-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of &alpha;-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of &alpha;-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar &alpha;-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2024-01-15 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Roger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4393521917,A5024539060,Katherine Ramos Chavez,0000-0001-8952-385X
392,10514256,2024-01-16T11:36:59.959539+00:00,10.5281/zenodo.10514256,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p>
<p><strong>Figure 1. &alpha;-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human &alpha;-synuclein in (C) duodenum (&alpha;-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (&alpha;-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (&alpha;-synuclein quantification in ng/mg of nodose tissue), from Snca&ndash;/&ndash; and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca&ndash;/&ndash; and SNCAA53T mice.&nbsp;</p>
<p><strong>Figure 3. Conditional human &alpha;-synuclein expression induces &alpha;-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p>
<p><strong>Figure 4. Conditional human &alpha;-synuclein expression in gut mucosal cells produces in &alpha;-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human &alpha;-synuclein protein in nodose ganglia of nontransgenic, Snca&ndash;/&ndash;, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca&ndash;/&ndash;, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca&ndash;/&ndash;, and SNCAbow mice.</p>
<p><strong>Figure 5. Vagotomy spares the nodose ganglia from &alpha;-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of &alpha;-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p>
<p>Epidemiological and histopathological findings have raised the possibility that misfolded &alpha;-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant &alpha;-synuclein fibrils to study gut-to-brain &alpha;-synuclein transfer, the possible origins of misfolded &alpha;-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express &alpha;-synuclein. Here, we employed mouse intestinal organoids expressing human &alpha;-synuclein to observe the transfer of &alpha;-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of &alpha;-synuclein. In mice expressing human &alpha;-synuclein, but no mouse &alpha;-synuclein, &alpha;-synuclein fibril-templating activity emerged in &alpha;-synuclein&ndash;seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human &alpha;-synuclein expression to intestinal epithelial cells, &alpha;-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of &alpha;-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of &alpha;-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar &alpha;-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2024-01-15 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Roger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4393521917,A5026190664,Rashmi Chandra,0000-0001-9591-8997
393,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5094341579,Cai Waijiao,
394,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5105473264,Wakamatsu Kazumasa,
395,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5112055476,Anna Fabio,
396,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5029957920,Kai Yang,0000-0001-6260-1192
397,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5094351093,Mohamadzadehonarvar Niyaz,
398,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5020152429,Pranay Srivastava,0000-0002-9289-2696
399,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5112188464,Hitomi Tanaka,
400,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5109698585,Holly Gabriel,
401,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5094351094,Casella Luigi,
402,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5065973944,Shosuke Ito,0000-0001-9182-5144
403,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5094351092,Zecca Luigi,
404,7637902,2023-02-14T04:11:00.486922+00:00,10.5281/zenodo.7637902,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease,<p>Raw data sets for the manuscript &quot;<strong>DOPA pheomelanin is increased in nigral neuromelanin of Parkinson&rsquo;s disease&quot;</strong></p>,Dataset,2022-09-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Cai Waijiao
Wakamatsu Kazumasa
Zucca Fabio A.
Yang Kai
Mohamadzadehonarvar Niyaz
Srivastava Pranay
Tanaka Hitomi
Holly Gabriel
Casella Luigi
Ito Shosuke
Zecca Luigi
Chen Xiqun",cc-by-4.0,W4393814874,A5012470875,Xiqun Chen,0000-0001-8582-8891
405,8219055,2023-08-09T04:14:28.646241+00:00,10.5281/zenodo.8219055,QC and WGS data on compound heterozygous PRKN-mutant (R275W/dEx8) PD patient,<p>Primary/raw&nbsp;data for QC on the characterisation of an iPSC line from a PD patient (Stem Cell Research)</p>,Dataset,2023-08-06 00:00:00,personal,Dmitry A. Ovchinnikov,cc-by-4.0,W4393597853,A5064216415,Dmitry A. Ovchinnikov,0000-0001-9603-8385
406,11122117,2024-07-08T19:58:01.569547+00:00,10.5281/zenodo.11122117,Phosphoglycerate kinase is a central leverage point in Parkinson's Disease driven neuronal metabolic deficits,"<p><span>Although certain drivers of familial Parkinson&rsquo;s Disease (PD) compromise mitochondrial integrity, whether metabolic deficits underly other idiopathic or genetic origins of PD is unclear. Here, we demonstrate that PGK1, a gene in the PARK12 susceptibility locus, <span>&nbsp;</span>is rate limiting in neuronal glycolysis and that modestly increasing PGK1 expression significantly boosts <span>&nbsp;</span>neuronal ATP production kinetics that is sufficient to suppress PARK20-driven synaptic dysfunction. We found that his activity enhancement depends on the molecular chaperone PARK7/DJ-1, whose loss of function significantly disrupts axonal bioenergetics. <em>In-vivo, </em>viral expression of PGK1 confers protection of striatal DA axons against metabolic lesions. These data support the notion that bioenergetic deficits may underpin PD associated pathologies and point to improving neuronal ATP production kinetics as a promising path forward in PD therapeutics.</span></p>",Dataset,2023-10-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Kokotos, Alexandros
Antoniazzi, Aldana M.
Unda, Santiago R.
Ko, Myung Soo
Park, Daehun
Eliezer, David
Kaplitt, Michael G.
De Camilli, Pietro
Ryan, Timothy A.",cc-by-4.0,,,,
407,8083724,2023-07-17T21:37:39.552267+00:00,10.5281/zenodo.8083724,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore: Molecular dynamics simulation data","<p>Atomistic molecular dynamics simulation data set accompanying manuscript &quot;Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore&quot;.</p>",Dataset,2023-07-17 00:00:00,"personal
personal","Shanlin Rao
Gerhard Hummer",cc-by-4.0,W4393569782,A5028861095,Shanlin Rao,0000-0003-4892-5523
408,8083724,2023-07-17T21:37:39.552267+00:00,10.5281/zenodo.8083724,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore: Molecular dynamics simulation data","<p>Atomistic molecular dynamics simulation data set accompanying manuscript &quot;Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore&quot;.</p>",Dataset,2023-07-17 00:00:00,"personal
personal","Shanlin Rao
Gerhard Hummer",cc-by-4.0,W4393569782,A5059945365,Gerhard Hummer,0000-0001-7768-746X
409,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5038944590,Hanqin Li,0000-0001-7995-1084
410,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5000495585,Oriol Busquets,0000-0002-1372-9699
411,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5088126377,Yogendra Verma,0000-0003-3380-6089
412,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5013626934,Khaja Syed,0000-0002-7682-7608
413,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5004265638,Nitzan Kutnowski,0000-0002-3012-4616
414,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5038011560,Gabriella Pangilinan,0000-0003-2662-7883
415,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5035219354,Luke A. Gilbert,0000-0001-5854-0825
416,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5089305536,Helen S. Bateup,0000-0002-0135-0972
417,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5034073565,Donald C. Rio,
418,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5045835078,Dirk Hockemeyer,0000-0002-5598-5092
419,6941599,2022-09-06T15:46:18.938180+00:00,10.5281/zenodo.6941599,Highly efficient generation of isogenic pluripotent stem cell models using prime editing - Datasets,"<p>This collection contains the following datasets:</p>

<p>1. AAVS1 knock-in genotyping</p>

<p>2. aCGH karyotyping</p>

<p>3. Tabular datasets for associated graphical figures&nbsp;</p>

<p>&nbsp;</p>",Dataset,2022-07-29 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393683470,A5070152031,Frank Soldner,0000-0002-7102-8655
420,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5013260183,Marta González-Sepúlveda,0000-0002-5627-847X
421,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5063862942,Joan Compte,0000-0001-5447-5122
422,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5103098387,Thais Cuadros,0000-0001-7376-7470
423,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5021245587,Alba Nicolau,0000-0002-0836-2802
424,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5012546198,Camille Guillard-Sirieix,0000-0002-2645-1892
425,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5088743556,Núria Peñuelas,0000-0001-6443-9790
426,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5090842506,Marina Lorente Picón,0000-0002-3629-9804
427,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5057918981,Annabelle Parent,0000-0002-6195-812X
428,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5081551825,Jordi Romero‐Giménez,0000-0002-8459-9895
429,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5002959173,Joana M. Cladera-Sastre,0000-0002-5680-5057
430,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5022347865,Ariadna Laguna,0000-0002-9732-6677
431,7075026,2022-09-13T13:03:31.090753+00:00,10.5281/zenodo.7075026,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,<p>Supplementary datasets (Supplementary tables 1 to 10)</p>,Dataset,2022-09-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","González-Sepúlveda, Marta
Compte, Joan
Cuadros, Thais
Nicolau, Alba
Guillard-Sirieix, Camille
Peñuelas, Nuria
Lorente-Picon, Marina
Parent, Annabelle
Romero-Giménez, Jordi
Cladera-Sastre, Joana M.
Laguna, Ariadna
Vila, Miquel",cc-by-4.0,W4393794406,A5059189782,Miquel Vila,0000-0002-1352-989X
432,13768680,2024-09-16T13:47:03.634124+00:00,10.5281/zenodo.13768680,Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,"<p>Raw data used to generate the figures in the paper ""Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits"" published as a bioRxiv preprint doi: https://doi.org/10.1101/2023.08.08.552400; v1 posted August 8, 2023; v2 posted August 14, 2024.</p>",Dataset,2024-09-16 00:00:00,"personal
personal
personal","Laguna Tuset, Ariadna
Peñuelas, Núria
Vila Bover, Miquel",cc-by-4.0,,,,
433,13378407,2024-08-27T08:26:18.139039+00:00,10.5281/zenodo.13378407,Parkinson's Families Project: a UK-wide study of early onset and familial Parkinson's disease,"<p>The Parkinson&rsquo;s Families Project is a UK-wide study aimed at identifying genetic variation associated with familial and early-onset Parkinson's disease (PD). We recruited individuals with a clinical diagnosis of PD and age at motor symptom onset &le; 45 years and/or a family history of PD in up to third-degree relatives. We analysed DNA samples with a combination of single nucleotide polymorphism (SNP) array genotyping, multiplex ligation-dependent probe amplification (MLPA), and whole-genome sequencing (WGS). We investigated the association between identified pathogenic mutations and demographic and clinical factors such as age at motor symptom onset, family history, motor symptoms (MDS-UPDRS) and cognitive performance (MoCA)<em>.</em> The files contain the cleaned datasets used to perform statistical and polygenic risk score analyses.&nbsp;</p>",Other,2024-08-27 00:00:00,personal,"Raquel, Raquel",cc-by-4.0,,,,
434,10469445,2024-01-09T13:58:03.845716+00:00,10.5281/zenodo.10469445,Polarisation camera PAINT movie of single Nile red dyes binding to lipid bilayer-coated silica microspheres,"<p>This PAINT dataset is a movie of the fluorescence of single Nile red molecules reversibly binding to a lipid bilayer (DPPC + 40% cholesterol) on a 5 &mu;m diameter silica microsphere (44054-5ML-F, Sigma-Aldrich). Images were recorded at 3 different focal planes; approximately at the midpoint of the bead (z1), the top of the bead (z3) and a position in between (z2).</p>
<p>The data was collected on a fluorescence microscope (Eclipse Ti2, Nikon) with a polarisation camera (CS505MUP, Thorlabs). The molecules were excited with a 514 nm DPSS laser with a measured power density at the sample plane of 6.08 kW/cm^2. An exposure time of 50 ms was used. The following filters were used: dichroic (Di03-R514-t1, Semrock) and emission filter (FF01-515/LP and FF01-650/200, Semrock).</p>",Dataset,2024-01-08 00:00:00,personal,"Bruggeman, Ezra",cc-by-4.0,W4393785505,A5014618738,Ezra Bruggeman,0000-0001-6100-1443
435,7887281,2023-05-02T17:23:28.525484+00:00,10.5281/zenodo.7887281,2022 Workshop on Synuclein Pre-Formed Fibrils,"<p>In 2022, MJFF and the ASAP Initiative formed a working group to discuss improving robustness and reproducibility of the alpha-synuclein pre-formed fibril model. The workshop was divided into three section to cover (1) characterizing the protein injectate, (2) understanding the model and interpreting phenotypes, and (3) choosing between recombinant protein, brain homogenate, and amplified patient material as injectate.&nbsp;This document contains the discussion summary.&nbsp;</p>",Conference paper,2023-05-02 00:00:00,"personal
personal","Polinski, Nicole
Volpicelli-Daley, Laura",cc-by-4.0,W4367667609,A5053530631,Nicole K. Polinski,0000-0003-4613-9115
436,7887281,2023-05-02T17:23:28.525484+00:00,10.5281/zenodo.7887281,2022 Workshop on Synuclein Pre-Formed Fibrils,"<p>In 2022, MJFF and the ASAP Initiative formed a working group to discuss improving robustness and reproducibility of the alpha-synuclein pre-formed fibril model. The workshop was divided into three section to cover (1) characterizing the protein injectate, (2) understanding the model and interpreting phenotypes, and (3) choosing between recombinant protein, brain homogenate, and amplified patient material as injectate.&nbsp;This document contains the discussion summary.&nbsp;</p>",Conference paper,2023-05-02 00:00:00,"personal
personal","Polinski, Nicole
Volpicelli-Daley, Laura",cc-by-4.0,W4367667609,A5049620072,Laura A. Volpicelli‐Daley,0000-0001-8934-4018
437,8260629,2023-09-24T22:38:55.930482+00:00,10.5281/zenodo.8260629,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,<p>Part 2 of NGS data associated with Uoselis et al (2023).</p>,Journal article,2023-08-18 00:00:00,personal,"Uoselis, Louise",cc-by-4.0,W4387001202,A5046225091,Louise Uoselis,0000-0001-8538-9817
438,11529071,2024-10-03T20:19:44.006491+00:00,10.5281/zenodo.11529071,Activity-Dependent Remodeling of Corticostriatal Axonal Boutons During Motor Learning,<p>Source Data</p>,Dataset,2024-06-08 00:00:00,personal,"Sheng, Mengjun",cc-by-4.0,,,,
439,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5060842798,Carmela Giachino,0000-0003-3650-8677
440,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5075407827,Cataldo Tirolo,0000-0003-1747-8134
441,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5021181399,Salvatore Caniglia,0000-0002-9416-8458
442,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5030796584,L'Episcopo Francesca,
443,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5074264245,Maria Francesca Serapide,0000-0001-6332-4772
444,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5078024953,Federico Bertoli,0000-0001-5600-1190
445,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5062913763,Claudio Giuliano,0000-0002-2329-6372
446,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5003743419,Marika Mearelli,
447,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5050011017,Meike Jakobi,0000-0003-2025-4385
448,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5025026489,Nicole Schneiderhan‐Marra,0000-0001-6785-181X
449,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5057481978,Alfredo Pulvirenti,0000-0002-9764-0295
450,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5056933907,Michela Deleidi,0000-0003-0357-0124
451,8360523,2023-09-30T22:29:15.196712+00:00,10.5281/zenodo.8360523,LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION,"<p>Mutations in the leucine-rich repeat kinase 2 (<em>LRRK2</em>) gene are the most frequent cause of familial Parkinson&#39;s disease (PD). The incomplete penetrance of <em>LRRK2</em> mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4<sup>+</sup> T-cell infiltration and &alpha;-synuclein aggregation in the colon. Peripheral immune activation and colonic &alpha;-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.</p>",Journal article,2022-09-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Giachino, Carmela
Tirolo, Cataldo
Caniglia, Salvatore
L'Episcopo Francesca
Serapide, Maria Francesca
Bertoli, Federico
Giuliano, Claudio
Mearelli, Marika
Jakobi, Meike
Schneiderhan-Marra, Nicole
Pulvirenti, Alfredo
Deleidi, Michela
Marchetti, Bianca",cc-by-4.0,W4387228847,A5020938978,Bianca Marchetti,0000-0002-9287-8448
452,7153508,2022-10-06T16:51:32.185504+00:00,10.5281/zenodo.7153508,FSCVread_Lrrk2:  Fast scanning cyclic voltammetric data in LRRK2 knockin mice,"<p>This script was used to generate the fast-scanning cyclic voltammetric (FSCV) data in the manuscript titled&nbsp;R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations by Xenias et al.&nbsp;</p>

<p>This script is for This program reads FSCV data from pClamp .abf files acquired using the pClamp protocol and displays the following:</p>

<p>(1) The non-Faradaic electrode waveform just before when a single 200 &micro;s 300 &micro;V electrical pulse is applied to evoke dopamine (DA) release.</p>

<p>(2) The colormap of the FSCV data showing the cyclic voltammograms along the y-axis with the cathodic rise of the applied 10 Hz cyclic 400 mV/ms ramp nearest the abscissas, which represents time. NOTE: the value of the maximum peak of DA oxidation is displayed as well as the voltage region where the maximum peak is located for the voltage regions where DA is oxidized (demarcated by two horizontal black lines).</p>",Software,2022-10-06 00:00:00,personal,"Harry Xenias, Savio Chan, Loukia Parisiadou",cc-by-4.0,,,,
453,10397773,2024-01-04T14:12:25.209419+00:00,10.5281/zenodo.10397773,Plotting interspike intervals (ISI) and spikes,"<p>The files used for plotting and analysis are in code&gt;plotting<br>Interspike invertal (ISI) plot takes an .MAT file output from plexon consisting of time stamps and unit numbers and returns the ISI plots for the unit&nbsp;<br>Spikes_PC takes a .MAT file from plexon consisting of timestamps, unit numbers, PC1, PC2, and the waveforms. It plots the PC sorting for the unit as well as the average and raw waveforms.&nbsp;<br>Percent_recovery takes the timestamps of the interpolated unit, after creating and removing the artifact, &nbsp;and the timestamps of the original unit as input and then calculates the percent recover by looping over both arrays to find matching elements, then total matching elements are divided by the number of elements in the original time stamps to get the percentage recovered.&nbsp;</p>",Software,2023-12-17 00:00:00,personal,"Schwerdt, Helen",cc-by-4.0,,,,
454,7370529,2022-11-28T06:08:17.176161+00:00,10.5281/zenodo.7370529,iPSC Sorting Data,<p>iPSC Sorting Data and analyses.</p>,Dataset,2022-11-28 00:00:00,"personal
personal","Albalakhi, Ali
Xia, Ning",cc-by-4.0,W4393921437,A5012096414,Ali Albalakhi,
455,7370529,2022-11-28T06:08:17.176161+00:00,10.5281/zenodo.7370529,iPSC Sorting Data,<p>iPSC Sorting Data and analyses.</p>,Dataset,2022-11-28 00:00:00,"personal
personal","Albalakhi, Ali
Xia, Ning",cc-by-4.0,W4393921437,A5101606812,Ning Xia,0000-0001-9356-841X
456,13321153,2024-08-14T13:02:44.541684+00:00,10.5281/zenodo.13321153,scASE_py: Python pacakge for loading single cell allele specific data,"<p>This is a basic python package to enable one to work with the output of our single cell allele specific expression pipeline (ASE). The pipeline itself is present at: <a href=""https://github.com/seanken/ASE_pipeline"">https://github.com/seanken/ASE_pipeline</a></p>
<p>An R package to work with the pipeline, as well as other downstream analysis, is at: <a href=""https://github.com/seanken/scAlleleExpression"">https://github.com/seanken/scAlleleExpression</a></p>
<p>Plan to add more statistical tools to this package as time goes on</p>",Software,2024-08-14 00:00:00,personal,"Sean, Simmons",mit,,,,
457,7988132,2023-07-07T18:21:10.163205+00:00,10.5281/zenodo.7988132,Membrane interaction and mechanism of LC3 lipidation machinery in autophagy raw GUV data,<p>Raw GUV data of fluorescent&nbsp;protein imaged on a&nbsp;Nikon A1 confocal microscope with a 63 &times; Plan 359 Apochromat 1.4 NA objective. Three biological replicates were performed for each experimental 360 condition. Identical laser power and gain settings were used during the course of all conditions.</p>,Dataset,2023-07-07 00:00:00,"personal
personal
personal","Lisa Strong
Shanlin Rao
James H Hurley",cc-by-4.0,W4393687686,A5071900726,Lisa Strong,0000-0002-4293-8131
458,7988132,2023-07-07T18:21:10.163205+00:00,10.5281/zenodo.7988132,Membrane interaction and mechanism of LC3 lipidation machinery in autophagy raw GUV data,<p>Raw GUV data of fluorescent&nbsp;protein imaged on a&nbsp;Nikon A1 confocal microscope with a 63 &times; Plan 359 Apochromat 1.4 NA objective. Three biological replicates were performed for each experimental 360 condition. Identical laser power and gain settings were used during the course of all conditions.</p>,Dataset,2023-07-07 00:00:00,"personal
personal
personal","Lisa Strong
Shanlin Rao
James H Hurley",cc-by-4.0,W4393687686,A5028861095,Shanlin Rao,0000-0003-4892-5523
459,7988132,2023-07-07T18:21:10.163205+00:00,10.5281/zenodo.7988132,Membrane interaction and mechanism of LC3 lipidation machinery in autophagy raw GUV data,<p>Raw GUV data of fluorescent&nbsp;protein imaged on a&nbsp;Nikon A1 confocal microscope with a 63 &times; Plan 359 Apochromat 1.4 NA objective. Three biological replicates were performed for each experimental 360 condition. Identical laser power and gain settings were used during the course of all conditions.</p>,Dataset,2023-07-07 00:00:00,"personal
personal
personal","Lisa Strong
Shanlin Rao
James H Hurley",cc-by-4.0,W4393687686,A5061450716,James H. Hurley,0000-0001-5054-5445
460,10397754,2024-01-16T11:37:39.918658+00:00,10.5281/zenodo.10397754,Task modulated data,<p>Data (.mat) for the sorted spikes is in sorted_spikes folder and used in the representative task-modulated data figures as well as for computing the average waveforms and interspike interval histograms.&nbsp;</p>,Dataset,2023-12-17 00:00:00,personal,"Schwerdt, Helen",cc-by-4.0,W4393619062,A5035254479,Helen N. Schwerdt,
461,8264482,2023-08-18T21:12:24.976002+00:00,10.5281/zenodo.8264482,LCC Serum+CSF Luminex Report,<p>LCC Serum+CSF Luminex Report generated by ASAP Team Chen</p>,Dataset,2023-08-18 00:00:00,"personal
personal
personal","Peng, Weiyi
Shi, Leilei
Chen, Xiqun",cc-by-4.0,W4393699677,A5071360122,Weiyi Peng,0000-0002-7785-6240
462,8264482,2023-08-18T21:12:24.976002+00:00,10.5281/zenodo.8264482,LCC Serum+CSF Luminex Report,<p>LCC Serum+CSF Luminex Report generated by ASAP Team Chen</p>,Dataset,2023-08-18 00:00:00,"personal
personal
personal","Peng, Weiyi
Shi, Leilei
Chen, Xiqun",cc-by-4.0,W4393699677,A5101425667,Leilei Shi,0009-0000-7014-3347
463,8264482,2023-08-18T21:12:24.976002+00:00,10.5281/zenodo.8264482,LCC Serum+CSF Luminex Report,<p>LCC Serum+CSF Luminex Report generated by ASAP Team Chen</p>,Dataset,2023-08-18 00:00:00,"personal
personal
personal","Peng, Weiyi
Shi, Leilei
Chen, Xiqun",cc-by-4.0,W4393699677,A5031896665,Xiqun Chen,0000-0001-8285-084X
464,7370540,2022-11-28T06:11:37.348343+00:00,10.5281/zenodo.7370540,SHSY5Y Sorting Data,<p>SHSY5Y Sorting Data and analyses</p>,Dataset,2022-11-28 00:00:00,"personal
personal","Albalakhi, Ali
Xia, Ning",cc-by-4.0,W4393531566,A5012096414,Ali Albalakhi,
465,7370540,2022-11-28T06:11:37.348343+00:00,10.5281/zenodo.7370540,SHSY5Y Sorting Data,<p>SHSY5Y Sorting Data and analyses</p>,Dataset,2022-11-28 00:00:00,"personal
personal","Albalakhi, Ali
Xia, Ning",cc-by-4.0,W4393531566,A5101606812,Ning Xia,0000-0001-9356-841X
466,8384706,2023-10-01T00:55:59.878851+00:00,10.5281/zenodo.8384706,ADP Glo Kinase assay for PI3KC3-C1,<p>ADP Glo kinase assay data from associated publication</p>,Dataset,2023-09-27 00:00:00,personal,Annan S. I. Cook,cc-by-4.0,W4393787946,A5054466750,Annan SI Cook,0000-0001-6415-9107
467,10908572,2024-04-12T17:35:20.323933+00:00,10.5281/zenodo.10908572,Reward perseveration is shaped by GABAA-mediated dopamine pauses: Histology from Behavior Data Mice,"<p>Histology images for the experimental +HTP behavior mice in the dataset&nbsp;10.5281/zenodo.10903566. This histology was used to generate the following figures in the paper ""Reward perseveration is shaped by GABAA-mediated dopamine pauses"":</p>
<ul>
<li>Ext. Fig 3, panel d</li>
</ul>
<p>Specifics of the data:</p>
<ul>
<li>HTP_Histo_Cohort_VX.zip contains the raw images (Olympus .vsi files) and drawn ROIs and fluorescence analysis (MATLAB files) for each mouse/tissue section in cohort VX</li>
<li>HTP_Histo_Cohort_VZ.zip contains the raw images (Olympus .vsi files) and drawn ROIs and fluorescence analysis (MATLAB files) for each mouse/tissue section in cohort VZ</li>
<li>HTP_Histo_Cohort_VAJ.zip contains the raw images (Olympus .vsi files) and drawn ROIs and fluorescence analysis (MATLAB files) for each mouse/tissue section in cohort VAJ</li>
<li>HTP_Histo_Cohort_VAK.zip contains the raw images (Olympus .vsi files) and drawn ROIs and fluorescence analysis (MATLAB files) for each mouse/tissue section in cohort VAK</li>
<li>&nbsp;Behavior_summary_data_HTP_Histology.csv contains the summarized fluorescence quantification per animal</li>
</ul>",Dataset,2024-04-02 00:00:00,"personal
personal","Burwell, Sasha
Tadross, Michael",cc-by-4.0,,,,
468,10630752,2024-03-21T20:25:52.852704+00:00,10.5281/zenodo.10630752,Data for LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,<p>Data that was analyzed and used to create figures in the paper.</p>,Dataset,2024-02-07 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Lubben, Noah
Brynildsen, Julia K.
Webb, Connor M.
Li, Howard L.
Leyns, Cheryl E. G.
Changolkar, Lakshmi
Zhang, Bin
Meymand, Emily S.
O'Reilly, Mia
Madaj, Zach
DeWeerd, Daniella
Fell, Matthew J.
Lee, Virginia M.Y.
Bassett, Dani S.
Henderson, Michael X.",cc-by-4.0,,,,
469,6477900,2022-04-22T14:09:29.146867+00:00,10.5281/zenodo.6477900,ipdgc/GP2-post-GWAS-analysis: GP2 Hackathon Post-GWAS Analysis,"<p>Code associated with Project 1: Post-GWAS analysis from the 2021 GP2/IPDGC Hackathon and manuscript &quot;The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson&#39;s disease data&quot;.</p>",Software,2022-04-22 00:00:00,"personal
personal
personal
personal
personal","Bharati Jadhav
Bernabe Bustos
Lesley Wu
Julie Lake
Raquel Real",other-open,,,,
470,4670341,2021-04-09T19:58:57.529873+00:00,10.5281/zenodo.4670341,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,"<p>TANK-binding kinase 1 (TBK1) is a multi-functional kinase with an essential role in mitophagy, the selective clearance of damaged mitochondria. More than 90 distinct mutations in TBK1 are linked to amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD), including missense mutations that disrupt the ability of TBK1 to dimerize, associate with the mitophagy receptor optineurin (OPTN), auto-activate, or catalyze phosphorylation. We investigated how ALS-associated mutations in TBK1 affect Parkin-dependent mitophagy using imaging to dissect the molecular mechanisms involved in clearing damaged mitochondria. Some mutations cause severe dysregulation of the pathway, while others induce limited disruption. Mutations that abolish either TBK1 dimerization or kinase activity were insufficient to fully inhibit mitophagy, while mutations that reduced both dimerization and kinase activity were more disruptive. Ultimately, both TBK1 recruitment and OPTN phosphorylation at S177 are necessary for engulfment of damaged mitochondra by autophagosomal membranes. Surprisingly, we find that ULK1 activity contributes to the phosphorylation of OPTN in the presense of either WT- or kinase inactive TBK1. In primary neurons, TBK1 mutants induce mitochondrial stress under basal conditions; network stress is exacerbated with further mitochondrial insult. Our study further refines the model for TBK1 function in mitophagy, demonstrating that some ALS-linked mutations likely contribute to disease pathogenesis by inducing mitochondrial stress or inhibiting mitophagic flux. Other TBK1 mutations exhibited much less impact on mitophagy in our assays, suggesting that cell-type specific effects, cumulative damage, or alternative TBK1-dependent pathways such as innate immunity and inflammation also factor into the development of ALS in affected individuals.</p>",Journal article,2021-04-09 00:00:00,"personal
personal
personal
personal
personal
personal","Harding, Olivia
Evans, Chantell S.
Ye, Junqiang
Cheung, Jonah
Maniatis, Tom
Holzbaur, Erika L.F.",cc-by-4.0,W4287235510,A5066177476,Olivia Harding,0000-0002-0719-2901
471,4670341,2021-04-09T19:58:57.529873+00:00,10.5281/zenodo.4670341,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,"<p>TANK-binding kinase 1 (TBK1) is a multi-functional kinase with an essential role in mitophagy, the selective clearance of damaged mitochondria. More than 90 distinct mutations in TBK1 are linked to amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD), including missense mutations that disrupt the ability of TBK1 to dimerize, associate with the mitophagy receptor optineurin (OPTN), auto-activate, or catalyze phosphorylation. We investigated how ALS-associated mutations in TBK1 affect Parkin-dependent mitophagy using imaging to dissect the molecular mechanisms involved in clearing damaged mitochondria. Some mutations cause severe dysregulation of the pathway, while others induce limited disruption. Mutations that abolish either TBK1 dimerization or kinase activity were insufficient to fully inhibit mitophagy, while mutations that reduced both dimerization and kinase activity were more disruptive. Ultimately, both TBK1 recruitment and OPTN phosphorylation at S177 are necessary for engulfment of damaged mitochondra by autophagosomal membranes. Surprisingly, we find that ULK1 activity contributes to the phosphorylation of OPTN in the presense of either WT- or kinase inactive TBK1. In primary neurons, TBK1 mutants induce mitochondrial stress under basal conditions; network stress is exacerbated with further mitochondrial insult. Our study further refines the model for TBK1 function in mitophagy, demonstrating that some ALS-linked mutations likely contribute to disease pathogenesis by inducing mitochondrial stress or inhibiting mitophagic flux. Other TBK1 mutations exhibited much less impact on mitophagy in our assays, suggesting that cell-type specific effects, cumulative damage, or alternative TBK1-dependent pathways such as innate immunity and inflammation also factor into the development of ALS in affected individuals.</p>",Journal article,2021-04-09 00:00:00,"personal
personal
personal
personal
personal
personal","Harding, Olivia
Evans, Chantell S.
Ye, Junqiang
Cheung, Jonah
Maniatis, Tom
Holzbaur, Erika L.F.",cc-by-4.0,W4287235510,A5033015769,Chantell S. Evans,0000-0001-9401-8604
472,4670341,2021-04-09T19:58:57.529873+00:00,10.5281/zenodo.4670341,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,"<p>TANK-binding kinase 1 (TBK1) is a multi-functional kinase with an essential role in mitophagy, the selective clearance of damaged mitochondria. More than 90 distinct mutations in TBK1 are linked to amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD), including missense mutations that disrupt the ability of TBK1 to dimerize, associate with the mitophagy receptor optineurin (OPTN), auto-activate, or catalyze phosphorylation. We investigated how ALS-associated mutations in TBK1 affect Parkin-dependent mitophagy using imaging to dissect the molecular mechanisms involved in clearing damaged mitochondria. Some mutations cause severe dysregulation of the pathway, while others induce limited disruption. Mutations that abolish either TBK1 dimerization or kinase activity were insufficient to fully inhibit mitophagy, while mutations that reduced both dimerization and kinase activity were more disruptive. Ultimately, both TBK1 recruitment and OPTN phosphorylation at S177 are necessary for engulfment of damaged mitochondra by autophagosomal membranes. Surprisingly, we find that ULK1 activity contributes to the phosphorylation of OPTN in the presense of either WT- or kinase inactive TBK1. In primary neurons, TBK1 mutants induce mitochondrial stress under basal conditions; network stress is exacerbated with further mitochondrial insult. Our study further refines the model for TBK1 function in mitophagy, demonstrating that some ALS-linked mutations likely contribute to disease pathogenesis by inducing mitochondrial stress or inhibiting mitophagic flux. Other TBK1 mutations exhibited much less impact on mitophagy in our assays, suggesting that cell-type specific effects, cumulative damage, or alternative TBK1-dependent pathways such as innate immunity and inflammation also factor into the development of ALS in affected individuals.</p>",Journal article,2021-04-09 00:00:00,"personal
personal
personal
personal
personal
personal","Harding, Olivia
Evans, Chantell S.
Ye, Junqiang
Cheung, Jonah
Maniatis, Tom
Holzbaur, Erika L.F.",cc-by-4.0,W4287235510,A5051236194,Junqiang Ye,0000-0002-4529-0713
473,4670341,2021-04-09T19:58:57.529873+00:00,10.5281/zenodo.4670341,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,"<p>TANK-binding kinase 1 (TBK1) is a multi-functional kinase with an essential role in mitophagy, the selective clearance of damaged mitochondria. More than 90 distinct mutations in TBK1 are linked to amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD), including missense mutations that disrupt the ability of TBK1 to dimerize, associate with the mitophagy receptor optineurin (OPTN), auto-activate, or catalyze phosphorylation. We investigated how ALS-associated mutations in TBK1 affect Parkin-dependent mitophagy using imaging to dissect the molecular mechanisms involved in clearing damaged mitochondria. Some mutations cause severe dysregulation of the pathway, while others induce limited disruption. Mutations that abolish either TBK1 dimerization or kinase activity were insufficient to fully inhibit mitophagy, while mutations that reduced both dimerization and kinase activity were more disruptive. Ultimately, both TBK1 recruitment and OPTN phosphorylation at S177 are necessary for engulfment of damaged mitochondra by autophagosomal membranes. Surprisingly, we find that ULK1 activity contributes to the phosphorylation of OPTN in the presense of either WT- or kinase inactive TBK1. In primary neurons, TBK1 mutants induce mitochondrial stress under basal conditions; network stress is exacerbated with further mitochondrial insult. Our study further refines the model for TBK1 function in mitophagy, demonstrating that some ALS-linked mutations likely contribute to disease pathogenesis by inducing mitochondrial stress or inhibiting mitophagic flux. Other TBK1 mutations exhibited much less impact on mitophagy in our assays, suggesting that cell-type specific effects, cumulative damage, or alternative TBK1-dependent pathways such as innate immunity and inflammation also factor into the development of ALS in affected individuals.</p>",Journal article,2021-04-09 00:00:00,"personal
personal
personal
personal
personal
personal","Harding, Olivia
Evans, Chantell S.
Ye, Junqiang
Cheung, Jonah
Maniatis, Tom
Holzbaur, Erika L.F.",cc-by-4.0,W4287235510,A5050439123,Jonah Cheung,0000-0002-1014-0707
474,4670341,2021-04-09T19:58:57.529873+00:00,10.5281/zenodo.4670341,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,"<p>TANK-binding kinase 1 (TBK1) is a multi-functional kinase with an essential role in mitophagy, the selective clearance of damaged mitochondria. More than 90 distinct mutations in TBK1 are linked to amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD), including missense mutations that disrupt the ability of TBK1 to dimerize, associate with the mitophagy receptor optineurin (OPTN), auto-activate, or catalyze phosphorylation. We investigated how ALS-associated mutations in TBK1 affect Parkin-dependent mitophagy using imaging to dissect the molecular mechanisms involved in clearing damaged mitochondria. Some mutations cause severe dysregulation of the pathway, while others induce limited disruption. Mutations that abolish either TBK1 dimerization or kinase activity were insufficient to fully inhibit mitophagy, while mutations that reduced both dimerization and kinase activity were more disruptive. Ultimately, both TBK1 recruitment and OPTN phosphorylation at S177 are necessary for engulfment of damaged mitochondra by autophagosomal membranes. Surprisingly, we find that ULK1 activity contributes to the phosphorylation of OPTN in the presense of either WT- or kinase inactive TBK1. In primary neurons, TBK1 mutants induce mitochondrial stress under basal conditions; network stress is exacerbated with further mitochondrial insult. Our study further refines the model for TBK1 function in mitophagy, demonstrating that some ALS-linked mutations likely contribute to disease pathogenesis by inducing mitochondrial stress or inhibiting mitophagic flux. Other TBK1 mutations exhibited much less impact on mitophagy in our assays, suggesting that cell-type specific effects, cumulative damage, or alternative TBK1-dependent pathways such as innate immunity and inflammation also factor into the development of ALS in affected individuals.</p>",Journal article,2021-04-09 00:00:00,"personal
personal
personal
personal
personal
personal","Harding, Olivia
Evans, Chantell S.
Ye, Junqiang
Cheung, Jonah
Maniatis, Tom
Holzbaur, Erika L.F.",cc-by-4.0,W4287235510,A5091116725,Tom Maniatis,0000-0002-2722-8633
475,4670341,2021-04-09T19:58:57.529873+00:00,10.5281/zenodo.4670341,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,"<p>TANK-binding kinase 1 (TBK1) is a multi-functional kinase with an essential role in mitophagy, the selective clearance of damaged mitochondria. More than 90 distinct mutations in TBK1 are linked to amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD), including missense mutations that disrupt the ability of TBK1 to dimerize, associate with the mitophagy receptor optineurin (OPTN), auto-activate, or catalyze phosphorylation. We investigated how ALS-associated mutations in TBK1 affect Parkin-dependent mitophagy using imaging to dissect the molecular mechanisms involved in clearing damaged mitochondria. Some mutations cause severe dysregulation of the pathway, while others induce limited disruption. Mutations that abolish either TBK1 dimerization or kinase activity were insufficient to fully inhibit mitophagy, while mutations that reduced both dimerization and kinase activity were more disruptive. Ultimately, both TBK1 recruitment and OPTN phosphorylation at S177 are necessary for engulfment of damaged mitochondra by autophagosomal membranes. Surprisingly, we find that ULK1 activity contributes to the phosphorylation of OPTN in the presense of either WT- or kinase inactive TBK1. In primary neurons, TBK1 mutants induce mitochondrial stress under basal conditions; network stress is exacerbated with further mitochondrial insult. Our study further refines the model for TBK1 function in mitophagy, demonstrating that some ALS-linked mutations likely contribute to disease pathogenesis by inducing mitochondrial stress or inhibiting mitophagic flux. Other TBK1 mutations exhibited much less impact on mitophagy in our assays, suggesting that cell-type specific effects, cumulative damage, or alternative TBK1-dependent pathways such as innate immunity and inflammation also factor into the development of ALS in affected individuals.</p>",Journal article,2021-04-09 00:00:00,"personal
personal
personal
personal
personal
personal","Harding, Olivia
Evans, Chantell S.
Ye, Junqiang
Cheung, Jonah
Maniatis, Tom
Holzbaur, Erika L.F.",cc-by-4.0,W4287235510,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114
476,10001842,2023-10-16T17:10:10.642139+00:00,10.5281/zenodo.10001842,"Source data for ""Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons""","<p><strong>Fig.1A_ChAT.tif</strong></p><p>Confocal image (green channel, anti-ChAT staining) for Fig.1A</p><p>&nbsp;</p><p><strong>Fig.1A_tdTomato.tif&nbsp;</strong></p><p>Confocal image (red channel, tdTomato) for Fig.1A</p><p>&nbsp;</p><p><strong>Fig.1B_ChAT.tif</strong></p><p>Confocal image (green channel, anti-ChAT staining) for Fig.1B</p><p>&nbsp;</p><p><strong>Fig.1B_tdTomato.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.1B</p><p>&nbsp;</p><p><strong>Fig.1C_DIC.png</strong></p><p>Differential interference contrast micrograph for Fig.1C left</p><p>&nbsp;</p><p><strong>Fig.1C_Fluo.png</strong></p><p>Epifluorescent illumination micrograph for Fig. 1C right</p><p>&nbsp;</p><p><strong>Fig.1DEH.xlsx</strong></p><p>Numerical data for the charts in Fig. 1D, Fig.1E, Fig.1H</p><p>&nbsp;</p><p><strong>Fig.1F.tif</strong></p><p>MAX projection of z-stack of 2PLSM images (red channel, Alexa 594) used to generate Fig.1F&nbsp;</p><p>&nbsp;</p><p><strong>Fig.1F_inset.tif</strong></p><p>2PLSM image (green channel, Fura-2) for the right inset of Fig.1F</p><p>&nbsp;</p><p><strong>Fig.2A_inset.tif</strong></p><p>Confocal image (green channel, GFP) for the higher magnification inset of Fig.2A</p><p>&nbsp;</p><p><strong>Fig.2A.tif</strong></p><p>Confocal image (green channel, GFP) for Fig.2A</p><p>&nbsp;</p><p><strong>Fig.2B_bottom.tif</strong></p><p>Confocal image (green channel, GFP) for Fig.2B (bottom and overlay panels)</p><p>&nbsp;</p><p><strong>Fig.2B_top.tif</strong></p><p>Confocal image (red channel, td Tomato) for Fig.2B (top and overlay panels)</p><p>&nbsp;</p><p><strong>Fig.2CE.xlsx</strong></p><p>Numerical data for the charts in Fig. 2C, Fig. 2E</p><p>&nbsp;</p><p><strong>Fig.3B.tif</strong></p><p>Confocal image (green channel, MitoGCaMP6) for Fig.3B and overlay in Fig.3D</p><p>&nbsp;</p><p><strong>Fig.3C.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.3C and overlay in Fig.3D</p><p>&nbsp;</p><p><strong>Fig.3E.tif</strong></p><p>2PLSM image (green channel, MitoGCaMP6) for Fig.3E</p><p>&nbsp;</p><p><strong>Fig.3GIJ.xlsx</strong></p><p>Numerical data for the charts in Fig. 3G, Fig. 3I, Fig.3J</p><p>&nbsp;</p><p><strong>Fig.4B.tif</strong></p><p>2PLSM image (green channel, MitoGCaMP6) for Fig.4B</p><p>&nbsp;</p><p><strong>Fig.4DFG.xlsx</strong></p><p>Numerical data for the charts in Fig.4D, Fig.4F, Fig.4G</p><p>&nbsp;</p><p><strong>Fig.5A.tif</strong></p><p>Confocal image (green channel, PercevalHR) for Fig.5A and overlay in Fig.5C</p><p>&nbsp;</p><p><strong>Fig.5B.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.5B and overlay in Fig.5C</p><p>&nbsp;</p><p><strong>Fig.5D.tif</strong></p><p>2PLSM image (green channel, PercevalHR) for Fig.5D</p><p>&nbsp;</p><p><strong>Fig.5GHJ.xlsx</strong></p><p>Numerical data for the charts in Fig.5G, Fig.5H, Fig.5J</p><p>&nbsp;</p><p><strong>Fig.6BCD.xlsx</strong></p><p>Numerical data for the charts in Fig.6b, Fig.6C, Fig.6D</p><p>&nbsp;</p><p><strong>Fig.7A.tif</strong></p><p>Confocal image (green channel, mito-roGFP) for Fig.7A and overlay in Fig.7C</p><p>&nbsp;</p><p><strong>Fig.7B.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.7B and overlay in Fig.7C</p><p>&nbsp;</p><p><strong>Fig.7D.tif</strong></p><p>2PLSM image (green channel, mito-roGFP) for Fig.7D</p><p>&nbsp;</p><p><strong>Fig.7F.xlsx</strong></p><p>Numerical data for the charts in Fig.7F</p>",Dataset,2023-10-13 00:00:00,"personal
personal","Tubert, Cecilia
Zampese, Enrico",cc-by-4.0,W4393417022,A5057169237,Cecilia Tubert,0000-0001-6766-5849
477,10001842,2023-10-16T17:10:10.642139+00:00,10.5281/zenodo.10001842,"Source data for ""Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons""","<p><strong>Fig.1A_ChAT.tif</strong></p><p>Confocal image (green channel, anti-ChAT staining) for Fig.1A</p><p>&nbsp;</p><p><strong>Fig.1A_tdTomato.tif&nbsp;</strong></p><p>Confocal image (red channel, tdTomato) for Fig.1A</p><p>&nbsp;</p><p><strong>Fig.1B_ChAT.tif</strong></p><p>Confocal image (green channel, anti-ChAT staining) for Fig.1B</p><p>&nbsp;</p><p><strong>Fig.1B_tdTomato.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.1B</p><p>&nbsp;</p><p><strong>Fig.1C_DIC.png</strong></p><p>Differential interference contrast micrograph for Fig.1C left</p><p>&nbsp;</p><p><strong>Fig.1C_Fluo.png</strong></p><p>Epifluorescent illumination micrograph for Fig. 1C right</p><p>&nbsp;</p><p><strong>Fig.1DEH.xlsx</strong></p><p>Numerical data for the charts in Fig. 1D, Fig.1E, Fig.1H</p><p>&nbsp;</p><p><strong>Fig.1F.tif</strong></p><p>MAX projection of z-stack of 2PLSM images (red channel, Alexa 594) used to generate Fig.1F&nbsp;</p><p>&nbsp;</p><p><strong>Fig.1F_inset.tif</strong></p><p>2PLSM image (green channel, Fura-2) for the right inset of Fig.1F</p><p>&nbsp;</p><p><strong>Fig.2A_inset.tif</strong></p><p>Confocal image (green channel, GFP) for the higher magnification inset of Fig.2A</p><p>&nbsp;</p><p><strong>Fig.2A.tif</strong></p><p>Confocal image (green channel, GFP) for Fig.2A</p><p>&nbsp;</p><p><strong>Fig.2B_bottom.tif</strong></p><p>Confocal image (green channel, GFP) for Fig.2B (bottom and overlay panels)</p><p>&nbsp;</p><p><strong>Fig.2B_top.tif</strong></p><p>Confocal image (red channel, td Tomato) for Fig.2B (top and overlay panels)</p><p>&nbsp;</p><p><strong>Fig.2CE.xlsx</strong></p><p>Numerical data for the charts in Fig. 2C, Fig. 2E</p><p>&nbsp;</p><p><strong>Fig.3B.tif</strong></p><p>Confocal image (green channel, MitoGCaMP6) for Fig.3B and overlay in Fig.3D</p><p>&nbsp;</p><p><strong>Fig.3C.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.3C and overlay in Fig.3D</p><p>&nbsp;</p><p><strong>Fig.3E.tif</strong></p><p>2PLSM image (green channel, MitoGCaMP6) for Fig.3E</p><p>&nbsp;</p><p><strong>Fig.3GIJ.xlsx</strong></p><p>Numerical data for the charts in Fig. 3G, Fig. 3I, Fig.3J</p><p>&nbsp;</p><p><strong>Fig.4B.tif</strong></p><p>2PLSM image (green channel, MitoGCaMP6) for Fig.4B</p><p>&nbsp;</p><p><strong>Fig.4DFG.xlsx</strong></p><p>Numerical data for the charts in Fig.4D, Fig.4F, Fig.4G</p><p>&nbsp;</p><p><strong>Fig.5A.tif</strong></p><p>Confocal image (green channel, PercevalHR) for Fig.5A and overlay in Fig.5C</p><p>&nbsp;</p><p><strong>Fig.5B.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.5B and overlay in Fig.5C</p><p>&nbsp;</p><p><strong>Fig.5D.tif</strong></p><p>2PLSM image (green channel, PercevalHR) for Fig.5D</p><p>&nbsp;</p><p><strong>Fig.5GHJ.xlsx</strong></p><p>Numerical data for the charts in Fig.5G, Fig.5H, Fig.5J</p><p>&nbsp;</p><p><strong>Fig.6BCD.xlsx</strong></p><p>Numerical data for the charts in Fig.6b, Fig.6C, Fig.6D</p><p>&nbsp;</p><p><strong>Fig.7A.tif</strong></p><p>Confocal image (green channel, mito-roGFP) for Fig.7A and overlay in Fig.7C</p><p>&nbsp;</p><p><strong>Fig.7B.tif</strong></p><p>Confocal image (red channel, tdTomato) for Fig.7B and overlay in Fig.7C</p><p>&nbsp;</p><p><strong>Fig.7D.tif</strong></p><p>2PLSM image (green channel, mito-roGFP) for Fig.7D</p><p>&nbsp;</p><p><strong>Fig.7F.xlsx</strong></p><p>Numerical data for the charts in Fig.7F</p>",Dataset,2023-10-13 00:00:00,"personal
personal","Tubert, Cecilia
Zampese, Enrico",cc-by-4.0,W4393417022,A5022357653,Enrico Zampese,0000-0002-8851-2566
478,8384710,2023-10-01T00:56:45.830321+00:00,10.5281/zenodo.8384710,Original gels associated with PI3KC3-C1 activation paper,<p>All gels associated with protein purifications from VPS34/VPS15 publication</p>,Other,2023-09-28 00:00:00,personal,Annan Cook,cc-by-4.0,,,,
479,8200336,2023-08-16T22:08:16.508300+00:00,10.5281/zenodo.8200336,Erythroid differentiation dependent interaction of VPS13A with XK at the plasma membrane of K562 cells,<p>This dataset contains the primary data associated with each figure of the manuscript.</p>,Journal article,2023-08-10 00:00:00,"personal
personal
personal","Chase Amos
Peng Xu
Pietro De Camilli",cc-by-4.0,W4385890595,A5011341629,Chase Amos,0000-0002-3176-9387
480,8200336,2023-08-16T22:08:16.508300+00:00,10.5281/zenodo.8200336,Erythroid differentiation dependent interaction of VPS13A with XK at the plasma membrane of K562 cells,<p>This dataset contains the primary data associated with each figure of the manuscript.</p>,Journal article,2023-08-10 00:00:00,"personal
personal
personal","Chase Amos
Peng Xu
Pietro De Camilli",cc-by-4.0,W4385890595,A5045181995,Peng Xu,0000-0001-5197-9560
481,8200336,2023-08-16T22:08:16.508300+00:00,10.5281/zenodo.8200336,Erythroid differentiation dependent interaction of VPS13A with XK at the plasma membrane of K562 cells,<p>This dataset contains the primary data associated with each figure of the manuscript.</p>,Journal article,2023-08-10 00:00:00,"personal
personal
personal","Chase Amos
Peng Xu
Pietro De Camilli",cc-by-4.0,W4385890595,A5037459294,Pietro De Camilli,0000-0001-9045-0723
482,6475864,2022-04-21T15:40:53.019552+00:00,10.5281/zenodo.6475864,AGDeleidi/MbOrganoids: Single cell workflow MbOrganoids,<p>Scripts/Code in R</p>,Software,2022-04-21 00:00:00,"personal
personal","MJPerez
AGDeleidi",other-open,,,,
483,10896135,2024-03-30T00:41:18.035391+00:00,10.5281/zenodo.10896135,Figure 4: The Pacer RH domain basic triad controls subcellular localization [FINAL],,Dataset,2024-03-29 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
484,5910970,2022-01-27T15:11:29.680305+00:00,10.5281/zenodo.5910970,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,"<p>Background: Activating V600E in BRAF is a common driver mutation in cancers of multiple tissue origins, including melanoma and glioma. BRAF V600E has also been implicated in neurodegeneration. The present study aims to characterize BRAF V600E on cell death and survival in three major cell types of the CNS: neurons, astrocytes, and microglia. Methods : Multiple primary cultures and cell lines of glial cells and neurons were employed. BRAF V600E as well as BRAF WT expression was mediated by lentivirus or retrovirus. Blockage of downstream effectors were achieved by siRNA. Gene expression data from patients with Parkinson&rsquo;s disease was analyzed. Results : In astrocytes and microglia, BRAF V600E induces cell proliferation, and the proliferative effect in microglia is mediated by activated ERK but not JNK. Conditioned medium from BRAF V600E -expressing microglia induced neuronal cell death. In neuronal cells, BRAF V600E directly induces cell death, through JNK but not ERK. We further show that BRAF-related genes are enriched in pathways in patients with Parkinson&rsquo;s disease. Conclusions : Our study identifies distinct consequences mediated by distinct downstream effectors in dividing glial cells and in neurons following the same BRAF mutational activation and a causal link between BRAF-activated microglia and neuronal cell death that does not require physical proximity. It provides insight into a possibly important role of BRAF in neurodegeneration as a result of either dysregulated BRAF in neurons or its impact on glial cells.</p>",Dataset,2022-01-27 00:00:00,"personal
personal
personal
personal","Qing Ye
Nasser Al-Kuwari
Pranay Srivastava
Xiqun Chen",cc-by-4.0,W4393733288,A5100347568,Qing Ye,
485,5910970,2022-01-27T15:11:29.680305+00:00,10.5281/zenodo.5910970,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,"<p>Background: Activating V600E in BRAF is a common driver mutation in cancers of multiple tissue origins, including melanoma and glioma. BRAF V600E has also been implicated in neurodegeneration. The present study aims to characterize BRAF V600E on cell death and survival in three major cell types of the CNS: neurons, astrocytes, and microglia. Methods : Multiple primary cultures and cell lines of glial cells and neurons were employed. BRAF V600E as well as BRAF WT expression was mediated by lentivirus or retrovirus. Blockage of downstream effectors were achieved by siRNA. Gene expression data from patients with Parkinson&rsquo;s disease was analyzed. Results : In astrocytes and microglia, BRAF V600E induces cell proliferation, and the proliferative effect in microglia is mediated by activated ERK but not JNK. Conditioned medium from BRAF V600E -expressing microglia induced neuronal cell death. In neuronal cells, BRAF V600E directly induces cell death, through JNK but not ERK. We further show that BRAF-related genes are enriched in pathways in patients with Parkinson&rsquo;s disease. Conclusions : Our study identifies distinct consequences mediated by distinct downstream effectors in dividing glial cells and in neurons following the same BRAF mutational activation and a causal link between BRAF-activated microglia and neuronal cell death that does not require physical proximity. It provides insight into a possibly important role of BRAF in neurodegeneration as a result of either dysregulated BRAF in neurons or its impact on glial cells.</p>",Dataset,2022-01-27 00:00:00,"personal
personal
personal
personal","Qing Ye
Nasser Al-Kuwari
Pranay Srivastava
Xiqun Chen",cc-by-4.0,W4393733288,A5007648760,Nasser Al-Kuwari,
486,5910970,2022-01-27T15:11:29.680305+00:00,10.5281/zenodo.5910970,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,"<p>Background: Activating V600E in BRAF is a common driver mutation in cancers of multiple tissue origins, including melanoma and glioma. BRAF V600E has also been implicated in neurodegeneration. The present study aims to characterize BRAF V600E on cell death and survival in three major cell types of the CNS: neurons, astrocytes, and microglia. Methods : Multiple primary cultures and cell lines of glial cells and neurons were employed. BRAF V600E as well as BRAF WT expression was mediated by lentivirus or retrovirus. Blockage of downstream effectors were achieved by siRNA. Gene expression data from patients with Parkinson&rsquo;s disease was analyzed. Results : In astrocytes and microglia, BRAF V600E induces cell proliferation, and the proliferative effect in microglia is mediated by activated ERK but not JNK. Conditioned medium from BRAF V600E -expressing microglia induced neuronal cell death. In neuronal cells, BRAF V600E directly induces cell death, through JNK but not ERK. We further show that BRAF-related genes are enriched in pathways in patients with Parkinson&rsquo;s disease. Conclusions : Our study identifies distinct consequences mediated by distinct downstream effectors in dividing glial cells and in neurons following the same BRAF mutational activation and a causal link between BRAF-activated microglia and neuronal cell death that does not require physical proximity. It provides insight into a possibly important role of BRAF in neurodegeneration as a result of either dysregulated BRAF in neurons or its impact on glial cells.</p>",Dataset,2022-01-27 00:00:00,"personal
personal
personal
personal","Qing Ye
Nasser Al-Kuwari
Pranay Srivastava
Xiqun Chen",cc-by-4.0,W4393733288,A5020152429,Pranay Srivastava,0000-0002-9289-2696
487,5910970,2022-01-27T15:11:29.680305+00:00,10.5281/zenodo.5910970,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,"<p>Background: Activating V600E in BRAF is a common driver mutation in cancers of multiple tissue origins, including melanoma and glioma. BRAF V600E has also been implicated in neurodegeneration. The present study aims to characterize BRAF V600E on cell death and survival in three major cell types of the CNS: neurons, astrocytes, and microglia. Methods : Multiple primary cultures and cell lines of glial cells and neurons were employed. BRAF V600E as well as BRAF WT expression was mediated by lentivirus or retrovirus. Blockage of downstream effectors were achieved by siRNA. Gene expression data from patients with Parkinson&rsquo;s disease was analyzed. Results : In astrocytes and microglia, BRAF V600E induces cell proliferation, and the proliferative effect in microglia is mediated by activated ERK but not JNK. Conditioned medium from BRAF V600E -expressing microglia induced neuronal cell death. In neuronal cells, BRAF V600E directly induces cell death, through JNK but not ERK. We further show that BRAF-related genes are enriched in pathways in patients with Parkinson&rsquo;s disease. Conclusions : Our study identifies distinct consequences mediated by distinct downstream effectors in dividing glial cells and in neurons following the same BRAF mutational activation and a causal link between BRAF-activated microglia and neuronal cell death that does not require physical proximity. It provides insight into a possibly important role of BRAF in neurodegeneration as a result of either dysregulated BRAF in neurons or its impact on glial cells.</p>",Dataset,2022-01-27 00:00:00,"personal
personal
personal
personal","Qing Ye
Nasser Al-Kuwari
Pranay Srivastava
Xiqun Chen",cc-by-4.0,W4393733288,A5012470875,Xiqun Chen,0000-0001-8582-8891
488,10904059,2024-04-12T17:35:34.898878+00:00,10.5281/zenodo.10904059,Reward perseveration is shaped by GABAA-mediated dopamine pauses: Electrophysiology Data,"<p>In vivo electrophysiological data, slice electrophysiological data, and HTP vs tyrosine hydroxylase immunohistochemistry data. These data were used to generate the following figures in the paper ""Reward perseveration is shaped by GABAA-mediated dopamine pauses"":</p>
<ul>
<li>Figure 1, panels c-f</li>
<li>Ext. Fig 1, all panels</li>
<li>Ext. Fig 2, all panels</li>
</ul>
<p>Specifics of the data:</p>
<ul>
<li>Slice_Ephys .csv files contain the summarized in vitro electrophysiology data.</li>
<li>HTP_Mouse_*.7z and ddHTP_Mouse_*.7z are zipped folders with the raw data, sorted data, and extracted cells for each recording, grouped by mouse the recordings were obtained from.</li>
<li>HTP final_grouped spiking analysis_n39.mat is the MATLAB data file with all the extracted firing metrics for all 39 +HTP cells.</li>
<li>ddHTP final_grouped spiking analysis_n18.mat is the MATLAB data file with all the extracted firing metrics for all 18 ddHTP cells.</li>
<li>&nbsp;Ephys_Summary_Data .csv files contain the summarized in vivo electrophysiology data.</li>
<li>VHist4_HTP and TH.7z contains the raw histological images, drawn ROIs, and ilastik cell counting performed to compare tyrosine hydroxylase and HTP expression.</li>
</ul>",Dataset,2024-04-01 00:00:00,"personal
personal
personal","Burwell, Sasha
Yan, Hai Dun
Tadross, Michael",cc-by-4.0,,,,
489,13837652,2024-09-25T18:08:51.597841+00:00,10.5281/zenodo.13837652,"Source data for ""α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease""",,Dataset,2024,"personal
personal
personal","Geibl, Fanni Fruzsina
Henrich, Martin Timo
Surmeier, D. James",cc-by-4.0,,,,
490,10637353,2024-04-12T17:33:51.016852+00:00,10.5281/zenodo.10637353,Control of mitophagy initiation and progression by  the TBK1 adaptors NAP1 and SINTBAD,"<p><span>Mitophagy preserves overall mitochondrial fitness by selectively targeting damaged mitochondria for degradation. The regulatory mechanisms that prevent PINK1/Parkin-dependent mitophagy and other selective autophagy pathways from overreacting while ensuring swift progression once initiated are largely elusive. Here, we demonstrate how the TBK1 adaptors NAP1 and SINTBAD restrict the initiation of OPTN-driven mitophagy by competing with OPTN for TBK1. Conversely, they promote the progression of NDP52-driven mitophagy by recruiting TBK1 to NDP52 and stabilizing its interaction with FIP200. Notably, OPTN emerges as the primary recruiter of TBK1 during mitophagy initiation, which in return boosts NDP52-mediated mitophagy. Our results thus define NAP1 and SINTBAD as cargo receptor rheostats, elevating the threshold for mitophagy initiation by OPTN while promoting the progression of the pathway once set in motion by supporting NDP52. These findings shed light on the cellular strategy to prevent pathway hyperactivity while still ensuring efficient progression. </span></p>",Dataset,2024-02-08 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Adriaenssens, Elias
Nguyen, Thanh Ngọc
Sawa-Makarska, Justyna
Khuu, Grace
Schuschnig, Martina
Shoebridge, Stephen
Watts, Emily Maria
Csalyi, Kitti Dora
Padman, Benjamin Scott
Lazarou, Michael
Martens, Sascha",cc-by-4.0,,,,
491,11397910,2024-05-30T20:44:45.003496+00:00,10.5281/zenodo.11397910,turner-lab-pitt/TouchTask_PD_study: v1.0.2,Simple reach task for parkinsonian non-human primate,Software,2024-05-30 00:00:00,personal,daisukekase,cc-by-4.0,,,,
492,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5077060611,Rekha Dhanwani,0000-0002-6592-8657
493,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5057542377,João Rodrigues Lima-Júnior,
494,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5109476794,Ashu Sethi,
495,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5114235233,John Pham,
496,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5046678361,Gregory P. Williams,0000-0001-9523-1781
497,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5044515449,April Frazier,0000-0002-4722-7304
498,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5075915109,Yaqian Xu,0000-0001-5890-3446
499,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5067845430,Amy W. Amara,0000-0003-0762-9656
500,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5000374325,David G. Standaert,0000-0003-2921-8348
501,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535
502,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5006709022,Irene Litvan,0000-0002-3485-3445
503,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5037098776,Roy N. Alcalay,0000-0002-5717-4875
504,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5023547268,Bjoern Peters,0000-0002-8457-6693
505,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5026787858,David Sulzer,0000-0001-7632-0439
506,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002
507,5248631,2021-08-24T20:54:56.885571+00:00,10.5281/zenodo.5248631,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Gene Validation FCS,"<p>FCS files corresponding to the gene validation experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>Funding provided in part by the&nbsp;Aligning Science Across Parkinson&rsquo;s ASAP-000375</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393837719,A5010966529,Alessandro Sette,0000-0001-7013-2250
508,10697254,2024-03-21T20:25:17.583146+00:00,10.5281/zenodo.10697254,scAlleleExpression: R package for downstream analysis of allele specific expression single cell data,"<p>This R package is build to use single cell or nuclei allele specific expression (ASE) data to investigate Cell Type specific regulatory genetics (eQTLs, etc). It is build to work with the output of our ASE pipeline (<a href=""https://github.com/seanken/ASE_pipeline"">https://github.com/seanken/ASE_pipeline</a>), but ourdownstream analysis tools should work with most allele specific expression pipelines.</p>
<p>The package is built to:</p>
<ol>
<li>Load the output of our ASE pipeline into a matrix or a Seurat object.</li>
<li>Load snps or gene level allele specific expression information in either a pseudobulk or cell specific count matrix.</li>
<li>Perform varying types of allele specific expression analysis.</li>
</ol>
<p>Tasks 1 and 2 are pipeline specific, but taks 3 is more general.</p>",Software,2024-02-23 00:00:00,personal,"Simmons, Sean",mit,,,,
509,7405544,2022-12-06T14:39:39.745804+00:00,10.5281/zenodo.7405544,ASAP Research Output Depositing Checklist v1,"<p>Checklist for logging and depositing research outputs such as datasets, software, protocols, and publications per ASAP&#39;s guidelines. Includes preferred repositories, type of persistent identifier for each output type, and funder-specified license.&nbsp;</p>",Other,2022-12-06 00:00:00,"personal
personal","Kristen Ratan
Sonya Dumanis",cc-by-4.0,,,,
510,7802755,2023-04-05T15:17:20.469310+00:00,10.5281/zenodo.7802755,Supplementary Tables and Figures for the LID genetic study,<p>This is the zip folder where we store the supplementary materials generated for the genetic study of LID</p>,Other,2023-04-05 00:00:00,personal,Alejandro Martinez,cc-by-4.0,,,,
511,7693103,2023-03-02T18:23:01.326842+00:00,10.5281/zenodo.7693103,AAV2 Syn vs AAV2 GFP CRMs single-cell sequencing code,<p>Code set for the analysis of CNS resident macrophages in AAV2-GFP or AAV2-SYN transduced animals. This dataset includes sequencing data for both border-associated macrophages and microglia.&nbsp;</p>,Software,2023-03-02 00:00:00,personal,David A. Figge,cc-by-4.0,,,,
512,10896142,2024-03-30T00:49:40.889557+00:00,10.5281/zenodo.10896142,Figure 5: Pacer Flux [FINAL],,Dataset,2024-03-29 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
513,7352955,2022-11-24T01:44:47.712379+00:00,10.5281/zenodo.7352955,7 day clodronate depletion: brain and meninges,<p>These files contain data from mice given either clodronate or saline liposomes i.c.v. Brains and meninges were collected at 7 days post liposome administration and processed for flow cytometry. A workspace file is included to clarify gating and quantification.</p>,Dataset,2022-11-24 00:00:00,personal,"Schonhoff, Aubrey M",cc-by-4.0,W4393674623,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
514,10644822,2024-02-27T03:02:40.527536+00:00,10.5281/zenodo.10644822,"Data accompanying ""A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis""","<p>brain_module_enrichment.csv : contains statistics from an anRichment anaylsis on all co-expression modules identified via WGCNA in brain samples (for Figure 7C)</p>
<p>brain_upregulated_module_enrichment_collapsed.csv : contains anRichment output from the gene list assembled by aggregating all 3 upregulated modules in brain samples (for Figure 6C)</p>
<p>brain_wgcna_results.csv : contains gene-level information for all genes in all brain regions, including gene-trait correlations and module membership statistics (for Figure 6B; this is Supplemental File 2 in the paper)</p>
<p>colon_module_enrichment.csv : contains anRichment output from all co-expression modules identified via WGCNA in our colon samples (for Figure 2)</p>
<p>colon_wgcna_results.csv : contains gene-level information for all genes in both colon regions (this is Supplemental File 1 in the paper)</p>
<p>raw_data.xlsx : contains raw tabular data for non-sequencing analyses in the paper, spanning several main and supplementary figures</p>
<p>All other files are from a DESeq2 analysis in each brain region at each time point in our study. The names of those files describe which region (the first field of the name) is being examined, and what time point (the second field of the name) is being compared to our 0d control time point.&nbsp;</p>
<p>Most of these data, especially output from RNA sequencing data, can be recreated by following the code at https://github.com/jakesboles/Boles_et-al_DSS_time-series.</p>",Dataset,2024-02-10 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Jake Boles
Krueger, Maeve
Jernigan, Janna
Cole, Cassandra
Neighbarger, Noelle
Uriarte Huarte, Oihane
Malu Gamez Tansey",cc-by-4.0,,,,
515,11262613,2024-05-23T15:59:02.442074+00:00,10.5281/zenodo.11262613,Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine,,Dataset,2024-05-23 00:00:00,"personal
personal
personal
personal
personal
personal","Zarrilli, Beatrice
Giacomet, Cecilia
Cossa, Francesca
Federici, Mauro
Berretta, Nicola
Mercuri, Nicola Biagio",cc-by-4.0,,,,
516,11189934,2024-08-06T17:44:34.994970+00:00,10.5281/zenodo.11189934,Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta - Tabular Dataset,"<p>Tabular dataset for all figures in preprint ""Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta"".&nbsp;</p>",Dataset,2024-05-14 00:00:00,"personal
personal
personal
personal","Conrad, William
Oriol, Lucie
Kollman, Grace
Hnasko, Thomas",cc-by-4.0,,,,
517,10776591,2024-03-04T09:45:53.220581+00:00,10.5281/zenodo.10776591,"Dataset related to publication ""Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19""","<p>This dataset is associated with the manuscript 'Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19';&nbsp; Lengacher et al., 2023; BioRxiv https://doi.org/10.1101/2023.12.18.572180</p>
<p>This dataset includes sample ID, group assignment, age, sex and the immunohistochemical scores for phospho alpha-synuclein (pSer129), phospho-Tau (AT8; pSer202, pThr205), amyloid beta and CD68 staining in the anterior olfactory nuclei of olfactory bulbs and tracts.</p>
<p>&nbsp;</p>",Dataset,2023-12-19 00:00:00,"personal
personal
personal
personal","Lengacher, Nathalie
Tomlinson, Julianna
Woulfe, John
Schlossmacher, Michael",cc-by-4.0,,,,
518,8256650,2023-08-17T16:06:47.233786+00:00,10.5281/zenodo.8256650,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling,"<p>Failure to clear damaged mitochondria via mitophagy disrupts physiological function and may initiate damage signaling via inflammatory cascades, though how these pathways intersect remains unclear. We discovered that NF-&kappa;B essential regulator NEMO is recruited to damaged mitochondria in a Parkin-dependent manner in a time-course similar to recruitment of the structurally-related mitophagy adaptor, OPTN. Upon recruitment, NEMO partitions into phase-separated condensates distinct from OPTN, but colocalizing with p62/SQSTM1. NEMO recruitment in turn recruits the active catalytic IKK component phospho-IKKb, initiating NF-&kappa;B signaling and the upregulation of inflammatory cytokines. Consistent with a potential neuroinflammatory role, NEMO is recruited to mitochondria in primary astrocytes upon oxidative stress. These findings suggest that damaged, ubiquitinated mitochondria serve as an intracellular platform to initiate innate immune signaling, promoting the formation of activated IKK complexes sufficient to activate NF-kB signaling. We propose that mitophagy and NF-&kappa;B signaling are initiated as parallel pathways in response to mitochondrial stress.&nbsp;</p>",Dataset,2023-07-31 00:00:00,"personal
personal
personal
personal
personal","Harding, Olivia
Holzer, Elisabeth
Riley, Julia F.
Martens, Sascha
Holzbaur, Erika L.F.",cc-by-4.0,W4393541490,A5066177476,Olivia Harding,0000-0002-0719-2901
519,8256650,2023-08-17T16:06:47.233786+00:00,10.5281/zenodo.8256650,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling,"<p>Failure to clear damaged mitochondria via mitophagy disrupts physiological function and may initiate damage signaling via inflammatory cascades, though how these pathways intersect remains unclear. We discovered that NF-&kappa;B essential regulator NEMO is recruited to damaged mitochondria in a Parkin-dependent manner in a time-course similar to recruitment of the structurally-related mitophagy adaptor, OPTN. Upon recruitment, NEMO partitions into phase-separated condensates distinct from OPTN, but colocalizing with p62/SQSTM1. NEMO recruitment in turn recruits the active catalytic IKK component phospho-IKKb, initiating NF-&kappa;B signaling and the upregulation of inflammatory cytokines. Consistent with a potential neuroinflammatory role, NEMO is recruited to mitochondria in primary astrocytes upon oxidative stress. These findings suggest that damaged, ubiquitinated mitochondria serve as an intracellular platform to initiate innate immune signaling, promoting the formation of activated IKK complexes sufficient to activate NF-kB signaling. We propose that mitophagy and NF-&kappa;B signaling are initiated as parallel pathways in response to mitochondrial stress.&nbsp;</p>",Dataset,2023-07-31 00:00:00,"personal
personal
personal
personal
personal","Harding, Olivia
Holzer, Elisabeth
Riley, Julia F.
Martens, Sascha
Holzbaur, Erika L.F.",cc-by-4.0,W4393541490,A5045960186,Elisabeth Holzer,0000-0003-1806-737X
520,8256650,2023-08-17T16:06:47.233786+00:00,10.5281/zenodo.8256650,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling,"<p>Failure to clear damaged mitochondria via mitophagy disrupts physiological function and may initiate damage signaling via inflammatory cascades, though how these pathways intersect remains unclear. We discovered that NF-&kappa;B essential regulator NEMO is recruited to damaged mitochondria in a Parkin-dependent manner in a time-course similar to recruitment of the structurally-related mitophagy adaptor, OPTN. Upon recruitment, NEMO partitions into phase-separated condensates distinct from OPTN, but colocalizing with p62/SQSTM1. NEMO recruitment in turn recruits the active catalytic IKK component phospho-IKKb, initiating NF-&kappa;B signaling and the upregulation of inflammatory cytokines. Consistent with a potential neuroinflammatory role, NEMO is recruited to mitochondria in primary astrocytes upon oxidative stress. These findings suggest that damaged, ubiquitinated mitochondria serve as an intracellular platform to initiate innate immune signaling, promoting the formation of activated IKK complexes sufficient to activate NF-kB signaling. We propose that mitophagy and NF-&kappa;B signaling are initiated as parallel pathways in response to mitochondrial stress.&nbsp;</p>",Dataset,2023-07-31 00:00:00,"personal
personal
personal
personal
personal","Harding, Olivia
Holzer, Elisabeth
Riley, Julia F.
Martens, Sascha
Holzbaur, Erika L.F.",cc-by-4.0,W4393541490,A5011795650,Julia F. Riley,0000-0001-8518-9786
521,8256650,2023-08-17T16:06:47.233786+00:00,10.5281/zenodo.8256650,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling,"<p>Failure to clear damaged mitochondria via mitophagy disrupts physiological function and may initiate damage signaling via inflammatory cascades, though how these pathways intersect remains unclear. We discovered that NF-&kappa;B essential regulator NEMO is recruited to damaged mitochondria in a Parkin-dependent manner in a time-course similar to recruitment of the structurally-related mitophagy adaptor, OPTN. Upon recruitment, NEMO partitions into phase-separated condensates distinct from OPTN, but colocalizing with p62/SQSTM1. NEMO recruitment in turn recruits the active catalytic IKK component phospho-IKKb, initiating NF-&kappa;B signaling and the upregulation of inflammatory cytokines. Consistent with a potential neuroinflammatory role, NEMO is recruited to mitochondria in primary astrocytes upon oxidative stress. These findings suggest that damaged, ubiquitinated mitochondria serve as an intracellular platform to initiate innate immune signaling, promoting the formation of activated IKK complexes sufficient to activate NF-kB signaling. We propose that mitophagy and NF-&kappa;B signaling are initiated as parallel pathways in response to mitochondrial stress.&nbsp;</p>",Dataset,2023-07-31 00:00:00,"personal
personal
personal
personal
personal","Harding, Olivia
Holzer, Elisabeth
Riley, Julia F.
Martens, Sascha
Holzbaur, Erika L.F.",cc-by-4.0,W4393541490,A5029002091,Sascha Martens,0000-0003-3786-8199
522,8256650,2023-08-17T16:06:47.233786+00:00,10.5281/zenodo.8256650,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling,"<p>Failure to clear damaged mitochondria via mitophagy disrupts physiological function and may initiate damage signaling via inflammatory cascades, though how these pathways intersect remains unclear. We discovered that NF-&kappa;B essential regulator NEMO is recruited to damaged mitochondria in a Parkin-dependent manner in a time-course similar to recruitment of the structurally-related mitophagy adaptor, OPTN. Upon recruitment, NEMO partitions into phase-separated condensates distinct from OPTN, but colocalizing with p62/SQSTM1. NEMO recruitment in turn recruits the active catalytic IKK component phospho-IKKb, initiating NF-&kappa;B signaling and the upregulation of inflammatory cytokines. Consistent with a potential neuroinflammatory role, NEMO is recruited to mitochondria in primary astrocytes upon oxidative stress. These findings suggest that damaged, ubiquitinated mitochondria serve as an intracellular platform to initiate innate immune signaling, promoting the formation of activated IKK complexes sufficient to activate NF-kB signaling. We propose that mitophagy and NF-&kappa;B signaling are initiated as parallel pathways in response to mitochondrial stress.&nbsp;</p>",Dataset,2023-07-31 00:00:00,"personal
personal
personal
personal
personal","Harding, Olivia
Holzer, Elisabeth
Riley, Julia F.
Martens, Sascha
Holzbaur, Erika L.F.",cc-by-4.0,W4393541490,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114
523,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5077060611,Rekha Dhanwani,0000-0002-6592-8657
524,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5057542377,João Rodrigues Lima-Júnior,
525,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5109476794,Ashu Sethi,
526,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5114235233,John Pham,
527,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5046678361,Gregory P. Williams,0000-0001-9523-1781
528,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5044515449,April Frazier,0000-0002-4722-7304
529,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5075915109,Yaqian Xu,0000-0001-5890-3446
530,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5067845430,Amy W. Amara,0000-0003-0762-9656
531,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5000374325,David G. Standaert,0000-0003-2921-8348
532,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535
533,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5006709022,Irene Litvan,0000-0002-3485-3445
534,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5037098776,Roy N. Alcalay,0000-0002-5717-4875
535,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5023547268,Bjoern Peters,0000-0002-8457-6693
536,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5026787858,David Sulzer,0000-0001-7632-0439
537,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002
538,5523274,2021-09-22T21:13:16.530894+00:00,10.5281/zenodo.5523274,Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS,"<p>FCS files corresponding to the cell surface&nbsp;experiment described in &quot;Transcriptional analysis of peripheral memory T cells reveals Parkinson&rsquo;s disease-specific gene signatures&quot;</p>

<p>&nbsp;</p>",Dataset,2021-08-24 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rekha Dhanwani
João Rodrigues Lima-Junior;
Ashu Sethi
John Pham
Gregory Williams
April Frazier
Yaqian Xu
Amy W. Amara
David G. Standaert
Jennifer G. Goldman
Irene Litvan
Roy N. Alcalay
Bjoern Peters
David Sulzer
Cecilia S. Lindestam Arlehamn
Alessandro Sette",cc-by-2.0,W4393472949,A5010966529,Alessandro Sette,0000-0001-7013-2250
539,10072984,2023-11-05T16:07:09.268645+00:00,10.5281/zenodo.10072984,Companion Pipeline - Population fraction of Parkinson's disease attributable to preventable risk factors,"<p>The complete R-based Posit project to reproduce the analyses and output in the article ""Population fraction of Parkinson's disease attributable to preventable risk factors"".&nbsp; All data can be found in in the 'input' folder. &nbsp;Also includes .Rproj file, renv lockfile for associated packages, folder with all workflow scripts, and wrapper scripts for output generation. See README.md for additional content details.</p><p>Access can also be found on GitHub at <a href=""https://github.com/cfmurch/DeepSouth_PD_PAF"">https://github.com/cfmurch/DeepSouth_PD_PAF</a></p><p>For questions please contact Chad Murchison at <a href=""mailto:cmurchison@uabmc.edu"">cmurchison@uabmc.edu</a></p>",Computational notebook,2023-11-07 00:00:00,"personal
personal
personal
personal
personal
personal","Payami, Haydeh
Cohen, Gwendolyn
Murchison, Charles F
Sampson, Timothy R
Standaert, David G
Wallen, Zachary D",mit,,,,
540,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5038944590,Hanqin Li,0000-0001-7995-1084
541,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5000495585,Oriol Busquets,0000-0002-1372-9699
542,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5088126377,Yogendra Verma,0000-0003-3380-6089
543,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5013626934,Khaja Syed,0000-0002-7682-7608
544,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5004265638,Nitzan Kutnowski,0000-0002-3012-4616
545,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5038011560,Gabriella Pangilinan,0000-0003-2662-7883
546,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5035219354,Luke A. Gilbert,0000-0001-5854-0825
547,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5089305536,Helen S. Bateup,0000-0002-0135-0972
548,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5034073565,Donald C. Rio,
549,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5045835078,Dirk Hockemeyer,0000-0002-5598-5092
550,6941502,2022-09-06T15:47:49.811117+00:00,10.5281/zenodo.6941502,Bulk NGS/allele quantification - Highly efficient generation of isogenic pluripotent stem cell models using prime editing,<p>This file contains sequencing results for bulk NGS and amplicons&nbsp;covering specific regions of interest related to prime editing of hPSCs.&nbsp;</p>,Dataset,2022-04-13 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Li, Hanqin
Busquets, Oriol
Verma, Yogendra
Syed, Khaja
Kutnowski, Nitzan
Pangilinan, Gabriella
Gilbert, Luke
Bateup, Helen
Rio, Donald
Hockemeyer, Dirk
Soldner, Frank",cc-by-4.0,W4393694132,A5070152031,Frank Soldner,0000-0002-7102-8655
551,7908382,2023-05-08T21:51:58.580736+00:00,10.5281/zenodo.7908382,Azcorra2023 - Histological images for fiber placement localization,"<p>Microscopy images of coronal mouse brain slices used for localization of fiber placement in striatum after acute fiber photometry experiments,&nbsp;as used in Azcorra et al. Nat Neuro 2023.</p>",Dataset,2023-05-10 00:00:00,personal,"Azcorra, Maite",cc-by-4.0,W4393778722,A5053163008,Maite Azcorra,0000-0002-2919-3825
552,6322951,2022-04-27T13:47:03.771063+00:00,10.5281/zenodo.6322951,SHIP164 is a Chorein Motif Lipid Transfer Protein that Controls Endosome-Golgi Membrane Traffic,<p>This dataset contains the primary data associated with the publication in the Journal of Cell Biology (https://doi.org/10.1083/jcb.202111018)</p>,Journal article,2022-04-27 00:00:00,"personal
personal
personal
personal
personal","Hanna, Michael
Suen, Patreece
Wu, Yumei
Reinisch, Karin
De Camilli, Pietro",cc-by-4.0,W4224958204,A5076782995,Michael G. Hanna,0000-0002-1975-0501
553,6322951,2022-04-27T13:47:03.771063+00:00,10.5281/zenodo.6322951,SHIP164 is a Chorein Motif Lipid Transfer Protein that Controls Endosome-Golgi Membrane Traffic,<p>This dataset contains the primary data associated with the publication in the Journal of Cell Biology (https://doi.org/10.1083/jcb.202111018)</p>,Journal article,2022-04-27 00:00:00,"personal
personal
personal
personal
personal","Hanna, Michael
Suen, Patreece
Wu, Yumei
Reinisch, Karin
De Camilli, Pietro",cc-by-4.0,W4224958204,A5034293964,Patreece Suen,
554,6322951,2022-04-27T13:47:03.771063+00:00,10.5281/zenodo.6322951,SHIP164 is a Chorein Motif Lipid Transfer Protein that Controls Endosome-Golgi Membrane Traffic,<p>This dataset contains the primary data associated with the publication in the Journal of Cell Biology (https://doi.org/10.1083/jcb.202111018)</p>,Journal article,2022-04-27 00:00:00,"personal
personal
personal
personal
personal","Hanna, Michael
Suen, Patreece
Wu, Yumei
Reinisch, Karin
De Camilli, Pietro",cc-by-4.0,W4224958204,A5004727785,Yumei Wu,0000-0003-0878-7605
555,6322951,2022-04-27T13:47:03.771063+00:00,10.5281/zenodo.6322951,SHIP164 is a Chorein Motif Lipid Transfer Protein that Controls Endosome-Golgi Membrane Traffic,<p>This dataset contains the primary data associated with the publication in the Journal of Cell Biology (https://doi.org/10.1083/jcb.202111018)</p>,Journal article,2022-04-27 00:00:00,"personal
personal
personal
personal
personal","Hanna, Michael
Suen, Patreece
Wu, Yumei
Reinisch, Karin
De Camilli, Pietro",cc-by-4.0,W4224958204,A5059224100,Karin M. Reinisch,0000-0001-9140-6150
556,6322951,2022-04-27T13:47:03.771063+00:00,10.5281/zenodo.6322951,SHIP164 is a Chorein Motif Lipid Transfer Protein that Controls Endosome-Golgi Membrane Traffic,<p>This dataset contains the primary data associated with the publication in the Journal of Cell Biology (https://doi.org/10.1083/jcb.202111018)</p>,Journal article,2022-04-27 00:00:00,"personal
personal
personal
personal
personal","Hanna, Michael
Suen, Patreece
Wu, Yumei
Reinisch, Karin
De Camilli, Pietro",cc-by-4.0,W4224958204,A5037459294,Pietro De Camilli,0000-0001-9045-0723
557,13897831,2024-10-07T10:25:37.780977+00:00,10.5281/zenodo.13897831,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,"<h3><strong>ABSTRACT</strong></h3>
<p>Astrocytes are increasingly thought to possess underestimated and important roles in modulating neuronal circuits. Astrocytes in striatum can regulate dopamine transmission by governing the extracellular tone of axonal neuromodulators, including GABA and adenosine. However, here we reveal that striatal astrocytes occupy a cell type-specific anatomical and functional relationship with cholinergic interneurons (ChIs), through which they rapidly excite ChIs and govern dopamine release via nicotinic acetylcholine receptors on subsecond timescales. We identify that ChI somata are in unexpectedly close proximity to astrocyte somata, in mouse and human, forming a &ldquo;soma-to-soma&rdquo; satellite-like configuration not typically observed for other striatal neurons. Transient depolarization of astrocytes in mouse striatum reversibly regulated ChI excitability by decreasing extracellular calcium. These findings reveal a privileged satellite astrocyte-interneuron interaction for striatal ChIs operating on subsecond timescales via regulation of extracellular calcium dynamics to shape downstream striatal circuit activity and dopamine signaling.</p>
<p>&nbsp;</p>
<h3><strong>FILE DESCRIPTIONS</strong></h3>
<p>This repository contains the following files:</p>
<ul>
<li>Key Resources Table (.xlsx) - Table containing details on key resources (antibodies, mouse lines, virus strains, software, equipment, and reagents), and the persistent identifiers for protocols and code used and generated in this study.&nbsp;</li>
<li>Source Data Folder (.zip):
<ul>
<li>_README_Source_Data (.txt) with detailed information about each dataset.</li>
<li>Individual tabular datasets corresponding to each panel shown in the Main Figures 1 to 5 (.csv).</li>
<li>Excel spreadsheet containing all tabular datasets plotted in Main Figures 1 to 5 (.xlsx)</li>
</ul>
</li>
<li>Supplementary Data Folder (.zip):
<ul>
<li>_README_Supplementary_Data (.txt) with detailed information about each dataset.</li>
<li>Individual tabular datasets corresponding to each panel shown in the Supplementary Figures 1-9, 11-14 (.csv).</li>
<li>Excel spreadsheet containing all tabular datasets plotted in Supplementary Figures 1-9, 11-14 (.xlsx)</li>
</ul>
</li>
</ul>",Dataset,2024-10-07 00:00:00,"personal
personal
personal
personal
personal","Stedehouder, Jeffrey
Roberts, Bradley M.
Raina, Shinil
Bossi, Simon
Cragg, Stephanie J.",cc-by-4.0,,,,
558,7868483,2023-04-28T10:50:48.647446+00:00,10.5281/zenodo.7868483,Protein network analysis links the NSL complex to Parkinson's disease via mitochondrial & nuclear biology,"<p>This online depository corresponds to manuscript :&nbsp;<em>Protein network analysis links the NSL complex to Parkinson&rsquo;s disease via mitochondrial &amp; nuclear biology.</em></p>

<p><strong>Authors:&nbsp;</strong><em>Katie Kelly, Patrick A. Lewis, Helene Plun-Favreau, Claudia Manzoni</em></p>

<p>Whilst the majority (~90-95%) of PD cases are sporadic, much of our understanding of the pathophysiological basis of disease can be traced back to the study of rare, monogenic forms of disease. However, in the past decade, the availability of Genome-Wide Association Studies (GWAS) has facilitated a shift in focus, toward identifying common risk variants conferring an increased risk of developing PD across the population.&nbsp;</p>

<p>A recently developed mitophagy screening assay of GWAS candidates, has functionally implicated the non-specific lethal (NSL) complex, a chromatin remodeler, in the regulation of PINK1-mitophagy. Here, a bioinformatics approach has been taken to investigate the interactome of the NSL complex, to unpick its relevance to PD progression. The mitochondrial interactome of the NSL complex has been built, mining 3 separate repositories: PINOT, HIPPIE and MIST, for curated, literature-derived protein-protein interaction (PPI) data. A multi-layered approach has been taken to; i) build the &lsquo;mitochondrial&rsquo; NSL interactome, applying PD gene-set enrichment analysis to explore the relevance of the NSL mitochondrial interactome to PD and, ii) build the PD-oriented NSL interactome, using functional enrichment, to uncover biological pathways underpinning the NSL /PD association.</p>",Dataset,2023-04-27 00:00:00,personal,Katie Kelly,cc-by-4.0,W4393810186,A5078740297,Katie Kelly,0000-0002-9466-1680
559,10896125,2024-03-30T00:24:31.066370+00:00,10.5281/zenodo.10896125,Figure 2. Rubicon and Pacer RH domain have inverted pRAB7A binding specificity [FINAL],,Dataset,2024-03-29 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
560,6508735,2022-05-03T16:45:21.010417+00:00,10.5281/zenodo.6508735,Jensen_etal_2022_membrane_tube_images,"<p>Membrane tube assay data for Jensen et al, 2022</p>",Dataset,2022-05-02 00:00:00,personal,"Jensen, Liv",cc-by-4.0,W4393546082,A5040157507,Liv Jensen,0000-0003-1492-1743
561,6896851,2022-07-26T12:34:54.182053+00:00,10.5281/zenodo.6896851,Impact of 100 LRRK2 variants linked to Parkinson's Disease on kinase activity and microtubule binding,"<p><strong>Raw data files used for the manuscript &quot;Impact of 100&nbsp;LRRK2 variants linked to Parkinson&rsquo;s Disease on kinase activity and microtubule binding&quot;. This is a revised version&nbsp;of the manuscript&nbsp;&quot;Impact of 98 LRRK2 variants linked to Parkinson&#39;s Disease on kinase activity and microtubule binding&quot;.</strong></p>

<p><strong>The Word document (File description v2.docx) contains a description of each file.</strong></p>",Journal article,2022-07-24 00:00:00,"personal
personal
personal
personal","Alexia Kalogeropulou
Elena Purlyte
Francesca Tonelli
Dario Alessi",cc-by-4.0,W4288055304,A5000257912,Alexia F. Kalogeropulou,0000-0001-5185-7694
562,6896851,2022-07-26T12:34:54.182053+00:00,10.5281/zenodo.6896851,Impact of 100 LRRK2 variants linked to Parkinson's Disease on kinase activity and microtubule binding,"<p><strong>Raw data files used for the manuscript &quot;Impact of 100&nbsp;LRRK2 variants linked to Parkinson&rsquo;s Disease on kinase activity and microtubule binding&quot;. This is a revised version&nbsp;of the manuscript&nbsp;&quot;Impact of 98 LRRK2 variants linked to Parkinson&#39;s Disease on kinase activity and microtubule binding&quot;.</strong></p>

<p><strong>The Word document (File description v2.docx) contains a description of each file.</strong></p>",Journal article,2022-07-24 00:00:00,"personal
personal
personal
personal","Alexia Kalogeropulou
Elena Purlyte
Francesca Tonelli
Dario Alessi",cc-by-4.0,W4288055304,A5002947066,Elena Purlyte,0000-0001-7291-1549
563,6896851,2022-07-26T12:34:54.182053+00:00,10.5281/zenodo.6896851,Impact of 100 LRRK2 variants linked to Parkinson's Disease on kinase activity and microtubule binding,"<p><strong>Raw data files used for the manuscript &quot;Impact of 100&nbsp;LRRK2 variants linked to Parkinson&rsquo;s Disease on kinase activity and microtubule binding&quot;. This is a revised version&nbsp;of the manuscript&nbsp;&quot;Impact of 98 LRRK2 variants linked to Parkinson&#39;s Disease on kinase activity and microtubule binding&quot;.</strong></p>

<p><strong>The Word document (File description v2.docx) contains a description of each file.</strong></p>",Journal article,2022-07-24 00:00:00,"personal
personal
personal
personal","Alexia Kalogeropulou
Elena Purlyte
Francesca Tonelli
Dario Alessi",cc-by-4.0,W4288055304,A5029388712,Francesca Tonelli,0000-0002-4600-6630
564,6896851,2022-07-26T12:34:54.182053+00:00,10.5281/zenodo.6896851,Impact of 100 LRRK2 variants linked to Parkinson's Disease on kinase activity and microtubule binding,"<p><strong>Raw data files used for the manuscript &quot;Impact of 100&nbsp;LRRK2 variants linked to Parkinson&rsquo;s Disease on kinase activity and microtubule binding&quot;. This is a revised version&nbsp;of the manuscript&nbsp;&quot;Impact of 98 LRRK2 variants linked to Parkinson&#39;s Disease on kinase activity and microtubule binding&quot;.</strong></p>

<p><strong>The Word document (File description v2.docx) contains a description of each file.</strong></p>",Journal article,2022-07-24 00:00:00,"personal
personal
personal
personal","Alexia Kalogeropulou
Elena Purlyte
Francesca Tonelli
Dario Alessi",cc-by-4.0,W4288055304,A5054181982,Dario R. Alessi,0000-0002-2140-9185
565,10471496,2024-03-21T20:25:47.950230+00:00,10.5281/zenodo.10471496,Polarisation camera movies of T cells on a cover glass,"<p>The plasma membrane of live T cells (J8 LFA-1) was labelled using the Nile red-derivative NR4A, and 3D movies were recorded using a polarisation camera. Two unprocessed datasets are included here:</p>
<ul>
<li><strong>Tcell_NR4A_EPI_stack</strong>: A 3D stack of a single T cell, imaged with the excitation in EPI configuration.</li>
<li><strong>Tcell_NR4A_HILO_stack_movie</strong>: A 3D movie of live T cells interacting with an OKT3 antibody-coated cover glass, imaged with the excitation in HILO configuration.</li>
</ul>
<p>For each .tif file, the corresponding Micro-Manager metadata file is included.</p>
<p><strong>Optical setup:</strong></p>
<p>Imaging was performed on a widefield microscope equipped with a polarisation camera (CS505MUP, Thorlabs). The sample was excited using a 515 nm laser, coupled into a square-core multi-mode fiber (M97L02, Thorlabs) with a custom vibration-motor-based mode scrambler. The measured power density at the image plane was on the order of 0.004 kW/cm^2. A dichroic (Di03-R514-t1, Semrock) was used to seperate fluorescence from the excitation. The emission was filtered using a long-pass filter (FF01-515/LP, Semrock) and bandpass filter (FF01-650/200, Semrock) before detection.</p>
<p><strong>Sample preparation:</strong></p>
<p>J8 LFA-1 cells were incubated overnight (~18 h) in complete-RPMI (StableCell RPMI-1640 media (Sigma) supplemented with 10 % (v/v) fetal calf serum (FCS), 1 % (v/v) HEPES buffer, and 1 % (v/v) pen/strep antibiotics. 1 mL of cells were collected by centrifugation and resuspended in phenol-red free RPMI supplemented with 1 % HEPES.</p>
<p>Round coverslips were rinsed with IPA, MilliQ, dried, and Ar-plasma cleaned for 20 minutes. Grace Bio-Labs CultureWells were attached, and the slide was incubated with OKT3 antibody (provided by the Human Immunology Unit, WIMM, Oxford) for 30 minutes. The slide was washed 5 times with phenol-red free RPMI supplemented with 1 % HEPES and a final wash with phenol-red free RPMI supplemented with 1 % HEPES and 200 nM NR4A before imaging.</p>",Dataset,2024-01-08 00:00:00,personal,"Bruggeman, Ezra",cc-by-4.0,,,,
566,7864259,2023-04-25T17:37:56.689007+00:00,10.5281/zenodo.7864259,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and Arf6 GTPase disrupts the axonal transport of autophagosomes","<p>Gain-of-function mutations in the <em>LRRK2</em> gene cause Parkinson&rsquo;s disease, increasing phosphorylation of RAB GTPases through hyperactive kinase activity. We find that LRRK2-hyperphosphorylated RABs disrupt the axonal transport of autophagosomes by perturbing the coordinated regulation of cytoplasmic dynein and kinesin motors. In iPSC-derived human neurons, knock-in of the strongly-hyperactive <em>LRRK2</em>-p.R1441H mutation caused striking impairments in autophagosome transport, inducing frequent directional reversals and pauses. Knock-out of the opposing Protein Phosphatase 1H (PPM1H) phenocopied the effect of hyperactive LRRK2. Overexpression of ADP-ribosylation factor 6 (ARF6), a GTPase that acts as a switch for selective activation of dynein or kinesin, attenuated transport defects in both p.R1441H knock-in and PPM1H knock-out neurons. Together, these findings support a model where a regulatory imbalance between LRRK2-hyperphosphorylated RABs and ARF6 induces an unproductive &ldquo;tug-of-war&rdquo; between dynein and kinesin, disrupting processive autophagosome transport. This disruption may contribute to PD pathogenesis by impairing the essential homeostatic functions of axonal autophagy.</p>

<p>&nbsp;</p>",Journal article,2023-03-16 00:00:00,"personal
personal
personal
personal
personal","Dan Dou
Erin M. Smith
Chantell S. Evans
C. Alexander Boecker
Erika L. F. Holzbaur",cc-by-4.0,W4367038981,A5087056018,Dan Dou,0000-0002-6939-4752
567,7864259,2023-04-25T17:37:56.689007+00:00,10.5281/zenodo.7864259,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and Arf6 GTPase disrupts the axonal transport of autophagosomes","<p>Gain-of-function mutations in the <em>LRRK2</em> gene cause Parkinson&rsquo;s disease, increasing phosphorylation of RAB GTPases through hyperactive kinase activity. We find that LRRK2-hyperphosphorylated RABs disrupt the axonal transport of autophagosomes by perturbing the coordinated regulation of cytoplasmic dynein and kinesin motors. In iPSC-derived human neurons, knock-in of the strongly-hyperactive <em>LRRK2</em>-p.R1441H mutation caused striking impairments in autophagosome transport, inducing frequent directional reversals and pauses. Knock-out of the opposing Protein Phosphatase 1H (PPM1H) phenocopied the effect of hyperactive LRRK2. Overexpression of ADP-ribosylation factor 6 (ARF6), a GTPase that acts as a switch for selective activation of dynein or kinesin, attenuated transport defects in both p.R1441H knock-in and PPM1H knock-out neurons. Together, these findings support a model where a regulatory imbalance between LRRK2-hyperphosphorylated RABs and ARF6 induces an unproductive &ldquo;tug-of-war&rdquo; between dynein and kinesin, disrupting processive autophagosome transport. This disruption may contribute to PD pathogenesis by impairing the essential homeostatic functions of axonal autophagy.</p>

<p>&nbsp;</p>",Journal article,2023-03-16 00:00:00,"personal
personal
personal
personal
personal","Dan Dou
Erin M. Smith
Chantell S. Evans
C. Alexander Boecker
Erika L. F. Holzbaur",cc-by-4.0,W4367038981,A5070127770,Erin Smith,0000-0002-6726-628X
568,7864259,2023-04-25T17:37:56.689007+00:00,10.5281/zenodo.7864259,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and Arf6 GTPase disrupts the axonal transport of autophagosomes","<p>Gain-of-function mutations in the <em>LRRK2</em> gene cause Parkinson&rsquo;s disease, increasing phosphorylation of RAB GTPases through hyperactive kinase activity. We find that LRRK2-hyperphosphorylated RABs disrupt the axonal transport of autophagosomes by perturbing the coordinated regulation of cytoplasmic dynein and kinesin motors. In iPSC-derived human neurons, knock-in of the strongly-hyperactive <em>LRRK2</em>-p.R1441H mutation caused striking impairments in autophagosome transport, inducing frequent directional reversals and pauses. Knock-out of the opposing Protein Phosphatase 1H (PPM1H) phenocopied the effect of hyperactive LRRK2. Overexpression of ADP-ribosylation factor 6 (ARF6), a GTPase that acts as a switch for selective activation of dynein or kinesin, attenuated transport defects in both p.R1441H knock-in and PPM1H knock-out neurons. Together, these findings support a model where a regulatory imbalance between LRRK2-hyperphosphorylated RABs and ARF6 induces an unproductive &ldquo;tug-of-war&rdquo; between dynein and kinesin, disrupting processive autophagosome transport. This disruption may contribute to PD pathogenesis by impairing the essential homeostatic functions of axonal autophagy.</p>

<p>&nbsp;</p>",Journal article,2023-03-16 00:00:00,"personal
personal
personal
personal
personal","Dan Dou
Erin M. Smith
Chantell S. Evans
C. Alexander Boecker
Erika L. F. Holzbaur",cc-by-4.0,W4367038981,A5033015769,Chantell S. Evans,0000-0001-9401-8604
569,7864259,2023-04-25T17:37:56.689007+00:00,10.5281/zenodo.7864259,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and Arf6 GTPase disrupts the axonal transport of autophagosomes","<p>Gain-of-function mutations in the <em>LRRK2</em> gene cause Parkinson&rsquo;s disease, increasing phosphorylation of RAB GTPases through hyperactive kinase activity. We find that LRRK2-hyperphosphorylated RABs disrupt the axonal transport of autophagosomes by perturbing the coordinated regulation of cytoplasmic dynein and kinesin motors. In iPSC-derived human neurons, knock-in of the strongly-hyperactive <em>LRRK2</em>-p.R1441H mutation caused striking impairments in autophagosome transport, inducing frequent directional reversals and pauses. Knock-out of the opposing Protein Phosphatase 1H (PPM1H) phenocopied the effect of hyperactive LRRK2. Overexpression of ADP-ribosylation factor 6 (ARF6), a GTPase that acts as a switch for selective activation of dynein or kinesin, attenuated transport defects in both p.R1441H knock-in and PPM1H knock-out neurons. Together, these findings support a model where a regulatory imbalance between LRRK2-hyperphosphorylated RABs and ARF6 induces an unproductive &ldquo;tug-of-war&rdquo; between dynein and kinesin, disrupting processive autophagosome transport. This disruption may contribute to PD pathogenesis by impairing the essential homeostatic functions of axonal autophagy.</p>

<p>&nbsp;</p>",Journal article,2023-03-16 00:00:00,"personal
personal
personal
personal
personal","Dan Dou
Erin M. Smith
Chantell S. Evans
C. Alexander Boecker
Erika L. F. Holzbaur",cc-by-4.0,W4367038981,A5072866258,C. Alexander Boecker,0000-0001-9701-5273
570,7864259,2023-04-25T17:37:56.689007+00:00,10.5281/zenodo.7864259,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and Arf6 GTPase disrupts the axonal transport of autophagosomes","<p>Gain-of-function mutations in the <em>LRRK2</em> gene cause Parkinson&rsquo;s disease, increasing phosphorylation of RAB GTPases through hyperactive kinase activity. We find that LRRK2-hyperphosphorylated RABs disrupt the axonal transport of autophagosomes by perturbing the coordinated regulation of cytoplasmic dynein and kinesin motors. In iPSC-derived human neurons, knock-in of the strongly-hyperactive <em>LRRK2</em>-p.R1441H mutation caused striking impairments in autophagosome transport, inducing frequent directional reversals and pauses. Knock-out of the opposing Protein Phosphatase 1H (PPM1H) phenocopied the effect of hyperactive LRRK2. Overexpression of ADP-ribosylation factor 6 (ARF6), a GTPase that acts as a switch for selective activation of dynein or kinesin, attenuated transport defects in both p.R1441H knock-in and PPM1H knock-out neurons. Together, these findings support a model where a regulatory imbalance between LRRK2-hyperphosphorylated RABs and ARF6 induces an unproductive &ldquo;tug-of-war&rdquo; between dynein and kinesin, disrupting processive autophagosome transport. This disruption may contribute to PD pathogenesis by impairing the essential homeostatic functions of axonal autophagy.</p>

<p>&nbsp;</p>",Journal article,2023-03-16 00:00:00,"personal
personal
personal
personal
personal","Dan Dou
Erin M. Smith
Chantell S. Evans
C. Alexander Boecker
Erika L. F. Holzbaur",cc-by-4.0,W4367038981,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114
571,7434965,2023-02-10T11:09:34.040511+00:00,10.5281/zenodo.7434965,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system.,<p>Raw data associated with each Figure and Supplementary Figures from &quot;Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system&quot;.</p>,Journal article,2022-12-13 00:00:00,"personal
personal","Houdou, Marine
Vangheluwe, Peter",cc-by-4.0,W4319831912,A5014957051,Marine Houdou,0000-0002-9766-3163
572,7434965,2023-02-10T11:09:34.040511+00:00,10.5281/zenodo.7434965,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system.,<p>Raw data associated with each Figure and Supplementary Figures from &quot;Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system&quot;.</p>,Journal article,2022-12-13 00:00:00,"personal
personal","Houdou, Marine
Vangheluwe, Peter",cc-by-4.0,W4319831912,A5008583951,Peter Vangheluwe,0000-0002-7822-2944
573,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5055196927,Julia Chocarro,0000-0002-3670-3459
574,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5029237737,Alberto J. Rico,0000-0002-9067-5444
575,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5046597231,Goiaz Ariznabarreta,0000-0002-8975-8971
576,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5002584391,Elvira Roda,0000-0002-2229-3639
577,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5001636938,Adriana Honrubia,0000-0001-7850-5234
578,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5007339532,María Collantes,0000-0003-1162-1470
579,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5013934560,Iván Peñuelas,0000-0001-8008-976X
580,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5025130042,Alfonso Vazquez,
581,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5048432018,Ana I. Rodríguez‐Pérez,0000-0003-1354-8799
582,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5005884041,José L. Labandeira‐García,0000-0002-8243-9791
583,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5059189782,Miquel Vila,0000-0002-1352-989X
584,8359416,2023-09-19T13:43:02.776231+00:00,10.5281/zenodo.8359416,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,"<p>Although neuromelanin (NMel) is a dark pigment characteristic of dopaminergic neurons in the human substantia nigra pars compacta (SNpc), its potential role in the pathogenesis of Parkinson&rsquo;s disease (PD) has often been neglected since most commonly used laboratory animals lack NMel. Here we took advantage of adeno-associated viral vectors encoding the human tyrosinase gene for triggering a time-dependent NMel accumulation within SNpc dopaminergic neurons in macaques up to similar levels of pigmentation as observed in elderly humans. Furthermore, NMel accumulation induced an endogenous synucleinopathy mimicking intracellular inclusions typically observed in PD together with a progressive degeneration of NMel-expressing dopaminergic neurons. Moreover, Lewy body-like intracellular inclusions were observed in cortical areas of the frontal lobe receiving dopaminergic innervation, supporting a circuit-specific anterograde spread of endogenous synucleinopathy by permissive trans-synaptic templating. In summary, the conducted strategy resulted in the development and characterization of a new macaque model of PD matching the known neuropathology of this disorder with unprecedented accuracy. Most importantly, evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation, therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.</p>",Preprint,2023-09-19 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Julia Chocarro
Alberto J. Rico
Goiaz Ariznabarreta
Elvira Roda
Adriana Honrubia
Maria Collantes
Ivan Peñuelas
Alfonso Vazquez
Ana I Rodriguez-Perez
Jose L Labandeira-Garcia
Miquel Vila
Jose L. Lanciego",cc-by-4.0,W4386841918,A5079288330,José L. Lanciego,0000-0003-2301-5419
585,13887806,2024-10-18T22:38:49.212939+00:00,10.5281/zenodo.13887806,"Data from ""GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes""","<p>Data from ""GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes"". Folders contain data corresponding to each figure. Additional readme files are included with each figure folder to explain the data contained there.</p>",Dataset,2024-10-03 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Savage, Justin
Sivadasan Bindu, Dhanesh
Brose, Nicholas
Bradley, Luke
Dimond, Kylie
Tan, Christabel
Eroglu, Cagla",cc-by-4.0,,,,
586,7149420,2022-10-13T14:42:52.815226+00:00,10.5281/zenodo.7149420,Native MS of MIGA2,<p>Native MS analysis datasheet of&nbsp;human MIGA2 soluble portion (purified from bacteria).</p>,Dataset,2022-10-13 00:00:00,personal,Zhouping Hong,cc-by-4.0,W4393536035,A5072197894,Zhouping Hong,0000-0002-8513-3288
587,8385479,2023-09-28T08:21:28.519473+00:00,10.5281/zenodo.8385479,Parkinson's VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,"<p>Primary data associated with the manuscript&nbsp;<strong>&quot;Parkinson&rsquo;s VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot; (Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A.Hecht, Pawel Lis, Raja S. Nirujogi,Toan K. Phung, Wondwossen M.Yeshaw, Ebsy Jaimon, Rotimi Fasimoye, Emily A. Dickie, MelanieWightman, Thomas Macartney, Suzanne R. Pfeffer and Dario R. Alessi)</strong></p>

<p>-- This is un updated version (after revision round #1) of Primary data associated with the manuscript &quot;<strong>Parkinson&rsquo;s VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot;&nbsp;</strong>(<strong>Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A. Hecht, Pawel Lis, Raja S. Nirujogi, Toan K. Phung, Emily A. Dickie, Mel Wightman, Thomas Macartney, Suzanne R. Pfeffer&nbsp;and Dario R. Alessi</strong>).&nbsp;These include&nbsp;raw immunoblotting data (annotated .tiff exports of Image Studio Lite Licor scans) with&nbsp;their quantitation (.xlsx files) and graphs with statistical analysis obtained using GraphPad Prism&nbsp;(.pzf files).</p>",Preprint,2023-05-02 00:00:00,"personal
personal
personal
personal","Prosenjit Pal
Matthew Taylor
Francesca Tonelli
Rotimi Fasimoye",cc-by-4.0,W4387208457,A5038587130,Prosenjit Pal,0000-0001-6848-4863
588,8385479,2023-09-28T08:21:28.519473+00:00,10.5281/zenodo.8385479,Parkinson's VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,"<p>Primary data associated with the manuscript&nbsp;<strong>&quot;Parkinson&rsquo;s VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot; (Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A.Hecht, Pawel Lis, Raja S. Nirujogi,Toan K. Phung, Wondwossen M.Yeshaw, Ebsy Jaimon, Rotimi Fasimoye, Emily A. Dickie, MelanieWightman, Thomas Macartney, Suzanne R. Pfeffer and Dario R. Alessi)</strong></p>

<p>-- This is un updated version (after revision round #1) of Primary data associated with the manuscript &quot;<strong>Parkinson&rsquo;s VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot;&nbsp;</strong>(<strong>Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A. Hecht, Pawel Lis, Raja S. Nirujogi, Toan K. Phung, Emily A. Dickie, Mel Wightman, Thomas Macartney, Suzanne R. Pfeffer&nbsp;and Dario R. Alessi</strong>).&nbsp;These include&nbsp;raw immunoblotting data (annotated .tiff exports of Image Studio Lite Licor scans) with&nbsp;their quantitation (.xlsx files) and graphs with statistical analysis obtained using GraphPad Prism&nbsp;(.pzf files).</p>",Preprint,2023-05-02 00:00:00,"personal
personal
personal
personal","Prosenjit Pal
Matthew Taylor
Francesca Tonelli
Rotimi Fasimoye",cc-by-4.0,W4387208457,A5000399121,Matthew Taylor,0000-0002-4003-3128
589,8385479,2023-09-28T08:21:28.519473+00:00,10.5281/zenodo.8385479,Parkinson's VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,"<p>Primary data associated with the manuscript&nbsp;<strong>&quot;Parkinson&rsquo;s VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot; (Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A.Hecht, Pawel Lis, Raja S. Nirujogi,Toan K. Phung, Wondwossen M.Yeshaw, Ebsy Jaimon, Rotimi Fasimoye, Emily A. Dickie, MelanieWightman, Thomas Macartney, Suzanne R. Pfeffer and Dario R. Alessi)</strong></p>

<p>-- This is un updated version (after revision round #1) of Primary data associated with the manuscript &quot;<strong>Parkinson&rsquo;s VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot;&nbsp;</strong>(<strong>Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A. Hecht, Pawel Lis, Raja S. Nirujogi, Toan K. Phung, Emily A. Dickie, Mel Wightman, Thomas Macartney, Suzanne R. Pfeffer&nbsp;and Dario R. Alessi</strong>).&nbsp;These include&nbsp;raw immunoblotting data (annotated .tiff exports of Image Studio Lite Licor scans) with&nbsp;their quantitation (.xlsx files) and graphs with statistical analysis obtained using GraphPad Prism&nbsp;(.pzf files).</p>",Preprint,2023-05-02 00:00:00,"personal
personal
personal
personal","Prosenjit Pal
Matthew Taylor
Francesca Tonelli
Rotimi Fasimoye",cc-by-4.0,W4387208457,A5029388712,Francesca Tonelli,0000-0002-4600-6630
590,8385479,2023-09-28T08:21:28.519473+00:00,10.5281/zenodo.8385479,Parkinson's VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,"<p>Primary data associated with the manuscript&nbsp;<strong>&quot;Parkinson&rsquo;s VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot; (Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A.Hecht, Pawel Lis, Raja S. Nirujogi,Toan K. Phung, Wondwossen M.Yeshaw, Ebsy Jaimon, Rotimi Fasimoye, Emily A. Dickie, MelanieWightman, Thomas Macartney, Suzanne R. Pfeffer and Dario R. Alessi)</strong></p>

<p>-- This is un updated version (after revision round #1) of Primary data associated with the manuscript &quot;<strong>Parkinson&rsquo;s VPS35[D620N] retromer lysosomal dysfunction induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B&quot;&nbsp;</strong>(<strong>Prosenjit Pal, Matthew Taylor, Pui Yiu Lam, Francesca Tonelli, Chloe A. Hecht, Pawel Lis, Raja S. Nirujogi, Toan K. Phung, Emily A. Dickie, Mel Wightman, Thomas Macartney, Suzanne R. Pfeffer&nbsp;and Dario R. Alessi</strong>).&nbsp;These include&nbsp;raw immunoblotting data (annotated .tiff exports of Image Studio Lite Licor scans) with&nbsp;their quantitation (.xlsx files) and graphs with statistical analysis obtained using GraphPad Prism&nbsp;(.pzf files).</p>",Preprint,2023-05-02 00:00:00,"personal
personal
personal
personal","Prosenjit Pal
Matthew Taylor
Francesca Tonelli
Rotimi Fasimoye",cc-by-4.0,W4387208457,A5056888177,Rotimi Fasimoye,0000-0001-8057-0879
591,13769802,2024-09-16T19:29:04.378396+00:00,10.5281/zenodo.13769802,ASAP Open Science Guides,"<p>This upload is a suite of guides and resources generated by the ASAP Open Science Team to promote open science best practices. As more are generated, we will continue to version this upload.&nbsp;</p>
<ul>
<li>ASAP Open Science Compliance Checklist: Draft to Publication</li>
<li>Readme for Datasets Guide</li>
<li>Formatting Tabular Data Guide</li>
<li>Uploading Data to Zenodo Guide</li>
<li>Writing Recipe-Style Protocols Guide</li>
<li>Preclinical Tool Registration Guide</li>
<li>Key Resource Table Guide</li>
<li>Licensing Guide</li>
<li>Readme for Code Guide</li>
</ul>
<p>To read more about the ASAP Open Science Policies, see: https://parkinsonsroadmap.org/open-science-policy/#</p>
<p>These guides are licensed with a CC BY 4.0 license to allow for re-distribution, re-use, and modification of these guides. We hope they will serve as a resource for the scientific community.&nbsp;</p>
<p>&nbsp;</p>
<p><em>Versioning record: </em></p>
<ul>
<li><em>Updated on 08/06/2024 to correct an error</em></li>
<li><em>Updated on 08/07/2024 to add the Licensing Guide</em></li>
<li><em>Updated on 09/16/2024 to add Readme for Code Guide</em></li>
</ul>",Lesson,2024-09-16 00:00:00,personal,"Lewis, Dana",cc-by-4.0,,,,
592,13897878,2024-10-07T10:33:10.195678+00:00,10.5281/zenodo.13897878,"Custom Phyton scripts related to Stedehouder & Roberts (2024) ""Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes","<p>This release contains scripts written by Jeffrey Stedehouder and Professor Kevin McGerty to analyse and plot FCV and patch-clamp experiments in <em>ex vivo</em> mouse brain slices, and to model the distance between cell types. These scripts were used in the study <a href=""https://www.biorxiv.org/content/10.1101/2024.05.15.594341v1"">&quot;Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes&quot;</a>.</p>",Software,2024-10-07 00:00:00,personal,ASAP Team Cragg,cc-by-4.0,,,,
593,5045023,2021-06-30T09:00:51.359673+00:00,10.5281/zenodo.5045023,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,"<p>LRRK2 serine/threonine kinase is associated with inherited Parkinson&rsquo;s disease. LRRK2 phosphorylates a subset of Rab GTPases within their switch 2 motif to control their interactions with effectors. Recent work has shown that the metal-dependent protein phosphatase PPM1H counteracts LRRK2 by dephosphorylating Rabs. PPM1H is highly selective and closely related PPM1J exhibits no activity toward substrates such as Rab8a phosphorylated at Thr72 (pThr72). Here we have identified the structural determinant of PPM1H specificity for Rabs. The crystal structure of PPM1H reveals that it is a dimer, confirmed by biophysical analysis, and possesses a conserved catalytic domain that strikingly has evolved a 110-residue flap domain adjacent to the active site. The flap domain distantly resembles tudor domains that interact with histones in the context of epigenetics. Cellular assays, crosslinking and 3-D modelling suggest that the flap domain encodes the docking motif for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J chimaera with the PPM1H flap domain dephosphorylates pThr72 of Rab8a both <em>in vitro</em> and in cellular assays. Therefore, PPM1H has acquired a Rab-specific interaction domain within a conserved phosphatase fold.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1D Rab8A.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Left:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab8A<br>
Right:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab8A</p>

<p><strong>Figure 1D Rab10.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Upper gel:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab10<br>
Lower gel:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab10</p>

<p><strong>Figure 2A gel.tif:</strong></p>

<p>Coomassie-stained SDS-PAGE gel showing the result of crosslinking of PPM1H D288A with phospho-Rab8A.</p>

<p><strong>Figure 2BC. List of cross-links with distances.xlsx:</strong></p>

<p>List of crosslinks identified between PPM1H D288A with phospho-Rab8A shown in Fig.2B and Fig.2C. In green crosslinks &le;32 &Aring;, in red crosslinks &gt;32 &Aring;, in grey crosslinks mapping to the flexible loops missing from the crystal structure.</p>

<p><strong>Figure 2DEF Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.2D, Fig.2E and Fig.2F.</p>

<p><strong>Figure 3B-WT.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (left)</p>

<p><strong>Figure 3B-2Glu.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (right)</p>

<p><strong>Figure 3C gel.tif:</strong><br>
Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.3C</p>

<p><strong>Figure 3D Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.3D</p>

<p><strong>Figure 4A - sequences of the chimaeras.txt:</strong></p>

<p>Aminoacid sequences of the chimaeric proteins used in the assays</p>

<p><strong>Figure 4B.tif:</strong><br>
Coomassie stained gel of recombinant PPM phosphatases shown in Fig.4B. Last lane containing phosphatase PPM1A not shown in figure.</p>

<p><strong>Figure 4CD Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.4C and Fig.4D.</p>

<p><strong>Figure 4E 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4E</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4E</li>
	<li>GAPDH loading controls for blots in Fig.4E</li>
	<li>HA blot for Rab8A shown in Fig.4E</li>
</ol>

<p><strong>Figure 4E 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab8A Thr72 blot shown in Fig.4E</li>
</ol>

<p><strong>Figure 4F 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4F</li>
	<li>HA blot for PPM phosphatases (PPM constructs). HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10. HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
</ol>

<p><strong>Figure 4F 700-2.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4F</li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10 shown in Fig.4F</li>
</ol>

<p><strong>Figure 4F 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.4F</li>
</ol>

<p><strong>Figure 5BE Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.5B and Fig.5E.</p>

<p><strong>Figure 5C.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5C</p>

<p><strong>Figure 5D 700.png:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5D</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5D</li>
	<li>GAPDH loading control for blots in Fig.5D</li>
	<li>HA blot for Rab10 shown in Fig.5D</li>
</ol>

<p><strong>Figure 5D 800.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5D</p>

<p><strong>Figure 5E.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5E</p>

<p><strong>Figure 5F 700 Rab8A.png:</strong></p>

<p>Top to bottom (Rab8A)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab8A shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab8A.png:</strong></p>

<p>Phospho-Rab8A pThr72 blot shown in Fig.5F</p>

<p><strong>Figure 5F 700 Rab10.png:</strong></p>

<p>Top to bottom (Rab10)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab10 shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab10.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5F</p>

<p><strong>Figure 6B 700.tif:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.6B</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.6B</li>
	<li>GAPDH loading controls for blots in Fig.6B</li>
	<li>HA blot for Rab10 shown in Fig.6B</li>
</ol>

<p><strong>Figure 6B 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.6B</li>
</ol>

<p><strong>Figure EV1A 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.EV1A</li>
	<li>GAPDH loading controls for blots in Fig.EV1A</li>
	<li>HA blot for Rab10 shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1A 800.tif:</strong></p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.EV1A</li>
	<li>Phospho-Rab10 Thr72 blot shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1B.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.EV1B</p>

<p><strong>Figure EV2C Malachite.xlsx:</strong></p>

<p>Numerical data for the chart shown in Fig.EV2C</p>",Dataset,2021-06-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Waschbüsch, Dieter
Berndsen, Kerryn
Lis, Pawel
Knebel, Axel
Lam, Yuko P. Y.
Alessi, Dario R.
Khan, Amir R.",cc-by-4.0,W4393586285,A5041063476,Dieter Waschbüsch,0000-0002-8953-2585
594,5045023,2021-06-30T09:00:51.359673+00:00,10.5281/zenodo.5045023,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,"<p>LRRK2 serine/threonine kinase is associated with inherited Parkinson&rsquo;s disease. LRRK2 phosphorylates a subset of Rab GTPases within their switch 2 motif to control their interactions with effectors. Recent work has shown that the metal-dependent protein phosphatase PPM1H counteracts LRRK2 by dephosphorylating Rabs. PPM1H is highly selective and closely related PPM1J exhibits no activity toward substrates such as Rab8a phosphorylated at Thr72 (pThr72). Here we have identified the structural determinant of PPM1H specificity for Rabs. The crystal structure of PPM1H reveals that it is a dimer, confirmed by biophysical analysis, and possesses a conserved catalytic domain that strikingly has evolved a 110-residue flap domain adjacent to the active site. The flap domain distantly resembles tudor domains that interact with histones in the context of epigenetics. Cellular assays, crosslinking and 3-D modelling suggest that the flap domain encodes the docking motif for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J chimaera with the PPM1H flap domain dephosphorylates pThr72 of Rab8a both <em>in vitro</em> and in cellular assays. Therefore, PPM1H has acquired a Rab-specific interaction domain within a conserved phosphatase fold.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1D Rab8A.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Left:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab8A<br>
Right:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab8A</p>

<p><strong>Figure 1D Rab10.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Upper gel:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab10<br>
Lower gel:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab10</p>

<p><strong>Figure 2A gel.tif:</strong></p>

<p>Coomassie-stained SDS-PAGE gel showing the result of crosslinking of PPM1H D288A with phospho-Rab8A.</p>

<p><strong>Figure 2BC. List of cross-links with distances.xlsx:</strong></p>

<p>List of crosslinks identified between PPM1H D288A with phospho-Rab8A shown in Fig.2B and Fig.2C. In green crosslinks &le;32 &Aring;, in red crosslinks &gt;32 &Aring;, in grey crosslinks mapping to the flexible loops missing from the crystal structure.</p>

<p><strong>Figure 2DEF Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.2D, Fig.2E and Fig.2F.</p>

<p><strong>Figure 3B-WT.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (left)</p>

<p><strong>Figure 3B-2Glu.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (right)</p>

<p><strong>Figure 3C gel.tif:</strong><br>
Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.3C</p>

<p><strong>Figure 3D Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.3D</p>

<p><strong>Figure 4A - sequences of the chimaeras.txt:</strong></p>

<p>Aminoacid sequences of the chimaeric proteins used in the assays</p>

<p><strong>Figure 4B.tif:</strong><br>
Coomassie stained gel of recombinant PPM phosphatases shown in Fig.4B. Last lane containing phosphatase PPM1A not shown in figure.</p>

<p><strong>Figure 4CD Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.4C and Fig.4D.</p>

<p><strong>Figure 4E 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4E</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4E</li>
	<li>GAPDH loading controls for blots in Fig.4E</li>
	<li>HA blot for Rab8A shown in Fig.4E</li>
</ol>

<p><strong>Figure 4E 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab8A Thr72 blot shown in Fig.4E</li>
</ol>

<p><strong>Figure 4F 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4F</li>
	<li>HA blot for PPM phosphatases (PPM constructs). HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10. HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
</ol>

<p><strong>Figure 4F 700-2.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4F</li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10 shown in Fig.4F</li>
</ol>

<p><strong>Figure 4F 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.4F</li>
</ol>

<p><strong>Figure 5BE Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.5B and Fig.5E.</p>

<p><strong>Figure 5C.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5C</p>

<p><strong>Figure 5D 700.png:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5D</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5D</li>
	<li>GAPDH loading control for blots in Fig.5D</li>
	<li>HA blot for Rab10 shown in Fig.5D</li>
</ol>

<p><strong>Figure 5D 800.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5D</p>

<p><strong>Figure 5E.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5E</p>

<p><strong>Figure 5F 700 Rab8A.png:</strong></p>

<p>Top to bottom (Rab8A)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab8A shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab8A.png:</strong></p>

<p>Phospho-Rab8A pThr72 blot shown in Fig.5F</p>

<p><strong>Figure 5F 700 Rab10.png:</strong></p>

<p>Top to bottom (Rab10)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab10 shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab10.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5F</p>

<p><strong>Figure 6B 700.tif:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.6B</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.6B</li>
	<li>GAPDH loading controls for blots in Fig.6B</li>
	<li>HA blot for Rab10 shown in Fig.6B</li>
</ol>

<p><strong>Figure 6B 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.6B</li>
</ol>

<p><strong>Figure EV1A 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.EV1A</li>
	<li>GAPDH loading controls for blots in Fig.EV1A</li>
	<li>HA blot for Rab10 shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1A 800.tif:</strong></p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.EV1A</li>
	<li>Phospho-Rab10 Thr72 blot shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1B.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.EV1B</p>

<p><strong>Figure EV2C Malachite.xlsx:</strong></p>

<p>Numerical data for the chart shown in Fig.EV2C</p>",Dataset,2021-06-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Waschbüsch, Dieter
Berndsen, Kerryn
Lis, Pawel
Knebel, Axel
Lam, Yuko P. Y.
Alessi, Dario R.
Khan, Amir R.",cc-by-4.0,W4393586285,A5047301907,Kerryn Berndsen,0000-0002-9353-7565
595,5045023,2021-06-30T09:00:51.359673+00:00,10.5281/zenodo.5045023,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,"<p>LRRK2 serine/threonine kinase is associated with inherited Parkinson&rsquo;s disease. LRRK2 phosphorylates a subset of Rab GTPases within their switch 2 motif to control their interactions with effectors. Recent work has shown that the metal-dependent protein phosphatase PPM1H counteracts LRRK2 by dephosphorylating Rabs. PPM1H is highly selective and closely related PPM1J exhibits no activity toward substrates such as Rab8a phosphorylated at Thr72 (pThr72). Here we have identified the structural determinant of PPM1H specificity for Rabs. The crystal structure of PPM1H reveals that it is a dimer, confirmed by biophysical analysis, and possesses a conserved catalytic domain that strikingly has evolved a 110-residue flap domain adjacent to the active site. The flap domain distantly resembles tudor domains that interact with histones in the context of epigenetics. Cellular assays, crosslinking and 3-D modelling suggest that the flap domain encodes the docking motif for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J chimaera with the PPM1H flap domain dephosphorylates pThr72 of Rab8a both <em>in vitro</em> and in cellular assays. Therefore, PPM1H has acquired a Rab-specific interaction domain within a conserved phosphatase fold.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1D Rab8A.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Left:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab8A<br>
Right:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab8A</p>

<p><strong>Figure 1D Rab10.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Upper gel:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab10<br>
Lower gel:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab10</p>

<p><strong>Figure 2A gel.tif:</strong></p>

<p>Coomassie-stained SDS-PAGE gel showing the result of crosslinking of PPM1H D288A with phospho-Rab8A.</p>

<p><strong>Figure 2BC. List of cross-links with distances.xlsx:</strong></p>

<p>List of crosslinks identified between PPM1H D288A with phospho-Rab8A shown in Fig.2B and Fig.2C. In green crosslinks &le;32 &Aring;, in red crosslinks &gt;32 &Aring;, in grey crosslinks mapping to the flexible loops missing from the crystal structure.</p>

<p><strong>Figure 2DEF Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.2D, Fig.2E and Fig.2F.</p>

<p><strong>Figure 3B-WT.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (left)</p>

<p><strong>Figure 3B-2Glu.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (right)</p>

<p><strong>Figure 3C gel.tif:</strong><br>
Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.3C</p>

<p><strong>Figure 3D Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.3D</p>

<p><strong>Figure 4A - sequences of the chimaeras.txt:</strong></p>

<p>Aminoacid sequences of the chimaeric proteins used in the assays</p>

<p><strong>Figure 4B.tif:</strong><br>
Coomassie stained gel of recombinant PPM phosphatases shown in Fig.4B. Last lane containing phosphatase PPM1A not shown in figure.</p>

<p><strong>Figure 4CD Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.4C and Fig.4D.</p>

<p><strong>Figure 4E 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4E</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4E</li>
	<li>GAPDH loading controls for blots in Fig.4E</li>
	<li>HA blot for Rab8A shown in Fig.4E</li>
</ol>

<p><strong>Figure 4E 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab8A Thr72 blot shown in Fig.4E</li>
</ol>

<p><strong>Figure 4F 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4F</li>
	<li>HA blot for PPM phosphatases (PPM constructs). HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10. HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
</ol>

<p><strong>Figure 4F 700-2.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4F</li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10 shown in Fig.4F</li>
</ol>

<p><strong>Figure 4F 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.4F</li>
</ol>

<p><strong>Figure 5BE Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.5B and Fig.5E.</p>

<p><strong>Figure 5C.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5C</p>

<p><strong>Figure 5D 700.png:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5D</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5D</li>
	<li>GAPDH loading control for blots in Fig.5D</li>
	<li>HA blot for Rab10 shown in Fig.5D</li>
</ol>

<p><strong>Figure 5D 800.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5D</p>

<p><strong>Figure 5E.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5E</p>

<p><strong>Figure 5F 700 Rab8A.png:</strong></p>

<p>Top to bottom (Rab8A)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab8A shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab8A.png:</strong></p>

<p>Phospho-Rab8A pThr72 blot shown in Fig.5F</p>

<p><strong>Figure 5F 700 Rab10.png:</strong></p>

<p>Top to bottom (Rab10)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab10 shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab10.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5F</p>

<p><strong>Figure 6B 700.tif:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.6B</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.6B</li>
	<li>GAPDH loading controls for blots in Fig.6B</li>
	<li>HA blot for Rab10 shown in Fig.6B</li>
</ol>

<p><strong>Figure 6B 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.6B</li>
</ol>

<p><strong>Figure EV1A 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.EV1A</li>
	<li>GAPDH loading controls for blots in Fig.EV1A</li>
	<li>HA blot for Rab10 shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1A 800.tif:</strong></p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.EV1A</li>
	<li>Phospho-Rab10 Thr72 blot shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1B.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.EV1B</p>

<p><strong>Figure EV2C Malachite.xlsx:</strong></p>

<p>Numerical data for the chart shown in Fig.EV2C</p>",Dataset,2021-06-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Waschbüsch, Dieter
Berndsen, Kerryn
Lis, Pawel
Knebel, Axel
Lam, Yuko P. Y.
Alessi, Dario R.
Khan, Amir R.",cc-by-4.0,W4393586285,A5027580687,Paweł Lis,0000-0002-4978-7671
596,5045023,2021-06-30T09:00:51.359673+00:00,10.5281/zenodo.5045023,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,"<p>LRRK2 serine/threonine kinase is associated with inherited Parkinson&rsquo;s disease. LRRK2 phosphorylates a subset of Rab GTPases within their switch 2 motif to control their interactions with effectors. Recent work has shown that the metal-dependent protein phosphatase PPM1H counteracts LRRK2 by dephosphorylating Rabs. PPM1H is highly selective and closely related PPM1J exhibits no activity toward substrates such as Rab8a phosphorylated at Thr72 (pThr72). Here we have identified the structural determinant of PPM1H specificity for Rabs. The crystal structure of PPM1H reveals that it is a dimer, confirmed by biophysical analysis, and possesses a conserved catalytic domain that strikingly has evolved a 110-residue flap domain adjacent to the active site. The flap domain distantly resembles tudor domains that interact with histones in the context of epigenetics. Cellular assays, crosslinking and 3-D modelling suggest that the flap domain encodes the docking motif for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J chimaera with the PPM1H flap domain dephosphorylates pThr72 of Rab8a both <em>in vitro</em> and in cellular assays. Therefore, PPM1H has acquired a Rab-specific interaction domain within a conserved phosphatase fold.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1D Rab8A.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Left:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab8A<br>
Right:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab8A</p>

<p><strong>Figure 1D Rab10.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Upper gel:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab10<br>
Lower gel:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab10</p>

<p><strong>Figure 2A gel.tif:</strong></p>

<p>Coomassie-stained SDS-PAGE gel showing the result of crosslinking of PPM1H D288A with phospho-Rab8A.</p>

<p><strong>Figure 2BC. List of cross-links with distances.xlsx:</strong></p>

<p>List of crosslinks identified between PPM1H D288A with phospho-Rab8A shown in Fig.2B and Fig.2C. In green crosslinks &le;32 &Aring;, in red crosslinks &gt;32 &Aring;, in grey crosslinks mapping to the flexible loops missing from the crystal structure.</p>

<p><strong>Figure 2DEF Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.2D, Fig.2E and Fig.2F.</p>

<p><strong>Figure 3B-WT.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (left)</p>

<p><strong>Figure 3B-2Glu.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (right)</p>

<p><strong>Figure 3C gel.tif:</strong><br>
Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.3C</p>

<p><strong>Figure 3D Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.3D</p>

<p><strong>Figure 4A - sequences of the chimaeras.txt:</strong></p>

<p>Aminoacid sequences of the chimaeric proteins used in the assays</p>

<p><strong>Figure 4B.tif:</strong><br>
Coomassie stained gel of recombinant PPM phosphatases shown in Fig.4B. Last lane containing phosphatase PPM1A not shown in figure.</p>

<p><strong>Figure 4CD Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.4C and Fig.4D.</p>

<p><strong>Figure 4E 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4E</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4E</li>
	<li>GAPDH loading controls for blots in Fig.4E</li>
	<li>HA blot for Rab8A shown in Fig.4E</li>
</ol>

<p><strong>Figure 4E 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab8A Thr72 blot shown in Fig.4E</li>
</ol>

<p><strong>Figure 4F 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4F</li>
	<li>HA blot for PPM phosphatases (PPM constructs). HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10. HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
</ol>

<p><strong>Figure 4F 700-2.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4F</li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10 shown in Fig.4F</li>
</ol>

<p><strong>Figure 4F 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.4F</li>
</ol>

<p><strong>Figure 5BE Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.5B and Fig.5E.</p>

<p><strong>Figure 5C.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5C</p>

<p><strong>Figure 5D 700.png:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5D</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5D</li>
	<li>GAPDH loading control for blots in Fig.5D</li>
	<li>HA blot for Rab10 shown in Fig.5D</li>
</ol>

<p><strong>Figure 5D 800.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5D</p>

<p><strong>Figure 5E.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5E</p>

<p><strong>Figure 5F 700 Rab8A.png:</strong></p>

<p>Top to bottom (Rab8A)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab8A shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab8A.png:</strong></p>

<p>Phospho-Rab8A pThr72 blot shown in Fig.5F</p>

<p><strong>Figure 5F 700 Rab10.png:</strong></p>

<p>Top to bottom (Rab10)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab10 shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab10.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5F</p>

<p><strong>Figure 6B 700.tif:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.6B</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.6B</li>
	<li>GAPDH loading controls for blots in Fig.6B</li>
	<li>HA blot for Rab10 shown in Fig.6B</li>
</ol>

<p><strong>Figure 6B 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.6B</li>
</ol>

<p><strong>Figure EV1A 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.EV1A</li>
	<li>GAPDH loading controls for blots in Fig.EV1A</li>
	<li>HA blot for Rab10 shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1A 800.tif:</strong></p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.EV1A</li>
	<li>Phospho-Rab10 Thr72 blot shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1B.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.EV1B</p>

<p><strong>Figure EV2C Malachite.xlsx:</strong></p>

<p>Numerical data for the chart shown in Fig.EV2C</p>",Dataset,2021-06-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Waschbüsch, Dieter
Berndsen, Kerryn
Lis, Pawel
Knebel, Axel
Lam, Yuko P. Y.
Alessi, Dario R.
Khan, Amir R.",cc-by-4.0,W4393586285,A5024724887,Axel Knebel,0000-0002-9197-6054
597,5045023,2021-06-30T09:00:51.359673+00:00,10.5281/zenodo.5045023,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,"<p>LRRK2 serine/threonine kinase is associated with inherited Parkinson&rsquo;s disease. LRRK2 phosphorylates a subset of Rab GTPases within their switch 2 motif to control their interactions with effectors. Recent work has shown that the metal-dependent protein phosphatase PPM1H counteracts LRRK2 by dephosphorylating Rabs. PPM1H is highly selective and closely related PPM1J exhibits no activity toward substrates such as Rab8a phosphorylated at Thr72 (pThr72). Here we have identified the structural determinant of PPM1H specificity for Rabs. The crystal structure of PPM1H reveals that it is a dimer, confirmed by biophysical analysis, and possesses a conserved catalytic domain that strikingly has evolved a 110-residue flap domain adjacent to the active site. The flap domain distantly resembles tudor domains that interact with histones in the context of epigenetics. Cellular assays, crosslinking and 3-D modelling suggest that the flap domain encodes the docking motif for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J chimaera with the PPM1H flap domain dephosphorylates pThr72 of Rab8a both <em>in vitro</em> and in cellular assays. Therefore, PPM1H has acquired a Rab-specific interaction domain within a conserved phosphatase fold.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1D Rab8A.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Left:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab8A<br>
Right:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab8A</p>

<p><strong>Figure 1D Rab10.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Upper gel:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab10<br>
Lower gel:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab10</p>

<p><strong>Figure 2A gel.tif:</strong></p>

<p>Coomassie-stained SDS-PAGE gel showing the result of crosslinking of PPM1H D288A with phospho-Rab8A.</p>

<p><strong>Figure 2BC. List of cross-links with distances.xlsx:</strong></p>

<p>List of crosslinks identified between PPM1H D288A with phospho-Rab8A shown in Fig.2B and Fig.2C. In green crosslinks &le;32 &Aring;, in red crosslinks &gt;32 &Aring;, in grey crosslinks mapping to the flexible loops missing from the crystal structure.</p>

<p><strong>Figure 2DEF Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.2D, Fig.2E and Fig.2F.</p>

<p><strong>Figure 3B-WT.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (left)</p>

<p><strong>Figure 3B-2Glu.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (right)</p>

<p><strong>Figure 3C gel.tif:</strong><br>
Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.3C</p>

<p><strong>Figure 3D Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.3D</p>

<p><strong>Figure 4A - sequences of the chimaeras.txt:</strong></p>

<p>Aminoacid sequences of the chimaeric proteins used in the assays</p>

<p><strong>Figure 4B.tif:</strong><br>
Coomassie stained gel of recombinant PPM phosphatases shown in Fig.4B. Last lane containing phosphatase PPM1A not shown in figure.</p>

<p><strong>Figure 4CD Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.4C and Fig.4D.</p>

<p><strong>Figure 4E 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4E</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4E</li>
	<li>GAPDH loading controls for blots in Fig.4E</li>
	<li>HA blot for Rab8A shown in Fig.4E</li>
</ol>

<p><strong>Figure 4E 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab8A Thr72 blot shown in Fig.4E</li>
</ol>

<p><strong>Figure 4F 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4F</li>
	<li>HA blot for PPM phosphatases (PPM constructs). HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10. HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
</ol>

<p><strong>Figure 4F 700-2.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4F</li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10 shown in Fig.4F</li>
</ol>

<p><strong>Figure 4F 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.4F</li>
</ol>

<p><strong>Figure 5BE Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.5B and Fig.5E.</p>

<p><strong>Figure 5C.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5C</p>

<p><strong>Figure 5D 700.png:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5D</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5D</li>
	<li>GAPDH loading control for blots in Fig.5D</li>
	<li>HA blot for Rab10 shown in Fig.5D</li>
</ol>

<p><strong>Figure 5D 800.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5D</p>

<p><strong>Figure 5E.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5E</p>

<p><strong>Figure 5F 700 Rab8A.png:</strong></p>

<p>Top to bottom (Rab8A)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab8A shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab8A.png:</strong></p>

<p>Phospho-Rab8A pThr72 blot shown in Fig.5F</p>

<p><strong>Figure 5F 700 Rab10.png:</strong></p>

<p>Top to bottom (Rab10)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab10 shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab10.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5F</p>

<p><strong>Figure 6B 700.tif:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.6B</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.6B</li>
	<li>GAPDH loading controls for blots in Fig.6B</li>
	<li>HA blot for Rab10 shown in Fig.6B</li>
</ol>

<p><strong>Figure 6B 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.6B</li>
</ol>

<p><strong>Figure EV1A 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.EV1A</li>
	<li>GAPDH loading controls for blots in Fig.EV1A</li>
	<li>HA blot for Rab10 shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1A 800.tif:</strong></p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.EV1A</li>
	<li>Phospho-Rab10 Thr72 blot shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1B.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.EV1B</p>

<p><strong>Figure EV2C Malachite.xlsx:</strong></p>

<p>Numerical data for the chart shown in Fig.EV2C</p>",Dataset,2021-06-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Waschbüsch, Dieter
Berndsen, Kerryn
Lis, Pawel
Knebel, Axel
Lam, Yuko P. Y.
Alessi, Dario R.
Khan, Amir R.",cc-by-4.0,W4393586285,A5018861529,Yuko P. Y. Lam,0000-0001-5486-091X
598,5045023,2021-06-30T09:00:51.359673+00:00,10.5281/zenodo.5045023,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,"<p>LRRK2 serine/threonine kinase is associated with inherited Parkinson&rsquo;s disease. LRRK2 phosphorylates a subset of Rab GTPases within their switch 2 motif to control their interactions with effectors. Recent work has shown that the metal-dependent protein phosphatase PPM1H counteracts LRRK2 by dephosphorylating Rabs. PPM1H is highly selective and closely related PPM1J exhibits no activity toward substrates such as Rab8a phosphorylated at Thr72 (pThr72). Here we have identified the structural determinant of PPM1H specificity for Rabs. The crystal structure of PPM1H reveals that it is a dimer, confirmed by biophysical analysis, and possesses a conserved catalytic domain that strikingly has evolved a 110-residue flap domain adjacent to the active site. The flap domain distantly resembles tudor domains that interact with histones in the context of epigenetics. Cellular assays, crosslinking and 3-D modelling suggest that the flap domain encodes the docking motif for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J chimaera with the PPM1H flap domain dephosphorylates pThr72 of Rab8a both <em>in vitro</em> and in cellular assays. Therefore, PPM1H has acquired a Rab-specific interaction domain within a conserved phosphatase fold.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1D Rab8A.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Left:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab8A<br>
Right:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab8A</p>

<p><strong>Figure 1D Rab10.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Upper gel:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab10<br>
Lower gel:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab10</p>

<p><strong>Figure 2A gel.tif:</strong></p>

<p>Coomassie-stained SDS-PAGE gel showing the result of crosslinking of PPM1H D288A with phospho-Rab8A.</p>

<p><strong>Figure 2BC. List of cross-links with distances.xlsx:</strong></p>

<p>List of crosslinks identified between PPM1H D288A with phospho-Rab8A shown in Fig.2B and Fig.2C. In green crosslinks &le;32 &Aring;, in red crosslinks &gt;32 &Aring;, in grey crosslinks mapping to the flexible loops missing from the crystal structure.</p>

<p><strong>Figure 2DEF Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.2D, Fig.2E and Fig.2F.</p>

<p><strong>Figure 3B-WT.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (left)</p>

<p><strong>Figure 3B-2Glu.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (right)</p>

<p><strong>Figure 3C gel.tif:</strong><br>
Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.3C</p>

<p><strong>Figure 3D Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.3D</p>

<p><strong>Figure 4A - sequences of the chimaeras.txt:</strong></p>

<p>Aminoacid sequences of the chimaeric proteins used in the assays</p>

<p><strong>Figure 4B.tif:</strong><br>
Coomassie stained gel of recombinant PPM phosphatases shown in Fig.4B. Last lane containing phosphatase PPM1A not shown in figure.</p>

<p><strong>Figure 4CD Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.4C and Fig.4D.</p>

<p><strong>Figure 4E 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4E</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4E</li>
	<li>GAPDH loading controls for blots in Fig.4E</li>
	<li>HA blot for Rab8A shown in Fig.4E</li>
</ol>

<p><strong>Figure 4E 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab8A Thr72 blot shown in Fig.4E</li>
</ol>

<p><strong>Figure 4F 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4F</li>
	<li>HA blot for PPM phosphatases (PPM constructs). HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10. HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
</ol>

<p><strong>Figure 4F 700-2.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4F</li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10 shown in Fig.4F</li>
</ol>

<p><strong>Figure 4F 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.4F</li>
</ol>

<p><strong>Figure 5BE Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.5B and Fig.5E.</p>

<p><strong>Figure 5C.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5C</p>

<p><strong>Figure 5D 700.png:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5D</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5D</li>
	<li>GAPDH loading control for blots in Fig.5D</li>
	<li>HA blot for Rab10 shown in Fig.5D</li>
</ol>

<p><strong>Figure 5D 800.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5D</p>

<p><strong>Figure 5E.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5E</p>

<p><strong>Figure 5F 700 Rab8A.png:</strong></p>

<p>Top to bottom (Rab8A)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab8A shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab8A.png:</strong></p>

<p>Phospho-Rab8A pThr72 blot shown in Fig.5F</p>

<p><strong>Figure 5F 700 Rab10.png:</strong></p>

<p>Top to bottom (Rab10)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab10 shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab10.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5F</p>

<p><strong>Figure 6B 700.tif:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.6B</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.6B</li>
	<li>GAPDH loading controls for blots in Fig.6B</li>
	<li>HA blot for Rab10 shown in Fig.6B</li>
</ol>

<p><strong>Figure 6B 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.6B</li>
</ol>

<p><strong>Figure EV1A 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.EV1A</li>
	<li>GAPDH loading controls for blots in Fig.EV1A</li>
	<li>HA blot for Rab10 shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1A 800.tif:</strong></p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.EV1A</li>
	<li>Phospho-Rab10 Thr72 blot shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1B.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.EV1B</p>

<p><strong>Figure EV2C Malachite.xlsx:</strong></p>

<p>Numerical data for the chart shown in Fig.EV2C</p>",Dataset,2021-06-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Waschbüsch, Dieter
Berndsen, Kerryn
Lis, Pawel
Knebel, Axel
Lam, Yuko P. Y.
Alessi, Dario R.
Khan, Amir R.",cc-by-4.0,W4393586285,A5054181982,Dario R. Alessi,0000-0002-2140-9185
599,5045023,2021-06-30T09:00:51.359673+00:00,10.5281/zenodo.5045023,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,"<p>LRRK2 serine/threonine kinase is associated with inherited Parkinson&rsquo;s disease. LRRK2 phosphorylates a subset of Rab GTPases within their switch 2 motif to control their interactions with effectors. Recent work has shown that the metal-dependent protein phosphatase PPM1H counteracts LRRK2 by dephosphorylating Rabs. PPM1H is highly selective and closely related PPM1J exhibits no activity toward substrates such as Rab8a phosphorylated at Thr72 (pThr72). Here we have identified the structural determinant of PPM1H specificity for Rabs. The crystal structure of PPM1H reveals that it is a dimer, confirmed by biophysical analysis, and possesses a conserved catalytic domain that strikingly has evolved a 110-residue flap domain adjacent to the active site. The flap domain distantly resembles tudor domains that interact with histones in the context of epigenetics. Cellular assays, crosslinking and 3-D modelling suggest that the flap domain encodes the docking motif for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J chimaera with the PPM1H flap domain dephosphorylates pThr72 of Rab8a both <em>in vitro</em> and in cellular assays. Therefore, PPM1H has acquired a Rab-specific interaction domain within a conserved phosphatase fold.</p>

<p>&nbsp;</p>

<p><strong>FILE DECRIPTIONS</strong></p>

<p><strong>Figure 1D Rab8A.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Left:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab8A<br>
Right:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab8A</p>

<p><strong>Figure 1D Rab10.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.1D:<br>
Upper gel:<br>
Coomassie stained Phos-tag gel of PPM1H with Rab10<br>
Lower gel:<br>
Coomassie stained Phos-tag gel of PPM1J with Rab10</p>

<p><strong>Figure 2A gel.tif:</strong></p>

<p>Coomassie-stained SDS-PAGE gel showing the result of crosslinking of PPM1H D288A with phospho-Rab8A.</p>

<p><strong>Figure 2BC. List of cross-links with distances.xlsx:</strong></p>

<p>List of crosslinks identified between PPM1H D288A with phospho-Rab8A shown in Fig.2B and Fig.2C. In green crosslinks &le;32 &Aring;, in red crosslinks &gt;32 &Aring;, in grey crosslinks mapping to the flexible loops missing from the crystal structure.</p>

<p><strong>Figure 2DEF Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.2D, Fig.2E and Fig.2F.</p>

<p><strong>Figure 3B-WT.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (left)</p>

<p><strong>Figure 3B-2Glu.afe7</strong></p>

<p>Astra data file with data shown in Fig.3B (right)</p>

<p><strong>Figure 3C gel.tif:</strong><br>
Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.3C</p>

<p><strong>Figure 3D Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.3D</p>

<p><strong>Figure 4A - sequences of the chimaeras.txt:</strong></p>

<p>Aminoacid sequences of the chimaeric proteins used in the assays</p>

<p><strong>Figure 4B.tif:</strong><br>
Coomassie stained gel of recombinant PPM phosphatases shown in Fig.4B. Last lane containing phosphatase PPM1A not shown in figure.</p>

<p><strong>Figure 4CD Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.4C and Fig.4D.</p>

<p><strong>Figure 4E 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4E</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4E</li>
	<li>GAPDH loading controls for blots in Fig.4E</li>
	<li>HA blot for Rab8A shown in Fig.4E</li>
</ol>

<p><strong>Figure 4E 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab8A Thr72 blot shown in Fig.4E</li>
</ol>

<p><strong>Figure 4F 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.4F</li>
	<li>HA blot for PPM phosphatases (PPM constructs). HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10. HA blot was not used for Fig.4F. Membrane was reblotted, shown in <strong>tif file Figure 4F 700-2</strong></li>
</ol>

<p><strong>Figure 4F 700-2.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.4F</li>
	<li>GAPDH loading controls for blots in Fig.4F</li>
	<li>HA blot for Rab10 shown in Fig.4F</li>
</ol>

<p><strong>Figure 4F 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.4F</li>
</ol>

<p><strong>Figure 5BE Malachite.xlsx:</strong></p>

<p>Numerical data for the charts shown in Fig.5B and Fig.5E.</p>

<p><strong>Figure 5C.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5C</p>

<p><strong>Figure 5D 700.png:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5D</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5D</li>
	<li>GAPDH loading control for blots in Fig.5D</li>
	<li>HA blot for Rab10 shown in Fig.5D</li>
</ol>

<p><strong>Figure 5D 800.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5D</p>

<p><strong>Figure 5E.tif:</strong></p>

<p>Coomassie stained gel of recombinant PPM1H WT and mutant proteins shown in Fig.5E</p>

<p><strong>Figure 5F 700 Rab8A.png:</strong></p>

<p>Top to bottom (Rab8A)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab8A shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab8A.png:</strong></p>

<p>Phospho-Rab8A pThr72 blot shown in Fig.5F</p>

<p><strong>Figure 5F 700 Rab10.png:</strong></p>

<p>Top to bottom (Rab10)</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.5F</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown in Fig.5F</li>
	<li>GAPDH loading control for blots in Fig.5F</li>
	<li>HA blot for Rab10 shown in Fig.5F</li>
</ol>

<p><strong>Figure 5F 800 Rab10.png:</strong></p>

<p>Phospho-Rab10 pThr73 blot shown in Fig.5F</p>

<p><strong>Figure 6B 700.tif:</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.6B</li>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.6B</li>
	<li>GAPDH loading controls for blots in Fig.6B</li>
	<li>HA blot for Rab10 shown in Fig.6B</li>
</ol>

<p><strong>Figure 6B 800.tif:</strong></p>

<ol>
	<li>Phospho-Rab10 Thr73 blot shown in Fig.6B</li>
</ol>

<p><strong>Figure EV1A 700.tif:</strong><br>
Top to bottom:</p>

<ol>
	<li>Total LRRK2 blot shown in Fig.EV1A</li>
	<li>GAPDH loading controls for blots in Fig.EV1A</li>
	<li>HA blot for Rab10 shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1A 800.tif:</strong></p>

<ol>
	<li>HA blot for PPM phosphatases (PPM constructs) shown In Fig.EV1A</li>
	<li>Phospho-Rab10 Thr72 blot shown in Fig.EV1A</li>
</ol>

<p><strong>Figure EV1B.tif:</strong></p>

<p>Scans of Coomassie stained gels shown in Fig.EV1B</p>

<p><strong>Figure EV2C Malachite.xlsx:</strong></p>

<p>Numerical data for the chart shown in Fig.EV2C</p>",Dataset,2021-06-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal","Waschbüsch, Dieter
Berndsen, Kerryn
Lis, Pawel
Knebel, Axel
Lam, Yuko P. Y.
Alessi, Dario R.
Khan, Amir R.",cc-by-4.0,W4393586285,A5015057310,Amir R. Khan,0000-0003-1176-6952
600,7257484,2022-10-27T11:06:16.704942+00:00,10.5281/zenodo.7257484,Association of genetic variation at the GJA5 locus with motor progression in Parkinson's,<p>These are the GWAS summary statistics generated from the study described in the title</p>,Dataset,2022-10-17 00:00:00,personal,Alejandro Martinez-Carrasco,cc-by-4.0,W4393592618,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703
601,13620762,2024-08-30T19:10:08.211846+00:00,10.5281/zenodo.13620762,Single nucleus transcriptomic dataset of AAV-infected mouse OE,"<h1>Version 4 Update - Fixed bugs and enhanced features</h1>
<ul>
<li>Improved anndata/txt file conversion to account for prefixes</li>
<li>Added prefix handling</li>
</ul>
<h1><strong>Comparative Analysis of AAV Serotypes for Transduction of Olfactory Sensory Neurons</strong></h1>
<h2><strong>Data Description&nbsp;</strong></h2>
<h3><span><span>Benjamin D.W. Belfort*,</span></span><span><span>&nbsp;<span>Johnathan </span></span><span><span>D. </span></span><span><span>Jia</span>*</span></span><span><span>, Alexandra Garza^</span></span><span><span>, Anthony M. Insalaco^</span></span><span><span>, JP McGinnis</span></span><span><span>, Brandon T. Pekarek</span></span><span><span>, Joshua Ortiz-Guzman</span></span><span><span>, Burak Tepe</span></span><span><span>, Hu </span><span>Chen</span></span><span><span>, </span><span>Zhandong</span><span> Liu</span></span><span><span>, Benjamin R. Arenkiel&deg;</span></span><span>&nbsp;</span></h3>
<p><span><span>*,^</span><span> These authors contributed equally</span></span><span>&nbsp;</span></p>
<div>
<p><span><span>&deg; Corresponding author: </span></span><span><span>Benjamin R. Arenkiel</span><span> </span></span><span>&nbsp;</span></p>
</div>
<div>
<p><span><span>Email:&nbsp;</span></span> <a href=""mailto:Arenkiel@bcm.edu"" target=""_blank"" rel=""noreferrer noopener""><span><span>Arenkiel@bcm.edu</span></span></a><span>&nbsp;</span></p>
</div>
<p>Four male adult mice were exposed to 4 serotypes with nsal lavage. Single nucleus sequencing was performed on the harvested and extrated nuclei from the mouse olfactory epithelium. 4 technical replicates were performed. Data was aligned using STARSolo and the raw count matrix underwent the standard preprocessing steps for scRNAseq data including ambient RNA correction (CellBender), filtering (Scanpy), doublet removal (scvi-Solo), processing, dimensional reduction, batch correction (scvi-scVI), and annotation using canonical markers derived from literature.</p>
<p>This repository contains each of the count matrices from the 4 technical replicates in the form of .txt files. The README file will explain how to use the script to reconstruct the AnnData objects the data was originally extracted from. It also contains the final object containing information such as annotations, Pseudotime values, dimensional reductions, and additional layers including spliced/unspliced counts. The README file also explains how to use the scripts to reconstruct the AnnData object using the .txt files. The prefixes match together.</p>
<h2><strong>Zenodo and Github Repo</strong></h2>
<h3><strong>Johnathan Jia</strong></h3>
<p><span>Email: johnathan.jia@bcm.edu</span></p>
<p><strong>&nbsp;</strong>Contains Jupyter notebooks and Python scripts used for each step of snRNAseq analysis starting from alignment and quantification to the downstream terminal fate probability using Palantir. All scripts from Github are available in:</p>
<table>
<tbody>
<tr>
<td>
<div><a href=""../records/13620762/files/LiuzLab/Mouse-AAV-OSN-v0.2-alpha.zip?download=1&amp;preview=1"">LiuzLab/Mouse-AAV-OSN-v0.2-alpha.zip</a></div>
</td>
</tr>
</tbody>
</table>
<p>Please look in the src/snrna/utils folder to find the scripts to reconstruct the AnnData object.</p>",Report,2024-08-30 00:00:00,"personal
personal","Johnathan Jia
Belfort, Benjamin",cc-by-4.0,,,,
602,10962119,2024-05-06T16:24:07.004258+00:00,10.5281/zenodo.10962119,Global Parkinson's Genetics Program Data Release 7,"<p>In April 2024, GP2 announced the seventh data release on the Terra and the Verily&reg; Workbench platforms in collaboration with AMP&reg; PD. This release includes &gt;9,000 additional genotyped participants.</p>
<ul>
<li>The genotype array data, including locally-restricted samples, now consists of a total of 54,180 genotyped participants (28,729 PD cases, 15,834 Controls, and 9,617 &lsquo;Other&rsquo; phenotypes)
<ul>
<li>When removing the locally-restricted samples, these now consist of 40,740 (20,507 PD cases, 11,841 Controls, and 8,392 &lsquo;Other&rsquo; phenotypes)</li>
</ul>
</li>
<li>17,496 total individuals who have deep clinical phenotyping information also have matching genetic information</li>
</ul>
<p>Please see the accompanying blog for further description of this release. To obtain data access, please see <a href=""https://amp-pd.org/researchers/data-use-agreement"">https://amp-pd.org/researchers/data-use-agreement</a>. For any publications using data from this release, please reference the DOI number and the following statement: ""<em>Data (DOI 10.5281/zenodo.10962119, release 7) used in the preparation of this article were obtained from the Global Parkinson&rsquo;s Genetics Program (GP2).""</em></p>",Dataset,2024-04-30 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Hampton Leonard
Mike Nalls
Dan Vitale
Mathew Koretsky
Kristin Levine
Mary Makarious
Zih-Hua Fang
Jones, Lietsel
Solle, J",cc-by-4.0,,,,
603,8020979,2023-06-09T14:16:59.271793+00:00,10.5281/zenodo.8020979,Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,"<p>Primary data associated with the manuscript &quot;<strong>Genome wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase&quot; </strong>(Herschel S. Dhekne, Francesca Tonelli, Wondwossen M. Yeshaw,&nbsp;Claire Y. Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte,&nbsp;Dario Alessi, and Suzanne Pfeffer).&nbsp;These include raw immunoblotting data (annotated .tiff exports of Image Studio Lite Licor scans) and their quantitation (.xlsx files) and graphs obtained using GraphPad Prism&nbsp;(.pzf files). The new version (published 09/06/2023) includes the primary data added for paper revision.</p>",Journal article,2023-02-12 00:00:00,personal,Francesca Tonelli,cc-by-4.0,W4379963771,A5029388712,Francesca Tonelli,0000-0002-4600-6630
604,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5026190664,Rashmi Chandra,0000-0001-9591-8997
605,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5072554284,Arpine Sokratian,0000-0001-6654-5773
606,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5024539060,Katherine Ramos Chavez,0000-0001-8952-385X
607,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5006733326,Stephanie L. King,0000-0003-2293-9185
608,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5065401534,Sandip M. Swain,0000-0002-2404-8186
609,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5087580101,Joshua C. Snyder,0000-0002-9787-3371
610,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5071278272,Andrew B. West,0000-0002-3034-4061
611,10214221,2023-11-29T20:18:24.882626+00:00,10.1172/jci.insight.172192,Data from: Gut mucosal cells transfer α-synuclein to the vagus nerve,"<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p><p><strong>Figure 1. α-Synuclein expression and seeding activity in SNCAA53T mice.</strong> ELISA quantification of human α-synuclein in (C) duodenum (α-synuclein quantification in ng/mg of nodose tissue), (D) nodose ganglia (α-synuclein quantification in pg/mg of nodose tissue), and (E) hindbrain (α-synuclein quantification in ng/mg of nodose tissue), from Snca–/– and SNCAA53T mice. RT-QuIC analysis of (F) duodenum, (G) nodose ganglia, and (H) hindbrain of Snca–/– and SNCAA53T mice.&nbsp;</p><p><strong>Figure 3. Conditional human α-synuclein expression induces α-synuclein seeding activity in gut organoids.</strong> (C) A representative ThT fluorescence profile for these genotypes is provided. (D) Endpoint values were collected after 100 hours of RT-QuIC relative to negative controls.</p><p><strong>Figure 4. Conditional human α-synuclein expression in gut mucosal cells produces in α-synuclein seeding activity in nodose ganglia.</strong> (C) ELISA quantification of human α-synuclein protein in nodose ganglia of nontransgenic, Snca–/–, and SNCAbow mice. (D) A representative ThT fluorescence profile (RT-QuIC) and endpoint analysis of nodose ganglia from nontransgenic (nTg), Snca–/–, and SNCAbow mice at 1 month of age. (E) RT-QuIC analysis of nodose ganglia from 6-month-old nTg, Snca–/–, and SNCAbow mice.</p><p><strong>Figure 5. Vagotomy spares the nodose ganglia from α-synuclein seeding activity and prevents spread to the hindbrain. </strong>(C) ELISA measurements of α-synuclein protein in the gut 3 months after tamoxifen treatment. RT-QuIC analysis of (D and E) vagal nodose ganglia and (F and G) hindbrain analyzed 3 months after tamoxifen treatment. Representative ThT fluorescence profiles are shown in D and F.</p><p>Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson's disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.</p>",Dataset,2023-11-28 00:00:00,"personal
personal
personal
personal
personal","West, Andrew
Liddle, Rodger
Sokratian, Arpine
Ramos Chavez, Katherine
Chandra, Rashmi",cc-by-4.0,W4389429458,A5058874182,Rodger A. Liddle,0000-0002-5498-4151
612,4900679,2021-06-04T19:10:51.227541+00:00,10.5281/zenodo.4900679,Hurley-Lab/GUVquantification: Chang_etal_SciAdv_2021,"<p>Scripts used in Chang C, Shi X, Jensen LE, Yokom AL, Fracchiolla D, Martens S, Hurley JH. Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy. Sci Adv. 2021 Apr 23;7(17):eabg4922. doi: 10.1126/sciadv.abg4922. PMID: 33893090; PMCID: PMC8064641.</p>",Software,2021-06-04 00:00:00,personal,livjensen7,other-open,,,,
613,5525370,2021-09-23T21:48:32.308558+00:00,10.5281/zenodo.5525370,huw-morris-lab/proband-nfl: Proband-NFL analysis,<p>No description provided.</p>,Software,2021-09-23 00:00:00,"personal
personal","nirosenv
huw101",other-open,,,,
614,5931188,2022-01-31T20:38:17.287056+00:00,10.5281/zenodo.5931188,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,<p>Raw Data Files for the manuscript entitled &quot;Oncogenic <em>BRAF</em> V600E induces glial proliferation through ERK and neuronal death through JNK&quot;.&nbsp;</p>,Dataset,2022-01-31 00:00:00,"personal
personal
personal
personal","Ye Qing
Srivastava Pranay
Al-Kuwari Nasser
Chen Xiqun",cc-by-4.0,W4393714075,A5103658641,YE Qing,
615,5931188,2022-01-31T20:38:17.287056+00:00,10.5281/zenodo.5931188,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,<p>Raw Data Files for the manuscript entitled &quot;Oncogenic <em>BRAF</em> V600E induces glial proliferation through ERK and neuronal death through JNK&quot;.&nbsp;</p>,Dataset,2022-01-31 00:00:00,"personal
personal
personal
personal","Ye Qing
Srivastava Pranay
Al-Kuwari Nasser
Chen Xiqun",cc-by-4.0,W4393714075,A5020152429,Pranay Srivastava,0000-0002-9289-2696
616,5931188,2022-01-31T20:38:17.287056+00:00,10.5281/zenodo.5931188,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,<p>Raw Data Files for the manuscript entitled &quot;Oncogenic <em>BRAF</em> V600E induces glial proliferation through ERK and neuronal death through JNK&quot;.&nbsp;</p>,Dataset,2022-01-31 00:00:00,"personal
personal
personal
personal","Ye Qing
Srivastava Pranay
Al-Kuwari Nasser
Chen Xiqun",cc-by-4.0,W4393714075,A5020041132,Al-Kuwari Nasser,
617,5931188,2022-01-31T20:38:17.287056+00:00,10.5281/zenodo.5931188,Oncogenic BRAF V600E induces glial proliferation through ERK and neuronal death through JNK,<p>Raw Data Files for the manuscript entitled &quot;Oncogenic <em>BRAF</em> V600E induces glial proliferation through ERK and neuronal death through JNK&quot;.&nbsp;</p>,Dataset,2022-01-31 00:00:00,"personal
personal
personal
personal","Ye Qing
Srivastava Pranay
Al-Kuwari Nasser
Chen Xiqun",cc-by-4.0,W4393714075,A5012470875,Xiqun Chen,0000-0001-8582-8891
618,7504034,2023-01-04T16:05:53.382084+00:00,10.5281/zenodo.7504034,"Research outputs associated with ""Policy to Practice: tracking open science funding""","<p>Datasets, code, figures, and other documents assocaited with &quot;From policy to practice: tracking an open science funding initiative&quot; (Ratan et al. 2023)</p>

<p>Contents:<br>
PDF files of figures 1 and 2<br>
- Figure_1.pdf<br>
- Figure_2.pdf</p>

<p>PDF file explaining rules and definitions used when creating an open science compliance report<br>
- Compliance_Report_Object_Rules.pdf</p>

<p>Tabular data sets constructed to produced figure 2<br>
- NewSharedData.csv<br>
- NewSharedCode.csv<br>
- NewSharedLabMat.csv<br>
- NewSharedProtocols.csv<br>
- ReuseCitedData.csv<br>
- ReuseCitedSoftware.csv<br>
- ReuseCitedLabMat.csv<br>
- ReuseCitedProtocols.csv</p>

<p>R Code used to produce figure 2 from the datasets listed above<br>
- researchOutputs_pairedData.R</p>

<p>&nbsp;</p>",Other,2023-01-04 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Kristen Ratan
Souad McIntosh
Hetal V. Shah
Matthew Lewis
Sonya B. Dumanis
Timothy H. Vines
Randy Schekman
Ekemini Riley",cc-by-4.0,,,,
619,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5009136361,Marc P. M. Soutar,0000-0003-0008-9423
620,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5023202307,Daniela Melandri,0000-0002-3630-5143
621,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5059141377,Benjamin O’Callaghan,0000-0002-1323-6843
622,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5044305625,Emily Annuario,0000-0002-0342-1113
623,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5047091121,Amy E. Monaghan,0000-0003-0302-6989
624,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5051992465,Natalie J. Welsh,0000-0002-2714-0367
625,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5008997142,Karishma D’Sa,
626,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5051204041,Sebastian Guelfi,0000-0002-0256-2686
627,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5037391977,David Zhang,0000-0003-2382-8460
628,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5021931896,Alan Pittman,0000-0002-8112-2987
629,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5044516423,Daniah Trabzuni,0000-0003-4826-9570
630,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5031176489,Anouk H. A. Verboven,0000-0002-9252-6020
631,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5001480287,Kylie S. Pan,0000-0003-1057-9119
632,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5110614420,Demis A. Kia,
633,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5041739625,Magda Bictash,0000-0002-7909-8076
634,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5101470156,Sonia Gandhi,0000-0003-4395-2661
635,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5082436384,Henry Houlden,0000-0002-2866-7777
636,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5064191051,Mark Cookson,0000-0002-1058-3831
637,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5049588515,Nael Nadif Kasri,0000-0002-7448-9289
638,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5064529704,Nicholas Wood,0000-0002-9500-3348
639,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5100694605,Andrew Singleton,0000-0001-5606-700X
640,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5020514779,John Hardy,0000-0002-3122-0423
641,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5055408422,Paul J. Whiting,0000-0002-4121-1379
642,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111
643,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5100762756,Alexander J. Whitworth,0000-0002-1154-6629
644,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5005572028,Claudia Manzoni,0000-0001-5367-4023
645,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5042439287,Mina Ryten,0000-0001-9520-6957
646,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5000831279,Patrick A. Lewis,0000-0003-4537-0489
647,6952972,2022-08-03T09:54:01.927464+00:00,10.5281/zenodo.6952972,Tabular Data for figures of Soutar et al. 2022,"<p>Tabular data of analysed data presented in figures of the manuscript &quot;Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson&rsquo;s disease at Chr16q11.2 and on the MAPT H1&nbsp;allele&quot; by Soutar et al., 2022.</p>",Dataset,2022-08-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Soutar, Marc P.M
Melandri, Daniela
O'Callaghan, Benjamin
Annuario, Emily
Monaghan, Amy E.
Welsh, Natalie J.
D'Sa, Karishma
Guelfi, Sebastian
Zhang, David
Pittman, Alan
Trabzuni, Daniah
Verboven, Anouk H. A.
Pan, Kylie S.
Kia, Demis A.
Bictash, Magda
Gandhi, Sonia
Houlden, Henry
Cookson, Mark R.
Nadif Kasri, Nael
Wood, Nicholas W.
Singleton, Andrew B.
Hardy, John
Whiting, Paul J.
Blauwendraat, Cornelis
Whitworth, Alexander J.
Manzoni, Claudia
Ryten, Mina
Lewis, Patrick A.
Plun-Favreau, Helene",cc-by-4.0,W4393604929,A5045997682,Hélène Plun‐Favreau,0000-0002-1401-9656
648,10896130,2024-03-30T00:32:55.502982+00:00,10.5281/zenodo.10896130,Figure 3: Rubicon - Rab7 binding colocalization [FINAL],,Dataset,2024-03-29 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
649,8221547,2023-08-07T16:14:11.556952+00:00,10.5281/zenodo.8221547,Unconventional secretion of alpha-synuclein mediated by palmitoylated DNAJC5 oligomers,"<p>Alpha-synuclein (&alpha;-syn), a major component of Lewy bodies found in Parkinson&rsquo;s disease (PD) patients, has been found exported outside of cells and may mediate its toxicity via cell-to-cell transmission. Here, we reconstituted soluble, monomeric &alpha;-syn secretion by the expression of DnaJ homolog subfamily C member 5 (DNAJC5) in HEK293T cells. DNAJC5 undergoes palmitoylation and anchors on the membrane. Palmitoylation is essential for DNAJC5-induced &alpha;-syn secretion, and the secretion is not limited by substrate size or unfolding. Cytosolic &alpha;-syn is actively translocated and sequestered in an endosomal membrane compartment in a DNAJC5-dependent manner. Reduction of &alpha;-syn secretion caused by a palmitoylation-deficient mutation in DNAJC5 can be reversed by a membrane-targeting peptide fusion-induced oligomerization of DNAJC5. The secretion of endogenous &alpha;-syn mediated by DNAJC5 is also found in a human neuroblastoma cell line, SH-SY5Y, differentiated into neurons in the presence of retinoic acid, and in human-induced pluripotent stem cell-derived midbrain dopamine neurons. We propose that DNAJC5 forms a palmitoylated oligomer to accommodate and export &alpha;-syn.</p>",Dataset,2023-08-07 00:00:00,"personal
personal
personal
personal
personal
personal","Shenjie Wu
Nancy Hernandez VIllegas
Daniel Siriks
Iona Thomas-Wright
Richard Wade-Martins
Randy Schekman",cc-by-4.0,W4393777979,A5101575954,Shenjie Wu,0000-0001-7547-0048
650,8221547,2023-08-07T16:14:11.556952+00:00,10.5281/zenodo.8221547,Unconventional secretion of alpha-synuclein mediated by palmitoylated DNAJC5 oligomers,"<p>Alpha-synuclein (&alpha;-syn), a major component of Lewy bodies found in Parkinson&rsquo;s disease (PD) patients, has been found exported outside of cells and may mediate its toxicity via cell-to-cell transmission. Here, we reconstituted soluble, monomeric &alpha;-syn secretion by the expression of DnaJ homolog subfamily C member 5 (DNAJC5) in HEK293T cells. DNAJC5 undergoes palmitoylation and anchors on the membrane. Palmitoylation is essential for DNAJC5-induced &alpha;-syn secretion, and the secretion is not limited by substrate size or unfolding. Cytosolic &alpha;-syn is actively translocated and sequestered in an endosomal membrane compartment in a DNAJC5-dependent manner. Reduction of &alpha;-syn secretion caused by a palmitoylation-deficient mutation in DNAJC5 can be reversed by a membrane-targeting peptide fusion-induced oligomerization of DNAJC5. The secretion of endogenous &alpha;-syn mediated by DNAJC5 is also found in a human neuroblastoma cell line, SH-SY5Y, differentiated into neurons in the presence of retinoic acid, and in human-induced pluripotent stem cell-derived midbrain dopamine neurons. We propose that DNAJC5 forms a palmitoylated oligomer to accommodate and export &alpha;-syn.</p>",Dataset,2023-08-07 00:00:00,"personal
personal
personal
personal
personal
personal","Shenjie Wu
Nancy Hernandez VIllegas
Daniel Siriks
Iona Thomas-Wright
Richard Wade-Martins
Randy Schekman",cc-by-4.0,W4393777979,A5104268627,Nancy Hernandez VIllegas,
651,8221547,2023-08-07T16:14:11.556952+00:00,10.5281/zenodo.8221547,Unconventional secretion of alpha-synuclein mediated by palmitoylated DNAJC5 oligomers,"<p>Alpha-synuclein (&alpha;-syn), a major component of Lewy bodies found in Parkinson&rsquo;s disease (PD) patients, has been found exported outside of cells and may mediate its toxicity via cell-to-cell transmission. Here, we reconstituted soluble, monomeric &alpha;-syn secretion by the expression of DnaJ homolog subfamily C member 5 (DNAJC5) in HEK293T cells. DNAJC5 undergoes palmitoylation and anchors on the membrane. Palmitoylation is essential for DNAJC5-induced &alpha;-syn secretion, and the secretion is not limited by substrate size or unfolding. Cytosolic &alpha;-syn is actively translocated and sequestered in an endosomal membrane compartment in a DNAJC5-dependent manner. Reduction of &alpha;-syn secretion caused by a palmitoylation-deficient mutation in DNAJC5 can be reversed by a membrane-targeting peptide fusion-induced oligomerization of DNAJC5. The secretion of endogenous &alpha;-syn mediated by DNAJC5 is also found in a human neuroblastoma cell line, SH-SY5Y, differentiated into neurons in the presence of retinoic acid, and in human-induced pluripotent stem cell-derived midbrain dopamine neurons. We propose that DNAJC5 forms a palmitoylated oligomer to accommodate and export &alpha;-syn.</p>",Dataset,2023-08-07 00:00:00,"personal
personal
personal
personal
personal
personal","Shenjie Wu
Nancy Hernandez VIllegas
Daniel Siriks
Iona Thomas-Wright
Richard Wade-Martins
Randy Schekman",cc-by-4.0,W4393777979,A5094326311,Daniel Siriks,
652,8221547,2023-08-07T16:14:11.556952+00:00,10.5281/zenodo.8221547,Unconventional secretion of alpha-synuclein mediated by palmitoylated DNAJC5 oligomers,"<p>Alpha-synuclein (&alpha;-syn), a major component of Lewy bodies found in Parkinson&rsquo;s disease (PD) patients, has been found exported outside of cells and may mediate its toxicity via cell-to-cell transmission. Here, we reconstituted soluble, monomeric &alpha;-syn secretion by the expression of DnaJ homolog subfamily C member 5 (DNAJC5) in HEK293T cells. DNAJC5 undergoes palmitoylation and anchors on the membrane. Palmitoylation is essential for DNAJC5-induced &alpha;-syn secretion, and the secretion is not limited by substrate size or unfolding. Cytosolic &alpha;-syn is actively translocated and sequestered in an endosomal membrane compartment in a DNAJC5-dependent manner. Reduction of &alpha;-syn secretion caused by a palmitoylation-deficient mutation in DNAJC5 can be reversed by a membrane-targeting peptide fusion-induced oligomerization of DNAJC5. The secretion of endogenous &alpha;-syn mediated by DNAJC5 is also found in a human neuroblastoma cell line, SH-SY5Y, differentiated into neurons in the presence of retinoic acid, and in human-induced pluripotent stem cell-derived midbrain dopamine neurons. We propose that DNAJC5 forms a palmitoylated oligomer to accommodate and export &alpha;-syn.</p>",Dataset,2023-08-07 00:00:00,"personal
personal
personal
personal
personal
personal","Shenjie Wu
Nancy Hernandez VIllegas
Daniel Siriks
Iona Thomas-Wright
Richard Wade-Martins
Randy Schekman",cc-by-4.0,W4393777979,A5035010942,Iona Thomas-Wright,
653,8221547,2023-08-07T16:14:11.556952+00:00,10.5281/zenodo.8221547,Unconventional secretion of alpha-synuclein mediated by palmitoylated DNAJC5 oligomers,"<p>Alpha-synuclein (&alpha;-syn), a major component of Lewy bodies found in Parkinson&rsquo;s disease (PD) patients, has been found exported outside of cells and may mediate its toxicity via cell-to-cell transmission. Here, we reconstituted soluble, monomeric &alpha;-syn secretion by the expression of DnaJ homolog subfamily C member 5 (DNAJC5) in HEK293T cells. DNAJC5 undergoes palmitoylation and anchors on the membrane. Palmitoylation is essential for DNAJC5-induced &alpha;-syn secretion, and the secretion is not limited by substrate size or unfolding. Cytosolic &alpha;-syn is actively translocated and sequestered in an endosomal membrane compartment in a DNAJC5-dependent manner. Reduction of &alpha;-syn secretion caused by a palmitoylation-deficient mutation in DNAJC5 can be reversed by a membrane-targeting peptide fusion-induced oligomerization of DNAJC5. The secretion of endogenous &alpha;-syn mediated by DNAJC5 is also found in a human neuroblastoma cell line, SH-SY5Y, differentiated into neurons in the presence of retinoic acid, and in human-induced pluripotent stem cell-derived midbrain dopamine neurons. We propose that DNAJC5 forms a palmitoylated oligomer to accommodate and export &alpha;-syn.</p>",Dataset,2023-08-07 00:00:00,"personal
personal
personal
personal
personal
personal","Shenjie Wu
Nancy Hernandez VIllegas
Daniel Siriks
Iona Thomas-Wright
Richard Wade-Martins
Randy Schekman",cc-by-4.0,W4393777979,A5028723665,Richard Wade‐Martins,0000-0001-6691-580X
654,8221547,2023-08-07T16:14:11.556952+00:00,10.5281/zenodo.8221547,Unconventional secretion of alpha-synuclein mediated by palmitoylated DNAJC5 oligomers,"<p>Alpha-synuclein (&alpha;-syn), a major component of Lewy bodies found in Parkinson&rsquo;s disease (PD) patients, has been found exported outside of cells and may mediate its toxicity via cell-to-cell transmission. Here, we reconstituted soluble, monomeric &alpha;-syn secretion by the expression of DnaJ homolog subfamily C member 5 (DNAJC5) in HEK293T cells. DNAJC5 undergoes palmitoylation and anchors on the membrane. Palmitoylation is essential for DNAJC5-induced &alpha;-syn secretion, and the secretion is not limited by substrate size or unfolding. Cytosolic &alpha;-syn is actively translocated and sequestered in an endosomal membrane compartment in a DNAJC5-dependent manner. Reduction of &alpha;-syn secretion caused by a palmitoylation-deficient mutation in DNAJC5 can be reversed by a membrane-targeting peptide fusion-induced oligomerization of DNAJC5. The secretion of endogenous &alpha;-syn mediated by DNAJC5 is also found in a human neuroblastoma cell line, SH-SY5Y, differentiated into neurons in the presence of retinoic acid, and in human-induced pluripotent stem cell-derived midbrain dopamine neurons. We propose that DNAJC5 forms a palmitoylated oligomer to accommodate and export &alpha;-syn.</p>",Dataset,2023-08-07 00:00:00,"personal
personal
personal
personal
personal
personal","Shenjie Wu
Nancy Hernandez VIllegas
Daniel Siriks
Iona Thomas-Wright
Richard Wade-Martins
Randy Schekman",cc-by-4.0,W4393777979,A5016859611,Randy Schekman,0000-0001-8615-6409
655,10887655,2024-03-27T16:07:39.804008+00:00,10.5281/zenodo.10887655,fluorescence quantification associated with manuscript (Autophagy preferentially degrades non-fibrillar polyQ aggregates https://doi.org/10.1101/2023.08.08.552291 ),,Dataset,2023-08-09 00:00:00,personal,"Zhao, Dorothy",cc-by-4.0,,,,
656,10774734,2024-03-03T17:36:18.221697+00:00,10.5281/zenodo.10774734,In vitro expansion of antigen-specific cells and FluoroSpot Assay,,Dataset,2024-02-12 00:00:00,"organizational
personal","Aligning Science Across Parkinson's
Lindestam Arlehamn, Cecilia",cc-by-4.0,,,,
657,8139875,2023-07-12T16:33:58.952980+00:00,10.5281/zenodo.8139875,"18, 28, 42 DPI neuron and macrophage quantifications","<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub> peptide in complete Freund&#39;s adjuvant (CFA), CFA alone, or PBS alone. Enteric neuron density (ANNA1<sup>+</sup>), tyrosine hydroxylase (TH) neuron density, TH<sup>+</sup>&nbsp;area and mean fluorescence intensity, and macrophage density (IBA1<sup>+</sup>) were quantified from the submucosal plexus and myenteric plexus of mice at 18, 28, and 42 days post immunization. These values were normalized to the CFA-only condition.&nbsp;</p>",Dataset,2023-07-12 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531047,A5012875579,Francesca Garretti,0000-0002-6609-8034
658,8139875,2023-07-12T16:33:58.952980+00:00,10.5281/zenodo.8139875,"18, 28, 42 DPI neuron and macrophage quantifications","<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub> peptide in complete Freund&#39;s adjuvant (CFA), CFA alone, or PBS alone. Enteric neuron density (ANNA1<sup>+</sup>), tyrosine hydroxylase (TH) neuron density, TH<sup>+</sup>&nbsp;area and mean fluorescence intensity, and macrophage density (IBA1<sup>+</sup>) were quantified from the submucosal plexus and myenteric plexus of mice at 18, 28, and 42 days post immunization. These values were normalized to the CFA-only condition.&nbsp;</p>",Dataset,2023-07-12 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531047,A5084707089,Connor Monahan,0000-0003-3245-6187
659,8139875,2023-07-12T16:33:58.952980+00:00,10.5281/zenodo.8139875,"18, 28, 42 DPI neuron and macrophage quantifications","<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub> peptide in complete Freund&#39;s adjuvant (CFA), CFA alone, or PBS alone. Enteric neuron density (ANNA1<sup>+</sup>), tyrosine hydroxylase (TH) neuron density, TH<sup>+</sup>&nbsp;area and mean fluorescence intensity, and macrophage density (IBA1<sup>+</sup>) were quantified from the submucosal plexus and myenteric plexus of mice at 18, 28, and 42 days post immunization. These values were normalized to the CFA-only condition.&nbsp;</p>",Dataset,2023-07-12 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531047,A5026787858,David Sulzer,0000-0001-7632-0439
660,8139875,2023-07-12T16:33:58.952980+00:00,10.5281/zenodo.8139875,"18, 28, 42 DPI neuron and macrophage quantifications","<p>MHC-II (-/-) mice expressing HLA DRB1*15:01 were immunized with a-synuclein<sub>32-46</sub> peptide in complete Freund&#39;s adjuvant (CFA), CFA alone, or PBS alone. Enteric neuron density (ANNA1<sup>+</sup>), tyrosine hydroxylase (TH) neuron density, TH<sup>+</sup>&nbsp;area and mean fluorescence intensity, and macrophage density (IBA1<sup>+</sup>) were quantified from the submucosal plexus and myenteric plexus of mice at 18, 28, and 42 days post immunization. These values were normalized to the CFA-only condition.&nbsp;</p>",Dataset,2023-07-12 00:00:00,"personal
personal
personal
personal","Francesca Garretti
Connor Monahan
David Sulzer
Dritan Agalliu",cc-by-4.0,W4393531047,A5085315691,Dritan Agalliu,0000-0002-5375-4143
661,11831299,2024-06-16T20:25:49.200405+00:00,10.5281/zenodo.11831299,"Datasets for ""Detecting rhythmic spiking through the power spectra of point process model residuals""","<p>This repository contains synthetic and empirical datasets that were analyzed in the preprint ""Detecting rhythmic spiking through the power spectra of point process model residuals.""</p>
<p>Relative to the previous version (1.0.0), this new version (1.0.1) only entails changes in the naming of some folders, and the text of an explanatory text file.&nbsp; The changes reflect the reordering of the figures in the newest version of the manuscript.</p>",Dataset,2024-06-16 00:00:00,"personal
personal
personal
personal","Karin Cox
Daisuke Kase
Taieb Znati
Robert Turner",cc-by-4.0,,,,
662,10887623,2024-03-27T16:05:07.412753+00:00,10.5281/zenodo.10887623,tomogram quantification related to manuscript (Autophagy preferentially degrades non-fibrillar polyQ aggregates) https://doi.org/10.1101/2023.08.08.552291,,Dataset,2023-08-09 00:00:00,personal,"Zhao, Dorothy",cc-by-4.0,,,,
663,10387118,2023-12-20T17:34:58.287558+00:00,10.5281/zenodo.10387118,Day2023 supplementary dataset,"<p>Day M., Belal M., Surmeier W. C., Melendez A., Wokosin, D., Tkatch T., Clarke V. R. J. and Surmeier D. J.</p>
<p><span><span>GABAergic </span><span>regulation of striatal spiny </span><span>projection </span><span>neuron </span></span><span><span>excitability </span></span><span><span>depends upon </span></span><span><span>their </span></span><span><span>activity </span></span><span><span>state&nbsp;</span></span>(2023)</p>
<p>Datasets for all supplementary figures S1-4</p>",Dataset,2023-12-15 00:00:00,personal,"Clarke, Vernon. R. J.",cc-by-4.0,W4393793896,A5018658974,Vernon R. J. Clarke,0000-0002-6154-6555
664,10819194,2024-04-19T22:58:29.865375+00:00,10.5281/zenodo.10819194,10X Visium Data Analysis for Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,"<p>An analytical tool to be used with the 10X Visium platform to compare spatial gene expression values. Code written by Zak Doric, Yoshitaka J Sei.</p>",Software,2024-03-14 00:00:00,"personal
personal","Doric, Zak
Sei, Yoshitaka",cc-by-4.0,,,,
665,10819065,2024-05-22T16:04:44.987944+00:00,10.5281/zenodo.10819065,ASAP Spatial Transcriptomics Code,"<p>This repository contains analysis scripts used by The University of Sydney collaborators to analyse spatial transcriptomics as part of&nbsp;<a href=""https://parkinsonsroadmap.org/"" rel=""nofollow"">Aligning Science Accross Parkinson's</a>.</p>",Software,2024-03-14 00:00:00,personal,"Chatterton, Zac",cc-by-4.0,,,,
666,7632198,2023-02-11T12:45:02.708389+00:00,10.5281/zenodo.7632198,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,"<p>The assembly of the autophagy initiation machinery nucleates autophagosome biogenesis, including in the PINK1- and Parkin-dependent mitophagy pathway implicated in Parkinson&#39;s disease. The structural interaction between the sole transmembrane autophagy protein, ATG9A, and components of the ULK1 complex is one of the major missing links needed to complete a structural map of autophagy initiation. We determined the 2.4 &Aring; x-ray crystallographic structure of the ternary structure of ATG9A C-terminal tail bound to the ATG13:ATG101 HORMA dimer, which is part of the ULK1 complex. We term the interacting portion of the extreme C-terminal part of the ATG9A tail the &ldquo;HORMA dimer interacting region&rdquo; (HDIR). This structure shows that the HDIR binds to the HORMA domain of ATG101 by&nbsp;&beta;-sheet complementation such that the ATG9A tail resides in a deep cleft at the ATG13:ATG101 interface. Disruption of this complex in cells impairs damage induced PINK1/Parkin mitophagy mediated by the cargo receptor NDP52.</p>",Journal article,2023-01-12 00:00:00,"personal
personal
personal","Yokom, Adam Lee
Hurley, James H
Nguyen, Thanh Ngoc",cc-by-4.0,W4320409065,A5048244508,Adam L. Yokom,0000-0002-3746-7961
667,7632198,2023-02-11T12:45:02.708389+00:00,10.5281/zenodo.7632198,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,"<p>The assembly of the autophagy initiation machinery nucleates autophagosome biogenesis, including in the PINK1- and Parkin-dependent mitophagy pathway implicated in Parkinson&#39;s disease. The structural interaction between the sole transmembrane autophagy protein, ATG9A, and components of the ULK1 complex is one of the major missing links needed to complete a structural map of autophagy initiation. We determined the 2.4 &Aring; x-ray crystallographic structure of the ternary structure of ATG9A C-terminal tail bound to the ATG13:ATG101 HORMA dimer, which is part of the ULK1 complex. We term the interacting portion of the extreme C-terminal part of the ATG9A tail the &ldquo;HORMA dimer interacting region&rdquo; (HDIR). This structure shows that the HDIR binds to the HORMA domain of ATG101 by&nbsp;&beta;-sheet complementation such that the ATG9A tail resides in a deep cleft at the ATG13:ATG101 interface. Disruption of this complex in cells impairs damage induced PINK1/Parkin mitophagy mediated by the cargo receptor NDP52.</p>",Journal article,2023-01-12 00:00:00,"personal
personal
personal","Yokom, Adam Lee
Hurley, James H
Nguyen, Thanh Ngoc",cc-by-4.0,W4320409065,A5061450716,James H. Hurley,0000-0001-5054-5445
668,7632198,2023-02-11T12:45:02.708389+00:00,10.5281/zenodo.7632198,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,"<p>The assembly of the autophagy initiation machinery nucleates autophagosome biogenesis, including in the PINK1- and Parkin-dependent mitophagy pathway implicated in Parkinson&#39;s disease. The structural interaction between the sole transmembrane autophagy protein, ATG9A, and components of the ULK1 complex is one of the major missing links needed to complete a structural map of autophagy initiation. We determined the 2.4 &Aring; x-ray crystallographic structure of the ternary structure of ATG9A C-terminal tail bound to the ATG13:ATG101 HORMA dimer, which is part of the ULK1 complex. We term the interacting portion of the extreme C-terminal part of the ATG9A tail the &ldquo;HORMA dimer interacting region&rdquo; (HDIR). This structure shows that the HDIR binds to the HORMA domain of ATG101 by&nbsp;&beta;-sheet complementation such that the ATG9A tail resides in a deep cleft at the ATG13:ATG101 interface. Disruption of this complex in cells impairs damage induced PINK1/Parkin mitophagy mediated by the cargo receptor NDP52.</p>",Journal article,2023-01-12 00:00:00,"personal
personal
personal","Yokom, Adam Lee
Hurley, James H
Nguyen, Thanh Ngoc",cc-by-4.0,W4320409065,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020
669,7349228,2022-11-23T00:08:47.377178+00:00,10.5281/zenodo.7349228,CX3CR1cre_IABflox_Tcell_counts,"<p>This excel contains the dataset from CX3CR1 Cre/+ and CX3CR1 Cre/+ IAB flox/flox mice transduced with AAV2-SYN. Four weeks post-transduction, brains were collected, labelled with anti-CD4, and imaged on a brightfield microscope. An ROI was drawn around the ventral midbrain and the total number of CD4+ cells within that ROI was quantified. This number was then divided by the total area of the ROI.&nbsp;</p>",Dataset,2022-11-22 00:00:00,personal,"Schonhoff, Aubrey M",cc-by-4.0,W4393700012,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
670,10499027,2024-05-22T16:08:16.924357+00:00,10.5281/zenodo.10499027,Data for Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,<p>Raw Data for publication titled Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine&nbsp;neuron degeneration.</p>,Dataset,2024-01-12 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Rademacher, Katerina
Nakamura, Ken
Kreitzer, Anatol
Garcia, Joseph
Creed, Rose
Nelson, Alexandra
Doric, Zak
Haddad, Dominik
Mamaligas, Aphroditi
Liao, Szu-Chi
Kano, Kohei
Chatterton, Zac
Fu, Yuhong
Sei, Yoshitaka
Vance, Victoria
Halliday, Glenda
Margolis, Elyssa",cc-by-4.0,,,,
671,7352402,2022-11-23T19:10:03.855636+00:00,10.5281/zenodo.7352402,Tmem119 IAB flow cytometry dataset,<p>These files contain raw data from Tmem119 CreERT2/+ or Tmem119 CreERT2/+ IAB fl/fl mice transduced with AAV2-SYN. Brains were collected and processed 4 weeks post-transduction and run on an Attune Nxt flow cytometer. A workspace file is included to demonstrate how gating and quantification were performed.</p>,Dataset,2022-11-23 00:00:00,personal,"Schonhoff, Aubrey M",cc-by-4.0,W4393774227,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
672,13380404,2024-08-27T20:31:56.000417+00:00,10.5281/zenodo.13380404,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,"<p><strong>EM Quantitation:</strong></p>
<p>Raw data gathered from EM images taken to determine nanodisc population size distribution.</p>
<p>&nbsp;</p>
<p><strong>NNB TGN46 analysis:</strong></p>
<p>Data analysis of the Native Nanobleach experiments of TGN46 in native nanodiscs to determine population distribution of oligomeric organizations.</p>
<p>&nbsp;</p>
<p><strong>Polymer conditions:</strong></p>
<p>Physiochemical characteristic and extraction conditions for all polymers in the library both commercially available and in-house.</p>
<p>&nbsp;</p>
<p><strong>Protein groups polymer screen original file:</strong></p>
<p>Original output of MaxQuant data processing of polymer screen data.</p>
<p>&nbsp;</p>
<p><strong>Organelle matching:</strong></p>
<p>Code used for mathcing proteins identified in the proteomics output to organelle or residence for all organellar annotations.</p>
<p>&nbsp;</p>
<p><strong>Polymer code:</strong></p>
<p>Code used to process and normalize the MaxQuant output and calulate extraction efficiency across all detected proteins.</p>
<p>&nbsp;</p>
<p><strong>MAP Library Details:</strong></p>
<p>Graphic and table explaining chemical details of all polymer used in the screen, both commerically available and in-house synthesized.</p>
<p>&nbsp;</p>
<p><strong>NNB TGN46:</strong></p>
<p>Raw scope files for the TIRF microscopy single molecule step photobleaching experiment with TGN46.</p>
<p>&nbsp;</p>
<p><strong>Organellar Breakdown Database:</strong></p>
<p>Proteins detected in the polymer screen through proteomics experiments stratified into organelle of residence.</p>
<p>&nbsp;</p>
<p><strong>Human Proteome FASTA:</strong></p>
<p>The FASTA file used for proteome searching in processing the proteomics data to build the screening database.</p>
<p>&nbsp;</p>
<p><strong>Hand Curated Organellar Proteomes:</strong></p>
<p>Organellar proteomes used for organellar sorting and identification of proteins detected in the screen.</p>
<p>&nbsp;</p>
<p><strong>Polymer SEC Superdex75:</strong></p>
<p>Size exculsion chromatography traces for chloroSMA series of polymers. Was used to characterize length and population polydispersity.</p>
<p>&nbsp;</p>
<p><strong>Negative Stain Raw:</strong></p>
<p>RAW TEM scope images of purified synaptophysin-vamp2 containing nanodiscs. Populatoin size distribution was determined.</p>
<p>&nbsp;</p>
<p><strong>FSEC Polymer CS80:</strong></p>
<p>Fluoresence size exclusion chromatogram for purified synaptophysin-vamp2 containing nanodiscs to ensure population homogeneity and purity.</p>
<p><strong>NMR Raw data:</strong></p>
<p>NMR raw files for characterizing the in-house synthesized Chloro-SMA series and AASTY series.</p>
<p>&nbsp;</p>",Dataset,2024-05-10 00:00:00,"personal
personal
personal","Brown, Caroline
GHOSH, SNEHASISH
Gupta, Kallol",cc-by-4.0,,,,
673,8007760,2023-06-05T19:31:43.831169+00:00,10.5281/zenodo.8007760,Macros for striatum quantifications,"<p>Macro used to mesure signal intensity and area after background removal.</p>

<p>&nbsp;</p>",Journal article,2023-06-05 00:00:00,personal,Nicolas Giguere,cc-by-4.0,W4379504973,A5088355635,Nicolas Giguère,0000-0001-8982-2411
674,10469323,2024-01-08T15:26:51.952052+00:00,10.5281/zenodo.10469323,Polarisation camera movie of single SYTOX Orange molecules on a cover glass,"<p>This image dataset is a movie of the fluorescence of single SYTOX Orange molecules (S34861, Invitrogen) dispersed on a cover glass. The data was collected on a fluorescence microscope (Ti-U, Nikon) with a polarisation camera (CS505MUP, Thorlabs). The molecules were excited with a 532 nm diode laser with a measured power density at the sample plane of 0.36 kW/cm^2. An exposure time of 100 ms was used. The following filters were used: dichroic (Di03-R532-t1, Semrock) and emission filter (FF01-582/64, Semrock).</p>",Dataset,2024-01-08 00:00:00,personal,"Bruggeman, Ezra",cc-by-4.0,W4393892128,A5014618738,Ezra Bruggeman,0000-0001-6100-1443
675,10791411,2024-03-18T14:36:08.275387+00:00,10.5281/zenodo.10791411,Figure S4: MW weight of gels [FINAL],,Dataset,2024-03-07 00:00:00,personal,"Tudorica, Dan",cc-by-4.0,,,,
676,7541954,2023-01-16T18:29:41.425796+00:00,10.5281/zenodo.7541954,Rscript,<p>R scripts for analysis of clinical data</p>,Software,2023-01-16 00:00:00,personal,Marco Toffoli,cc-by-4.0,,,,
677,11118235,2024-05-06T03:31:31.309717+00:00,10.5281/zenodo.11118235,turner-lab-pitt/outlier-waveform-detection: First Zenodo release,<p><strong>Full Changelog</strong>: https://github.com/turner-lab-pitt/outlier-waveform-detection/compare/1.0.0...1.0.1</p>,Software,2024-05-06 00:00:00,personal,"Cox, Karin",cc-by-4.0,,,,
678,10850011,2024-03-21T17:46:04.391140+00:00,10.5281/zenodo.10850011,FRAP dataset associated with manuscript (https://doi.org/10.1101/2023.08.08.552291 ),,Dataset,2024-03-21 00:00:00,personal,"Zhao, Dorothy",cc-by-4.0,,,,
679,6607749,2022-06-02T16:32:18.559303+00:00,10.5281/zenodo.6607749,Anna-Bieber/autophagy-tomo-analysis: autophagy-tomo-analysis v1.0.0,"<p>Scripts for analysis of autophagy-related structures in cryo-electron tomography data. Used in the manuscript &quot;In situ structural analysis reveals membrane shape transitions during autophagosome formation&quot; by Bieber, Capitanio et al. 2022 (<a href=""https://doi.org/10.1101/2022.05.02.490291"">https://doi.org/10.1101/2022.05.02.490291</a>). Additional contributor: Cristina Capitanio @cptcst</p>",Software,2022-06-02 00:00:00,"personal
personal","Bieber, Anna
Capitanio, Cristina",other-open,,,,
680,6581800,2022-05-25T17:44:17.249223+00:00,10.5281/zenodo.6581800,Basal Ganglia Neurons in Healthy and Parkinsonian Primates Generate Recurring Sequences of Spikes,"<p>These data are the source data for the manuscript entitled &quot;Basal Ganglia Neurons in Healthy<br>
and Parkinsonian Primates Generate Recurring Sequences of Spikes&quot;, authored by Adriana Galvan<br>
and Thomas Wichmann (Emory University, Atlanta, GA). &nbsp;</p>

<p>The data are interspike interval measurements generated from electrophysiological recordings<br>
of spontaneous spiking activities of single neurons in the basal ganglia of awake monkeys, before<br>
and after rendering them parkinsonian by treatment with MPTP. THe animals were not engaged in any<br>
task or other structured activity.</p>

<p>The data format is a one-column listing of successive interspike intervals, and are presented in<br>
milliseconds. The data are structured into different folders:</p>

<p>GPe normal - data collected in the external pallidal segment, under normal conditions<br>
GPe MPTP - data collected in the external pallidal segment, under parkinsonian conditions<br>
STN normal - data collected in the subthalamic nucleus, under normal conditions<br>
STN MPTP - data collected in the subthalamic nucleus, under parkinsonian conditions<br>
GPi normal - data collected in the internal pallidal segment, under normal conditions<br>
GPi MPTP - data collected in the internal pallidal segment, under parkinsonian conditions</p>

<p>A &#39;Read Me&#39; file is included, containing these explanations.</p>

<p>For questions, please contact the corresponding author, Dr. Thomas Wichmann (twichma@emory.edu).</p>

<p>&nbsp;</p>",Dataset,2022-05-25 00:00:00,"personal
personal","Galvan, Adriana
Wichmann, Thomas",cc-by-4.0,W4393843376,A5056482545,Adriana Galván,0000-0001-9939-0130
681,6581800,2022-05-25T17:44:17.249223+00:00,10.5281/zenodo.6581800,Basal Ganglia Neurons in Healthy and Parkinsonian Primates Generate Recurring Sequences of Spikes,"<p>These data are the source data for the manuscript entitled &quot;Basal Ganglia Neurons in Healthy<br>
and Parkinsonian Primates Generate Recurring Sequences of Spikes&quot;, authored by Adriana Galvan<br>
and Thomas Wichmann (Emory University, Atlanta, GA). &nbsp;</p>

<p>The data are interspike interval measurements generated from electrophysiological recordings<br>
of spontaneous spiking activities of single neurons in the basal ganglia of awake monkeys, before<br>
and after rendering them parkinsonian by treatment with MPTP. THe animals were not engaged in any<br>
task or other structured activity.</p>

<p>The data format is a one-column listing of successive interspike intervals, and are presented in<br>
milliseconds. The data are structured into different folders:</p>

<p>GPe normal - data collected in the external pallidal segment, under normal conditions<br>
GPe MPTP - data collected in the external pallidal segment, under parkinsonian conditions<br>
STN normal - data collected in the subthalamic nucleus, under normal conditions<br>
STN MPTP - data collected in the subthalamic nucleus, under parkinsonian conditions<br>
GPi normal - data collected in the internal pallidal segment, under normal conditions<br>
GPi MPTP - data collected in the internal pallidal segment, under parkinsonian conditions</p>

<p>A &#39;Read Me&#39; file is included, containing these explanations.</p>

<p>For questions, please contact the corresponding author, Dr. Thomas Wichmann (twichma@emory.edu).</p>

<p>&nbsp;</p>",Dataset,2022-05-25 00:00:00,"personal
personal","Galvan, Adriana
Wichmann, Thomas",cc-by-4.0,W4393843376,A5042569468,Thomas Wichmann,0000-0002-2751-9545
682,11176979,2024-05-10T21:35:01.091304+00:00,10.5281/zenodo.11176979,turner-lab-pitt/TomSort: 1.01,No description provided.,Software,2024-05-10 00:00:00,personal,daisukekase,cc-by-4.0,,,,
683,8288831,2023-08-28T08:44:44.713372+00:00,10.5281/zenodo.8288831,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,"<p>This deposit contains :</p>

<p>- a&nbsp;RMarkdown filte containing the&nbsp;codes for the mcirobial analysis of saliva samples</p>

<p>- the html report with codes,&nbsp;results and figures</p>

<p>- a RData containing microbial datasets (MSp species abundance table, genus, family and phylum abundance tables, matrix of genes correlations, taxonomy)</p>

<p>- a RData containing associated metadata&nbsp;</p>",Dataset,2023-08-28 00:00:00,"personal
personal","Victoria Meslier
Mathieu Almeida",cc-by-4.0,W4393771872,A5002977326,Victoria Meslier,0000-0003-2699-0092
684,8288831,2023-08-28T08:44:44.713372+00:00,10.5281/zenodo.8288831,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,"<p>This deposit contains :</p>

<p>- a&nbsp;RMarkdown filte containing the&nbsp;codes for the mcirobial analysis of saliva samples</p>

<p>- the html report with codes,&nbsp;results and figures</p>

<p>- a RData containing microbial datasets (MSp species abundance table, genus, family and phylum abundance tables, matrix of genes correlations, taxonomy)</p>

<p>- a RData containing associated metadata&nbsp;</p>",Dataset,2023-08-28 00:00:00,"personal
personal","Victoria Meslier
Mathieu Almeida",cc-by-4.0,W4393771872,A5067904253,Mathieu Almeida,0000-0003-4971-0049
685,10908502,2024-04-12T17:35:30.275492+00:00,10.5281/zenodo.10908502,Reward perseveration is shaped by GABAA-mediated dopamine pauses: Fiber Photometry Data,"<p>Fiber photometry data. These data were used to generate the following figures in the paper ""Reward perseveration is shaped by GABAA-mediated dopamine pauses"":</p>
<ul>
<li>Figure 3, all panels</li>
<li>Ext. Fig 4, all panels</li>
</ul>
<p>Specifics of the data:</p>
<ul>
<li>FiberPho_Cohort_*.zip files contain all of the raw fiber photometry and behavior data for each mouse, grouped by cohort.</li>
<li>FiberPho_Histo_Cohort_*.zip files contain the histological images and ROIs for each mouse, grouped by cohort.&nbsp;</li>
<li>HTP_grouped_data.zip contains the grouped analysis fiber photometry and behavior MATLAB files for the experimental group.</li>
<li>ddHTP_grouped_data.zip contains the grouped analysis fiber photometry and behavior MATLAB files for the control group.</li>
<li>The various .csv files contain the summarized mouse, cohort, and analysis details and data.</li>
</ul>
<p>&nbsp;</p>",Dataset,2024-04-02 00:00:00,"personal
personal","Burwell, Sasha
Tadross, Michael",cc-by-4.0,,,,
686,13381814,2024-08-27T23:21:46.670346+00:00,10.5281/zenodo.13381814,Code for: Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,<p>New preprocessing code and masks</p>,Software,2024-08-27 00:00:00,personal,Liz Rizor,cc-by-4.0,,,,
687,10956842,2024-04-12T17:35:15.192304+00:00,10.5281/zenodo.10956842,"Image distortion data from ""An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys""",,Dataset,2024-04-10 00:00:00,personal,"Liang, Lucy",cc-by-4.0,,,,
688,10463426,2024-01-16T11:37:49.443252+00:00,10.5281/zenodo.10463426,"EMG data from ""An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys""",,Dataset,2024-01-05 00:00:00,"personal
personal","Liang, Lucy
Schaeffer, David",cc-by-4.0,W4393617937,A5062343908,Lucy Liang,0009-0003-5462-832X
689,10463426,2024-01-16T11:37:49.443252+00:00,10.5281/zenodo.10463426,"EMG data from ""An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys""",,Dataset,2024-01-05 00:00:00,"personal
personal","Liang, Lucy
Schaeffer, David",cc-by-4.0,W4393617937,A5103180866,David J. Schaeffer,0000-0003-2201-7092
690,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5091866133,Hankum Park,0000-0001-5795-3249
691,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5079127441,Frances V Hundley,0000-0001-9469-301X
692,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5040242042,Qing Yu,0000-0003-0468-5353
693,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5010446056,Katherine A. Overmyer,0000-0002-1929-1229
694,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5031630272,Dain R. Brademan,0000-0002-0971-9711
695,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5080707475,Luís Serrano,0000-0002-5276-1392
696,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5026734370,João A. Paulo,0000-0002-4291-413X
697,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5023479457,Julia C. Paoli,0000-0001-8266-1766
698,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5035448367,Sharan Swarup,0000-0003-0226-5582
699,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5086840789,Joshua J. Coon,0000-0002-0004-8253
700,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5079793809,Steven P. Gygi,0000-0001-7626-0034
701,7177916,2022-10-09T15:18:31.359660+00:00,10.5281/zenodo.7177916,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,<p>Source datasets for Western blot quantification in Figures S1d and S5a for Park et al. &quot;Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics&quot;.&nbsp;&nbsp;</p>,Dataset,2022-10-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Park, Hankum
Hundley, Frances V.
Yu, Qing
Overmyer, Katherine A.
Brademan, Dain R.
Serrano, L.
Paulo, Joao A.
Paoli, Julia C.
Swarup, Sharan
Coon, Joshua J.
Gygi, Steven P.
Harper, J. Wade",cc-by-3.0-us,W4393721627,A5047746208,J. Wade Harper,0000-0002-6944-7236
702,7324262,2022-11-15T16:36:28.060644+00:00,10.5281/zenodo.7324262,Datasets - Vermilyea et al 2022,"<p>Datasets for Vermilyea et al., 2022: &quot;Loss of tau expression attenuates Neurodegeneration associated with a-synucleinopathy&quot;</p>",Dataset,2022-11-15 00:00:00,personal,"Vermilyea, Scott",cc-by-4.0,W4394029756,A5061285720,Scott Vermilyea,0000-0001-7827-8166
703,10150539,2023-11-17T18:53:38.117708+00:00,10.5281/zenodo.10150539,Curve fitting routines to fit postsynaptic currents and potentials,<p>Curve fitting routines to fit postsynaptic currents and potentials. The provided code fits simple alpha functions and product forms commonly used to model postsynaptic responses. The code optimizes starting values by a user-defined brute force method by specifying the number of attempts. This is then used to generate a fit by maximum likelihood estimation (MLE).</p>,Computational notebook,2023-11-17 00:00:00,"personal
personal","Clarke, Vernon R.J.
Surmeier, D. James",cc-by-4.0,,,,
704,7734867,2023-03-14T21:31:21.946952+00:00,10.5281/zenodo.7734867,Liposome_BAM_depletion_4wk,<p>This dataset contains files from flow cytometry performed on brain and meninges. Tissue was taken from animals transduced with AAV2-SYN&nbsp; and given clodronate or PBS filled liposomes i.c.v. Data represents inflammation at 4 weeks post-treatment.</p>,Dataset,2023-03-14 00:00:00,personal,Aubrey M. Schonhoff,cc-by-4.0,W4393687046,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
705,11518850,2024-07-09T16:22:12.659018+00:00,10.5281/zenodo.11518850,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,<p>Raw data for Figure 2. Readme file with info regarding the data. Zip file is about 40 GB as contains all raw images used for quantification presented in figure 2 and in supplementary 7</p>,Dataset,2024-06-07 00:00:00,personal,"Bagnoli, Enrico",cc-by-4.0,,,,
706,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5011836535,Mingyi Xia,0000-0003-0861-419X
707,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5056817782,Busra Nur Agca,0000-0003-1145-9899
708,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5103221437,Tomoko Yoshida,0000-0003-3961-0095
709,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5005054739,Jiwon Choi,0000-0002-2801-7854
710,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5045944438,Usamma Amjad,0000-0001-5455-3207
711,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5000246911,Kade Bose,0000-0002-0593-0392
712,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5025434731,Nikol Keren,0000-0001-9071-9710
713,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5008841667,Shahar Zukerman,
714,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5061683153,Michael J. Cima,0000-0003-2379-6139
715,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5081686751,Ann M. Graybiel,0000-0002-4326-7720
716,7818783,2023-07-28T22:59:15.720186+00:00,10.5281/zenodo.7818783,"Datasets for ""Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents""","<p>Datasets used in the manuscript titled, &quot;<strong>Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents</strong>&quot; are uploaded here.&nbsp;</p>

<p><strong>Brightfield and fluorescent&nbsp;stained images of brain tissue used for Fig. 5(a):</strong></p>

<p>Malt3-20190624_Region 009_DAPI.png</p>

<p>Malt3-20190624_Region 009_qCy5.png</p>

<p>Malt3-20190624_Region 009_qFITC.png</p>

<p>Malt3-20190624_Region 009_qTexasRed.png</p>

<p>Malt3_BF20190628_Region 001.png</p>

<p><strong>Fluorescent image of brain with embedded CFETs:</strong></p>

<p>MALT2_Rat_100um_MOR1_x500_TSA_AF488.jpg</p>

<p>Rat_100um_MOR1_x500_TSA.czi</p>

<p><strong>In vivo dopamine recording data for Fig. 3:</strong></p>

<p>ratarrays822_163.mat</p>

<p>ratarrays822_57.mat</p>",Dataset,2023-04-11 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Mingyi Xia
Busra Nur Agca
Tomoko Yoshida
Jiwon Choi
Usamma Amjad
Kade Bose
Nikol Keren
Shahar Zukerman
Michael J. Cima
Ann M. Graybiel
Helen N. Schwerdt",cc-by-4.0,W4393572866,A5035254479,Helen N. Schwerdt,
717,10397715,2023-12-17T21:49:01.060480+00:00,10.5281/zenodo.10397715,Day2024 R code and analysis,"<p>Recreates graphical outputs and statistical analyses in the manuscript:</p>
<p>Day M., Belal M., Surmeier W. C., Melendez A., Wokosin, D., Tkatch T., Clarke V. R. J. and Surmeier D. J.&nbsp; GABAergic regulation of striatal spiny projection neurons depends upon their activity state (2024). PLoS Biol 22(1): e3002483. <a href=""https://doi.org/10.1371/journal.pbio.3002483"">https://doi.org/10.1371/journal.pbio.3002483</a></p>
<p>This script and accompanying folder containing *.csv files of data should reproduce figures 1-4 and supplementary figure S1 of the manuscript.</p>
<p>v1.1 corrects for error in one dataset (Fig2J -61.0 to -61.5 mV)</p>",Computational notebook,2023-12-17 00:00:00,personal,"Clarke, Vernon R. J.",cc-by-4.0,,,,
718,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5058322950,Michael J. Hurley,0000-0001-8022-9283
719,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5062367843,Elisa Menozzi,0000-0003-3565-7910
720,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5080523651,Sofia Koletsi,0000-0002-6661-7797
721,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5031944389,Rachel Bates,0000-0002-4768-6869
722,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5070560226,Matthew E. Gegg,0000-0001-8093-0723
723,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5052572031,Kai‐Yin Chau,0000-0002-5797-2922
724,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5002329761,Jane Macnaughtan,0000-0003-1211-9298
725,7712730,2023-04-02T15:18:50.252580+00:00,10.5281/zenodo.7712730,Differential response of α-synuclein expression to bacterial ligands and metabolites in mouse enteroendocrine cells,<p>Dataset for manuscript <em>&quot;<strong>&nbsp;</strong></em><strong>&alpha;</strong><strong>-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells</strong><em>&quot;.&nbsp;</em>Tabs in excel file are title with the figure number.&nbsp;</p>,Dataset,2023-04-02 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Michael J Hurley
Elisa Menozzi
Sofia Koletsi
Rachel Bates
Matthew E Gegg
Kai-Yin Chau
Jane Macnaughtan
Anthony H V Schapira",cc-by-4.0,W4393592244,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966
726,6985167,2022-08-12T12:20:15.272725+00:00,10.5281/zenodo.6985167,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.,<p>Raw data corresponding to graphs in publication:&nbsp;The GBA&nbsp;variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. Files are titled with the figure number. Each graph is on a different tab within the excel spreadsheet.</p>,Dataset,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Smith, L. J
Bolsinger, M. M
Chau, K. Y
Gegg, M. E
Schapira, A. H. V",cc-by-4.0,W4393748798,A5051840211,L. J. Smith,0000-0002-0806-168X
727,6985167,2022-08-12T12:20:15.272725+00:00,10.5281/zenodo.6985167,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.,<p>Raw data corresponding to graphs in publication:&nbsp;The GBA&nbsp;variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. Files are titled with the figure number. Each graph is on a different tab within the excel spreadsheet.</p>,Dataset,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Smith, L. J
Bolsinger, M. M
Chau, K. Y
Gegg, M. E
Schapira, A. H. V",cc-by-4.0,W4393748798,A5045059502,Magdalena M. Bolsinger,0000-0002-3020-9943
728,6985167,2022-08-12T12:20:15.272725+00:00,10.5281/zenodo.6985167,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.,<p>Raw data corresponding to graphs in publication:&nbsp;The GBA&nbsp;variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. Files are titled with the figure number. Each graph is on a different tab within the excel spreadsheet.</p>,Dataset,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Smith, L. J
Bolsinger, M. M
Chau, K. Y
Gegg, M. E
Schapira, A. H. V",cc-by-4.0,W4393748798,A5052572031,Kai‐Yin Chau,0000-0002-5797-2922
729,6985167,2022-08-12T12:20:15.272725+00:00,10.5281/zenodo.6985167,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.,<p>Raw data corresponding to graphs in publication:&nbsp;The GBA&nbsp;variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. Files are titled with the figure number. Each graph is on a different tab within the excel spreadsheet.</p>,Dataset,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Smith, L. J
Bolsinger, M. M
Chau, K. Y
Gegg, M. E
Schapira, A. H. V",cc-by-4.0,W4393748798,A5070560226,Matthew E. Gegg,0000-0001-8093-0723
730,6985167,2022-08-12T12:20:15.272725+00:00,10.5281/zenodo.6985167,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.,<p>Raw data corresponding to graphs in publication:&nbsp;The GBA&nbsp;variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. Files are titled with the figure number. Each graph is on a different tab within the excel spreadsheet.</p>,Dataset,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Smith, L. J
Bolsinger, M. M
Chau, K. Y
Gegg, M. E
Schapira, A. H. V",cc-by-4.0,W4393748798,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966
731,7443697,2022-12-15T20:07:56.658638+00:00,10.5281/zenodo.7443697,4wk_AAV_SNpc,<p>4 week flow cytometry from C57Bl/6 mice transduced with AAV2-SYN or AAV2-GFP.</p>,Dataset,2022-12-15 00:00:00,personal,"Schonhoff, Aubrey M",cc-by-4.0,W4393628686,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125
732,7795604,2023-04-03T15:02:05.234292+00:00,10.5281/zenodo.7795604,Time to LiD GWAS dataset,"<p>This is the zipped folder containing a gzipeed&nbsp;GWAS dataset we derived on the study of&nbsp; LiD genetic determinants.</p>

<p>In addition, a README explaining what each column manes is provided.</p>

<p>Link to code that was used to generate this GWAS file (https://doi.org/10.5281/zenodo.7794491)</p>",Dataset,2023-04-03 00:00:00,personal,Alejandro Martinez,cc-by-4.0,W4393485506,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703
733,10606989,2024-02-01T19:49:47.753392+00:00,10.5281/zenodo.10606989,Combinatorial selective ER-phagy remodels the ER during neurogenesis,"<p><span>Datasets related to the following manuscript:</span></p>
<p><span>Combinatorial selective ER-phagy remodels the ER during neurogenesis</span></p>
<p><span>Melissa J. Hoyer<sup>1,2</sup>, Cristina Capitanio<sup>2,3,*</sup>, Ian R. Smith<sup>1,*,#</sup>, Julia C. Paoli<sup>1,2</sup>, Anna Bieber<sup>2,3</sup>, Yizhi Jiang<sup>1,2</sup>, Joao A. Paulo<sup>1</sup>, Miguel A. Gonzalez-Lozano<sup>1,2</sup>, Wolfgang Baumeister<sup>2,3,4</sup>, Florian Wilfling<sup>2,3,5</sup>, Brenda A. Schulman<sup>2,3</sup>, J. Wade Harper<sup>1,2</sup>&nbsp;</span></p>
<p><sup><span>1</span></sup><span>Department of Cell Biology, Harvard Medical School, Boston MA 02115</span></p>
<p><sup><span>2</span></sup><span>Aligning Science Across Parkinson&rsquo;s (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA</span></p>
<p><sup><span>3</span></sup><span>Department of Molecular Machines and Signaling, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany</span></p>
<p><sup><span>4</span></sup><span>Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany</span></p>
<p><sup><span>5</span></sup><span>Mechanisms of Cellular Quality Control, Max Planck Institute of Biophysics, 60438 Frankfurt a. M., Germany</span></p>
<p><span>*, equal contribution</span></p>
<p><span># Current Address: </span><span>Velia Therapeutics, San Diego, CA</span></p>
<p><span>Corresponding author: </span><a href=""mailto:wade_harper@hms.harvard.edu""><span><span><span>wade_harper@hms.harvard.edu</span></span></span></a></p>
<p><span><strong><span>The endoplasmic reticulum (ER) employs a diverse proteome landscape to orchestrate many cellular functions ranging from protein and lipid synthesis to calcium ion flux and inter-organelle communication. A case in point concerns the process of neurogenesis: a refined tubular ER network is assembled via ER shaping proteins into the newly formed neuronal projections to create highly polarized dendrites and axons. Previous studies have suggested a role for autophagy in ER remodeling, as autophagy-deficient neurons <em>in vivo</em> display axonal ER accumulation within synaptic boutons, and the membrane-embedded ER-phagy receptor FAM134B has been genetically linked with human sensory and autonomic neuropathy. However, our understanding of the mechanisms underlying selective removal of ER and the role of individual ER-phagy receptors is limited. Here, we combine a genetically tractable induced neuron (iNeuron) system for monitoring ER remodeling during <em>in vitro</em> differentiation with proteomic and computational tools to create a quantitative landscape of ER proteome remodeling via selective autophagy. Through analysis of single and combinatorial ER-phagy receptor mutants, we delineate the extent to which each receptor contributes to both magnitude and selectivity of ER protein clearance. We define specific subsets of ER membrane or lumenal proteins as preferred clients for distinct receptors. Using spatial sensors and flux reporters, we demonstrate receptor-specific autophagic capture of ER in axons, and directly visualize tubular ER membranes within autophagosomes in neuronal projections by cryo-electron tomography. This molecular inventory of ER proteome remodeling and versatile genetic toolkit provides a quantitative framework for understanding contributions of individual ER-phagy receptors for reshaping ER during cell state transitions.</span></strong></span></p>",Dataset,2024-02-01 00:00:00,"personal
personal","Hoyer, Melissa
Capitanio, Cristina",cc-by-4.0,,,,
734,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5041656783,D. J. Vidyadhara,0000-0003-0974-0307
735,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5108914443,Somayaji Mahalakshmi,
736,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339023,Wade Nigel,
737,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339024,Yucel Betul,
738,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339025,Zhao Helen,
739,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5070899335,N Shashaank,
740,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5108914032,Ribaudo Joseph,
741,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339026,Gupta Jyoti,
742,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339027,T. Lam Tukiet,
743,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339020,Sames Dalibor,
744,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339021,E. Greene Lois,
745,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5108316956,L. Sulzer David,
746,7786834,2023-03-30T18:55:39.027591+00:00,10.5281/zenodo.7786834,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease,"<p>Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (<em>PARK19</em>) cause Parkinson&rsquo;s disease. Using auxilin KO mice, Vidyadhara et&nbsp;al. (2023) show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson&rsquo;s disease in&nbsp;<em>PARK19</em>&nbsp;patients. This file&nbsp;contains the data set used to generate all the main figures.</p>",Dataset,2023-03-28 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Vidyadhara D.J.
Somayaji Mahalakshmi
Wade Nigel
Yucel Betul
Zhao Helen
Shashaank N
Ribaudo Joseph
Gupta Jyoti
T. Lam Tukiet
Sames Dalibor
E. Greene Lois
L. Sulzer David
S. Chandra Sreeganga",cc-by-4.0,W4393626328,A5094339022,S. Chandra Sreeganga,
747,11065277,2024-04-25T09:44:58.074669+00:00,10.5281/zenodo.11065277,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system - Main Figures,"<p><strong>Loss of function mutations in PTEN-induced kinase 1 (PINK1) are a frequent cause of earlyonset Parkinson&rsquo;s disease (PD). Stabilisation of PINK1 at the Translocase of Outer Membrane&nbsp; (TOM) complex of damaged mitochondria is a critical step for its activation. To date the&nbsp; mechanism of how PINK1 is activated in the TOM complex is unclear. Herein we report co-expression of human PINK1 and all seven TOM subunits in Saccharomyces cerevisiae is&nbsp; sufficient for PINK1 activation. We use this reconstitution system to systematically assess the&nbsp; role of each TOM subunit towards PINK1 activation. We unambiguously demonstrate that the TOM20 and TOM70 receptor subunits are required for optimal PINK1 activation and map their sites of interaction with PINK1 using AlphaFold structural modelling and mutagenesis. We also demonstrate an essential role of the pore-containing subunit TOM40 and its structurally associated subunits TOM7 and TOM22 for PINK1 activation. These molecular findings will aid in the development of small molecule activators of PINK1 as a therapeutic strategy for PD.&nbsp;</strong></p>
<p><strong>Description of files</strong></p>
<p><strong>Figure1B</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUB</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1(pS228)</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM70</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone. <strong>Below</strong>: <strong>TOM22</strong> Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM20</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM7</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM6</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CDC28</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane3-4: WT PINK1+TOM complex; Lane5-6: PINK1(KI)+TOM complex; Lane7-8: WT PINK1 alone.</p>
<p>&nbsp;</p>
<p><strong>Figure1D: </strong></p>
<p>Image under bright field</p>
<p>Image with Mitotracker</p>
<p>PINK1-GFP image</p>
<p>Merged Image</p>
<p><strong>Figure 2</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUb</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1(pS228)</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70 .</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM70</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM22</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM20</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM7</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM6</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CDC28</strong></p>
<p>o&nbsp;&nbsp; Lane1-2: Uninduced cells; Lane3-4: WT-PINK1 + TOM complex; Lane5-6: PINK1(KI) + TOM complex; Lane 7-8: -TOM5; Lane9-10: -TOM6; Lane11-12: -TOM7; Lane 13-14: -TOM20; Lane 15-16: -TOM22; Lane 17-18: -TOM40; Lane19-20: -TOM70; Lane21-22: -TOM2-/70.</p>
<p><strong>&nbsp;</strong></p>
<p><strong>&nbsp;</strong></p>
<p><strong>Figure3D</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUB</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1(pS228)</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM70</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM22</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM20</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CDC28</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 L532A; Lane 9-10: hPINK1 L539A; Lane 11-12: hPINK1 L540A; Lane 13-14: hPINK1 L532A/L539A/L540A.</p>
<p><strong>&nbsp;</strong></p>
<p><strong>Figure 3E</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUB</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1(pS228)</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM70</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM22</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM20</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CDC28</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM20 Q67E; Lane 9-10: hTOM20 E78Q; Lane 11-12: hTOM20 E78R; Lane 13-14: -TOM20.</p>
<p><strong>Figure 4D</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUB</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1(pS228)</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM70</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM22</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM20</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CDC28</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hPINK1 R83A/R88A/R98A; Lane 9-10: hPINK1 R83E/R88E/R98E.</p>
<p><strong>Figure 4E</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUb</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1(S288)</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM70</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM22</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM20</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CDC28</strong></p>
<p>o&nbsp;&nbsp; Lane 1-2: Uninduced cells; Lane 3-4: WTPINK1+TOM complex; Lane 5-6: PINK1(KI) + TOM complex; Lane 7-8: hTOM70 D488A; Lane 9-10: hTOM70 D545A; Lane 11-12: hTOM70 E549A; Lane 13-14: -TOM70.</p>
<p><strong>&nbsp;</strong></p>
<p><strong>Figure 5B</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: hPINK1 WT (-A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (-A/O), Lane 9-10: hPINK1 KI (+A/O), Lane 11-12: hPINK1 L532A (-A/O), Lane 13-14: hPINK1 L532A (+A/O), Lane 15-16: hPINK1 L539A (-A/O), Lane 17-18: hPINK1 L539A (+A/O), Lane 19-20: hPINK1 L540A (-A/O), Lane 21-22: hPINK1 L540A (+A/O), Lane 23-24: hPINK1 L532A L539A L540A (-A/O), Lane 25-26: hPINK1 L532A L539A L540A (+A/O).</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUb</strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: hPINK1 WT (-A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (-A/O), Lane 9-10: hPINK1 KI (+A/O), Lane 11-12: hPINK1 L532A (-A/O), Lane 13-14: hPINK1 L532A (+A/O), Lane 15-16: hPINK1 L539A (-A/O), Lane 17-18: hPINK1 L539A (+A/O), Lane 19-20: hPINK1 L540A (-A/O), Lane 21-22: hPINK1 L540A (+A/O), Lane 23-24: hPINK1 L532A L539A L540A (-A/O), Lane 25-26: hPINK1 L532A L539A L540A (+A/O).</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>OPA1 (Low exposure)</strong></p>
<p>o&nbsp;&nbsp; PINK1 blot reblotted for OPA1 and GAPDH. Lane 1: marker, Lane 3-4: hPINK1 WT (-A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (-A/O), Lane 9-10: hPINK1 KI (+A/O), Lane 11-12: hPINK1 L532A (-A/O), Lane 13-14: hPINK1 L532A (+A/O), Lane 15-16: hPINK1 L539A (-A/O), Lane 17-18: hPINK1 L539A (+A/O), Lane 19-20: hPINK1 L540A (-A/O), Lane 21-22: hPINK1 L540A (+A/O), Lane 23-24: hPINK1 L532A L539A L540A (-A/O), Lane 25-26: hPINK1 L532A L539A L540A (+A/O).</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>GAPDH (High exposure)</strong></p>
<p>o&nbsp;&nbsp; PINK1 blot reblotted for OPA1 and GAPDH. Lane 1: marker, Lane 3-4: hPINK1 WT (-A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (-A/O), Lane 9-10: hPINK1 KI (+A/O), Lane 11-12: hPINK1 L532A (-A/O), Lane 13-14: hPINK1 L532A (+A/O), Lane 15-16: hPINK1 L539A (-A/O), Lane 17-18: hPINK1 L539A (+A/O), Lane 19-20: hPINK1 L540A (-A/O), Lane 21-22: hPINK1 L540A (+A/O), Lane 23-24: hPINK1 L532A L539A L540A (-A/O), Lane 25-26: hPINK1 L532A L539A L540A (+A/O).</p>
<p><strong>Figure 5C</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1</strong></p>
<p>o&nbsp;&nbsp; Bigger blot: Lane 1: marker, Lane 3-4: empty-FLAG (-A/O), Lane 5-6: empty FLAG (+A/O), Lane 7-8: hPINK1 WT (-A/O), Lane 9-10: hPINK1 WT (+A/O), Lane 11-12: hPINK1 KI (-A/O), Lane 13-14: hPINK1 KI (+A/O), Lane 15-16: hPINK1 R83A (-A/O), Lane 17-18: hPINK1 R83A (+A/O), Lane 19-20: hPINK1 R88A (-A/O), Lane 21-22: hPINK1 R88A (+A/O), Lane 23-24: hPINK1 R98A (-A/O), Lane 25-26: hPINK1 R98A (+A/O).</p>
<p>o&nbsp;&nbsp; Smaller blot: Lane 1: marker, Lane 3-6: not included in paper (2A mutant), Lane 7-8: hPINK1 R83A R88A R98A (-A/O), Lane 9-10: hPINK1 R83A R88A R98A (+A/O), Lane 11-12: hPINK1 R83E R88E R98E (-A/O), Lane 13-14: hPINK1 R83E R88E R98E (+A/O), Lane18: WT control</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>pUb</strong></p>
<p>o&nbsp;&nbsp; Upper blot: Lane 1: marker, Lane 3-4: empty-FLAG (-A/O), Lane 5-6: empty FLAG (+A/O), Lane 7-8: hPINK1 WT (-A/O), Lane 9-10: hPINK1 WT (+A/O), Lane 11-12: hPINK1 KI (-A/O), Lane 13-14: hPINK1 KI (+A/O), Lane 15-16: hPINK1 R83A (-A/O), Lane 17-18: hPINK1 R83A (+A/O), Lane 19-20: hPINK1 R88A (-A/O), Lane 21-22: hPINK1 R88A (+A/O), Lane 23-24: hPINK1 R98A (-A/O), Lane 25-26: hPINK1 R98A (+A/O).</p>
<p>o&nbsp;&nbsp; Lower blot: Lane 1: marker, Lane 3-4: hPINK1 R83A R88A R98A (-A/O), Lane 5-6: hPINK1 R83A R88A R98A (+A/O), Lane 7-8: hPINK1 R83E R88E R98E (-A/O), Lane 9-10: hPINK1 R83E R88E R98E (+A/O)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>GAPDH </strong></p>
<p>o&nbsp;&nbsp; Bigger blot: Lane 1: marker, Lane 3-4: empty-FLAG (-A/O), Lane 5-6: empty FLAG (+A/O), Lane 7-8: hPINK1 WT (-A/O), Lane 9-10: hPINK1 WT (+A/O), Lane 11-12: hPINK1 KI (-A/O), Lane 13-14: hPINK1 KI (+A/O), Lane 15-16: hPINK1 R83A (-A/O), Lane 17-18: hPINK1 R83A (+A/O), Lane 19-20: hPINK1 R88A (-A/O), Lane 21-22: hPINK1 R88A (+A/O), Lane 23-24: hPINK1 R98A (-A/O), Lane 25-26: hPINK1 R98A (+A/O).</p>
<p>o&nbsp;&nbsp; Smaller blot: Lane 1: marker, Lane 3-4: hPINK1 R83A R88A R98A (-A/O), Lane 5-6: hPINK1 R83A R88A R98A (+A/O), Lane 7-8: hPINK1 R83E R88E R98E (-A/O), Lane 9-10: hPINK1 R83E R88E R98E (+A/O)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>OPA1</strong></p>
<p>o &nbsp;Bigger blot:: Lane 1: marker, Lane 3-4: empty-FLAG (-A/O), Lane 5-6: empty FLAG (+A/O), Lane 7-8: hPINK1 WT (-A/O), Lane 9-10: hPINK1 WT (+A/O), Lane 11-12: hPINK1 KI (-A/O), Lane 13-14: hPINK1 KI (+A/O), Lane 15-16: hPINK1 R83A (-A/O), Lane 17-18: hPINK1 R83A (+A/O), Lane 19-20: hPINK1 R88A (-A/O), Lane 21-22: hPINK1 R88A (+A/O), Lane 23-24: hPINK1 R98A (-A/O), Lane 25-26: hPINK1 R98A (+A/O).</p>
<p>o &nbsp; Smaller blot: Lane 1: marker, Lane 3-4: hPINK1 R83A R88A R98A (-A/O), Lane 5-6: hPINK1 R83A R88A R98A (+A/O), Lane 7-8: hPINK1 R83E R88E R98E (-A/O), Lane 9-10: hPINK1 R83E R88E R98E (+A/O)</p>
<p><strong>Figure 6B</strong></p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1 native </strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: Veh 3FLAG (+A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (+A/O), Lane 9-10: hPINK1 L532A L539A L540A (+A/O), Lane 11-12: hPINK1 R83E R88E R98E (+A/O), Lane 13-14: not shown in paper (6E mutant) (+A/O)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40 native </strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: Veh 3FLAG (+A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (+A/O), Lane 9-10: hPINK1 L532A L539A L540A (+A/O), Lane 11-12: hPINK1 R83E R88E R98E (+A/O), Lane 13-14: not shown in paper (6E mutant) (+A/O)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1 native Ponceau </strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: Veh 3FLAG (+A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (+A/O), Lane 9-10: hPINK1 L532A L539A L540A (+A/O), Lane 11-12: hPINK1 R83E R88E R98E (+A/O), Lane 13-14: not shown in paper (6E mutant) (+A/O)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40 native Ponceau</strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: Veh 3FLAG (+A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (+A/O), Lane 9-10: hPINK1 L532A L539A L540A (+A/O), Lane 11-12: hPINK1 R83E R88E R98E (+A/O), Lane 13-14: not shown in paper (6E mutant) (+A/O)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>PINK1 SDS blot </strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: Veh 3FLAG (+A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (+A/O), Lane 9-10: hPINK1 L532A L539A L540A (+A/O), Lane 11-12: hPINK1 R83E R88E R98E (+A/O)</p>
<p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>TOM40 SDS blot </strong></p>
<p>o&nbsp;&nbsp; Lane 1: marker, Lane 3-4: Veh 3FLAG (+A/O), Lane 5-6: hPINK1 WT (+A/O), Lane 7-8: hPINK1 KI (+A/O), Lane 9-10: hPINK1 L532A L539A L540A (+A/O), Lane 11-12: hPINK1 R83E R88E R98E (+A/O)</p>",Image,2024,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Raimi, Olawale
Ojha, Hina
Ehses, Kenneth
Dederer, Verena
Lange, Sven M
Rivera, Cristian Polo
Deegan, Tom D
Chen, Yinchen
Wightman, Melanie
Toth, Rachel
Labib, Karim P.M.
Mathea, Sebastian
Ranson, Neil
Fernandez-Busnadiego, Ruben
Muqit, Miratul",cc-by-4.0,,,,
748,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5108206730,Minee L. Choi,
749,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5046671995,Alexandre Chappard,0000-0002-9522-2575
750,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5007823997,Bhanu Pratap Singh,0000-0002-3666-578X
751,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5033957982,Catherine Maclachlan,0000-0002-3606-6672
752,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5101640801,Margarida Rodrigues,0000-0001-6364-7125
753,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5069153255,Evgeniya I. Fedotova,0000-0001-6619-4563
754,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5070232549,Alexey V. Berezhnov,0000-0003-0271-6179
755,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5056814808,Suman De,0000-0003-1675-0773
756,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5037445001,Christopher J. Peddie,0000-0002-8329-5419
757,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5043990676,Dilan Athauda,0000-0001-8594-2483
758,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5040895889,Gurvir S. Virdi,0000-0002-8942-0903
759,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5100457936,Weijia Zhang,0000-0001-6928-0416
760,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5041647947,James R. Evans,0000-0003-2923-281X
761,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5091523616,Plamena R. Angelova,
762,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5038020678,Noemí Esteras,0000-0002-7938-6131
763,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5033318012,Katie Morris,0000-0002-8944-2264
764,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5062158055,Laura Tosatto,0000-0002-5966-8131
765,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5059735139,Daniel Little,0000-0003-3162-2614
766,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5085511830,Paul Gissen,0000-0002-9712-6122
767,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5032614754,Lucy Collinson,0000-0003-0260-613X
768,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5042822683,David Klenerman,0000-0001-7116-6954
769,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5055353781,Andrey Y. Abramov,0000-0002-7646-7235
770,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5041913324,Mathew H. Horrocks,0000-0001-5495-5492
771,6473201,2022-05-13T13:27:02.112069+00:00,10.5281/zenodo.6473201,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Data sets,"<p>Lists of data sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Single-molecule confocal Quantification_Images (SNCA-A53T TIRF Images)</p>

<p>TIRF Image Quantification</p>

<p>TIRF Emission Data</p>

<p>Single Vesicle Emission Data</p>

<p>DLS Emission Data</p>

<p>CD Measurements</p>

<p>Amyloid Fibril TIRFM Emission Data&nbsp;</p>

<p>&alpha;-Syn WT, A53T, A30P and E46K Confirmatory LCMS&nbsp;</p>

<p>SNCA A53T iPSC mutation confirmatory Sanger Sequencing</p>

<p>ELISA</p>

<p>Immunocytochemistry (MAP2 and TRB1)</p>

<p>Pierce BCA Protein Assay</p>

<p>Aggregation Assay</p>

<p>Copy of Empiar_upload_info (CLEM quantification); metadata spreadsheet for&nbsp;TEM and FIB-SEM Image Quantification</p>

<p>Live-cell imaging data</p>

<ul>
	<li>Superoxide Emission Data</li>
	<li>MitoTracker&reg; Red Emission Data</li>
	<li>MembranePotentialEmissionData (the same experiment for&nbsp;&#39; TMRM Emission data&#39;)</li>
	<li>Ca 2+ Emission Data</li>
	<li>NADH Autofluorescence and Redox Quantification</li>
	<li>ATP Emission Data</li>
	<li>mPTP Emission Data</li>
	<li>Cell Death Emission Data (PI &amp; SYTOX)</li>
	<li>FRET Emission Data</li>
	<li>MitoTracker&reg; Red Assay</li>
	<li>Cell Death Assay</li>
</ul>",Dataset,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,W4393482539,A5101470156,Sonia Gandhi,0000-0003-4395-2661
772,8015472,2023-06-07T21:14:15.561624+00:00,10.5281/zenodo.8015472,GP2-TNC-WG/GP2_TRAINEES-PTPA: PTPA variants and the risk for Parkinson's disease in diverse ancestry populations,<p>No description provided.</p>,Software,2023-06-07 00:00:00,personal,Global Parkinson's Genetics Program,other-open,,,,
773,7882388,2023-05-01T05:01:59.650770+00:00,10.5281/zenodo.7882388,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 5: Whole cell patch clamping showed the differentiated neurons are functional.</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal
personal","Gautam Wali
Yan Li
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4394032250,A5022317877,Gautam Wali,0000-0003-2961-3954
774,7882388,2023-05-01T05:01:59.650770+00:00,10.5281/zenodo.7882388,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 5: Whole cell patch clamping showed the differentiated neurons are functional.</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal
personal","Gautam Wali
Yan Li
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4394032250,A5025946389,Yan Li,0009-0009-4346-8037
775,7882388,2023-05-01T05:01:59.650770+00:00,10.5281/zenodo.7882388,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 5: Whole cell patch clamping showed the differentiated neurons are functional.</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal
personal","Gautam Wali
Yan Li
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4394032250,A5005036101,Dad Abu-Bonsrah,0000-0002-2687-3526
776,7882388,2023-05-01T05:01:59.650770+00:00,10.5281/zenodo.7882388,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 5: Whole cell patch clamping showed the differentiated neurons are functional.</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal
personal","Gautam Wali
Yan Li
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4394032250,A5083016310,Deniz Kirik,0000-0002-1360-1265
777,7882388,2023-05-01T05:01:59.650770+00:00,10.5281/zenodo.7882388,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 5: Whole cell patch clamping showed the differentiated neurons are functional.</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal
personal","Gautam Wali
Yan Li
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4394032250,A5044118193,Clare L. Parish,0000-0001-8212-9884
778,7882388,2023-05-01T05:01:59.650770+00:00,10.5281/zenodo.7882388,Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation,<p>Figure 5: Whole cell patch clamping showed the differentiated neurons are functional.</p>,Dataset,2023-05-01 00:00:00,"personal
personal
personal
personal
personal
personal","Gautam Wali
Yan Li
Dad Abu-Bonsrah
Deniz Kirik
Clare L Parish
Carolyn M Sue",cc-by-4.0,W4394032250,A5045037139,Carolyn M. Sue,0000-0003-1255-3617
779,6474033,2022-05-13T13:27:18.414386+00:00,10.5281/zenodo.6474033,Structural conversion of α-synuclein at the mitochondria induces neuronal toxicity; Image data,"<p>Lists of image sets included in <strong>&quot;Structural conversion of &alpha;-synuclein at the mitochondria induces neuronal toxicity&quot;</strong></p>

<p>&nbsp;</p>

<p>Duplex-1 and Duplex-2 Images</p>

<p>Amyloid Fibril TIRFM Images (SNCA-A53T ImagesTIRF Images)</p>

<p>TEM Fibril Images</p>

<p>DLS Images&nbsp;</p>

<p>SMLM Images 1 &amp; 2</p>

<p>&nbsp;</p>

<p>CLEM Images</p>

<ul>
	<li>FIB SEM Images (videos)</li>
	<li>TEM Images&nbsp;</li>
</ul>

<p>&nbsp;</p>

<p>Live-cell imaging</p>

<ul>
	<li>Superoxide Images</li>
	<li>MitoTracker&reg; Red Images</li>
	<li>Membrane Potential (TMRM) Images&nbsp;</li>
	<li>Ca 2+ Images</li>
	<li>NADH Autofluorescence Images</li>
	<li>Cell Death Images</li>
	<li>Amytracker Images</li>
	<li>Cardiolipin Images</li>
	<li>FRET Images</li>
</ul>",Figure,2022-04-20 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Minee L. Choi
Alexandre Chappard
Bhanu P. Singh
Catherine Maclachlan
Margarida Rodrigues
Evgenia Fedotova
Alexey V. Berezhnov
Suman De
Chris Peddie
Dilan Athauda
Gurvir S. Virdi
Weijia  Zhang
James R. Evans
Plamena R. Angelova
Noemi Esteras
Katie Morris
Laura Tosatto
Daniel Little
Paul Gissen
Lucy Collinson
David Klenerman
Andrey Y. Abramov
Mathew H. Horrocks
Sonia Gandhi",cc-by-4.0,,,,
780,10607238,2024-03-21T20:25:28.811174+00:00,10.5281/zenodo.10607238,Images of mouse VTA and SNc sections labeled for neurotransmitter phenotype markers via RNAscope,"<p>48 coronal sections from 3 male and 3 female C57Bl/6J mice were labeled for mRNAs encoding the canonical vesicular transporters for dopamine (VMAT2), GABA (VGAT), and glutamate (VGLUT2). These sections were then imaged via confocal microscopy and saved as CZI files, editable with Zeiss Zen software. These image files include 'event marker' graphics, indicating where neurons positive for one or more of the above transporters are.&nbsp;</p>
<p>The protocols used for sample preparation, labeling, imaging, and counting are linked in the Related Works section.&nbsp;</p>
<p>Cell count data are organized by subregion (SUBREGION counts for R.csv), anterior-posterior (e.g. VGATVTA.csv), or anterior-posterior and medial-lateral distribution (e.g. 'snc triple.csv' or 'snc vmat2 AP and ML.csv').</p>
<p>The R code provided uses these csv files to visualize expression patterns across VTA and SNc.&nbsp;</p>",Dataset,2024-02-04 00:00:00,"personal
personal
personal","Conrad, William
Oriol, Lucie
Hnasko, Thomas",cc-by-4.0,,,,
781,10903566,2024-04-02T20:39:40.699244+00:00,10.5281/zenodo.10903566,Reward perseveration is shaped by GABAA-mediated dopamine pauses: Behavior Data,"<p>Behavior assay data used to generate the following figures in the paper ""Reward perseveration is shaped by GABAA-mediated dopamine pauses"":</p>
<ul>
<li>Figure 2, all panels</li>
<li>Figure 4, all panels</li>
<li>Ext. Fig 3, panels a-c, e, f</li>
<li>Ext. Fig 5, all panels</li>
</ul>
<p>Specifics of the data:</p>
<ul>
<li>ddHTP.zip contains the control raw data in MATLAB files</li>
<li>HTP.zip contains the experimental raw data in MATLAB files</li>
<li>The various Behavior_summary_data.csv files contain the subject details and extracted analyses, as detailed in each title.</li>
<li>ddHTP_other_DART_pilots.zip and the corresponding .csv file hold the raw and analyzed data for the ddHTP controls of ongoing experiments shown in Ext. Fig 5c.&nbsp;</li>
</ul>",Dataset,2024-04-01 00:00:00,"personal
personal","Burwell, Sasha
Tadross, Michael",cc-by-4.0,,,,
782,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5053245720,Marta Sanz Murillo,0000-0002-6175-9315
783,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5092762755,Amalia Villagran Suarez,0000-0003-3400-2330
784,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5102848969,Verena Dederer,0009-0006-7557-5388
785,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5086343829,Deep Chatterjee,0000-0001-8190-9213
786,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5068728058,Jaime Alegrio Louro,0000-0002-2800-923X
787,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5013336817,Stefan Knapp,0000-0001-5995-6494
788,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5042127936,Sebastian Mathea,0000-0001-8500-4569
789,10055134,2023-10-30T16:24:28.846320+00:00,10.5281/zenodo.10055134,Inhibition of Parkinson's Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures,"<p>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson&rsquo;s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients. This has made LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-EM structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type-I inhibitor MLi-2 and the broad-spectrum type-II inhibitor GZD-824. Our structures revealed LRRK2&rsquo;s kinase in the active-like state, stabilized by type-I inhibitor interactions, and an inactive DYG-out type-II inhibitor complex. The structures also showed how inhibitor-induced conformational changes are affected by the N-terminal half of LRRK2. The structural models provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.</p>",Dataset,2023-09-09 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Sanz Murillo, Marta
Villagran Suarez, Amalia
Dederer, Verena
Chatterjee, Deep
Alegrio Louro, Jaime
Knapp, Stefan
Mathea, Sebastian
Leschziner, Andres",cc-by-4.0,W4393630055,A5011173483,Andres E. Leschziner,0000-0002-7732-7023
790,10386854,2023-12-20T17:34:14.667738+00:00,10.5281/zenodo.10386854,Day2023 dataset,"<p>Day M., Belal M., Surmeier W. C., Melendez A., Wokosin, D., Tkatch T., Clarke V. R. J. and Surmeier D. J.</p>
<p>GABAergic regulation of striatal spiny projection neuron excitability depends upon their activity state</p>
<p>Image is taken from Fig 1B inset and illustrates RiboTag-eGFP in SPNs of the striatum.</p>
<p>Datasets for all figures 1-8</p>",Dataset,2023-12-15 00:00:00,personal,"Clarke, Vernon R. J.",cc-by-4.0,W4393735762,A5018658974,Vernon R. J. Clarke,0000-0002-6154-6555
791,10822458,2024-06-26T17:27:01.332013+00:00,10.5281/zenodo.10822458,"Dautan et al 2024 "" Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson's Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder""","<p><span>Parkinson&rsquo;s disease (PD) is characterized by progressive motor as well as less recognized non-motor symptoms that arise often years before motor manifestation, including sleep and gastrointestinal disturbances. Despite the heavy burden on the patient&rsquo;s quality of life, these non-motor manifestations are poorly understood. To elucidate the temporal dynamics of the disease, we employed a mice model involving injection of alpha-synuclein (&alpha;Syn) pre-formed fibrils (PFF) in the duodenum and antrum as a gut-brain model of Parkinsonism. Using anatomical mapping of &alpha;Syn PFF propagation and behavioral and physiological characterizations, we unveil a correlation between post-injection time the temporal dynamics of &alpha;Syn propagation and non-motor/motor manifestations of the disease. We highlight the concurrent presence of aggregates in key brain regions, expressing acetylcholine or dopamine and their functions in sleep duration, wakefulness, and particularly REM-associated atonia corresponging to REM behavioral disorder-like symptoms. This study presents a novel and in-depth exploration into the multifaceted nature of PD, unraveling the complex connections between &alpha;-synucleinopathies, gut-brain connectivity, and the emergence of non-motor phenotypes.</span></p>",Dataset,2024-06-05 00:00:00,personal,"daniel, dautan",cc-by-4.0,,,,
792,7938084,2023-07-24T21:09:46.679576+00:00,10.5281/zenodo.7938084,LRRK2 Suppresses Lysosome Degradative Activity in Macrophages and Microglia Through MiT-TFE Transcription Factor Inhibition,<p>This data set contains the primary data associated with the publication in PNAS</p>,Journal article,2023-05-13 00:00:00,"personal
personal","Narayana Yadavalli
Shawn M. Ferguson",cc-by-4.0,W4385228338,A5022806006,Narayana Yadavalli,0000-0001-9015-0464
793,7938084,2023-07-24T21:09:46.679576+00:00,10.5281/zenodo.7938084,LRRK2 Suppresses Lysosome Degradative Activity in Macrophages and Microglia Through MiT-TFE Transcription Factor Inhibition,<p>This data set contains the primary data associated with the publication in PNAS</p>,Journal article,2023-05-13 00:00:00,"personal
personal","Narayana Yadavalli
Shawn M. Ferguson",cc-by-4.0,W4385228338,A5091271525,Shawn M. Ferguson,0000-0002-3092-7718
794,12751640,2024-07-17T20:31:44.249414+00:00,10.5281/zenodo.12751640,A comparative analysis of Parkinson's disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,"<p><strong>Abstract: </strong>Epidemiological studies reveal that a diagnosis of inflammatory bowel disease (IBD) is associated with an increased risk of developing Parkinson&rsquo;s disease (PD). The presence of gut dysbiosis has been documented in both PD and IBD patients, but it is currently unknown how alterations in the gut microbiome may contribute to the epidemiological link between both diseases. To identify shared and distinct features of the PD and IBD microbiome, we performed the first joint analysis of 54 PD, 26 IBD, and 16 healthy control gut metagenomes recruited from clinics at the University of Florida, directly comparing the gut microbiomes from PD and IBD persons for the first time. Larger, publicly available PD and IBD metagenomic datasets were also analyzed to validate and extend our findings. Depletions in short-chain fatty acid (SCFA) producing bacteria, including <em>Roseburia intestinalis, Faecalibacterium prausnitzii, Anaerostipes hadrus, </em>and<em> Eubacterium rectale</em>, as well as depletions in SCFA-synthesis pathways, were demonstrated across PD and IBD datasets. We posit that direct comparison of PD and IBD gut microbiomes will be important in identifying features within the IBD gut which may be associated with PD. The data revealed a consistent depletion in SCFA-producing bacteria across both PD and IBD, suggesting that loss of these microbes may influence the pathophysiology of both disease states.&nbsp;</p>
<p><strong>Zenodo contents:</strong> In this Zenodo archive we provide the post-QC and taxonomic and functional profiling ""Source Data"" used in all downstream analyses to generate tables and figures seen in our manuscript. We also provide the link to our GitHub repository where we have stored the code used to perform the bioinformatic processing of the shotgun metagenomic sequences and stastical analyses. Individual sample raw shotgun metagenomic sequences and metadata from our UFPF dataset are available on NCBI Sequence Read Archive (SRA) under BioProject&nbsp;<a href=""https://www.ncbi.nlm.nih.gov/bioproject/1096686"">PRJNA1096686</a>.&nbsp;</p>",Dataset,2024,"personal
personal
personal
personal
personal
personal
personal
personal
personal","Krueger, Maeve E.
Boles, Jake Sondag
Simon, Zachary D.
Alvarez, Stephen D.
McFarland, Nikolaus R.
Okun, Michael S.
Zimmermann, Ellen M.
Forsmark, Christopher E.
Tansey, Malú Gámez",cc-by-4.0,,,,
795,13160664,2024-08-02T01:34:01.994817+00:00,10.5281/zenodo.13160664,kc13/residuals_spectral_analysis: 1.2.3,<p><strong>Full Changelog</strong>: https://github.com/kc13/residuals_spectral_analysis/compare/1.2.2...1.2.3</p>,Software,2024-08-02 00:00:00,personal,kc13,cc-by-4.0,,,,
796,10146089,2024-01-25T04:51:04.048566+00:00,10.5281/zenodo.10146089,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment,<p>Source Data for Nature manuscript: D<strong>ynamic behaviour restructuring mediates dopamine-dependent credit assignment</strong></p>,Dataset,2023-12-13 00:00:00,personal,"Tang, Chung Yiu Jonathan",cc-by-4.0,W4393530473,A5039142692,Jonathan C. Y. Tang,0000-0002-2376-6901
797,7153453,2022-10-06T16:16:04.585552+00:00,10.5281/zenodo.7153453,Tabular data of striatal motor learning experiments in LRRK2 KI mice,"<p>The tabular data of the behavioral experiments described in the manuscript titled &quot;<strong>R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations.&quot;</strong></p>",Dataset,2022-10-06 00:00:00,personal,"Chuyu Chen, Loukia Parisiadou",cc-by-4.0,W4393804524,A5066027781,Loukia Parisiadou,0000-0002-2569-4200
798,10886973,2024-03-27T14:14:33.507379+00:00,10.5281/zenodo.10886973,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson's GBA-N370S mutation,"<p><strong>ABSTRACT</strong></p>
<p>Understanding medium spiny neuron (MSN) physiology is essential to understand motor impairments in Parkinson&rsquo;s disease (PD) given the architecture of the basal ganglia. Here, we developed a custom three-chambered microfluidic platform and established a cortico-striato-nigral microcircuit partially recapitulating the striatal presynaptic landscape in vitro using induced pluripotent stem cell (iPSC)-derived neurons. We found that, cortical glutamatergic projections facilitated MSN synaptic activity, and dopaminergic transmission enhanced maturation of MSNs in vitro. Replacement of wild-type iPSC-derived dopamine neurons (iPSC-DaNs) in the striatal microcircuit with those carrying the PD-related GBA-N370S mutation led to a depolarisation of resting membrane potential and an increase in rheobase in iPSC-MSNs, as well as a reduction in both voltage-gated sodium and potassium currents. Such deficits were resolved in late microcircuit cultures, and could be reversed in younger cultures with antagonism of protein kinase A activity in iPSC-MSNs. Taken together, our results highlight the unique utility of modelling striatal neurons in a modular physiological circuit to reveal mechanistic insights into GBA1 mutations in PD.</p>
<p><strong>FILE DESCRIPTIONS</strong></p>
<p>Source Data.xlsx: Tabular datasets plotted on main figures 1, 3, 4, 5 and 6.</p>
<p>Supplementary Data.xlsx: Tabular datasets plotted on supplementary figures 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, and 12.</p>
<p>Key Resources Table.xlsx: Table containing key resources (primary and secondary antibodies, cell lines and software) used in this study.</p>
<p>List of Primers.xlsx: Primers used in&nbsp;RT-qPCR.</p>",Dataset,2024-03-27 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Do, Quyen B.
Noor, Humaira
Marquez Gomez, Ricardo
Cramb, Kaithlyn
Ng, Brian
Abbey, Ajantha
Ibarra-Aizpura, Naroa
Caiazza, Maria-Claudia
Sharifi, Parnaz
Lang, Chairmaine
Beccano-Kelly, Dayne
Baleriola, Jimena
Bengoa-Vergniory, Nora
Wade-Martins, Richard",cc-by-4.0,,,,
799,7023264,2022-08-25T15:01:39.887202+00:00,10.5281/zenodo.7023264,Nicotine-mediated rescue of α-synuclein toxicity requires synaptic vesicle glycoprotein 2,<p>Tabular data underlying all figures.&nbsp;</p>,Dataset,2022-08-25 00:00:00,"personal
personal
personal","Olsen, Abby L.
Clemens, Sabrina G.
Feany, Mel B.",cc-by-4.0,W4393507189,A5008890762,Abby L. Olsen,0000-0002-7680-1758
800,7023264,2022-08-25T15:01:39.887202+00:00,10.5281/zenodo.7023264,Nicotine-mediated rescue of α-synuclein toxicity requires synaptic vesicle glycoprotein 2,<p>Tabular data underlying all figures.&nbsp;</p>,Dataset,2022-08-25 00:00:00,"personal
personal
personal","Olsen, Abby L.
Clemens, Sabrina G.
Feany, Mel B.",cc-by-4.0,W4393507189,A5061999530,Sabrina G. Clemens,
801,7023264,2022-08-25T15:01:39.887202+00:00,10.5281/zenodo.7023264,Nicotine-mediated rescue of α-synuclein toxicity requires synaptic vesicle glycoprotein 2,<p>Tabular data underlying all figures.&nbsp;</p>,Dataset,2022-08-25 00:00:00,"personal
personal
personal","Olsen, Abby L.
Clemens, Sabrina G.
Feany, Mel B.",cc-by-4.0,W4393507189,A5002571663,Mel Β. Feany,0000-0003-0315-7970
802,10606795,2024-02-01T16:36:21.842039+00:00,10.5281/zenodo.10606795,"harperlaboratory/iNeuron_ERphagy: Scripts for figure generation in ""Combinatorial selective ER-phagy remodels the ER during neurogenesis""",<p>Scripts to create figures in &quot;Combinatorial selective ER-phagy remodels the ER during neurogenesis&quot;</p>,Software,2024-02-01 00:00:00,personal,harperlaboratory,mit,,,,
803,12702249,2024-10-08T20:10:05.387333+00:00,10.5281/zenodo.12702249,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,"<p>Flow cytometry (Immune profiling) Tidy Data: Figure 1d,e, 2d</p>
<p>ELISA Tidy Data: Figure 2c, 4b</p>
<p>qRT-PCR Tidy Data: Figure 1b, 3a, 4c,d</p>
<p>Cell count Tidy Data: Figure 2b</p>
<p>&nbsp;</p>
<p>&nbsp;</p>",Dataset,2024-03-03 00:00:00,personal,"Zheng, Ningbo",cc-by-4.0,,,,
804,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5026148952,Asad Malik,0000-0001-8550-9604
805,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5082080959,Athanasios Karapetsas,
806,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566
807,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5086343829,Deep Chatterjee,0000-0001-8190-9213
808,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5004300103,Toan K. Phung,0000-0002-2964-6070
809,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5017025792,Melanie Wightman,
810,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5078460066,Robert Gourlay,0000-0003-1592-1972
811,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5028009861,Nick Morrice,
812,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5042127936,Sebastian Mathea,0000-0001-8500-4569
813,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5013336817,Stefan Knapp,0000-0001-5995-6494
814,6974577,2022-08-19T07:18:17.126586+00:00,10.5281/zenodo.6974577,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","<p><strong>Abstract</strong></p>

<p>Leucine-rich-repeat-kinase 1 (LRRK1) and its homologue LRRK2 are multidomain kinases possessing a ROC-COR<sub>A</sub>-COR<sub>B</sub> containing GTPase domain and phosphorylate distinct Rab proteins. LRRK1 loss of function mutations cause the bone disorder osteosclerotic metaphyseal dysplasia, whereas LRRK2 missense mutations that enhance kinase activity cause Parkinson&rsquo;s disease. Previous work suggested that LRRK1 but not LRRK2, is activated via a Protein Kinase C (PKC)-dependent mechanism. Here we demonstrate that phosphorylation and activation of LRRK1 in HEK293 cells is blocked by PKC inhibitors including LXS-196 (Darovasertib), a compound that has entered clinical trials. We show multiple PKC isoforms phosphorylate and activate recombinant LRRK1 in a manner reversed by phosphatase treatment. PKC&alpha; phosphorylates LRRK1 at a cluster of conserved residues (Ser1064, Ser1074 and Thr1075) located within a region of the COR<sub>B</sub> domain that lies at the equivalent region of the LRRK2 DK helix that is reported to stabilize the kinase domain &alpha;C-helix in the active conformation. Thr1075 lies within an optimal PKC site phosphorylation motif and its mutation to Ala, blocked PKC-mediated activation of LRRK1. A triple Glu mutation ofSer1064/Ser1074/Thr1075 to mimic phosphorylation, enhanced LRRK1 kinase activity ~3-fold. From analysis of available structures, we postulate that phosphorylation of Ser1064, Ser1074 and Thr1075 could activate LRRK1 by promoting interaction of these residues with the aC-helix on the kinase domain. This study provides fundamental insights into the mechanism controlling LRRK1 activity.</p>

<p>&nbsp;</p>

<p><strong>LI-COR (.tif files)</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 1, Figure 1A</strong></p>

<p><strong>Figure 1A Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 Total ERK1_2.tif</strong></p>

<p>ERK1/2 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1A Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1B, top panel</strong></p>

<p><strong>Figure 1B Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1B Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 1C</strong></p>

<p><strong>Figure 1C Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK2 (Total)</li>
	<li>Rab10 (Total)</li>
	<li>Tubulin</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pERK1_2.tif</strong></p>

<p>pT202/Y204 ERK1/2</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 1C Channel 800 High Exposure pRab10.tif</strong></p>

<p>pT73 Rab10</p>

<p>&nbsp;</p>

<p><strong>Figure 1D</strong></p>

<p><strong>Figure 1D Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 1D Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 2, Figure 2A</strong></p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 2B</strong></p>

<p><strong>Figure 2B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 2B Lysates Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3, Figure 3A, top panel</strong></p>

<p><strong>Figure 3A GFP IP Channel 800 PKC Substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3A GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 3A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 3B</strong></p>

<p><strong>Figure 3B Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pSer PKC substrate.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 pPKD1.tif</strong></p>

<p>pS910 PKD1</p>

<p>&nbsp;</p>

<p><strong>Figure 3B Lysates Channel 800 Total PKD1.tif</strong></p>

<p>PKD1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3C</strong></p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Tubulin</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3C Lysates Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 3D IP Kinase Assay Channel 700.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 3D GFP IP Kinase Assay Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4, Figure 4A</strong></p>

<p><strong>Figure 4A Channel 700.tif</strong></p>

<p>Total LRRK1</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Channel 800.tif</strong></p>

<p>pSer-PKC Substrate</p>

<p>&nbsp;</p>

<p><strong>Figure 4A Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 4C</strong></p>

<p><strong>Figure 4C Channel 700.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>LRRK1 (Total)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Channel 800.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>pSer-PKC Substrate</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 4C Merge.tif</strong></p>

<p>Top to bottom:</p>

<ol>
	<li>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</li>
	<li>Merge of pS72 Rab7A substrates in green (channel 800), and total Rab7A in red (channel 700)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5, Figure 5A, top panel</strong></p>

<p><strong>Figure 5A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5B, top panel</strong></p>

<p><strong>Figure 5B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha; (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>PKC&alpha;</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 5B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 5B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 5C</strong></p>

<p><strong>Figure 5C GFP IP Channel 700.tif</strong></p>

<p>LRRK1 (Total)</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel 800.tif</strong></p>

<p>pSer-PKC substrates</p>

<p>&nbsp;</p>

<p><strong>Figure 5C GFP IP Channel Merge.tif</strong></p>

<p>Merge of pSer-PKC substrates in green (channel 800), and total LRRK1 in red (channel 700)</p>

<p>&nbsp;</p>

<p><strong>Figure 6, Figure 6A</strong></p>

<p><strong>Figure 6A Channel 700.tif</strong></p>

<p>Scanned gel of kinase assay employing LRRK1 (upper band) and PKC&alpha; (lower band)</p>

<p>&nbsp;</p>

<p><strong>Figure 7, Figure 7A</strong></p>

<p><strong>Figure 7A Channel 700.tif</strong></p>

<ol>
	<li>Top left: LRRK1 (Gel 1)</li>
	<li>Top right: LRRK1 (Gel 2)</li>
	<li>Bottom left: Rab7A (Total) (Gel 1)</li>
	<li>Bottom left: Rab7A (Total) (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A Channel 800.tif</strong></p>

<ol>
	<li>Left: pS72 Rab7A (Gel 1)</li>
	<li>Right: pS72 Rab7A (Gel 2)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom Panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 7B</strong></p>

<p><strong>Figure 7B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 7B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>Figure 7A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of Figure 7A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8, Figure 8A</strong></p>

<p><strong>Figure 8A Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>Tubulin (Not used in final panel)</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 700 GAPDH.tif</strong></p>

<p>GAPDH</p>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>Na-K ATPase</li>
	<li>pT202/Y204 ERK1/2</li>
	<li>pS72 Rab7A</li>
</ol>

<p>&nbsp;</p>

<p><strong>Figure 8A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>Figure 9</strong></p>

<p><strong>Figure 9.tif</strong></p>

<p>Annotated AlphaFold model of LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3, SFigure 3A, top panel</strong></p>

<p><strong>SFigure 3A Channel 700 LRRK1.tif</strong></p>

<p>LRRK1</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 700 Total Rab7A.tif</strong></p>

<p>Rab7A (Total)</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 PKC Alpha.tif</strong></p>

<p>PKC&alpha;</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A Channel 800 pRab7A.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 13A were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, top panel</strong></p>

<p><strong>SFigure 3B Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 3B Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 3B, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 1B were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4</strong></p>

<p><strong>SFigure 4 Channel 700.tif</strong></p>

<p>Top to bottom</p>

<ol>
	<li>LRRK1</li>
	<li>PKC&alpha;</li>
	<li>Rab7A (Total)</li>
</ol>

<p>&nbsp;</p>

<p><strong>SFigure 4 Channel 800.tif</strong></p>

<p>pS72 Rab7A</p>

<p>&nbsp;</p>

<p><strong>SFigure 4, bottom panel (pRab7A quantification)</strong></p>

<p>pS72 Rab7A and blots outlined in top panel of SFigure 2 were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Microscopy Images (.lsm files)</strong></p>

<p><strong>Figure 8</strong></p>

<p><strong>Figure 8B, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8B - DOX - PMA 1.lsm, F8B - DOX - PMA 2.lsm, F8B + DOX - PMA 1.lsm, F8B + DOX - PMA 2.lsm, F8B + DOX - PMA 3.lsm, F8B + DOX - PMA 4.lsm, F8B + DOX - PMA 5.lsm, F8B + DOX - PMA 6.lsm, F8B + DOX + PMA 1.lsm, F8B + DOX + PMA 2.lsm, F8B + DOX + PMA 3.lsm, F8B + DOX + PMA 4.lsm, F8B + DOX + PMA 5.lsm, F8B + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>Figure 8B, bottom panel (LRRK1, </strong><strong>PKC&alpha;</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Figure 8C, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and PKC&alpha; in the red channel (594)</p>

<p><strong>F8C - DOX - PMA 1.lsm, F8C - DOX - PMA 2.lsm, F8C - DOX - PMA 3.lsm, F8C + DOX - PMA 1.lsm, F8C + DOX - PMA 2.lsm, F8C + DOX - PMA 3.lsm, F8C + DOX - PMA 4.lsm, F8C + DOX - PMA 5.lsm, F8C + DOX - PMA 6.lsm, F8C + DOX + PMA 1.lsm, F8C + DOX + PMA 2.lsm, F8C + DOX + PMA 3.lsm, F8C + DOX + PMA 4.lsm, F8C + DOX + PMA 5.lsm, F8C + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6</strong></p>

<p><strong>SFigure 6, left panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p><strong>SF6 - DOX - PMA 1.lsm, SF6 - DOX - PMA 2.lsm, SF6 - DOX - PMA 3.lsm, SF6 + DOX - PMA 1.lsm, SF6 + DOX - PMA 2.lsm, SF6 + DOX - PMA 3.lsm, SF6 + DOX - PMA 4.lsm, SF6 + DOX - PMA 5.lsm, SF6 + DOX - PMA 6.lsm, SF6 + DOX + PMA 1.lsm, SF6 + DOX + PMA 2.lsm, SF6 + DOX + PMA 3.lsm, SF6 + DOX + PMA 4.lsm, SF6 + DOX + PMA 5.lsm, SF6 + DOX + PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 6, right panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in left panel) were used for quantification in right panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7, top panel</strong></p>

<p>All named files below present .lsm files with LRRK1 stained in the green channel (488) and Na-K ATPase in the red channel (594)</p>

<p>&nbsp;</p>

<p><strong>SF7 WT + PMA 1.lsm, SF7 WT + PMA 2.lsm, SF7 WT + PMA 3.lsm, SF7 WT + PMA 4.lsm, SF7 WT + PMA 5.lsm, SF7 WT + PMA 6.lsm, SF7 3Ala + PMA 1.lsm, SF7 3Ala + PMA 2.lsm, SF7 3Ala + PMA 3.lsm, SF7 3Ala + PMA 4.lsm, SF7 3Ala + PMA 5.lsm, SF7 3Ala + PMA 6.lsm, SF7 3Glu + PMA 1.lsm, SF7 3Glu + PMA 2.lsm, SF7 3Glu + PMA 3.lsm, SF7 3Glu + PMA 4.lsm, SF7 3Glu + PMA 5.lsm, SF7 3Glu + PMA 6.lsm, SF7 WT - PMA 1.lsm, SF7 WT - PMA 2.lsm, SF7 WT - PMA 3.lsm, SF7 WT - PMA 4.lsm, SF7 WT - PMA 5.lsm, SF7 WT - PMA 6.lsm, SF7 3Ala - PMA 1.lsm, SF7 3Ala - PMA 2.lsm, SF7 3Ala - PMA 3.lsm, SF7 3Ala - PMA 4.lsm, SF7 3Ala - PMA 5.lsm, SF7 3Ala - PMA 6.lsm, SF7 3Glu - PMA 1.lsm, SF7 3Glu - PMA 2.lsm, SF7 3Glu - PMA 3.lsm, SF7 3Glu - PMA 4.lsm, SF7 3Glu - PMA 5.lsm, SF7 3Glu - PMA 6.lsm</strong></p>

<p>&nbsp;</p>

<p><strong>SFigure 7, bottom panel (LRRK1, </strong><strong>Na-K ATPase</strong><strong> colocalization quantification)</strong></p>

<p>Microscopy images outlined above (and in top panel) were used for quantification in bottom panel.</p>

<p>&nbsp;</p>

<p><strong>Instant Blue-stained Gels</strong></p>

<p><strong>Figure 4</strong></p>

<p><strong>Figure 4A and 4C Stained Gels.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 4B Stained Gel.tif</strong></p>

<p>Scanned gel of PKC isoforms employed in kinase assays for 4A and 4C</p>

<p>&nbsp;</p>

<p><strong>Figure 5</strong></p>

<p><strong>Figure 5C Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in Figure 4A and 4B</p>

<p>&nbsp;</p>

<p><strong>SFigure 2</strong></p>

<p><strong>SFigure 2 Stained Gel.tif</strong></p>

<p>Instant Blue-stained gels from <sup>32</sup>P-ATP kinase assays performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Autoradiograph Films</strong></p>

<p><strong>Figure 4:</strong></p>

<p><strong>Figure 4A Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4A</p>

<p>&nbsp;</p>

<p><strong>Figure 4C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 4B</p>

<p>&nbsp;</p>

<p><strong>Figure 5C Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in Figure 5C</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Autoradiograph.tif</strong></p>

<p>Autoradiograph from <sup>32</sup>P-ATP kinase assay performed in SFigure 2</p>

<p>&nbsp;</p>

<p><strong>Graphpad files:</strong></p>

<p><strong>Figure 3A Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in Figure 8B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 1.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 6.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.pzfx</strong></p>

<p>Graphpad Prism file containing the data shown in SFigure 7.</p>

<p>&nbsp;</p>

<p><strong>Excel files:</strong></p>

<p><strong>Figure 3A Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 3A.</p>

<p>&nbsp;</p>

<p><strong>Figure 5A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 5A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 7A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 7A and B.</p>

<p>&nbsp;</p>

<p><strong>Figure 8B Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in Figure 8B, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 1 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in Figure 1B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 2 Quantification.xlsx</strong></p>

<p>Excel file containing the scintillation counts (performed using QuantaSmart) shown in SFigure 2.</p>

<p>&nbsp;</p>

<p><strong>SFigure 3A and B Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 3A and B.</p>

<p>&nbsp;</p>

<p><strong>SFigure 4 Quantification.xlsx</strong></p>

<p>Excel file containing the immunoblotting data quantitation (performed using ImageStudio) shown in SFigure 4.</p>

<p>&nbsp;</p>

<p><strong>SFigure 6 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 6, left panel.</p>

<p>&nbsp;</p>

<p><strong>SFigure 7 Quantification.xlsx</strong></p>

<p>Excel file containing the colocalization data quantitation (performed using JaCoP plug-in in ImageJ) shown in SFigure 7, top panel.</p>

<p>&nbsp;</p>",Journal article,2022-08-17 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Malik, Asad U
Karapetsas, Athanasios
Nirujogi, Raja S
Chatterjee, Deep
Phung, Toan K
Wightman, Melanie
Gourlay, Robert
Morrice, Nick
Mathea, Sebastian
Knapp, Stefan
Alessi, Dario R",cc-by-4.0,W4299332341,A5054181982,Dario R. Alessi,0000-0002-2140-9185
815,7149052,2022-10-05T14:33:20.946672+00:00,10.5281/zenodo.7149052,MIGA2 lipidomics datasheet,<p>Lipidomics analysis datasheet of&nbsp;human MIGA2 soluble portion (purified from Expi293&nbsp;cells and gel filtrated).</p>,Dataset,2022-10-05 00:00:00,personal,Zhouping Hong,cc-by-4.0,W4393786863,A5072197894,Zhouping Hong,0000-0002-8513-3288
816,6979998,2022-08-10T13:13:34.783047+00:00,10.5281/zenodo.6979998,ASAP Blueprint for Collaborative Open Science,"<p>Open access extends beyond our research principals. It also includes transparency in how ASAP is structured and developed. Our Blueprint report details our structure and founding principles.</p>

<p>The ASAP Blueprint for Collaborative Open Science is a comprehensive report on how Aligning Science Across Parkinson&rsquo;s (ASAP) has worked towards its goals to date. This Blueprint presents initial findings on how our approach to open science has solidified and evolved over its first three years, data and metrics on progress, and CC-BY versions of assets that can be adopted and adapted by others. ASAP plans to update the Blueprint with new findings and updated versions of these assets on a regular basis.</p>",Report,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Kristen Ratan
Hetal Shah
Sonya Dumanis
Randy Schekman
Ekemini Riley",cc-by-4.0,W4301244241,A5047055598,Kristen Ratan,0000-0001-9697-0367
817,6979998,2022-08-10T13:13:34.783047+00:00,10.5281/zenodo.6979998,ASAP Blueprint for Collaborative Open Science,"<p>Open access extends beyond our research principals. It also includes transparency in how ASAP is structured and developed. Our Blueprint report details our structure and founding principles.</p>

<p>The ASAP Blueprint for Collaborative Open Science is a comprehensive report on how Aligning Science Across Parkinson&rsquo;s (ASAP) has worked towards its goals to date. This Blueprint presents initial findings on how our approach to open science has solidified and evolved over its first three years, data and metrics on progress, and CC-BY versions of assets that can be adopted and adapted by others. ASAP plans to update the Blueprint with new findings and updated versions of these assets on a regular basis.</p>",Report,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Kristen Ratan
Hetal Shah
Sonya Dumanis
Randy Schekman
Ekemini Riley",cc-by-4.0,W4301244241,A5110941275,Hetal Shah,
818,6979998,2022-08-10T13:13:34.783047+00:00,10.5281/zenodo.6979998,ASAP Blueprint for Collaborative Open Science,"<p>Open access extends beyond our research principals. It also includes transparency in how ASAP is structured and developed. Our Blueprint report details our structure and founding principles.</p>

<p>The ASAP Blueprint for Collaborative Open Science is a comprehensive report on how Aligning Science Across Parkinson&rsquo;s (ASAP) has worked towards its goals to date. This Blueprint presents initial findings on how our approach to open science has solidified and evolved over its first three years, data and metrics on progress, and CC-BY versions of assets that can be adopted and adapted by others. ASAP plans to update the Blueprint with new findings and updated versions of these assets on a regular basis.</p>",Report,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Kristen Ratan
Hetal Shah
Sonya Dumanis
Randy Schekman
Ekemini Riley",cc-by-4.0,W4301244241,A5050386074,Sonya B. Dumanis,0000-0002-3345-9497
819,6979998,2022-08-10T13:13:34.783047+00:00,10.5281/zenodo.6979998,ASAP Blueprint for Collaborative Open Science,"<p>Open access extends beyond our research principals. It also includes transparency in how ASAP is structured and developed. Our Blueprint report details our structure and founding principles.</p>

<p>The ASAP Blueprint for Collaborative Open Science is a comprehensive report on how Aligning Science Across Parkinson&rsquo;s (ASAP) has worked towards its goals to date. This Blueprint presents initial findings on how our approach to open science has solidified and evolved over its first three years, data and metrics on progress, and CC-BY versions of assets that can be adopted and adapted by others. ASAP plans to update the Blueprint with new findings and updated versions of these assets on a regular basis.</p>",Report,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Kristen Ratan
Hetal Shah
Sonya Dumanis
Randy Schekman
Ekemini Riley",cc-by-4.0,W4301244241,A5016859611,Randy Schekman,0000-0001-8615-6409
820,6979998,2022-08-10T13:13:34.783047+00:00,10.5281/zenodo.6979998,ASAP Blueprint for Collaborative Open Science,"<p>Open access extends beyond our research principals. It also includes transparency in how ASAP is structured and developed. Our Blueprint report details our structure and founding principles.</p>

<p>The ASAP Blueprint for Collaborative Open Science is a comprehensive report on how Aligning Science Across Parkinson&rsquo;s (ASAP) has worked towards its goals to date. This Blueprint presents initial findings on how our approach to open science has solidified and evolved over its first three years, data and metrics on progress, and CC-BY versions of assets that can be adopted and adapted by others. ASAP plans to update the Blueprint with new findings and updated versions of these assets on a regular basis.</p>",Report,2022-08-12 00:00:00,"personal
personal
personal
personal
personal","Kristen Ratan
Hetal Shah
Sonya Dumanis
Randy Schekman
Ekemini Riley",cc-by-4.0,W4301244241,A5060915100,Ekemini Riley,
821,10578308,2024-01-29T00:45:34.151489+00:00,10.5281/zenodo.10578308,"Pixel-dependent offset, gain, variance and readnoise maps for CS505MUP polarisation camera","<p>These four tif files are the pixel-dependent camera offset (in ADU counts), gain (in ADU counts/photoelectron), variance (in ADU counts^2) and readout noise (in photoelectrons) for the full sensor of a polarization camera (CS505MUP, Thorlabs), as measured using the camera calibration method described in the Supplementary material of the following paper:</p>
<ul>
<li>Huang, F., Hartwich, T., Rivera-Molina, F.&nbsp;<em>et al.</em>&nbsp;Video-rate nanoscopy using sCMOS camera&ndash;specific single-molecule localization algorithms.&nbsp;<em>Nat Methods</em>&nbsp;<strong>10</strong>, 653&ndash;658 (2013). https://doi.org/10.1038/nmeth.2488</li>
</ul>",Dataset,2024-01-28 00:00:00,personal,"Ezra, Bruggeman",cc-by-4.0,,,,
822,7656899,2023-02-25T09:28:21.784373+00:00,10.5281/zenodo.7656899,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content","<p>Raw data files used for the manuscript &quot;Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content&quot;.&nbsp;</p>

<p>The Word document <strong>(GolgiTAG paper_ file description Zenodo.docx)</strong> contains a description of each file.</p>",Journal article,2022-11-22 00:00:00,"personal
personal","Rotimi Fasimoye
Dario Alessi",cc-by-4.0,W4321994710,A5056888177,Rotimi Fasimoye,0000-0001-8057-0879
823,7656899,2023-02-25T09:28:21.784373+00:00,10.5281/zenodo.7656899,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content","<p>Raw data files used for the manuscript &quot;Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content&quot;.&nbsp;</p>

<p>The Word document <strong>(GolgiTAG paper_ file description Zenodo.docx)</strong> contains a description of each file.</p>",Journal article,2022-11-22 00:00:00,"personal
personal","Rotimi Fasimoye
Dario Alessi",cc-by-4.0,W4321994710,A5054181982,Dario R. Alessi,0000-0002-2140-9185
824,13249956,2024-09-19T20:30:05.007145+00:00,10.5281/zenodo.13249956,Key Resource Tables for Dynamic behaviour restructuring mediates dopamine-dependent credit assignment,"<p>All materials, reagents, methods, datasets and code used with PIDs in the paper: Dynamic behaviour restructuring mediates dopamine-dependent credit assignment.&nbsp;</p>",Other,2024-08-07 00:00:00,personal,"Tang, Jonathan",cc-by-4.0,,,,
825,13946597,2024-10-21T10:36:50.498199+00:00,10.5281/zenodo.13946597,Updated: Data upload for Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,"<p>Lysosomes are implicated in a wide spectrum of human diseases including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration and cancer. Profiling lysosomal content using tag-based lysosomal immunoisolation (LysoTagIP) in cell and animal models allowed major discoveries in the field, however, studying lysosomal dysfunction in human patients remains a challenge. Here, we report the development of the tagless LysoIP method to enable rapid enrichment of lysosomes, via immunoisolation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines. Isolated lysosomes are intact and suitable for subsequent multimodal omics analyses. To validate the utility of our approach, we employed the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells (PBMCs) derived from fresh blood of patients with CLN3 Batten disease, a neurodegenerative LSD. Metabolic profiling of isolated lysosomes showed massive accumulation of glycerophosphodiesters (GPDs) in patients&rsquo; lysosomes. Interestingly, a patient with a milder phenotype and genotype, displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify novel biomarkers and discover human-relevant disease mechanisms.</p>",Dataset,2024,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Saarela, Daniel
Lis, Pawel
Gomes, Sara
Nirujogi, Raja
Dong, Wentao
Rawat, Eshaan
Glendinning, Sophie
Zeneviciute, Karolina
Bagnoli, Enrico
Fasimoye, Rotimi
Lin, Cindy
Nyame, Kwamina
Boros, Fanni A.
Zunke, Frederike
Lamoliatte, Frederic
Elshani, Sadik
Jaconelli, Matthew
Jans, Judith
Huisman, Margriet A.
Posern, Christian
Westermann, Lena
Schulz, Angela
van Hasselt, Peter
Alessi, Dario
Abu-Remaileh, Monther
Sammler, Esther",cc-by-4.0,,,,
826,10044967,2024-06-06T18:41:16.055426+00:00,10.5281/zenodo.10044967,Raw data Manuscript Wouters et al BBA 2023,,Dataset,2023-12-26 00:00:00,personal,"Vangheluwe, Peter",cc-by-4.0,,,,
827,11099669,2024-05-01T20:03:37.515201+00:00,10.5281/zenodo.11099669,Datasets for doi: 10.1101/2023.10.12.562063,"<p>Datasets for doi: 10.1101/2023.10.12.562063 entitled '</p>
<h1>The&nbsp;<em>R1441C-LRRK2</em> mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner'</h1>",Dataset,2023-12-10 00:00:00,personal,"wallings, rebecca",cc-by-4.0,,,,
828,8367352,2023-09-21T14:18:06.700281+00:00,10.5281/zenodo.8367352,Structural basis of LRRK2 membrane recruitment and activation,"<p><strong>Primary&nbsp;data associated with&nbsp;the manuscript &quot;Structural basis of LRRK2 membrane recruitment and activation&quot; (Hanwen Zhu*, Francesca Tonelli*, Mansoore Esmaili, Martin Turk, Alan Prescott, Dario R. Alessi, Ji Sun). These include immunoblotting data and their quantitation, representative confocal microscopy images, and quantitation and statistical analysis of confocal microscopy images.</strong></p>

<p><strong>&nbsp;</strong></p>

<p>&nbsp;</p>",Journal article,2023-02-02 00:00:00,personal,Francesca Tonelli,cc-by-4.0,W4386908626,A5029388712,Francesca Tonelli,0000-0002-4600-6630
829,8023364,2023-06-28T09:55:13.247482+00:00,10.5281/zenodo.8023364,Whole Proteome Copy Number Dataset in Primary Mouse Cortical Neurons,<p>Raw data-Supplementary table- &quot;Whole Proteome Copy Number Dataset in Primary Mouse Cortical Neurons&quot;</p>,Dataset,2023-06-10 00:00:00,"personal
personal
personal","Odetta Antico
Raja S. Nirujogi
Miratul M.K. Muqit",cc-by-4.0,W4393847883,A5039704196,Odetta Antico,0000-0002-7325-3303
830,8023364,2023-06-28T09:55:13.247482+00:00,10.5281/zenodo.8023364,Whole Proteome Copy Number Dataset in Primary Mouse Cortical Neurons,<p>Raw data-Supplementary table- &quot;Whole Proteome Copy Number Dataset in Primary Mouse Cortical Neurons&quot;</p>,Dataset,2023-06-10 00:00:00,"personal
personal
personal","Odetta Antico
Raja S. Nirujogi
Miratul M.K. Muqit",cc-by-4.0,W4393847883,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566
831,8023364,2023-06-28T09:55:13.247482+00:00,10.5281/zenodo.8023364,Whole Proteome Copy Number Dataset in Primary Mouse Cortical Neurons,<p>Raw data-Supplementary table- &quot;Whole Proteome Copy Number Dataset in Primary Mouse Cortical Neurons&quot;</p>,Dataset,2023-06-10 00:00:00,"personal
personal
personal","Odetta Antico
Raja S. Nirujogi
Miratul M.K. Muqit",cc-by-4.0,W4393847883,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404
832,4792489,2021-05-26T23:32:10.036252+00:00,10.5281/zenodo.4792489,Image Dataset for Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,"<p>Selective autophagy of damaged mitochondria, protein aggregates, and other cargoes is essential for health. Cargo initiates phagophore biogenesis, which entails the conjugation of LC3 to phosphatidylethanolamine. Current models suggest that clustered ubiquitin chains on a cargo trigger a cascade from autophagic cargo receptors through the core complexes ULK1 and class III phosphatidylinositol 3-kinase complex I, WIPI2, and the ATG7, ATG3, and ATG12ATG5-ATG16L1 machinery of LC3 lipidation. This was tested using giant unilamellar vesicles (GUVs), GST-Ub4&nbsp;as a model cargo, the cargo receptors NDP52, TAX1BP1, and OPTN, and the autophagy core complexes. All three cargo receptors potently stimulated LC3 lipidation on GUVs. NDP52- and TAX1BP1-induced LC3 lipidation required all components, but not ULK1 kinase activity. However, OPTN bypassed the ULK1 requirement. Thus, cargo-dependent stimulation of LC3 lipidation is common to multiple autophagic cargo receptors, yet the details of core complex engagement vary between the different receptors. This dataset contains all the GUV images of the reconstitution assay.&nbsp;&nbsp;</p>",Dataset,2021-05-29 00:00:00,personal,Chunmei Chang,cc-by-4.0,W4393698516,A5002623700,Chunmei Chang,0000-0002-5607-7985
833,13769766,2024-09-16T19:02:34.780977+00:00,10.5281/zenodo.13769766,ASAP Open Science Policy Handbook,"<p>The Aligning Science Across Parkinson&rsquo;s (ASAP) Open Science Policy Handbook is a comprehensive reference guide. It provides fine-grained detail and unambiguous explanations of what ASAP expects from its grantees in the Collaborative Research Network (CRN) in terms of open science for their original research. This document constitutes the official ASAP Open Science Policy, itemizing all requirement specifications around policy compliance within our five (5) overarching requirements.</p>
<p>To read more about the ASAP Open Science Policy, see: https://parkinsonsroadmap.org/open-science-policy/#</p>",Other,2024-09-16 00:00:00,personal,"Thibault, Robert",cc-by-4.0,,,,
834,10475643,2024-01-09T17:18:29.689744+00:00,10.5281/zenodo.10475643,sCMOS calibration software,"<p>This is software for calibrating sCMOS cameras, written in MATLAB. The readme file gives instructions on how to record experimental data and use the code to estimate the pixel-dependent offset, gain, variance and read noise of a sCMOS camera.</p>",Software,2024-01-09 00:00:00,personal,"Bruggeman, Ezra",cc-by-4.0,,,,
835,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5037780867,Zachary D. Wallen,0000-0002-2278-7348
836,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5001432320,Ayşe Demirkan,0000-0002-7546-0867
837,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5045056363,Guy Twa,0000-0002-8409-7844
838,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5026253406,Gwendolyn Cohen,0000-0002-5084-061X
839,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5062505725,Marissa Dean,0000-0002-9318-769X
840,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5000374325,David G. Standaert,0000-0003-2921-8348
841,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5058647225,Timothy R. Sampson,0000-0002-2486-8766
842,7246185,2022-10-26T16:53:32.714816+00:00,10.5281/zenodo.7246185,Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,"<p><strong>Abstract:</strong>&nbsp;Parkinson&#39;s disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome,&nbsp;we conducted a large-scale study, at high taxonomic resolution,&nbsp;using uniform standardized methods from start to end.&nbsp;&nbsp;We enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association at species and genus level,&nbsp;followed by network analysis to identify polymicrobial clusters, and functional profiling based on microbial genes and pathways. Here we show that over&nbsp;30% of species, genes&nbsp;and pathways tested have altered abundances in PD, depicting a widespread dysbiosis. PD-associated species form polymicrobial clusters that grow or shrink together, and some compete.&nbsp;&nbsp;PD microbiome is disease permissive, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover.&nbsp;&nbsp;We validate, in human PD, findings that were observed in experimental models; reconcile and resolve human PD microbiome literature, and&nbsp;provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.&nbsp;&nbsp;</p>

<p><strong>Zenodo contents:</strong>&nbsp;In this Zenodo archive we provide (1) post sequence QC and post taxonomic and functional profiling&nbsp;&quot;Source Data&quot; used to generate tables and figures&nbsp;in the manuscript and (2) &quot;Supplementary Code&quot; that contains the workflow and code used&nbsp;to perform bioinformatic processing of shotgun sequences and statistical analyses of microbial profiles and subject metadata. The code provided here is the same &quot;Supplementary Code&quot;&nbsp;that is provided&nbsp;in the supplement&nbsp;of the manuscript.&nbsp;Individual level raw shotgun sequences and metadata&nbsp;are available on NCBI Sequence Read Archive (SRA) under BioProject ID <a href=""https://www.ncbi.nlm.nih.gov/bioproject/834801"">PRJNA834801</a>.</p>",Dataset,2022-10-26 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Zachary D Wallen
Ayse Demirkan
Guy Twa
Gwendolyn Cohen
Marissa N Dean
David G Standaert
Timothy Sampson
Haydeh Payami",cc-by-4.0,W4393698374,A5055969440,Haydeh Payami,0000-0001-9084-5338
843,6374061,2022-03-21T18:06:38.908436+00:00,10.5281/zenodo.6374061,dzhang32/ggtranscript:,"<p>The goal of ggtranscript is the simplify the process of visualizing transcript structure and annotation. To achieve this, ggtranscript introduces 5 new geoms (geom_range(), geom_half_range(), geom_intron(), geom_junction() and geom_junction_label_repel()) as well as several helper functions. As a ggplot2 extension, ggtranscript inherits ggplot2&#39;s familiarity and flexibility, enabling users to intuitively adjust aesthetics, parameters, scales etc as well as complement ggtranscript geoms with existing ggplot2 geoms to create informative, publication-ready plots.</p>",Software,2022-03-21 00:00:00,"personal
personal
personal
personal
personal","David Zhang
Emil K Gustavsson
Regina H. Reynolds
Sonia Garcia-Ruiz
Mina Ryten",cc-by-4.0,,,,
844,13969544,2024-10-22T10:09:28.164301+00:00,10.5281/zenodo.13969544,Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson's disease overexpressing human alpha synuclein,"<p><span>Parkinson&rsquo;s disease (PD) involves genetic and<span> </span>environmental risk factors. Increasing research efforts have been made to understand how they interact<span> </span>to<span> </span>impair<span> </span>homeostasis<span> </span>and<span> </span>elevate<span> </span>risk. Inflammation could be one unifying factor. In this study, <em>wild-type</em> (WT) and overexpressing human </span><span>&alpha;</span><span>-synuclein (<em>Snca</em><sup>+/+</sup>) rats <span>were intraperitoneally injected with a single dose of </span>lipopolysaccharide<span> </span>(LPS) or with saline (SAL). In these animals we assessed </span><span>the development of PD-like symptoms by&nbsp;immunohistology, high-dimensional flow cytometry, electrophysiology, and behavioral analyses. A single injection of LPS to both WT and <em>Snca<sup>+/+</sup> </em>rats triggered long-lasting increased activation of pro-inflammatory microglial markers, infiltrating monocytes and T-lymphocytes. However, only LPS <em>Snca</em><sup>+/+</sup> rats displayed dopaminergic neuronal loss in the <em>substantia<span> </span>nigra pars compacta<span> </span></em>(SNpc), associated with a reduction of evoked dopamine<span> release </span>in the striatum. No significant<span> </span>changes were observed in the behavioral domain. </span></p>
<p><span>&nbsp;</span></p>",Dataset,2024-10-22 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal
personal","Massaro Cenere, Mariangela
Tiberi, Marta
Paldino, Emanuela
D'Addario, Sebastian Luca
Federici, Mauro
Giacomet, Cecilia
Cutuli, Debora
Matteocci, Alessandro
Cossa, Francesca
Zarrilli, Beatrice
Nicolas, Casadei
Ledonne, Ada
Petrosini, Laura
Berretta, Nicola
Fusco, Francesca R.
Chiurchiù, Valerio
Mercuri, Nicola Biagio",cc-by-4.0,,,,
845,10062179,2023-11-01T19:24:42.606231+00:00,10.5281/zenodo.10062179,FASlpr gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus,,Preprint,2023-11-01 00:00:00,"personal
personal","Bohat, Ritu
Peng, Weiyi",cc-by-4.0,,,,
846,13379191,2024-08-27T11:22:56.825543+00:00,10.5281/zenodo.13379191,Jbrenton191/RNAseq_splicing_pipeline: Human RNAseq Alignment and QC for Differential Expression and Splicing Analysis,<p>This pipeline is used to QC and alignment Human RNA sequencing fastq files. The aligned read files output from the pipeline can be used for differential expression and splicing analyses.</p>,Software,2024-08-27 00:00:00,personal,"Brenton, Jonathan",cc-by-4.0,,,,
847,10797936,2024-03-11T08:41:05.179594+00:00,10.5281/zenodo.10797936,Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons,<p>The tabular dataset for all graphs in Rafiq et al 2024 can be found in the ASAP data repository</p>,Dataset,2024-03-08 00:00:00,personal,"Mohd Rafiq, Nisha",cc-by-4.0,,,,
848,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5056728588,Jonathan S. Marvin,0000-0003-2294-4515
849,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5075174957,Alexandros C. Kokotos,0000-0003-4024-9866
850,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5051850846,Mukesh Kumar,0000-0002-0277-2958
851,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5056730601,Camila Pulido,0000-0002-5648-066X
852,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5045181969,Ariana N. Tkachuk,0000-0001-8991-9643
853,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5072896554,J. Yao,0000-0002-8007-8160
854,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5052320233,Timothy A. Brown,0000-0001-8941-7678
855,11165874,2024-07-23T18:07:07.188122+00:00,10.1073/pnas.2314604121,iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP,<p>Here we develop a next-generation genetically encoded ratiometric fluorescent ATP sensor that allows subcellular tracking of ATP levels in living cells.</p>,Data paper,2024-05-15 00:00:00,"personal
personal
personal
personal
personal
personal
personal
personal","Marvin, Jonathan
Kokotos, Alexandros
Kumar, Mukesh
Pulido, Camila
Tkachuk, Ariana
Yao, Jocelyn
Brown, Timothy
Ryan, Timothy",cc-by-4.0,W4396919562,A5051928889,Timothy A. Ryan,0000-0003-2533-9548
856,10046587,2023-10-27T12:54:03.680698+00:00,10.5281/zenodo.10046587,Dan Lab sleep datasets for MCI-Park mice 24-hour recordings,,Dataset,2023-10-27 00:00:00,personal,"Huang, Xiaolin",cc-by-4.0,W4394032932,A5101465278,Xiaolin Huang,0000-0001-7367-8347
857,10600748,2024-07-10T22:11:21.342649+00:00,10.5281/zenodo.10600748,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Antipsychotic Therapy,,Dataset,2024-07-09 00:00:00,"personal
personal
personal","Vrijsen, Stephanie
Abou El Asrar, Rania
Vangheluwe, Peter",cc-by-4.0,,,,
